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 Chapter 1: Drug Discovery 
 
1.1 The Drug Discovery Process 
 
Drug discovery is the combined processes by which new drugs are invented, 
evaluated for pharmacological activity and selected for lead identification and 
optimization.  Basic scientific investigation reveals key biological components and 
mechanisms of both normal physiological function and disease states that drug discovery 
scientists take advantage of in hopes of developing novel pharmacotherapeutics as tools 
for controlled medical intervention.  These newly-discovered biological mechanisms and 
processes are seen as potential novel drug targets to the discovery scientist.  Targets can 
be molecular in scale, like peptides, receptors or nuclear genetic material or they can 
encompass larger cellular and systemic processes like cell signaling events, intracellular 
signal amplification cascades, endocrine response or a systemic response to stimuli.  
Once a biological target has been established it is the goal of drug design and drug 
discovery scientists to generate a drug entity which can be used for experimental 
applications or therapeutic intervention.      
 Major steps in the drug discovery process include 1) drug design, 2) drug 
molecule synthesis, 3) pharmacological evaluation of the desired biological effect and 4) 
comparative structure-activity relationship (SAR) analysis.  Results from SAR are then 
used to derive a better understanding of the nature of the interaction in addition to 
improving the success of secondary drug synthesis.   
Several important factors must be thoughtfully considered when planning the drug 
design phase.  The target’s structure, location in the body, local target environment, local 
target density, potential drug molecule stability, ease of drug molecule synthesis, 
potential undesired metabolic products, potential for drug-drug interaction or interactions 
with coupled or related biological systems and local and systemic compensatory feedback 
responses are just a few of the myriad factors important in the design of a compound that 
can be used to successfully exert a desired effect on the target biological process.  These 
are a few of the things that make drug design a challenging and often slow process.  Most 
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 major roadblocks, however, may be avoided or overcome with a little insight into the 
nature of the potential drug target.   
Traditionally most drugs have been discovered by one of two methods; either by 
isolation from natural medicinal sources or by an unintended and fortuitous laboratory 
accident that reveals a compound’s desired effect.  While fortuitous accidents can’t be 
planned or predicted, and while natural product chemistry and pharmacognancy continue 
to provide promising drug candidates through isolation from new and traditional sources, 
today there is a growing emphasis on two distinct and modern drug discovery strategies.  
These common methods are rational drug design and high-throughput synthesis.   
Rational drug design (as its title indicates) is based on a detailed understanding of 
the molecular pathophysiology of the disease process and attempts to build molecules 
which target specific, known molecular interactions and mechanisms.  Ideally rational 
drug design allows for improved drug activity profiles with higher selectivity and lower 
toxicity when compared to an HTS approach because the drug molecule libraries are a 
priori, custom made to selectively interact with a known target.  By applying all that is 
known about the location, function and nature of the target, complicated synthetic 
chemistry methods are used to generate compounds specifically made to interact with 
known molecular features on the target.  Rational drug design may, for example, take 
advantage of physiochemical features of a known active site on an enzyme or binding 
pocket on a receptor to evolve complex interactions between ligand and receptor, thereby 
in one step improving compound library hit rate, and at the same time improving lead 
compound selectivity and toxicity profiles.   
With high-throughput synthesis and high-throughput screening (HTS) methods, 
synthetic efforts focus on generating a tremendous number of compounds that can each 
be made simply, rapidly, and in small enough amounts so as to make the entire process 
cost effective.  HTS attempts to find active compounds by applying the power of large-
scale medicinal chemistry (like parallel organic synthesis or polymer resin-based and 
microwave synthetic methods) to generate a tremendous number of initial candidates.  
This process must be coupled to (HTS) due to the problems inherent in handling and 
testing large libraries of compounds.  A major drawback of high-throughput synthesis is 
that it proceeds with little or no initial regard to improving hit rates or the drug candidate 
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 toxicity or “drugability” profile through application of rational drug design principles.  
HTS approaches, however, make up for this low initial hit rates and drug profile 
selectivity through the sheer number of initial hits and the high number of preliminary 
drug candidates.  The ultimate goal of high-throughput synthesis and screening is to 
reduce the cost of identifying high quality lead compounds for a pharmacological target.  
By employing molecular and synthetic diversity technologies to the traditional fields of 
synthetic chemistry and rational drug design, HTS methods generate novel and often 
times unforeseeable lead candidates and structure-activity data which come together to 
allow facilitated optimization of novel lead drug candidates.   
 Biological evaluation efforts are forced to become more streamlined while part of 
a larger drug discovery process.  Early in the testing process, evaluation is often limited 
to a simple screening effort where compounds are evaluated for a single biological effect.  
This often entails foregoing a complete pharmacological characterization in favor of a 
one or two data point “first look”.  Compounds exhibiting a promising result (often little 
more than a positive or negative result) are considered hits and will only then be held 
over for further biological testing in an attempt to reduce the number of compounds that 
undergo further evaluation.  In this manner ineffectual compounds are weeded out and 
more time-consuming and costly pharmacological tests are carried out on compounds 
demonstrating some measure of drug potential.  From this more extensive pre-clinical 
testing “lead drug candidates” are chosen as the compounds with the most attractive 
physiochemical, pharmacological and toxicological profiles.  In addition to identifying 
lead candidates, pharmacological data (positive and negative results) from a library or 
libraries of compounds later become valuable in ongoing drug design refinement and 
characterization as structure-activity relationship (SAR) analysis reveals important details 
about the drug molecule’s biological interactions and effects. 
SAR is the science of measuring and evaluating molecular interactions between 
the drug molecule and the target it interacts with.  Much of the current SAR work 
requires powerful computational resources as mathematical models of the drug-target 
relationship continue to become ever more complex.  Virtual synthesis via computational 
chemistry exists as a natural extension of traditional SAR investigation and is used to 
support continuing synthetic efforts.  By exploiting desirable molecular features 
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 ascertained from previous rounds of synthesis and biological experimentation, 
computational SAR efforts provide new direction and ideas for chemical modification 
and help guide general synthetic direction.  The two most common methods of 
computational chemistry both attempt to describe the drug interaction on a molecular 
level allowing for improved chemical intervention.  These methods include: 1) the 
development of a ligand-receptor models (i.e. a docking model in the specific case where 
a receptor or target structure has been previously defined), or 2) the development of a 
pharmacophore model, a method where SAR modeling is based on certain molecular 
features of the ligand molecules alone when little is known about the drug target or when 
critical molecular features of the target are ill-defined.  Once the nature of the molecular 
interaction is defined in this manner SAR-based computer models can be employed to 
predict new candidate compounds for synthesis.  Theoretically this feedback to the 
synthesis will lead to compounds that possess improved drug candidate characteristics.  
This SAR leads to refinement in the next synthetic round and not only leads to improved 
hit rates but can also lead to improvements in potency, efficacy, selectivity and 
toxicity…all highly desirable qualities to have in a drug molecule.   
 
1.2 Research Plan 
 
It is the goal of this research project to carry out a small-scale drug discovery 
research project.  The main features include 1) the rational design of a novel class of 
compounds exhibiting nicotinic receptor activity, 2) generation of compounds using 
parallel organic synthesis technology and methods, 3) evaluation of the product 
compound library in a nicotinic receptor activity screen to identify initial hits, 4) 
pharmacological evaluation of lead compounds through the use of a variety of receptor 
binding and receptor functional activity assays and 5) traditional SAR and computer-
based pharmacophore model development and application in order to predict some 
second generation lead drug candidates for future synthesis and biological testing.     
 
 
Copyright © Aaron Joseph Haubner 2008  
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Figure 1.1  Flow chart briefly describing major steps in the drug design and testing process.  Rational synthesis and HT 
synthesis generate compound libraries that are evaluated for activity.  Additional evaluation is carried out on active 
compounds while SAR data is fed into computer models to improve the quality and productivity of ongoing synthesis. 
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 Chapter 2: Background and Introduction 
 
 
2.1 Nicotinic Receptor Background with Nicotine Usage and History 
 
Early receptor discovery 
Although first pioneered by Paul Ehrlich (Leipzig, GER) as early as the 1880’s, 
the concept of small molecules acting at receptors to affect a physiological response did 
not exist until after the work of John Langley, (Cambridge, UK) conducted 1900-1907 
(see review by Bennett 1999).  In these studies Langley demonstrated that nicotine could 
cause muscular tonic contractions and that this effect could be blocked with prior 
application of the South American paralytic poison, curare (Langley 1907).  Early 
experiments by Claude Bernard (Paris, FR) using curare identified an intermediate zone 
between nerve and muscle.  This intermediate zone would later be identified as the 
neuromuscular junction and it would become a major focus of receptor research for the 
next forty years.   Thomas Elliot (Cambridge, UK) and others used renal extracts 
(enriched epinephrine isolates from a natural source) and the common plant alkaloid 
nicotine (NIC), in experiments to affect smooth muscle and ganglionic cells.  This led to 
the further characterization of the neuron-muscular junction (Bennett 1999).  By 1906, 
Langley found that curare inhibits nicotine-induced nervous stimulation and it was then 
hypothesized that there exists a “receptive substance” at neuron-somatic junctions 
throughout the body that are intimately involved in normal physiological function 
(Langley 1907).   
The actions of acetylcholine (ACh) and other choline esters on muscle fibers were 
characterized by Reid Hunt in 1907 (Hardman and Limbird 1996).  Between 1914 and 
1929 Henry Dale (London, UK) and Otto Loewi (Graz, Austria) carried out more detailed 
physiological experiments with ACh, looking at neuron-somatic junction effects on blood 
pressure and response in heart and intestine tissue.  In one of his classical experiments, 
Loewi isolated the hearts of two frogs, the first with associated nerves and the second 
without (reviewed in Karczmark 1996).  The first heart was stimulated for a few minutes 
until a decrease in contractility was observed.  The ringer’s buffer from that bath was 
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 applied to the second heart and the same decrease was observed in the non-innervated 
heart.  Chemical analysis later determined that it was acetylcholine that was the 
compound responsible for the transfer effect.  Together Dale and Loewi developed the 
concept of neuron-humoral transmission and characterized ACh as the likely small 
molecule synaptic transmitter that stimulated the “receptive substance” at the body’s 
neuron-effector junctions, now commonly referred to a receptor.  It was in such a manner 
that the nicotinic-acetylcholine receptor (nAChR) became the first receptor-transmitter 
system to be characterized (Bennett 1999).   
It was in 1914 that Dale also first observed two distinct responses to ACh and 
successfully demonstrated that one was mimicked by nicotine (NIC) and the other by 
muscarine (Hardman and Limbird 1996).  Interestingly, this simple distinction 
corresponded to two distinct classes of the acetylcholine receptor: the fast-acting ligand-
gated ion channel receptors sensitive to NIC and the slower-acting metabotropic G 
protein-coupled receptors sensitive to muscarinic compounds.  These findings pioneered 
later work that focused on the pharmacological characterization of nicotinic acetylcholine 
receptors.   
 (S)-(-)-Nicotine (NIC) is the most abundant alkaloid isolated from the Nicotiana 
tabacum plant.  It was named after Jean Nicot, who was credited with the introduction of 
tobacco to France in the 16th century (Gorrod 1999).  NIC was first isolated from this  
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Figure 2.1  Representations of the nicotine and acetylcholine molecules.  Note the physiochemical and structural 
similarities. 
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 natural source by Posselt and Reimann in 1828 (King’s American Dispensory, 1898) and 
its empirical formula was first proposed by Melsens in 1843 (Pictet 1904).  In 1883 
Pinner became the first to correctly suggest the correct structure of NIC (Pinner 1893), 
while the first total synthesis of NIC was carried out by Pictet and Rotshy in 1904 (Pictet, 
1913).  It wasn’t until 1978 however, that Pitner identified the S-(-)-enantiomer of natural 
NIC.   
 
Nicotine History and Usage 
NIC-producing tobacco varieties are cultivated throughout the world for use in the 
manufacture of cigars, cigarettes, snuff, pipe and chewing tobacco.  NIC content varies 
widely between varieties and species but usually constitutes between 3-8% of the dry 
weight of the cured leaf.  NIC is found primarily as the S-(-)-enantiomer, although when 
ingested through inhalation of tobacco smoke it has been reported that as much as 11% of 
NIC is found in the R-(+)-state due to pyrrolytic racimization of the S-(-)-isomer.  
Burning the dried tobacco leaf generates a gaseous phase of smoke where NIC and other 
active alkaloids are distilled out and delivered to the lungs.  This gaseous component 
contains toxic substances such as carbon dioxide, carbon monoxide, hydrogen cyanide 
and a variety of aldehydes and ketones.  The second component of tobacco smoke is the 
particulate phase and includes toxic substances like tar and carcinogenic hydrocarbons 
thought to be responsible for neoplastic diseases and cancers of the lung, bladder, throat 
and pancreas among others (Hardman and Limbird 1996)    
 As a natural product compound, NIC serves the purpose of defending the parent 
plant from attack by sucking insects and pests as well as from would-be herbivorous 
consumers.  Since it is a natural plant toxin, ingestion of sufficient amounts of NIC 
results in unpleasant physiological effects.  NIC poisoning involves unwanted central and 
peripheral nervous system effects.  Common symptoms of toxic exposure range from 
nausea and vomiting to cardiac palpitations, and at higher doses neuromuscular blockade, 
paralysis, and death (Saxena 1985).  One can see that in fulfilling its roll as a natural 
chemical defense mechanism NIC is intended, through its natural design, to be a potent 
and non-selective toxic compound.  
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 NIC has been used for centuries to control sucking pests and insects responsible 
for agricultural damage despite its poor efficacy and high toxicity to humans and 
livestock mammals.  NIC was used as early as 1746 when the infusions of tobacco leaves 
was used for treating aphids on agricultural crops.  As a commercial-agricultural 
pesticide, NIC use hit its peak in the 1940s when over one million pounds of nicotine 
sulfate solutions were sold commercially in the US.  This, of course, was prior to the era 
of synthetic insecticide production which offered safe and effective miracle compounds 
like DDT, with higher efficacy in targeting insects and a highly desirable toxicity profile 
for human handling use.  Although commercially successful due to its ease of isolation 
and low cost, NIC made for a poor agricultural use product due to its rapid degradation, 
lack of selectivity and it’s toxicity to both human and non-human vertebrates, although 
aqueous solutions of nicotine sulfate are still used in many poorer parts of the world 
today as an insecticide (Reviewed at http://entweb...). 
 In addition to its use as an insecticide, NIC has a long history of being cultivated 
and used by humans for pharmacological purposes due to its myriad effects in the body.  
NIC is absorbed rapidly through cigarette smoke and within 20 seconds is distributed to 
major body tissues.  Serum levels vary greatly throughout the day and in an intermittent 
manner between cigarettes.  Serum NIC levels will routinely reach levels of .2µM or 
greater for a typical two pack per day smoker (Russell 1980), although physiological 
effects have been demonstrated for concentrations of NIC much lower than what is 
typically observed in serum and brain of smokers.  NIC is extensively metabolized in the 
liver.  There 80% or more of NIC is efficiently converted to cotinine and about 5% to 
nicotine-oxide (Benowitz 1996).  Elimination is a bi-phasic process, where the half-life 
relevant to accumulation of NIC averages 2-3 hours.  The conversion of NIC to cotinine 
by CYP450A6 is a multi-step process and appears to be the rate-limiting step for 
elimination. 
NIC has been shown to exert the majority of its effects through its interaction at 
the nAChR.  NIC has been shown to modulate the release of neurotransmitters, induce 
the discharge of several pituitary and adrenal hormones, influence regulation of gene 
transcription, modulate CNS and PNS synaptic activity and affects several psychological 
and behavioral states (Lena, Changeux, 1993, Yu and Wecker 1994, Role and Berg 1996, 
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 Zevin 1998, Cadoni and Di Chiara 2000).  Native cultures have long cultivated Nicotiana 
species and utilized tobacco for its stimulant effects, its ability to improve attention and 
focus and paradoxically its perceived calming effects, in addition to its ability to mitigate 
anxiety.  NIC’s well-known and powerful addictive properties sustain its use in society 
today as it did long ago.  These many effects of NIC are due to the interaction of the NIC 
molecule with nicotinic acetylcholine receptors (nAChRs).  nAChRs are distributed 
widely throughout the body, allowing for NICs multi-systemic pharmacological effects.  
The neuronal nAChRs of the central nervous system (CNS) are the major targets for NIC 
in the body and responsible for the addictive properties and psychoactive effects of the 
drug.   
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 2.2 Nicotinic Receptor Structure, Subunit Discovery and Introduction to 
Neuronal Nicotinic Receptors 
 
Nicotinic Receptor Structure 
Nicotinic receptors are transmembrane-spanning, allosteric proteins that mediate 
the endogenous effects of ACh in the body.  nAChRs belong to the superfamily of ligand-
gated ionotropic channel receptors.  Other well-known members of this family include 
the glycine receptors, the γ-aminobutyric acid (GABA) receptors and the 5-
hydroxytryptamine (5-HT3) serotonin family of receptors.  Characteristic of this class, 
nAChRs possess a large Cys-Cys stabilized, extracellular, N-terminal region where the 
two cysteine residues form a sulfide bridge around 13 hydrophobic bases (Karlin 2002).  
The nAChR channel complex arises from five polypeptide subunits assembled like 
“staves of a barrel around a central, water-filled pore” (Cooper 1991).  In nearly all 
instances, nAChRs mediate rapid inward currents of selected cations down their 
concentration gradients into the cytoplasm to affect cellular processes and cell signaling 
(Sargent 1993).  
The nAChR is a pentameric structure of individual subunits, presenting a flower-
like surface on the extracellular portion surrounding a central channel or pore (Cartaud 
1973, Cooper 1991, Green 1995).  Each subunit shares the same hydropathy profile and 
consists of three distinct domains: 1) a large N-terminal hydrophilic domain (~210 amino 
acids, including a disulfide-linked loop between cysteines 128 and 142 of the 
extracellular portion that accommodates the ligand-binding domain, 2) a transmembrane 
region containing four separate hydrophobic transmembrane (TMD) segments (denoted 
as M1, M2, M3, and M4) that crosses the lipid bilayer and forms the inner wall of the 
central, membrane-spanning channel, and 3) a variable C-terminal cytoplasmic domain 
between segments M3 and M4 that is believed to be involved in regulation and 
phosphorylation events in addition to a short extracellular terminal carboxy segment 
(Grutter and Changeux 2001, Bertrand 1999).  The transmembrane segments traverse the 
membrane as an α-helix.  The ion channel pore is believed to be formed from the M2 and 
top third of the M1 transmembrane domains of each of the subunits (Karlin and Akabas 
1995) and contains a stretch of electronegative glutamic acid residues which are  
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Figure 2.2.  Structure of the nicotinic acetylcholine receptor.  A)  The threading pattern of receptor subunits through 
the membrane. B)  A schematic representation of the quaternary structure, showing the arrangement of the subunits in 
the muscle-type receptor, the location of the two acetylcholine (ACh)-binding sites (at the junction of an α and a β 
subunit, and an α and γ subunit), and the axial cation-conducting channel. C)  A cross-section through the 4.6-Å 
structure of the receptor determined by electron microscopy of tubular crystals of Torpedo membrane embedded in ice. 
Dashed line indicates proposed path to binding site. 
 
 
Image reproduced with permission (A. Karlin/Nature Publishing Group) 
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 believed to selectively gate the entry of cations into the cell (Pascual and Karlin 1998).  
Due to their critical function in channel conductance/gating and receptor activation, the 
four hydrophobic TMD segments and the ACh binding site, respectively, are highly 
conserved in most nAChR subunits, while the large cytoplasmic domain contains the 
most sequence diversity among the subunits (Leonard and Bertrand 2001).  nAChRs are 
assembled from multiple gene products which enables multiple receptor subtype 
combinations each with distinct expression, distribution, physiological and 
pharmacological properties.  The fully assembled nAChR weighs 270-300kDa and is 
composed of five subunits between 40-70 kDa each (Sargent 1993). 
 Typically nAChRs contain two binding sites for the endogenous ligand ACh that 
are located on the extracellular portion of the receptor.  The binding site is formed at the 
interface between an α and a β subunit (Hussy and Bertrand 1994).  Binding of an agonist 
or antagonist to the orthosteric sites of the nAChR results in the stabilization of the 
receptor in either its active open or closed inactive (desensitized) conformation.  
Additional binding interactions at, as yet poorly defined allosteric sites are believed to 
affect otherwise normal nAChR function by altering channel kinetics and 
electrophysiological properties such as conductance and gating (reviewed in Itier 2001 
and Jensen 2004) although these properties remain unclear at this time.   
Due to its hydrophobic nature and allosteric properties, it has proven impossible 
to solve the entire nAChR structure to date (Grutter and Changeux 2001).  For X-ray 
crystallographers this is a common problem with non-water soluble peptide structures 
like the nAChR, since they do not readily form regular crystalline lattice superstructures 
suitable for X-ray diffraction analysis, although the basic shape of the nAChR has been 
revealed using electron microscopy of the electric organ (Kunath and Hucho 1989, 
Beroukhim and Unwin 1995).  Recently, the homologous structure of the Torpedo 
nAChR was moderately resolved with advanced cryo-electron microscopy from tubular 
crystals of postsynaptic membranes to a resolution of 4.6 Å (Miyazawa 1999).  The 
extracellular portions appear to have a binding pocket for molecules like ACh and NIC 
~30Å away from the membrane surface.  The central channel has been estimated to be a 
65 Å long and 20 Å wide water-filled vestibule that narrows sharply at the membrane 
surface.  Additionally, the recent publication of the resolved crystal structure of a soluble 
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 peptide homologous to the extracellular binding portion of the nAChR has helped define 
the structure immensely (Brejc 2001).  The resolution studies of this highly-homologous, 
pentameric, soluble ACh-binding protein secreted from molluscan glia has been found to 
support the previously predicted overall structure, positioning, domain definition(s) and 
the location of the theorized ligand binding site of the native nAChR. 
 
Early Subtype Investigations 
 Following the initial identification of the neurotransmitter receptor (see section 
2.1), research focused on the nAChRs found in vertebrate muscle cells and ganglionic 
preparations as these were easily obtainable sources of experimental material.  The first 
hint of multiple, unique and distinguishable nAChR subtypes was realized when nAChRs 
from the muscle endplate (the traditional target) could be distinguished from nAChRs of 
the sympathetic ganglia by taking advantage of their functional selectivity for 
decamethonium and hexamethonium (both bis-alkylammonium compounds) respectively 
(Paton and Zaimis 1949).  This work provided the first evidence that nAChRs may fulfill 
multiple physiological roles in the body.  Investigational work using biochemical 
methods was carried out through the 1970s and took advantage of the muscle-like 
nAChRs found in the electric ray’s (Torpedo californica) electroplaque organ membranes 
(Karlin 1993, Galzi 1991, Sugiyama 1978, McNamee 1982).  Due to its high structural 
homology with and similar function to the mammalian nAChR type(s), membrane 
preparations from this organ provided researchers with an easily-obtainable source of 
nAChR experimental model material that was of the most interest to researchers.    
In order to generate a powerful defensive electric shock, the nAChRs of the 
Torpedo electro-plaque organ structures are so densely packed that they provide a ready-
to-use, highly-enriched source of membrane bound nAChRs (Conti-Tronconi 1994, 
Lindstrom 1996).  Use of the electroplaque membranes as source materials coupled with 
advances in receptor isolation and purification using natural bungarotoxins provided 
researchers with the necessary material for the resolution of four major muscle subunits 
that compose the muscle-type nAChR.  The muscle-type nAChRs were found to be 
heteropentamers composed of four subunits (α,β,γ, and δ), assembled in a stoichiometry 
of 2α,1β,1γ, and 1δ subunit in fetal tissue nAChRs.  When the innervations of the muscle 
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 occurs in the post-fetal period, the δ subunit is substituted with the highly homologous ε 
subunit while retaining the same (2,1,1,1) composition described above (Raftery 1980, 
Dolly 1984).  The amino acid sequences for muscle-type nicotinic receptor subunits was 
determined after solubilization of the receptor from the electric organ of Torpedo using 
anionic detergents like SDS and isolating these subunits using affinity chromatography.  
More specifically, isolation was carried out successfully by running a preparation of 
electroplaque membranes through columns presenting the alpha-toxins from snake 
venom, specifically α–bungarotoxin (α–Bgt) to capture the nAChR subunits.  nAChR 
ligands were then used to elute the subunits, and they were later purified to allow for 
more precise structural determinations to be carried out (Lindstrom 1980, Mathew 1981, 
Changeux 1990).   
Early work on the neuro-muscular junction and autonomic ganglia revealed 
significant pharmacological differences between the nAChRs expressed in these two 
locations.  One important study revealed that the Bungarus snake venom α-Bgt derived 
from the venom of the banded crait, is an irreversible blocker of neuromuscular nAChR 
function but has no effect on ganglionic nAChRs.  On the other hand, a similar molecule, 
κ-bungarotoxin (κ-Bgt) blocks ganglionic nAChRs irreversibly with no effect on the 
muscle-type.  Despite their similarities, α-Bgt and κ-Bgt present opposite binding 
selectivity for these two major nAChR subtypes and thus provided a powerful tool for 
nAChR subtype selective research (Ascher 1979, Conti-Tronconi 1994).  This result, in 
addition to results from the alkylmethonium experiments (above), offered strong support 
for the hypothesis that there existed multiple, distinct nAChR subtypes throughout the 
body that were involved in complex signaling events and physiological control.  Later 
research focused on the discovery and definition of nAChRs found in the CNS and 
described as neuronal nAChRs, which are the focus of the work in this thesis.  
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 2.3 Neuronal Nicotinic Receptor Distribution, Pharmacology and Subtypes 
 
Subunit Identification and Subtype Discovery  
Since its initial characterization, research efforts have focused on the nAChR 
using a variety of techniques, including: physiology, chemical labeling, biochemical 
techniques and electromicroscopy.  nAChR research efforts redoubled, however 
following the advent and application of molecular techniques, in particular the 
sequencing of the primary structure of nAChR subunits by Numa and Heinemann a little 
over twenty years ago (Numa 1983, Boulter 1986, Deneris 1989).  While the muscle type 
nAChR and its Torpedo receptor model system were still being investigated, little 
progress was being made identifying neuronal nAChRs.  Early work at characterizing 
these receptors had been hampered by the fact that while many of these tissues contained 
bungarotoxin binding sites, the binding of this toxin had little effect on function even 
though preliminary binding data suggested that nAChRs were present in the CNS.  This 
made it difficult to make experimental observations to identify potential receptor 
candidates.  However, that changed with the finding that mAb35, a monoclonal antibody 
raised against the Torpedo nAChR cross-reacted with neuronal-type receptors and also 
inhibited their function.  It is interesting to note that the isolation and purification of 
mammalian neuronal nAChR subunits was only made possible with the application of 
biochemical tools and reagents initially developed for studies of the skeletal muscle 
nAChR and derived from experiments using antibodies to the nAChR of a marine animal. 
This result first opened up research to the possibility of using muscle cDNAs to 
probe the central nervous system (Lindstrom and Sargent 1987, Whiting 1987).  Tritium-
labeled nicotine ([3H]NIC) was used for the first time in a radioligand experiment where 
it was found that [3H]NIC labeled binding sites in rat brain preparations that were not 
blocked by the application of α-Bgt (Lippiello and Fernandes 1987, Wonnacott 1986, 
Whiting 1986).  These results indicated that there existed more than one NIC binding site 
in the CNS.  This possibility was the impetus of research efforts looking into the 
existence of multiple neuronal subtypes (Clarke 1992).  Later, by probing cDNA libraries 
from PC-12 cells (under low stringency conditions) with the α-subunit of the 
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 neuromuscular junction nAChR, researchers were able to clone the first neuronal 
nAChRs (Clarke 1985, Boulter 1986, Wada 1988).    
Although subunit composition at the neuromuscular junction had been previously 
defined, little was understood concerning neuronal nAChR subunit composition until the 
application of molecular techniques.  Subsequent to the discovery of additional CNS 
nAChR subunits, molecular biological techniques were applied to identify, clone and 
characterize these multiple neuronal nAChR subunits.  To date 17 nAChR subunits have 
been identified and cloned (Green 1995).  In addition to the five nAChR subunits that 
encode the muscle-type (α1, β1, γ, δ, ε) as detailed earlier, twelve additional genes 
encoding the nAChRs in brain have been cloned from the mammalian genome and have 
been designated as neuronal types (α2-10, and β2-4).  The α-subfamily of neuronal 
subunits is comprised of nine distinct subunits α2-α10 while the non-α subfamily is 
composed of three neuronal β2-β4 subunits.  All the α-subunits are traditionally 
characterized by the presence of two vicinal cysteines (C192 and C193 of the α-subunit 
primary amino acid sequence) which are believed to play a critical role in the formation 
of the ACh binding domain of the functional receptor.  All non-α subunits are classified 
by their lack of this distinct Cys-Cys pair.  Although it is believed that the α-subunit is 
required for the formation of the ligand-binding site on the nAChR, the α-designation 
was not meant to indicate structural or functional importance. Interestingly, the 
designation of the original muscle-type subunits is merely the result of the standards of 
electrophoretic reporting, as the Greek letters reflect the rank order of the individual 
nAChR subunit’s denatured molecular weight as read from the electrophoresis separation 
gel (Popot and Changeux 1984).   
The overall sequence homology between the genes that comprise the neuronal 
nAChRs is 40-55% (Sargent 1993).  The homology is the highest (near 100%) throughout 
the membrane-spanning regions of the subunits (M1, M2 and M3 especially) as well as in 
certain regions of the N-terminal domains, however, as noted earlier, a great deal of 
sequence divergence is observed in the M3-M4 cytoplasmic loop segment.  The 
identification of the high homology shared among these gene products indicate that they 
share a common ancestory, which has been demonstrated by a method of phylogenetic 
reconstruction (Le Novere and Changeux 1995).  Despite the high sequence homology 
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 shared among subunits, structural dissimilarities and differential assemblies results in 
distinct biophysical properties between neuronal nAChR subtypes and muscle-type 
nAChRs.  Two characteristics that distinguish neuronal nAChRs from muscle-type 
nAChRs are their larger inward rectification currents and their higher permeability to 
Ca2+ versus Na+ and K+ which is common between muscle and neuronal types (Bertrand 
1990, Vernino 1992, Seguela 1993,).         
 
Subunit Assembly and Distribution 
Despite the large number of individual subunits that had been discovered, it was 
learned early on that only a certain few subunit combinations could be expressed and 
assembled into functional nAChRs.  Much of what is currently known about the 
functional composition of neuronal nAChR subunit expression has come from studies in 
heterologous expression systems.  Functional experiments in which neuronal nAChR 
subunit mRNAs or cDNAs were heterologously expressed in Xenopus oocytes, quickly 
revealed the limitations of nAChR subunit expression.  Injections of individual subunits 
alone (α2, α3, α4, β2 or β4) failed to express functionally-active receptors supporting the 
idea that neuronal nAChRs can only be formed from precise subunit combinations 
(Sargent 1993).  Initial experiments found that only α2, α3, or α4 subunits in a pair wise 
combination with β2 or β4 subunits resulted in a functionally-active receptor, whereas α5, 
α6 and β3 were unable to form functional receptors at all.  Originally these non-
functional subunits were considered “orphan receptor” subunits and believed to not be 
biologically relevant (Lindstrom 2000).  Later studies demonstrated that these subunits 
could, in fact form functional receptors when co-expressed with an appropriate α or β 
subunit (Deneris and Heinemann 1989, Leutje 1991, Gerzanich 1997, Wang 1996).  It 
was revealed that unlike the muscle-type nAChR, that involves the assembly of at least 
four structural subunits, the neuronal nAChR subtypes assemble from usually no more 
than two subunits, with the stoichiometry of the common heteromeric neuronal subtypes 
being composed of 2α subunits and 3β subunits in the pentamer while the homomeric 
subtypes require five subunits of a single α-subunit.  Thus the neuronal subtypes can be 
roughly classified into two major types, 1) hetero-oligomeric subunits (α2-α6 and β2-β4) 
that  
 18
  
 
 
Figure 2.3  Regional distribution of nicotinic receptor subtypes. (a) Regional distribution of major nicotinic receptor subtypes in the 
rodent CNS. The subtypes present in the cortex, cerebellum, hippocampus, interpeduncular nucleus, medial habenula and pineal gland 
have been identified by binding, immunoprecipitation and/or immunopurification assays in tissue from rat and/or wild-type and/or 
receptor subunit knockout mice. The subtypes present in the amygdala,  hypothalamus, locus coeruleus, olfactory bulb, raphe nuclei, 
spinal cord, substantia nigra–ventral tegmental area and thalamus have been deduced from in situ hybridization, single-cell PCR and 
binding studies of tissues obtained from rat and/or wild-type and/or knockout mice.  (b) Organization and structure of 
heteropentameric and homopentameric subtypes. The pentameric arrangement of nicotinic acetylcholine receptor subunits in the 
heteropentameric a4b2, a4a6b2b3, a6b2b3 and homopentameric a7 subtypes and localization of the subunit interfaces of the ACh-
binding site are shown. The homomeric a7 subtype has five identical ACh-binding sites per receptor molecule (one on each subunit 
interface). The heteropentameric a4b2 receptors have two identical binding sites per receptor molecule, located at the interface 
between an a4 and a b2 subunit. The heteropentameric a6a4b2b3 subtype has two different binding sites per receptor molecule, 
located at the interface between an a4 and a b2 subunit, and at the interface between an a6 and a b2 subunit. The heteropentameric 
a6b2b3 subtypes has two identical binding sites per receptor molecule, located at the interface between an a6 and a b2 subunit. In 
homopentameric receptors, the interface comprises opposite sides of the same subunit; in heteropentameric receptors, the interface is 
located between two adjacent subunits – one carrying the primary (P) component and the other carrying the complementary (C) 
component of the site.  
     Image reproduced with permission (Clementi/TIPS) 
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 form nAChRs in αβ combinations and 2) homo-oligomeric subunits (α7-α10) that are 
capable of forming nAChRs with five copies of a single subunit that are also inhibited by 
α-bungarotoxin (LeNovere 2002).  nAChRs are distributed widely throughout 
mammalian brain with the major subtype believed to be composed of α4β2* (Whiting 
1991).  Among the heteromeric nAChRs, the α4β2* subtype is believed to be the 
predominant neuronal nAChR in the mammalian CNS (Schoepfer 1991, Nordberg 1993).  
[For additional details of early subtype characterizations see review by Sargent 1993].  
 Binding studies using [3H]NIC and [3H]ACh indicate that nAChRs are widely 
distributed in mammalian brain tissue, including the interpeduncular nucleus, thalamic 
nuclei, superior colliculus, layers III and IV of the cortex, striatum, dorsal tegmental 
nuclei, cerebellum, hippocampus and hypothalamus (Clarke 1989, Sargent 1993).  Due to 
their location, nAChRs are believed to play important roles in a variety of process 
including memory, learning and higher cognitive processes, mood, reward and behavioral 
processes and a variety of homoestatic and neuroendocrine functions.  
 
Receptor Pharmacology 
As stated previously, nAChRs mediate numerous responses throughout the body.  
NIC is the common natural alkaloid found in tobacco and is commonly used as a 
recreational drug for activation of nAChRs.  Like ACh, NIC has been shown to positively 
modulate the opening of the receptor.  The binding of NIC creates conditions where 
conformational changes within the receptor are induced, leading to the opening of the 
central channel and thus, ion channel opening.  Upon binding of neurotransmitter the 
nAChR undergoes conformational changes, opening the channel and allowing ions to 
flow inward at a rate of ~107/sec (10,000 ions/mS) through each channel pore.  Three-
dimensional images indicate that agonist binding leads to a transient channel opening via 
a series of propagated rotations from extracellular regions downward toward membrane 
spanning regions of the nAChR (Sansom 1995, Mongan 1998, Adcock 2000, Law 2000). 
In muscle tissues, propagation of a nerve impulse along the motor nerve 
stimulates the pre-synaptic terminal to release ACh.  The ACh released into the synapse 
binds to and activates the opening of post-synaptic nAChRs on the muscle membrane.  
Synaptic transmission is quite rapid exhibiting a short delay of ~.7mS.  Upon a 
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 coordinated cation influx the cell becomes depolarized prompting opening of voltage-
gated sodium channels and thus propagating signaling and resulting in muscular 
contraction.    nAChRs at the NMJ are found in densities greater than 1000-fold higher 
than in any other synaptic region.  In this manner muscle-type nAChRs on the muscle 
endplate are found on the post-synaptic face of target tissues and are directly mediate the 
physiological response of ACh (reviewed in Wessler 1996).   
In the CNS neuronal signaling propagates much the same as in the PNS however, 
here nAChRs appear to exert a less direct and predominantly modulatory influence on 
synaptic signaling.  Although they have been found post-synaptically, neuronal nAChRs 
are found primarily pre-synaptically where they have been found to influence local 
depolarization with Na+ and Ca2+ influx, and contribute to long-term neuron and synaptic 
changes through persistent signaling of Ca2+-sensitive pathways (reviewed in Wonnacott 
and Jones 2006).  Pre-synaptic nAChRs influence the strength of terminal depolarization 
as well as the relative importance of signaling from nearby neuronal inputs.  Modulation 
of NT release by pre-synaptic nAChRs was first evidenced in sympathetic ganglion tissue 
(reviewed in Hogg 2003) and pharmacological evidence supports the role of functional 
pre-synaptic nAChRs in the modulation of DA release from nigrostriatal terminals (Hogg 
2003, Soliakov and Wonnacott 1996).  Pre-synaptic nAChRs have been studied 
extensively in functional experiments using dopaminergic nerve terminals in striatum and 
nucleus accumbens.  It has been suggested that in striatal terminals pre-synaptic nAChRs 
may be post-synaptic to cholinergic interneurons (Lehmann and Langer 1983).  In this 
manner ACh/NIC-containing nerve terminals are believed to exert their main influence 
through modulation of excitatory and inhibitory neurotransmission (reviewed in Lucas-
Meunier and Amar 2003, Mansvelder and Brussaard 2006). 
The binding site of activation of the nAChR has been fairly well-established and 
it is believed that the open channel state of the receptor is likely to be associated with the 
binding of two molecules of agonist than a single molecule (Changeux 1984).  Activators 
of nAChRs bind specifically to amino acids within the subunit interface in the 
extracellular region of the receptor and associate with loops A, B, and C of the α subunit 
and D, E, and F of the β subunit Sargent 1993, Paterson and Nordberg 2000).  Upon 
binding of agonist, conformational change occurs that results in the rotation and opening 
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 of the subunits around the central pore axis allowing free, gated flow of ions into the cell 
(mechanisms and structures reviewed in Arias and Bouzat 2006).  While some molecules 
interact in a slightly different mode within the agonist binding site, the binding site for 
most major nAChR agonists are believed to be located in the same location on the 
membrane and has been reasonably well confirmed by homologous binding and 
crystallography studies (Sixma and Smit 2003).   
Sites of binding for allosteric modulators and inhibitors like the non-competitive 
antagonists vary between drug classes and nAChR subtypes.  Some molecules like MEC 
are non-selective channel blockers that bind to the open channel and physically block the 
flow of ions.  Others act at a site more distant to the channel and affect its changes by 
inhibiting the large-scale conformational changes required for channel opening.        
There are numerous ways an inhibitor can bind and stabilize a closed or non-conducting 
conformation state.  This explains the broad diversity in the structure of molecules that 
are known to inhibit nAChR function relative to the limited molecular designs that can 
possibly affect a channel activation event, as the conformational changes that drive this 
action are more coordinated, precise, and of a higher order and so requires a more precise 
ligand-receptor interaction.  It is enough to mention here that inhibition of either ligand 
binding and/or functional activation of nAChRs involves a complex and numerous set of, 
as yet only partially understood, interactions and kinetics.  It is for these reasons that 
affinities, inhibitory efficacies and mechanisms vary greatly among the various classes of 
non-competitive inhibitors (mechanisms reviewed in Arias and Bouzat 2006).  
Additionally, a variety of allosteric inhibitory and modulatory sites have also been 
suggested as these mechanisms play an important role in normal, disease state and 
pharmacotherapy-influenced nAChR function (reviewed in Changeux and Edelstein 
1998). 
After activation nAChRs undergo a conformational change in which the nAChR 
becomes refractory or desensitized (reviewed in Quick and Lester 2002, Sun and Wang 
2004, Giniatullin and Yakel 2005).  The process of desensitization is an intrinsic 
characteristic of nAChRs whereby a decrease or loss of function occurs following 
prolonged or repeated activation.  In this state the channel is closed and the receptor is in 
a resting state.  At this point continued exposure to agonist no longer evokes ion influx 
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 and synaptic signaling returns to the pre-nAChR effected state.  Interestingly, following 
desensitization affinity for an agonist like NIC is actually increased even though the 
receptor no longer functions revealing that these two events (activation and high-
affinity/desensitized binding) are not coupled (Sharples and Wonnacott 2001).  
Concentrations of agonist needed to desensitize the receptor are much lower than the 
concentrations needed for activation further indicating that the two processes are 
independent (Rowell and Hillebrand 1994).  A variety of ligand-receptor gating models 
have been developed to describe this complex set of kinetics, however it will not be 
discussed here at any great length as it is beyond the scope of this work.  It is mentioned 
here only for general review purposes of binding and activation of the nAChR.  It should 
come as no surprise however that differences have been found in the response of various 
subtypes to desensitization.  It appears that these differences may alter relative signaling 
contribution as some nAChR subtypes seem to be less dramatically affected than others 
(Olale 1997).  Desensitization is considered an intrinsic quality of nAChRs as it has been 
demonstrated in native tissues, cell culture systems and in recombinant expression 
systems (Quick and Lester 2002).  Heterologously expressed nAChRs and even purified 
nAChRs reconstituted in artificial lipid bilayers can undergo desensitization supporting 
the idea that this functional quality is an intrinsic property of the nAChR (Ochoa 1989).  
Given the time course of desensitization and recovery events it is likely that 
phosphorylation of the intercellular loops of the receptor play a critical role in regulating 
desensitization (Vijayaraghavan 1990).  There is evidence suggesting that their high Ca2+ 
permeability induces desensitization either directly or indirectly via activation of protein 
kinases (Quick and Lester 2002).  Receptor desensitization is believed to be a mechanism 
for protection from excitotoxity however desensitization may itself function as an 
important signaling mechanism in the cell.  Desensitization processes are currently being 
investigated for their potential role(s) in numerous biological processes and disease states 
and disorders.   
Another unusual property of nAChR physiology is the fact that nAChRs tend to 
upregulate upon chronic exposure to a variety of ligands, including NIC (Flores and 
Kellar 1991, Marks and Collins 1993).  This runs counter to traditional pharmacological 
thinking where a functional response will undergo a negative feedback event or will 
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 down-regulate its own activity in response to chronic activation.  Upon activation, 
nAChRs transition into a desensitized state which would make the process of receptor 
upregulation in response to long term agonist exposure more understandable as a 
compensatory mechanism.  However as with most biological systems things are not this 
simple as it seems that desensitization may itself trigger and/or contribute to additional 
intracellular signaling events (Sabban 2002, Giniatullin 2005).  Upregulation has been 
observed in cell surface binding and in the total cellular pool, seemingly without altering 
nAChR message (Marks 1983, Benwell 1988, Whiteaker 1998).  This effect has been 
demonstrated in humans as an increase in post-mortem NIC binding in smokers (Benwell 
1988), in vivo using rat and mouse systems among others (Schwartz and Kellar 1985, 
Marks 1983), and in vitro using a variety of cell lines (Gopalakrishnan 1997, Peng 1994, 
Whiteaker 1997).  In all cases chronic exposure to activating nicotinic ligands leads to a 
concentration/dose-dependent increase in nAChR measures.  The effect of NIC-induced 
nAChR upregulation has been reported occurring in multiple subtypes as demonstrated 
by NIC-induced increases in [125I] α-Bgt binding (Barrantes 1995) and in ganglionic 
nAChRs (Wang 1998), however it has been noted that non-α4β2* subtypes require a 
much higher concentration of NIC to elicit a comparable response α4β2* upregulation.   
Human smokers are known to have elevated levels of brain NIC binding 
compared to non smokers (Benwell 1988).  Other agonists like cytisine, anabasine, and 
anatoxin have all been shown to result in upregulation (Schwartz and Kellar 1985, Bhat 
1991, Rowell and Wonnacott 1991).  These effects were noted to be both time and dose 
dependent and Scatchard analysis indicates that the process does not alter receptor 
binding kinetics but represents an increase in the number of receptors on the cell surface.  
This effect is not restricted to binding of agonists however as chronic infusion 
experiments with inhibitors like DHβE and d-tubocurarine result in increased nAChR 
density as measured by [3H]cytisine binding in rat brains (Hogue and Martyn 1992).  
Even chronic treatments with non-classical functional antagonists like mecamylamine 
that block open channel function have been shown to increase nAChR density (Pauly and 
Collins 1996).  These results suggest that upregulation is not unique to ligands that 
induce activation but rather is the result of a ligand binding function of the molecule to 
the receptor.  Investigations into the mechanism of nAChR upregulation have revealed 
 24
 that NIC-induced upregulation is not dependent on increases in mRNA encoding the 
subunits either in whole animals or in cell culture systems (Marks 1992, Peng 1994).  
Upregulation is even observed in recombinant oocytes systems (Fenster 1999).  Taken 
together, these results indicate a post-transcriptional peptide processing or cellular 
trafficking mechanism underlies the process.  While there are some differences among 
subtypes, all nAChR subtypes appear to upregulate in a similar manner.  Currently 
chronic NIC-induced nAChR upregulation is being investigated for a possibly role in 
many of the behavioral and possibly addictive effects of NIC use.    
 
Major neuronal nAChR subtypes 
The predominant nAChR subunits which assemble to form functional nAChRs in 
the CNS include the α4, β2, and α7 while the α3 and β4 subunits are more prevalent in 
the PNS.  The majority of all high-affinity NIC binding sites in CNS are believed to be 
composed of α4β2*.  [NOTE:  Native nAChR subtypes are usually represented as 
putative since they may contain additional subunits in as yet, unidentified configuration, 
hence all native subtype designations will be designated with the asterisk (*)].  The α7* 
subtype is the second most prominent subtype and presents a lower affinity binding site 
for NIC.  The major α3β4* “ganglionic” subtype is prominent throughout the PNS.   
While muscle type nAChRs are found post-synaptically, neuronal nAChRs are 
located preferentially presynaptically and pre-terminally (reviewed in Wonnacott 1997).  
Presynaptic nAChRs have been detected in several populations in cortex, nigrostriatal 
terminals, hippocampus and cerebellum.  Here they are believed to play a modulatory 
role in the excitability of their parent neuron by facilitating the release of NT, and more 
recent results suggest they may play a more subtle role in long term and metabolic 
cellular signaling (Reviewed Hogg 2003).  While neuronal nAChRs have been located 
post-synaptically and in unconventional combinations, their physiological role here is 
less clear.   
Neuronal nAChRs are known to mediate rapid depolarization and signal 
propogation via neurotransmitter (NT) into the synapse.  Two characteristics that 
distinguish neuronal nAChRs from muscle are large inward rectification currents and 
high calcium permeability.  The pCa2+ /pNa2+ for neuronal nAChRs range from 0.5-15, 
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 while the muscle type has a pCa2+ /pNa2+ of ~0.2 (Adams and Nutter 1992, Vernino 
1992).  In addition to their roles in rapid signaling and modulation of NT release, 
neuronal nAChRs also appear to play an important role in long term and sub-threshold 
signaling, leading to changes in metabolic kinase cascade signaling and ultimately gene 
expression changes (Dajas-Bailador and Wonnacott 2004).  It is believed that the large 
permeability of neuronal nAChRs to Ca2+, especially the α7 subtype, also plays a 
function in neuronal plasticity and development by influencing glutamate signaling and 
guiding neural growth (Sher 2004). 
Efforts to map nAChR brain distribution in an attempt to help understand their 
physiological function is made difficult by the fact that discreet brain regions often 
contain multiple subtypes in varying densities and in varying combinations (Court 2000).  
Often, this same mixed composition can be found on individual neurons where two or 
more nAChR subtypes may be found co-localized with possibly additional poorly defined 
subtypes.  On the other hand, expression levels (as measured by mRNA copy number) do 
not usually correspond well to cell surface nAChR populations indicating a complex 
regulation of expression, transport, assembly and activation.  It appears that these 
regional and inter-neuronal differences are responsible for the fine control exerted by 
nAChRs on a variety of NT signaling mechanisms throughout the CNS.  It is precisely 
the differences among the various neuronal subtypes that make identifying and 
characterizing individual subtypes so important, as each subtype population will 
contribute uniquely to the signaling events of the neuron and brain region where they are 
found.  By understanding these important differences and developing tools to exploit 
them we will be better able to treat diseases and disorders associated with major neuronal 
nAChR function/dysfunction.   
 
The α4β2* Neuronal nAChR Subtype 
The α4β2* subtype is ubiquitous throughout the brain.  Comparing binding results 
to data from immunoprecipitation studies of major subunits reveals that the α4β2* 
subtype accounts for >80% of high affinity [3H]NIC and [3H]ACh binding in the brain 
(Whiting 1987, Goldman 1987, Lippiello 1987, Wada 1988, Nakayama 1991, Flores 
1992).  The highest levels of α4β2* expression is typically found in the thalamus, cortex 
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 and the dorsal hippocampus, making these nAChRs important in memory, cognition and 
sensory gating.  A complete loss of high-affinity NIC binding is observed in studies using 
β2 knockout animals (Picciotto 1997), and a dramatic decrease is seen in α4 knockouts 
(Marubio 2000) confirming that the majority subunit is composed, at least in part, of α4 
and β2 subunits.  Interestingly, complete loss of the major CNS nAChR subtype, as 
observed in KO mice, does not lead to major dysfunction.  Bothe α4 and β2 knockouts 
have been reported to be viable and phenotypically normal with changes limited to 
altered antinociception and minor effects on behaviors including altered reinforcement 
and self-administration of NIC and conditioning among some others (reviewed in Drago 
2002).  It is believed that other subtypes like α4β4* are successfully employed to 
compensate for the lost α4β2* signaling.  As might be expected, however, β2/β4 double 
KO mice showed drastic phenotypic changes including severely impaired growth, 
autonomic abnormalities, and increased perinatal mortality.  The vast majority of α4β2* 
receptors exist in the usual 2(α)/3(β) subunit ratio, however alternative α4β2* subtypes of 
different stoichiometries may form with altered functionalities (Liu 1996, Nelson 2003, 
Moroni 2006).  Although by definition, all neuronal nAChR subtypes bind NIC, α4β2* 
the subtype has an affinity at least 100-fold higher affinity than any other subtype in its 
desensitized state (Ki=1-3nM) and can easily be distinguished in this manner.  
Additionally, the α4β2* has a high (and subtype selective) affinity for the nicotinic ligand 
cytisine (CYT), (Ki=1-3nM).  Thus, binding experiments using low concentrations of 
NIC and broad concentrations of CYT are believed to selectively probe for the α4β2* 
nAChR even in mixed nAChR preparations.  The α4β2* subtype also demonstrates the 
highest functional sensitivity of any nAChR to NIC at 1-5µM (Gotti 1997).  The α4β2* 
subtype is unique in that it alone binds ligands in the characteristic high-affinity state.  
While all nAChRs undergo some form of desensitization following activation by agonist 
application, binding of NIC by α4β2* in the high-affinity state causes the receptor to 
remain in the inactive or desensitized state for a prolonged period of time (reviewed by 
Quick 2002), and it is this receptor state that binds NIC in the classical high-affinity state.  
Both normal and impaired α4β2* function is currently implicated in numerous 
cholinergic deficiencies and health-related disorders such as Alzheimer’s disease and 
cognition disorders that will be discussed more in depth in the health section of the 
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 introduction.  Naturally there are numerous drug design projects targeting α4β2* for a 
variety of health-related applications. 
 
The α7* Neuronal nAChR Subtype 
Of the homomeric subtypes the α7* is the most abundant and is the second most 
prominent subtype in the brain.  It is found distributed in discrete brain regions and is 
most prominent in the cortex, hypothalamus, hippocampus, and in the geniculate nuclei 
(Whiteaker 2000).  Although it is widely believed that the α7* subtype is composed of 
five α7 subunits there is evidence that alternative stoichiometries employing the β2 
subunit are functionally active and may exist in native populations (Khiroug 2002), 
although this remains speculative.  Traditionally the α7* subtype has been characterized 
by α-Bgt binding and distribution mapped by [125I] α-Bgt autoradiograpgy (Clarke 1985, 
Green and Millar1995).  Unlike the α4β2* subtype, α7* is noted for its low affinity for 
NIC and in fact, was only identified initially by its affinity for the muscle-type ligand α-
Bgt.  Like the α4β2* subtype, α7* nAChR knockout animals appear to be healthy and 
viable despite their relative abundance in brain and their important role in NT signaling, 
Ca2+ regulation, and their potential role in neuronal development (Drago 2003).  Loss of 
α7* does not affect high-affinity NIC binding yet completely extinguishes α-Bgt binding 
(Orr-Urtreger 1997), reinforcing the fact that α-Bgt is a selective probe for α7* among 
CNS subtypes.  Functionally, they are characterized by the highest conductance for Ca2+ 
of all neuronal subtypes and an atypically rapid desensitization rate following stimulation 
by agonists (Zhao and Wu 2002).  As with all neuronal nAChRs, up-regulation of the α7* 
subtype occurs following chronic exposure to ligands (both agonists and antagonists) by 
mechanisms that remain unclear (Lukas 2002).  It is believed that due to its high 
functional conductance (Delbono 1996), the α7* nAChR plays a key role is modulating 
not only rapid signaling and NT release but slower Ca2+-dependent intracellular signaling 
(Morley 2000), neuronal plasticity, (Corringer 2006) and cell motility (Fucile 2004).  
Becase of its discrete distribution, unique pharmacology and role in numerous diseae 
states and dysfunctions the α7* nAChR is presently a therapeutic target for myriad 
conditions like schizophrenia, cognition and memory, and Alzheimer’s disease among 
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 others (see health and disease section below).  Currently numerous α7*-selective nAChR 
ligands are being evaluated for application in these and other physiological disorders. 
 
The Dopamine-Releasing (α3/α6-containing) Neuronal nAChR Subtype 
While all neuronal nAChRs are involved in the modulation of NT release, the 
third major subtype in the brain to be described here is believed to be intimately involved 
in catecholamine release, and more specifically the NT dopamine (DA).  These 
dopaminergic brain regions include areas receiving inputs from the substantia nigra and 
the vental tegmental area (VTA), and include the striatum and nucleus accumbens among 
other regions (reviewed in Mansvelder 2003).  The DA-releasing subtype (as it will be 
referred to) was characterized initially by matching nAChR mRNA expression patterns in 
nigrostriatal regions of the brain with subunit combinations that were known to be 
functionally active in recombinant systems (Azam 2002).  Based on regional mRNA 
expression, antagonist sensitivity, and binding studies using neuronal bungarotoxin and 
α-conotoxin MII (a selective DA-releasing nAChR subtype ligand) the nAChR initially 
believed to be involved in DA release was characterized as an α3/ β2*-containing subtype 
(Schulz 1989, Luetje 1990, Harvey 1997).  It was discovered that elimination of the α3 
subunit does not eliminate all α-conotoxin MII binding (Whiteaker 2002) suggesting 
additional subtype input.  The α6 and β3 subtypes, to this point believed to be orphan 
subtypes that failed to form functionally active nAChRs in vivo, were found to co-
localize with the β2 in catacholinergic regions and were later found to form functional 
subtypes sensitive to α-conotoxin MII binding (Kuryatov 2000).  Subsequent studies 
found that MPTP-induced striatal damage corresponded to α3 and α6 binding suggesting 
that these nAChR subtypes are present concurrently on individual dopaminergic 
terminals (McCallum).  Currently the DA-releasing subtype is believed to be composed 
of some combination of α4, α6, α3, β2, and β3 (Zoli 2002) with α6 being a necessary 
component (Champtiaux 2002), and has been suggested to be a α6β3β2* and α4α6β3β2* 
(Salminen 2004), α6α5β4β3* (Grinevich 2004) and it has even been suggested that the 
all-important asterisk(*) is no longer needed for this subtype, and that the DA-releasing 
subtype is one of four potential combinations similar to the above, (Luetje 2004) even 
though subsequent publications on the issue still include the glyph.  It is clear that more 
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 work needs to be done to better define the DA-releasing nAChR.  The dopaminergic-
mesolimbic system is known to be intimately involved with processes involved in 
reward, addiction and the reinforcing effect of substances of abuse (Spanagel 1999, 
Gerdeman 2003, Mansvelder 2003).   Due to its unique distribution and strategic 
functional role in dopamine signal modulation, pharmacotherapeutics that target the DA-
releasing nAChRs will become invaluable for both continued research efforts and the 
intervention in addiction disorders, OCDs, and behavioral disorders in addition to the 
implications associated with Parkinson’s disease (discussed later). 
 
The α3β4* (ganglionic) nAChR Subtype 
The neuronal nAChRs are found distributed throughout the CNS while the 
predominant non-neuronal nAChR (excluding muscle) is the α3-containing nAChR found 
on autonomic ganglionic neurons (Heinemann 1991, Sargent 1993).  In vitro and in vivo 
studies using subtype specific nAChR inhibitors demonstrate that ganglionic transmission 
in cardiac parasympathetic neurons is mediated by α3β4* and α3β2* subtypes with no 
significant contribution from neuronal subtypes like α7* (Bibevski 2000).  nAChRs 
composed of α3 and β4 have also been shown to be involved in ganglionic transmission 
in the bladder (De Biasi 2000) and in other ganglionic regulatory regions implicating this 
unique subtype combination.  40% of α3 null KO animals die within the first few days 
and all display severe growth and developmental impairments as would be expected if 
normal ganglionic signaling was disrupted.  Test animals had bladder dysfunction and 
unresponsive dilated pupils, both functions usually coordinated via normal autonomic 
control (Xu 1999).  Both β4 and β2 animals displayed less severe phenotypic responses 
however the β2/β4 double KO displayed similar defects as observed in the α3 KO 
indicating that the β subunit is somewhat promiscuous allowing β2 to compensate for β4, 
but the non-dopaminergic α3 subunit appears to be crucial to normal nAChR-mediated 
ganglionic signaling (Xu 1999, Wang 2003).  Functional α3β4* nAChRs have been 
located in distinct brain regions such as the pineal gland and the interpenduncular 
nucleus, (Grady 2001, Yeh 2001, Salas 2003) but it is most abundant in the peripheral 
tissues such as the adrenal gland, and ganglia such as the superior cervical ganglia and 
the trigeminal ganglia and retinal pathways (Flores 1997, Davila-Garcia 2003) and is 
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 speculated to be localized in many additional brain regions (Perry 2002).  The α3β4* 
subtype can be identified by binding the relatively non-selective nAChR ligand [3H]Ebt, 
provided that the high-affinity α4β2* sites are first protected with a more selective ligand 
like cytisine.  Many of the peripheral effects of NIC are due to increases in circulating 
catacholamines from adrenal gland tissues and vascular nerve endings.  Common α3β4* 
nAChR-mediated peripheral effects include vasoconstriction in skin, vasodilation in 
smooth muscle, increases in metabolic rate, headache, nervousness, dry mouth and a 
variety of endocrine effects (reviewed in RCP: Nicotine Addiction in Britain).  α3β4* 
nAChRs are known to have robust responses to NIC stimulation compared to major 
neuronal subtypes which could contribute to their powerful peripheral influence (Luetje 
and Patrick 1991).  Currently, ganglionic nAChRs are the target for a variety of 
autoimmune-induced autonomic neuropathies (Vernino 2000).  However, in terms of 
developing pharmacotherapeutics aimed at neuronal nAChRs subtypes, the goal is to 
develop drugs with little or no ganglionic activity to limit or avoid altogether unpleasant 
and potentially dangerous autonomic side effects. 
Although there are potentially hundreds of possible subtype combinations that 
may be formed, thankfully only a manageable handful of nAChRs have been discovered 
that are experimentally and biologically relevant.  Having stated that, it remains a 
tremendously complicated situation.  Current research is focused on defining the role 
individual subtypes play in signaling, defining how subtype populations interact with and 
influence each other, understanding the influence of nAChR activity in various nAChR 
health disorders and disease states, and learning how to apply this knowledge to generate 
pharmacological tools and research tools to intervene and treat neuronal nAChR-related 
disorders.       
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Figure 2.4  Cartoon representation of major nAChR subtypes.  CNS and PNS subtypes all have the characteristic 
pentameric assembly and share two alpha subunits among the heteromeric nAChRs and five alpha subunits for the 
homomeric subunits. 
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 2.4 Neuronal nAChRs:  Implications and Interest in Health and Disease 
 
a. Smoking, Tobacco Use, and Addiction 
 
The connection between NIC use and human health and disease is a complicated 
one.  On one hand NIC drug use, mainly through smoking of cigarettes and cigars, has 
been shown to contribute to, and exacerbate a variety of disease states including 
emphysema, COPD, cardiovascular diseases, and myriad cancers.  Smoking-related 
illnesses place a tremendous burden on the medical and healthcare systems of the world.  
On the other hand nicotinic drugs may turn out to be one of the most important and 
versatile class of pharmacotherapeutics ever developed, as nicotinic drugs are currently 
being investigated for the potential treatment of Alzheimer’s disease, Parkinson’s disease, 
epileptic conditions, schizophrenia, pain management issues and a number of 
phychological and mental disorders.      
 
Smoking and Tobacco Use 
 Tobacco use is the most preventable cause of death, disability and disease in the 
United States (Morb. Mort. Wkl. Rep. 2002).  National estimates of smoking rates 
regularly reveal 20-25% of adult males smoke in western, industrialized countries and 
can reach as high as 65% among the same population in some developing and third-world 
countries, like S. Korea for instance.  Worldwide, regular smoking rates among adult 
populations routinely reaches the 30% level, and although rates among women are almost 
always lower than men, they usually aren’t very far behind their male counterparts (WHO 
website, worldwide smoking estimates 2006).  As recently as 2002 an estimated 46 
million adults in the U.S. were regular cigarette smokers with an estimated 38 million 
smoking daily (Morb. Mort. Wkl. Rep. 2002).  Cigarette smoking accounts for nearly 
450,000 deaths annually in the U.S. or 18.1% of all deaths nationwide.  About 155,000 
(35%) of these deaths are cancer-related while about 250,000 (56%) are cardiovascular-
related deaths (Morb. Mort. Wkl. Rep. 2002, Mokdad 2000).  In addition, cigar smokers 
can carry a cancer risk comparable to cigarette smokers under the right conditions and 
smokeless tobacco use carries a high risk for head, neck, and mouth cancers in addition to 
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 common problems like oral and dental diseases (Hatsukami 1999).  Furthermore, an 
additional 40,000 nonsmokers are believed to die every year in the US as a result of 
chronic exposure to second-hand smoke (Morb. Mort. Wkl. Rep. 2002).  Smoking and 
tobacco use-related health problems present one of the most significant and important 
challenges to health scientists attempting to invent new pharmacotherapeutic 
interventions.   
 The addictive liability of tobacco use is well known and generally accepted at this 
time.  The majority of regular smokers would like to stop and many try, but NIC 
addiction is powerful and every year only 3-5% of regular smokers successfully manage 
to quit (USDHSS Report 2000).  The effects of NIC (through smoking and smokeless 
tobacco use) associated with dependence include the increased expression of nAChRs in 
the brain, changes in brain glucose usage patterns and locations, brain-wave and synaptic 
signaling changes, the release of major brain neurotransmitters like dopamine, 
epinephrine and other catacholamines, tolerance, and physiological dependence 
(USDHHS report 1988).  There is also an associated increase in positive reinforcement, 
or compulsion to smoke, with chronic use and administration of NIC (Heatherton 1991).  
NIC addiction is widely recognized as one of the most difficult addictive challenges 
facing society and would not be nearly as important an issue if tobacco use was not so 
strongly associated with its well-known and disastrous health consequences.   
 The most widely-used effective pharmacotherapy for aiding smoking cessation is 
the therapeutic administration of NIC as a replacement therapy (NRT) (Hennigfield et. al. 
2005).  This strategy makes it easier to abstain from smoking by partially replacing the 
NIC previously obtained through tobacco use.  It also delivers NIC as the smoker would 
normally self-administer, while disassociating the NIC delivery with the physical, tactile, 
and psychological habits and behaviors normally associated with cigarette smoking 
(Henningfield 1995).  Unfortunately, NRT clinical results are less exciting that early 
results indicated.  NRT-aided, post-cessation success rates at six months range from 7% 
improvement versus placebo for nicotine gum to 4%-7% improvements over placebo for 
transdermal patch delivery.  After 12 months the success rates drop even further with 0-
2% improvement with the gum and a 1%-4% improvement with the patch (Silagy 2004, 
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 Fiore 2000).  Despite these unimpressive results, NRT is the most successful drug 
therapy available to assist patients in smoking cessation efforts.   
Along with NRT, buproprion, a drug initially used to treat depression, is the only 
other pharmacotherapy FDA-approved to aid in smoking cessation.  Sustained release 
buproprion has been shown to produce significantly higher abstinence rates compared 
with placebo and results appeared to be on-par with NRT.  Six month abstinence rates 
showed improvements of 10-12% over placebo, however, extending the studies to twelve 
months and longer, a steep drop off, as seen with NRT, is also observed for buproprion 
therapy (Dalsgareth 2004, Hurt 1997, Tonnesen 2003).  As seen with NRT, several 
combinations of therapies initially showed promise, (NRT, Buproprion, counseling and 
behavior modification therapy) however successful continued abstinence of smoking is 
likely in only 15-20% of smokers in any of the above combinations.  Finally, a few drugs 
have been used in “off-label” applications for smoking cessation, such as the opiate 
antagonist Naltrexone, and the serotonin-selective reuptake inhibitor antidepressant 
Fluoxetine and have shown some promise but with very mixed results (Wewers 1998, 
Sutherland 1995, Covey 1999, Ahmadi 2003).  Despite these modest results, nicotinic 
drug design and discovery efforts hope to improve on these medicines’ effectiveness in 
aiding smoking cessation efforts.   
Recently, Varenicline has been approved as a smoking cessation aid and is 
marketed in the US under the brand Chantix (Stack 2007).  This compound is a known 
α4β2 selective partial agonist (Lam 2007).  It is speculated that the mechanism of action 
involves inhibition of burst firing-associated DA release while preserving tonic DA 
release which is believed to allow normal DA functioning while inhibiting the large 
releases that are associated with reward, reinforcement, and error signaling in the reward 
centers of the brain (Exley ).  It appears to be the most promising breakthrough in 
smoking cessation drug therapy in years and while the jury is still out on the long-term 
advantages of this drug early results look promising with sustained abstinence rates 
exceeding those of Bupropion and NRT in some measures.   
Due to the multiple, and often times overlapping effects of NIC, and its 
interactions at multiple nAChR subtypes, the complexity of NIC dependence makes it a 
difficult condition to treat with a single drug therapy.  With relevant differences among 
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 patients, including; biochemical, psychological, pharmacogenetic, and behavioral playing 
an increasingly well-understood role in the liability of NIC addiction, it is no surprise that 
a single drug therapy or a simple combination of two therapies is effective in a large 
percentage of patients (Berrettini 2005).  Recent work has identified a new class of 
nicotinic compounds that may hold promise in terms of development as a smoking 
cessation therapy.  A series of novel mono and bis-azaaromatic nicotine analogs have 
demonstrated efficacy and selectivity for the inhibition of NIC-induced DA release in 
vitro (Dwoskin 2003).  These, and like compounds may prove to be valuable selective 
tools and/or therapeutic agents that target the rewarding and addictive effects associated 
with NIC abuse through smoking.  Additional novel nicotinic drugs are needed that can 
interact more specifically with individual components associated with the underlying 
biochemical and cellular mechanisms associated with NIC dependence.  It is precisely for 
this reason that safe, efficacious and highly selective novel nicotinic drug molecules must 
be discovered and developed for clinical use.  It is currently an exciting and promising 
area of investigation, and it is believed that with the development of novel subtype-
selective NIC agents, clinical success in combination therapies for those trying to abstain 
from smoking all together will likely follow.   
 
  
b.  Myasthenia Gravis and Neuronal Dysfunctions: AD, PD, and Epilepsy 
 
Myasthenia Gravis 
Myasthenia gravis (MG) results from an autoimmune response to the muscle-type 
nAChR.  Myasthenia patients suffering from this condition are known to produce 
antibodies that bind to the extracellular portion of the skeletal muscle nAChR (Lindstrom 
1998).  MG is a chronic disorder characterized by weakness and rapid fatigue of any of 
the muscles under voluntary control and is caused by a breakdown in normal 
neuromuscular signaling (MayoClinic.com resource 2006).  MG presents in a variety of 
forms and it is believed that a mixture of various congenital mutations and environmental 
triggers are responsible for different types of myasthenic syndromes.  Several known 
mutations are believed to impair neuromuscular transmission at the pre-synaptic, 
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 synaptic, and post-synaptic levels (Celesia 2001).  Various symptoms of MG are known 
to be associated with altered ACh packaging and release, endplate acetylcholinesterase 
(AChE) activity and kinetic abnormalities associated with the channel opening and 
closing (Donger 1998, Milone 1998, Gomez 2002).  Current MG therapies employ the 
use of pyridostigmine and edrophonium, both AChE inhibitors, to prolong the action of 
ACh in the synapse and thus strengthen voluntary muscular signaling (Hughes 2004).  
This therapy is less than optimal due to the non-selective nature of systemically 
administered AChE inhibitors and the associated patient compliance issues.  Since the 
MG immune response in known to specifically incapacitate a large percentage of the 
nAChRs at the neuromuscular junction it follows that nicotinic receptor drugs that could 
selectively activate or potentiate muscle-type nAChRs would be a more attractive therapy 
by increasing cholinergic signaling and providing subsequent therapeutic compensation 
of voluntary muscular control.  Being essentially a condition of muscle-type nAChR 
dysfunction, nicotinic drugs have been the subject of intense investigation for years as a 
means to alleviate symptoms and successfully treat this terrible malady.           
 
Epilepsy 
Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) is a genetic 
condition of partial epilepsy characterized by the presentation of brief-duration seizures 
occurring during periods of light sleep that can often be misdiagnosed and nightmares 
(Scheffer 1995, Lindstrom 1997, Paterson and Nordberg 2000).  ADNFLE was the first 
disorder to be conclusively associated with nAChR dysfunction in the brain, and it is 
believed that mutations of the M2 domain in the genes that express either α4 or β2 
subunits are responsible for this disorder, and implicates the major α4β2* subtype 
(DeFusco 2000, Raggenbass 2002, Fonck 2005).  Currently five single nucleotide 
polymorphisms of nAChR subunits have been identified that lead to ADNFLE.  
Impairment of nAChR function has been demonstrated when mutant varieties expressed 
in Xenopus oocyte systems (Weiland 1996, Steinlein 1997, Bertrand 1998, Picard 1999).  
The mutant types responsible for ADNFLE appear to exhibit and enhanced sensitivity to 
and slower recovery from desensitization, lower overall conductance, short channel open 
times, and a reduction in calcium permeability (Ortells 2002).   
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 Although seemingly paradoxical how a reduction in measured nAChR activity 
could lead to excessive neuronal activation that distinguishes the disease, a possible 
explanation is that affected nAChRs belong to and participate in a signaling circuit that 
also regulates the release of the inhibitory neurotransmitter GABA, thus leading to a state 
of hyper excitability that triggers ADNFLE episodes (Celesia 2001, Paterson 2000).  
Reports in the literature indicate that therapeutic dosing of NIC to ADNFLE patients is 
significantly associated with freedom from seizure frequency and intensity.  A great deal 
of promising work is currently underway in developing novel nicotinic agents that can be 
used to selectively treat these forms of epilepsy (Willoughby 2003, Brodtkorb 2006).   
 
Alzheimer’s Disease 
Alzheimer’s disease (AD) is a progressive, debilitating, neurodegenerative disease 
that affects nearly 10% of people over the age of 65.  AD is characterized by a loss of 
short-term memory and higher cognitive functions, anxiety, depression, and in the worst 
cases severe dementia.  Postmortem analysis of brains from AD patients reveals 
characteristic intracellular neurofibrillary tangles and extracellular neuritic, β-amyloid-
containing senile plaques associated with massive cerebral and striatal cell loss, severe 
cortical shrinkage, and decreases in nAChR density in addition to associated losses in 
other neurotransmitter receptor systems (Nordberg 1986, Sihver 1999).  AD is 
distinguished by extensive loss of cholinergic innervation to the cortex and hippocampus, 
and the activity of choline acetyltransferase (ChAT) is significantly reduced in AD 
patients (Coyle 1983) thus lowering cholinergic signaling even further by inhibiting ACh 
production in surviving cholinergic neurons.  Such data led researchers to the cholinergic 
hypothesis of AD pathology which claims that the symptoms of the disease are 
essentially the result of the loss of important cholinergic signaling pathways from the 
basal forebrain to the cortex and hippocampus (Bartus 1982) as supported by the specific 
loss of neurons expressing nAChRs (Warpman 1995, Whitehouse 1986).   
Early interest in the link between AD and NIC as a potential therapy resulted from 
epidemiological studies showing that smokers had a lower risk for the disease (Brenner 
1993, Wang 1997).  Postmortem analysis again revealed that the significant nAChR loss 
associated with AD is somewhat attenuated in the brains of former smokers (Hellstrom-
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 Lindahl 2004) thereby supporting epidemiological results and strengthening the 
cholinergic hypothesis.  Furthermore, postmortem analysis reveals a similar improvement 
in senile plaque formation among patient-matched former smokers (Hellstrom-Lindahl 
2004).  These plaques, which distinguish AD, are composed mainly of small β-amyloid 
peptides (Aβ).  AD patients show a decreased number of high-affinity NIC binding sites 
in various brain regions, while α-Bgt binding sites appear to remain largely intact across 
brain regions, suggesting that α7* nAChR-containing neurons are not intimately involved 
in the pathology of AD, but is associated more closely with the major α4β2* subtype 
(Nordberg 1995, Rusted 2000, Sugaya 1990).  However, in other studies strong 
correlations have been found between the expression of the α7* nAChR and the 
accumulation of Aβ (1-42).  Additionally, AD patients with Lewy body dementia (LBD) 
showed a reduction in α7* binding in frontal cortex versus age-matched controls, 
suggesting that α7* nAChRs may be prove to be promising targets for AD therapies, 
especially in cases with a pronounced LBD-associated component (Reid 2000).   
There exists an interesting two-way relationship between nAChRs and AD-
associated amyloid plaques.  It was recently found that β-amyloid peptides downregulate 
the expression of nAChRs which may significantly contribute to the mental deterioration 
of AD patients (Guan 2001).  It has also been shown that β-amyloid peptides (peptide β1-
42 specifically) bind to α7* nAChRs with picomolar affinity and that β-amyloid peptides 
inhibit whole-cell and single-channel nicotinic currents from rat hippocampal 
interneurons by directly blocking postsynaptic nAChR channels at nanomolar 
concentrations (Wang 2000, Pettit 2001, Liu 2001).  There is also evidence to suggest 
that activation of both α7* and α4β2* nAChRs can reduce β-amyloid toxicity (Kihara 
1998).  NIC itself has been shown to attenuate Aβ-induced deficits in delayed alternation, 
passive avoidance, and Morris maze learning (Maurice 1996).  As suggested above, it has 
been speculated that there is a dynamic interaction between nAChR activation and Aβ-
pathology since cholinergic signaling may influence β-amyloid peptide metabolism 
(Efthimiopoulos 1996).  While much work has yet to be done in defining the role of 
neuronal nAChRs in the many cognitive dysfunctions associated with AD, these findings 
and others like them imply nAChRs are important as potential targets for AD 
pharmacotherapy.   
 39
 In terms of current pharmacotherapeutics, the most widely-used, FDA-approved 
therapy for AD is cholinesterase inhibitors.  These medicines act by inhibiting the 
breakdown of ACh in the synapse thereby lengthening the duration and improving the 
intensity of ACh signaling thereby improving higher cognitive brain function (Wilkinson 
2004).  In addition to their anti-cholinesterase activity, it is currently believed that some 
of these drugs, such as tacrine and galantamine interact with the nAChR directly, and 
may modify nAChR activity by acting as allosteric, potentiating ligands (Maelicke 2001, 
Samochocki 2000, Wilkinson 2004).  So far, these therapies have provided the AD 
sufferers with only modest cognitive improvements.  Also, many of the side-effects 
associated with cholinesterase inhibitors (diarrhea, nausea, bradycardia) are related to 
their lack of selectivity for AD-associated neuronal nAChRs and their effect at muscle 
and ganglionic-type nAChRs in the periphery (Wilkinson 2004).  An alternative to AChE 
inhibitors is dosing with direct nAChR agonists especially considering the cognitive 
enhancing effects of NIC.  GTS-21 a selective α7* partial agonist is currently under 
investigation for the treatment of AD-associated memory loss (Arendash 1995).  Other 
efforts have focused on the development of allosterically potentiating compounds to 
enhance nAChR-mediated NT release (Maelicke 2000).  Drug discovery research efforts 
continue in the hopes of improving the safety, efficacy and selectivity of nicotinic 
compounds for use in the treatment of AD.  As in the case of MG, in AD there is a need 
for selective nAChR ligands that can be applied to selectively modulate AD-associated 
nicotinic-cholinergic subtype signaling.  While research is currently being conducted 
with precisely that focus, much is still to be learned in order to successfully exploit the 
nAChR-AD connection.  Currently there is tremendous scope for the creation of nAChR 
subtype-selective agonists and antagonists as new research tools and as potential 
therapeutic agents for AD treatment.            
 
 Parkinson’s Disease 
 Parkinson’s Disease (PD) is a progressive neurodegenerative disorder 
characterized by motor dysfunction that includes symptoms such as muscular rigidity, 
tremors and difficulty with speech, walking gate, and sustaining voluntary movements.  It 
typically has an onset later in life with most symptoms typically presenting after age 55.  
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 Having lost many of the tonic inhibitory inputs affecting voluntary muscles, PD patients 
suffer from an inability to control hyper-motor function (Lloyd 1975, Olanow 2004, 
Levin 2005, Hogg 2003).  These motor control problems occur due to massive losses in 
dopaminergic signaling in the striatum (Braak 1996).  These deficits are the result of a 
loss of stimulatory signaling originating from the substantia nigra pars compacta 
(German 1989).  L-dihydroxyphenylamine (L-DOPA), a dopamine (DA) prodrug, has 
been used as a form of DA therapy whereby following treatment L-DOPA is converted to 
DA in the brain and motor control-associated dopaminergic signaling is partially restored 
by the artificially higher levels of DA (Lindstrom 1997).  Treatment in this way 
successfully attenuates the symptoms and tends to retard degenerative effects for 3-5 
years before tolerance and peripheral side effects prevent its further use. Another therapy 
focuses on the inhibition of MAO-B, an enzyme that breaks down endogenous DA in the 
brain.  This therapy is also problematic because as with L-DOPA therapy there is an 
attenuation of results over time and MAO-B inhibitors are notorious for their 
incompatibility with numerous other drugs making multiple therapies, common in the 
elderly, difficult to manage.     
Multiple epidemiological studies suggest that chronic NIC administration, via 
smoking, provides significant protection against the onset of PD and there exists an 
inverse relationship between the number of cigarettes smoked and the onset of PD (Allam 
2004, Gorell 1999, Fratiglioni and Wang 2000).  This appears to hold true even when 
comparing subjects within populations of smoking and non-smoking twins (Baron 1986, 
Morens 1995).  Additionally, postmortem analysis of brains from PD patients reveals a 
significant loss of nAChR total number and density when compared to age-matched and 
tobacco-matched controls (Court 2000).  In addition to its prophylactic effects, NIC 
administration to PD patients appears to be successful in alleviating a number of PD 
symptoms (Ishikawa and Miyatake 1993, Kelton 2000) and may be due to an increase in 
NIC-mediated synaptic DA signaling in the substantia nigra and mesolimbic systems 
(Lichtensteiger 1982, Kita 1992).  Although the exact mechanism(s) remain undefined, 
NIC’s neuroprotective effects may be the result of chronic stimulation of DA-systems, 
upregulation of PD-related nAChRs, or some unforeseen physiochemical effect of NIC in 
the affected brain regions.            
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  PD patients have significantly reduced high-affinity NIC binding in the substantia 
nigra pars compacta and dorsolateral tegmentum (Perry 1995) mapping the loss of 
α4β2*-containing neurons in this region of the brain.  Furthermore, a decrease in the 
number of α3/α6 nAChRs in brain has been reported following niagrostriatal damage 
(McCallum 2005).  Studies suggest that targeting heterologously expressed nAChRs 
(α4β2* and α6-containing nAChRs specifically) may lead to important treatments for PD 
symptoms.  α6-containing nAChRs have been implicated in modulating DA release from 
the striatum and have been suggested as a therapeutic target for PD therapy.  Selective 
modulation of these nAChR subtypes may result in relief from PD symptoms without the 
negative side effects associated with L-DOPA therapy (O’Neill 2002).  The nicotinic 
analog SIB-1508Y has shown promise in improving cognition in PD model monkeys and 
has already entered phase 3 trials as a potential treatment for PD and may held promise 
due to its apparent low toxicity and potency for nAChRs (Schneider 1999, Arneric and 
Brioni 1999). 
 
 
c.  Psychiatric Disorders: Tourette’s, Schizophrenia, and Anxiety 
 
 Schizophrenia 
Schizophrenia is a psychiatric mental disorder characterized by chronically 
deteriorating psychosis with initial onset in late adolescence or early adulthood (reviewed 
by Leonard 1996).  Symptoms of this disease include delusions, hallucinations, blunt 
afferent, altered self-awareness and perception, coupled with intermittent chaotic thinking 
and speech (Arnold and Trojanowski 1996).  Many schizophrenics are incapable of 
normal social interactions which makes them even more difficult to treat.  Schizophrenia 
is complicated further because of intervening physiological, biological, and sociological 
factors that combine to contribute to the pathology of this behavioral disease.  Around 
1% of the population is affected worldwide, with an additional 1%-2% suffering from 
schizotypal personality disorders which is a milder form of the disease.  Most 
Schizophrenics suffer from sensory imbalances making it difficult for them to regulate or 
properly process auditory and visual stimuli.  Dopaminergic hyperactivity has long been 
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 believed to play a key role in schizophrenia.  While much effort has been applied to 
discovering the underlying molecular mechanisms of the disease many of the 
pathological mechanisms remain unclear. 
 There is plenty of evidence to suggest that schizophrenia symptoms can be treated 
through nicotinic pharmacotherapy.  The incidence of cigarette smoking in 
schizophrenics is around 90% and has been well-established (Lohr and Flynn 1992, 
Dalack 1998).  It is postulated that the high incidence of smoking is a form of self 
medication of NIC to overcome deficits in nAChR signaling (Goff 1992, Sacco 2005).  
NIC normalizes the gating deficit as measured in the P50 auditory-evokes response test 
(Adler 1993, Bencherif 2002) and has been linked to the α7* nAChR (Freedman 1997).  
Decreased levels of the α7* nAChR subunit in the hippocampus, neocortex and striatum 
of schizophrenic patients has been reported (Court 2000, Leonard 2000) while α7* 
antagonists have been shown to impair auditory gating in rodent schizophrenia models 
(Luntz-Leybman 1992).  Aberrant expression and regulation have been found in 
postmortem brain of schizophrenics, and higher levels of serum anti-nAChR antibodies 
have been found in schizophrenic patients possibly contributing to nAChR-mediated 
dysfunction (Mukherjee 1994).  Clozapine, the most effective drug used to treat refractive 
schizophrenia has been shown to improve the auditory gating in mice and this effect is 
blocked by α-Bgt, indicating a nicotinic receptor-mediated mechanism (Kane 1988).  
Currently several drugs are in various stages of development and testing to treat 
schizophrenia symptoms, including the αβ4* agonist ABT-418, the α7*-selective agonist 
DMXBA, and the ACh analog AR-R 17779 (reviewed by Reuter 2004).  Given the 
experimentally implied role of nAChRs, the tight association between smoking and the 
pathology of schizophrenia, and the success of nAChR drug development and testing in 
clinical settings, nicotinic drugs appear to be a promising lead in the development of 
novel schizophrenic therapies.                
  
 Tourette’s syndrome 
Gilles de la Tourette’s syndrome (Tourette’s disorder, TD) is a hyperkinetic 
psychiatric disorder of unknown etiology characterized by uncontrollable motor and 
verbal tics, aggression, hyperactivity and obsessive-compulsive disorders and generalized 
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 anxiety.  TD affects between 0.1%-0.15% of school age children and usually appears 
before the age of 18 (Kadesjo and Gillberg 2000).  Although not well-defined, TD has 
been associated with impaired signaling in the basal ganglia.  TD is usually treated with 
haloperidol but side effects limit usefulness (Paterson and Nordberg 2000).  NIC 
administration has been shown to reduce symptoms in animal models as well as in human 
subjects (Sanberg 1997).  The mechanism of this effect is speculated to be an inactivation 
of the α4β2* and α7* nAChR subtypes (Lindstrom 1997, Sanberg 1997).  The non-
selective nAChR channel blocker mecamylamine has also been tested as a potential 
therapy (Silver 2001, Singh 2006).  Although not conclusive, these findings suggest a 
putative role of nAChRs in the potential pharmacotherapy of TD symptoms. 
  
 Attention and mood disorders 
There is an increase in interest in the link between nicotinic dependence and 
depression, bipolar disorder, anxiety, attention-deficit hyperactivity disorder (ADHD) 
and other forms of mental illness.  It has been noted that rates of smoking among patients 
with these disorders is higher that in the general population.  Smoking rates are very high 
among anxiety sufferers and is higher than 50% among depression and bipolar cases 
(Pomerleau 1994, George and Vessicchio 2002).  Transdermal NIC administration has 
been shown to cause improvements in non-smoking depressive patients (Salin-Pascual 
and Drucker-Colin 1998).  NIC administration has shown similar improvements among 
ADHD cases (Pomerleau 1995).  Successful crossover treatments between 
antidepressants and NIC addiction have been well established with the antidepressant 
buproprion gaining FDA approval as a smoking cessation aid (Holm and Spencer 2000).  
It is believed that this may be due to a non-competitive inhibition between these drugs 
and neuronal nAChRs (Fryer and Lukas 1999).  It is believed that upon smoking 
cessation there follows an increase in depressive symptoms and it is known that patients 
with depression, anxiety and ADHD have a lower success rate of smoking cessation than 
unaffected controls (Glassman 1990, Killen 2003, Breslau 1991).  All of these findings 
suggest the potential for a nicotinic pharmacotherapeutic intervention in many of these 
severe mental illnesses.       
 
 44
  
d.  Learning and Memory, Pain, and Other Possibilities 
 
There is a well established connection between NIC administration and 
therapeutic levels of improvement in cognition and memory.  NIC-associated 
improvements in learning and memory have been demonstrated in a variety of 
experimental systems using humans, non-human primates, zebrafish, rodents, and other 
laboratory animals.  Several experimental systems have been developed which are 
believed to mimic normal learning and cognitive processing in humans (reviewed in 
Sacco 2004).  Administration of NIC and nAChR agonists has been shown to positively 
affect learning and memory performance in a variety of experimental systems (reviewed 
by Levin 1992).  Recent findings using α7 KO mice suggest that cholinergic modulation 
of learning and memory performance is mediated by non-α7 nAChR mediated processes 
involving neuronal circuits in the hippocampus (Paylor 1998).  Developmental exposure 
to NIC is believed to induce a form of neurotoxicity and lead to altered normal cognitive 
function (Slikker 2005).  On the other hand there is an abundance of evidence that both 
acute and chronic NIC exposure enhances working memory.  The nAChR activation-
cognition enhancement relationship is further supported by the fact that the non-selective 
nAChR antagonist MEC has been shown to dose-dependently worsen both verbal 
learning and recall measures in non-smokers (Newhouse 1992).  Additional studies have 
demonstrated similar positive effects on memory tasks, visual object learning, selective 
attention, and delayed recall in healthy volunteers (Mancuso 1999, Min 2001, reviewed 
in Levin 2006).  Finally, NIC administration and smoking has been shown to positively 
affect outcomes in tests measuring attentional function such as the Continuous 
Performance Test (Lawrence and Ross 2002), and an opposite result is observed upon 
abstinence of smoking.   
Interestingly, there appears to be a lag in NIC’s cognitive enhancing effects 
following administration.  NIC improves cognition immediately following administration 
and this effect continues even after many half-lives of NIC, where serum concentration of 
NIC is essentially zero (Buccafusco 1991, Levin 1990).  This effect has been observed in 
humans and rodents.  Although the mechanism is still unclear this may be due to the 
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 effect of long-lived active NIC metabolites such as cotinine, NIC induced long term 
potentiation or sensitization, prolonged desensitization, and/or regulatory effects on the 
surface nAChR following both acute and chronic NIC administration (Buccafusco 2003, 
Gould 2003).  Currently a variety of drugs including ABT-089, Ispronicline, TC-1734, 
and other nicotinic drugs are in development for a variety of neuroprotective and 
cognitive enhancement applications (Gatto 2004).     There is a tremendous amount of 
experimental evidence that potential exists for development of novel NIC analogs that 
target neuronal nAChRs for therapeutic use as learning aids and adjunct therapies in 
disorders with altered learning and memory components. 
 
 Pain and antinociception  
 Recent discoveries in the nicotinic field have stimulated interest in nAChR-
targeting compounds as potential analgesic agents.  Drug therapies for pain focus on two 
classes of compounds, NSAIDS and opioids.  NSAIDS are effective in dealing with mild 
to moderate pain associated with inflammation while opioids are commonly used to treat 
more severe acute and chronic pain.  Both classes have their drawbacks and limitations as 
NSAIDS are often not well-tolerated due to gastrointestinal side effects and are limited in 
scope of therapy and opioids, while effective at treating more serious pain, can produce a 
variety of side effects including constipation and respiratory depression, and at higher 
doses leads to respiratory depression and carries a well known and powerful addictive 
liability (reviewed in Decker 1999).  More recently introduced classes like selective 
COX-2 inhibitors offered tremendous promise but recently many of these drugs have 
been taken off the market over safety issues and very few drugs offer effective relief from 
chronic and persistent neuropathic pain.  NIC is known to have demonstrated 
antinociceptive effects in both experimental animals and in humans (Sahley 1979, 
Tripathi 1982, Fertig 1986), and NIC administration in known to provide moderate and 
transient pain relief (Sahley 1979, Tripathi et al. 1982). The not-too recent discovery of 
the nicotinic agonist epibatidine by Daly et al, generated a new wave of interest in the 
development of NIC-related analgesics and antinociceptive agents due to the compound’s 
profound analgetic properties (Badio 1994).  Epibatidine results in potent 
mecamylamine-sensitive antinociception in animals (Badio and Daly 1994, Sullivan et al. 
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 1994) but due to its inherent toxicity Ebt itself is not a promising candidate for 
development (Decker and Meyer 1999).  nAChR-mediated antinociception is lost in 
nAChR knock-down rat model (Bitner 2000) and in nAChR KO animal models (Marubio 
1999).  Currently a number of potent and efficacious nicotinic compounds have been 
identified and are in various staged of development and testing (reviewed by Decker 
2004).  Additional work reveals an especially important role may exist for nicotinics in 
the area of neuropathic and nerve-damage-associated pain (Vincler 2005).  Some 
nicotinic compounds have demonstrated efficacies comparable to morphine and with 
100-200 fold higher potencies than some of the strongest opioids, yet many nicotinic 
compounds share narrow therapeutic windows and result in significant toxicities at high 
doses making them unsuitable for development.  With such tremendous potential, a great 
effort has been directed toward the design and development of novel powerful nicotinic 
drugs that retain the desirable efficacies and potencies without the toxicity.  One method 
is the design of compounds with pain-killing properties that are highly selective for 
various individual nAChR subtypes.  In this way researchers hope to develop safer 
nicotinics as a new class of drug therapy for pain.          
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 2.5. Neuronal nAChR Ligands:  Structure-Activity Relationship Introduction  
 
Acetylcholine and Nicotine-like Molecules 
Acetylcholine (1) (ACh) is the native neurotransmitter molecule responsible for 
rapid transmission across neuronal synapses.  As noted earlier, upon neuronal stimulation 
ACh is liberated from nerve endings into the intercellular space.  It rapidly diffuses to 
adjacent cells where it binds to axonal or somatic ACh receptors including nAChRs.  The 
molecule is a choline ester of acetic acid formed by the action of the choline-
acetyltransferase enzyme that acts on the substrates acetyl coenzyme A and choline.  
Following release, ACh is rapidly and efficiently degraded by choline esterases into 
choline and acetate to arrest synaptic ACh signaling.  ACh possesses affinity for all 
nAChR subtypes and efficiently activates receptor opening.  The molecule features a 
positively charged quaternary amine functionality and a negatively charged acetate 
moiety separated by an ethylene bridge.  These two molecular features are critical for 
both high affinity and functionality for many nAChR ligands, and a more detailed SAR 
analysis and pharmacophore section will be covered in later chapters.  Since it serves as 
the native stimulatory ligand for the nAChR, it follows that maximal ACh-induced 
response is often used in experimental systems as the theoretical 100% activation level 
for nAChR functional model systems.  ACh affinity varies nearly 100-fold for major 
nAChR subtypes (1-10nM for α4β2*, 73-520nM for α3β4*, and 1600-2200nM for α7*) 
although it is important to note that functional activation of neuronal nAChRs often 
requires a much greater concentration of ACh and responses differ among nAChR 
subtypes (reviewed in Daly 2005).  In early studies labeled [3H]ACh was used in the 
presence of NIC and muscarinic ligands such as atropine to distinguish NIC-binding sites 
in brain and allow for their mapping by autoradiographic methods and their initial 
characterization (reviewed in Sharples 2001).  
 Nicotine (NIC) is the most abundant alkaloid produced in the Nicotiana tobaccum 
plant and is generally accepted as the compound responsible for tobacco’s physiological 
and addictive properties.  Nicotinic analogs of ACh mimic the quaternary nitrogen of the 
ACh molecule with the ring pyrrolidino nitrogen which carries a positive charge at 
physiological pH, and the acidic acetate function with its acidic pyridine-nitrogen, all  
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 while retaining similar intramolecular distances between these critical features.  NIC 
exists in two major enantiomeric forms, S-(-)-NIC (2) and R-(+)-NIC (3) depending on 
the orientation of the pyridine-pyrrolidine 3’-2’ bridge, carbon-carbon bond.  This minor 
structural difference however, changes the pharmacological properties of the molecule(s) 
significantly.  Binding studies reveal that (2) has a much higher affinity for the major 
nAChR in brain compared to (3), (1-3nm vs. 20-40nM respectively) (reviewed in 
Bunnelle 2004).  The R-isomer possesses about 1/50th the psychotropic effects of S-NIC 
and around 1/10th the binding affinity generally (Wang 1998), and it also appears that R-
NIC carries more of the undesirable toxicological properties.  S-(-)-NIC binds selectively 
to α4β2* vs. α7* nAChRs with a 100-1000-fold preference for the α4β2* subtype.  NIC 
activates α4β2* receptors at about 1µM while requiring around 500 times higher 
concentration to activate neuronal α7* nAChRs making S-(-)-NIC selective for high-
affinity nAChRs in binding and functional studies where NIC concentrations are held 
below 50nM (reviewed in Sharples 2001).  Currently most studies utilize S-NIC 
preferentially as a research tool and as a platform for drug design.  S-(-)-NIC comprises 
the vast majority of NIC in the tobacco plant although other minor alkaloids are present 
also.   
Radiolabeled [3H]-NIC is commonly used in binding and autoradiographic 
mapping studies and has proven invaluable in the quest to elucidate neuronal nAChR 
subtypes.  Alone it selectively labels high-affinity subtypes at low concentrations, and 
when used in tandem with other ligands like epibatidine and α-Bgt to mask high-affinity 
subtypes it can be used to label other minor subtypes in brain (Sharples 2001).  In terms 
of SAR, the NIC molecule tends not to tolerate many structural changes.  Studies have 
demonstrated that additions to either the pyridine or pyrrolidino ring lower affinity and 
function at the nAChR.  One exception is additions at the 6’ position of the pyridine ring 
where a methyl addition is well tolerated and addition of a chlorine group (6’-chloro-
NIC) actually improves binding affinity several fold.  Expansion of either the pyridine or 
pyrrolidine rings decreases affinity dramatically, as does the elongation of the alkyl 
bridge between the two ring structures to generate homonicotine with affinity 500 times 
lower than NIC, (Bunnelle 2004).  Additionally, positional isomers of NIC where the 
pyrrolidine ring is bound to the 2’ or the 4’ position on the pyridine ring is not well 
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 tolerated at all and causes a dramatic loss in affinity (reviewed in Wang 1998, reviewed 
in Tonder and Olesen 2001).  To date, very little progress has been made in increasing 
affinity by altering the parent NIC molecule although a great deal of work is ongoing in 
attempts to design nicotine analogs with improved characteristics and more desirable 
pharmacological properties.     
Nornicotine (4) is a modified NIC molecule where the pyrrolidine methyl group is 
absent.  It exists naturally as a minor alkaloid component of tobacco as well as a 
demethylation metabolite of NIC in the body.  It appears to accumulate in the brain where 
it is regionally demethylated.  It accounts for around 8% of normal NIC metabolism in 
vivo.  Nornicotine, as with other metabolites of NIC, possesses significant physiological 
activity (reviewed in Crooks and Dwoskin 1997).  Nornicotine displaces [3H]NIC in 
brain with a Ki=47nM suggesting a 10-fold loss of α4β2* affinity compared to NIC 
(Crooks 1997), while demonstrating similar affinities for α7* and α3β4* nAChRs 
(Ki=770nM for NIC and 1340nM for nornicotine) (Xu 2001).  Similar values are reported 
in a recent review (Daly 2005).  Nornicotine appears to stimulate functional response in 
nAchR subtypes expressed in oocyte systems (EC50~17µM for α7 and EC50~4µM for 
α3/α6-chimeras) although producing an Imax of around only half that elicited by ACh 
indicating some alternative mechanism of interaction with these nAChRs in vitro (Papke 
2007).  Nornicotine is also self-administered in rat models (Bardo 1999), stimulates DA 
release in striatal brain slices (Green 2001), and inhibits DA clearance in striatum by 
altering DA-transporter function, presumably via a nAChR-mediated interaction 
(Middleton 2007).  Despite the trend for nicotinics to lose affinity and function upon 
removal of the N-methyl group, nornicotine is unique in not only retaining moderately 
high affinity but also remains functionally active at multiple nAChR subtypes.  
Nornicotine is currently being developed as a drug therapy for a variety of nAChR-
related applications. 
Modification of the structure of S-(-)-NIC by the addition of an unsaturated alkyl 
chain to the pyridine ring nitrogen yields a series of NIC analogs with altered 
pharmacological properties and with potential for drug development.  In this series, 
quaternization of the pyridine nitrogen of NIC by addition of a methyl group to generate 
NMNI (5) leads to a dramatic decrease in affinity for neuronal nAChRs (Ki value 
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 changes from 2.0nM for NIC to 3.8µM for NMNI).  Upon extension of alkyl chain length 
to nine (NNNI) (7), ten (NDNI), and twelve carbons (NDDNI) (8), the NIC analogs of 
this series once again regain high affinity for the α4β2* (Ki=840nM, 14nM and 9nM 
respectively (Wilkins 2002).  Another compound in the series containing an 8-carbon 
alkyl chain addition (NONI) (6) appears to retain the low α4β2* affinity exhibited by the 
shorter chain length compounds (Ki=20µM), while gaining the ability to completely 
abolish NIC-evoked DA release in striatal preparations.  This inhibition takes place in a 
manner competitive with NIC binding and has an IC50 of around 600nM.  Interestingly, 
all of the compounds in this series exhibited very low affinity for the α7* nAChR as 
measured in [3H]MLA binding experiments (Wilkins 2002) indicating that a long alkyl 
chain is not well-tolerated at the binding site at the α7- α7 subunit interface.  In addition 
to a trend improving α4β2* affinity, an increased inhibition of NIC-mediated DA release 
is also strongly correlated to increasing chain length, indicating an interesting, and 
possibly shared binding commonality between α4β2* and α3α6β2*-containing nAChR 
subtype(s) (Wilkins 2002).  This and other series of similarly alkylated pyridine and bis-
nicotinium compounds are currently being developed in the Crooks/Dwoskin labs as 
therapeutics for a variety of neuropharmacological applications (Ayers 2002, Dwoskin 
2004). 
While in general ring modifications of NIC are not well tolerated, several selected 
compounds featuring modifications of the pyrrolidine ring structure of NIC demonstrate 
high affinity for neuronal nAChRs.  Positional isomerization of the pyrrolidine ring 
attachment yields the compound isonicotine (9).  This molecule binds α4β2* subtype 
nAChRs with high affinity (Ki=8.0-12.5nM) indicating some flexibility in the binding of 
the cationic position in the NIC molecule to the receptor binding site (Tonder and Olesen 
2001, Glennon 2000).   
A series of unsaturated trans-metanicotine analogs was synthesized by opening of 
the pyrrolidine ring of NIC with the introduction of a double bond in the chain (Bencherif 
1996).  Among these compounds, metanicotine (10) demonstrated tremendous binding 
selectivity for α4β2* over α7* nAChRs (Ki=26nM vs. 36,000nM respectively) (Sharples 
2001).  Functionally it exhibits a similar degree of subtype selectivity.  In [86Rb+] efflux 
experiments using thalamic synaptosome preparations (believed to measure α4β2*  
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 nAChR activation), metanicotine exhibited a potency in the high nanomolar range for full 
activation while requiring a concentration of ~250 micromolar for activation of α7* 
nAChRs (Sharples 2001).  It is also claimed that metanicotine is functionally active at 
inducing DA release and interacts weakly at muscle and ganglionic nAChR subtypes (10-
30 fold lower than NIC) making it a good candidate as a model compound for selective 
neuronal nAChR therapy (Lin and Meyer 1998).  Additionally, recent findings suggest 
metanicotine may possess interesting antinociceptive properties that could be exploited 
for drug development.   
Anabasine (11), a homolog of nornicotine, has been isolated from Anabasis plants 
and is a minor tobacco alkaloid.  Anabasine was found to be a potent agonist at both 
muscle and major neuronal nAChRs, although it appears to be less efficacious than NIC 
in experimental systems (Kem 1997).   This compound is characterized by ring expansion 
from a 5-membered pyrrolidine ring to a 6-membered piperidine ring.  Despite the ring 
modifications in anabasine, the molecule retains high affinity for neuronal nAChRs and 
acts as an agonist in multiple functional assays.  While contraction of the pyrrolidine ring 
appears to have little effect on nAChR binding or function when compared to NIC, ring 
expansion appears to lower α4β2* affinity 200-fold vs. NIC (Glennon 2000).  This 
suggests that while a pyrrolidine ring is not required for α4β2* binding it appears that it is 
ideal.  On the other hand this simple modification leads to a five-fold increase in affinity 
for α7* nAChRs (reviewed in Bunnelle 2004).  This would indicate that the binding 
recognition site in α7* nAChRs can tolerate a larger hydrophobic grouping by retaining 
and even improving affinity, while the same may not be claimed for the α4β2* subtype.  
Indeed, continued expansion of the pyrrolidine ring to include 7 and 8-membered ring 
systems results in only a modest reduction in affinity (Tonder and Olesen 2001). 
A variety of substituted aminomethylpyridine analogs of NIC have been 
synthesized and tested for activity at nAChRs (Dukat 2005).  A small selected group 
from this series is reviewed here.  These compounds (12-15) are secondary and tertiary 
amine-containing analogs of NIC where the pyrrolidine moiety has been stripped down to 
the basic anime supported by a short alkyl chain; in this manner mimicking the NIC’s 
major binding features while removing the characteristic pyrrolidine ring.  Some 
interesting SAR of high-affinity nAChR binding is revealed for this series (α4β2* Ki= 
 53
 540nM, 28nM, 289nM, and 18nM for compounds 12-15 respectively).  It appears that for 
this series the extension of the alkyl chain from N-methylene to N-ethylene confers 
improvements in affinity values for compounds with both a methylene bridge and an 
ethylene bridge (12, 14, 13 and 15) respectively (reviewed by Glennon 2000).  In both 
cases the addition of the second ethyl group to the chain nitrogen improves affinity over 
its protonated or methylated counterpart, indicating that groups larger than a small methyl 
grouping are tolerated.  This is not the case with the NIC molecule where ring 
substitutions larger than a methyl grouping usually abolish high-affinity binding.  It also 
reveals the fact that for a family of compounds that are to be developed, varying the 
length of the NIC alkyl bridge may prove to be a promising modification in the quest to 
generate compounds that retain good nAChR affinity while exploring structural diversity 
within the set.   
 
Non-traditional Nicotine-like Molecules 
Epibatidine (16) is a natural product compound isolated from the skin of the Ecuadorian 
tree frog Epipedobates tricolor.  It was quickly reported that Ebt binds to nAChRs in the 
brain (Daly 1995), acts a potent nAChR agonist at ganglionic subtypes (Fisher 1994) and 
that the compound possessed powerful analgetic properties (reviewed in Decker 1999).  
In fact, Ebt displayed full efficacy in pain models relative to opiates such as morphine, 
and with an improved potency, making the Ebt molecule a popular platform for the 
design of novel antinociceptive agents (Badio and Daly 1994).  Ebt binds with very high 
affinity to the α4β2* subtype, with reported binding affinity (Ki) values ranging in the 
literature from 19pM up to 90pM depending on the experimental system.  It is relatively 
non-selective among nAChR subtypes with affinities ranking α4β2* (~50pM) > α3β4* 
(380pM) > α7* (~300nM)) (reviewed in Sharples 2001).  Ebt is the most potent agonist 
ever discovered for nAChRs, and at lower concentrations its action is believed to be 
mediated selectively by the α4β2* receptor subtype (reviewed in Carroll 2004).  It 
activates multiple nAChR subtypes with EC50 values in the nM range (including assays 
for the DA-releasing nAChR subtype), often demonstrating both improved potency and 
efficacy compared to NIC, generally demonstrating little selectivity among major 
subtypes (Gerzanich 1995).  Ebt is a commercially available in radio-labeled form, and is 
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 used commonly as a high-affinity nAChR ligand for binding and functional studies at 
multiple subtypes.  Due to its non-selective tendencies, Ebt itself has been ruled out as a 
potential therapeutic because of peripheral side effects and its small therapeutic window.  
So far, a tremendous number of Ebt analogs have been synthesized and evaluated for a 
variety of peripheral and central nAChR activities and although there are few 
extraordinary lead drug candidates from this pool, Ebt-based drug development continues 
to be a hot area of medicinal chemistry and pharmacology research (Carroll 2004).   
 (-)-Cytisine (Cyt) (17) is a natural product, toxic plant alkaloid isolated from the 
Leguminosae plant family.  It is well characterized and is a commonly used compound in 
nicotinic research.  It was first reported over 90 years ago as having similar peripheral 
effects as NIC.  It displays high affinity for neuronal α4β2* nAChRs comparable to NIC 
(Ki=1-3nM) in S-(-)-NIC binding studies using native brain preparations and has been 
shown to possess even higher binding affinity than NIC for ganglionic subtype 
combinations (Anderson 1994, reviewed in Sharples 2001).  Unlabeled Cyt has been used 
in conjunction with [3H]-Ebt to distinguish populations of non-α4β2* nAChRs in brain 
(Whiteaker 1998, Whiteaker 2000).  Cyt appears to have full efficacy at β4-containing 
nAChRs however at major neuronal nAChR subtypes it shows diminished efficacy 
indicating that a β4 subunit is required for functional activation by Cyt.  Cyt remains a 
partial agonist at α4β2* subtypes. 
 Dihydro-β-erythroidine (DHβE) (18) is a natural product of the Erythrina 
compound family isolated from the Erythrina crista-galli plant and others of this family.  
It was characterized long ago as having inhibitory properties at the neuromuscular 
nAChR junction (Hanna and McHugo 1960) and has since been extensively characterized 
as a potent and classic competitive nAChR antagonist (Williams and Robinson 1984).  
Because of its extensive history of nAChR interaction, DHβE has long been used in 
laboratory settings to help define and characterize a number of nAChR subtypes.  DHβE 
selectively binds α4β2* nAChRs displacing [3H]Cyt binding with a Ki of 35nM while 
displaying a greatly reduced affinity for non-α4β2* subtypes (Ki of 9,000nM and 
11,000nM for [125I]Bgt binding in brain preparations and muscle preparations 
respectively).  DHβE inhibits α4β2*-induced currents in hippocampal preparations at 
100nM yet fails to block α7*-induced currents in the same manner (Alkondon and 
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 Albuquerque 1993).  It also completely inhibits NIC-induced DA release in striatal slices 
at 30nM (Crooks 1995) which is likely due to its α4β2* affinity but may incriminate 
α3/α6-containing DA specific nAChR subtypes as well.  Despite its ease in crossing the 
blood-brain barrier and its apparent selectivity among neuronal nAChR subtypes, 
DHβE’s agonist activity at ganglionic and muscle subtypes has ruled out its use for 
potential drug development. 
 Mecamylamine (MEC) (19) is one of a relatively small group of compounds 
known to be purely non-competitive antagonists.  It was originally characterized in a 
series of experiments looking at peripheral and sympathetic effects as early as the 1950s 
(Corcoran and Schneckloth 1956, Blackman and Ray 1964).  It is known to block most 
neuronal nAChR subtypes non-selectively in the low micromolar range, although the α7* 
subtype is somewhat less sensitive than the α/β-containing nAChRs (Jensen 2004, 
reviewed in Papke 2001).  It is generally believed to exert its action through direct 
blockade of the nAChR channel pore (an open channel blocker).  Upon channel opening, 
MEC binds to a site within the channel and physically hinders ion flow into the cell.  
Since MEC readily crosses the blood-brain barrier and inhibits nAChR function it has 
found great utility in the laboratory setting as non-specific nAChR blocker.  It is routinely 
injected at up to 1mg/kg in rat models and is sufficient to block all nAChR-mediated 
effects (reviewed in Sharples 2001).  In recent studies it has been reported that 
administration of MEC inhibits locomotor sensitization to amphetamine in mice models, 
inhibits cue-induced cravings in cocaine abusers and reduces reinforcing effects of 
alcohol in animal models (reviewed in Papke 2001).  MEC appears to have little benefit 
in human models of smoking cessation, however, either alone or in combination with 
nicotine-replacement therapies mainly due to tolerability issues at effective doses and its 
unpleasant gastro-intestinal side effects (Lancaster 2000).  MEC displays moderate 
selectivity for neuronal subtypes versus muscle type and crosses the blood-brain barrier 
easily, yet despite this there has been little success in development of MEC as a nAChR 
therapeutic (Young 2001).  It has proved invaluable however as an experimental tool for 
both in vitro functional studies and for in vivo functional and behavioral studies.   
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 Methyllycaconitine (MLA) (20) is a norditerpine alkaloid isolated from the 
Delphinium genus of plants and is the most selective small molecule compound for α7* 
nAChR known.  It has high affinity for α7* nAChR (Ki=1-3nM) while having a 1000-
fold lower affinity for the α4β2* subtype (Jensen 2004), and unlike the well known α7*-
selective peptide ligand α-Bgt, MLA discriminates between neuronal α7* and muscle-
type nAChRs (Whiteaker and Wonnacott 1999).  It is a potent and selective antagonist at 
neuronal nAChRs in both native and expressed systems (Alkondon 1992, Davies 1999) 
inhibiting functional responses in the low nanomolar range.  Although MLA is selective 
for α7* nAChRs, like α-Bgt, autoradiographic mapping experiments suggest they may 
label a slightly different population or state of α7* nAChR receptor and there is evidence 
that MLA may interact with a minor non-α7* population in striatum although this has not 
been well established.  MLA crosses the blood-brain barrier it has been useful in animal 
experiments studying α7* receptor activity however it is difficult to regulate actual brain 
levels in this manner and therefore results must be interpreted with some caution 
(reviewed in Sharples 2001).  Synthesis and evaluation of a series of compounds 
analogous to the E-ring system of MLA have been synthesized and evaluated and 
indicate that this structural feature is the key to activity and selectivity for the MLA 
molecule (Bergmeier 1999).  Radiolabeled [3H]MLA offers an alternative to labeled α-
Bgt, it is commercially available and widely used in binding experiments to probe α7* 
sites in mixed native brain preparations as well as in expressed systems such as oocytes.  
While MLA’s large size and complexity makes it a challenging candidate for SAR 
development as it presents an unusual and intriguing puzzle since most nicotinic 
pharmacophore models would predict poor affinity for MLA for any of the major nAChR 
subtypes. 
The natural product d-tubocurarine (d-Tub) (21) is a classical antagonist for 
nAChRs and was one of the first compounds used to study and help characterize nAChR 
function in experimental systems (see section 2.1).  It is isolated from members of the 
Chondodendron plant species and has a long history of use among South American 
natives as an arrow and dart tip poison used to immobilize and paralyze game, and it was 
around the turn of the century that its mechanism of action was first elucidated.  d-Tub is 
not a typical nicotinic ligand molecule, with a molecular weight >600 and containing 
 58
 unconventional molecular features relative to the typical nicotinic pharmacophore.  d-Tub 
may be the least selective nicotinic ligand and antagonist known as it fully antagonizes 
function in muscle, ganglionic and all major neuronal subtypes within a 10-fold 
concentration range (α4β4=0.86µM, α3β4=2.2 µM, α3β2=2.4 µM, α7=3.1 µM, α4β2=3.2 
µM, α2β4=4.2 µM, reviewed in Jensen 2005).  The interaction at nAChRs is generally 
considered competitive although a non-competitive mechanism has been proposed 
(reviewed briefly in Sharples 2001).  Given the fantastic that lack of selectivity this 
compound demonstrates, the molecule’s large size and complexity, and the fact that d-
Tub is a well known lethal toxin with peripheral paralytic activity it is no surprise that it 
has not been aggressively developed ad a potential drug development platform.  Its 
unconventional structure and its characteristic lack of selectivity do make it an interesting 
molecule continued analysis and further study, although it has already contributed greatly 
to nAChR understanding as an early research tool.               
 The conotoxins (Ctx) are small peptide toxin molecules (12-20aa long) produced 
by marine (Conus) cone snails that have been found to possess selectivity at nAChRs.  
These molecules have proven to be an invaluable source of non-traditional small 
molecule, subtype-selective entities useful for study and as platforms for novel drug 
design and development.  A large number of these toxins have been shown to act on a 
variety of receptor targets including 5-HT3, NMDA, and GPCR in the brain, but the α-
Ctx subclass (classes defined mainly by their cysteine bonding structure) has specific 
activity at nAChRs.  The α-Ctx MI was the first Ctx reported to inhibit neuronal nAChR 
signaling and since then several Ctx varieties have been discovered with remarkable 
selectivity (reviewed extensively in Jensen 2005).  α-Ctx MI has been shown to be highly 
selective for α7* nAChR binding and inhibition, and is believed to occupy sites distinct 
from α-Bgt indicating a different binding microenvironment on the α7*-receptor, and 
opening up a new target for investigative studies (Ellison and Olivera 2003).  Recent 
studies suggest the closely related α-Ctx MII is highly selective for α3 and α6*-nAChRs 
making it a valuable recent addition as a research tool investigating nAChR subtypes 
involved in mediating DA release (Dowell and McIntosh 2003).  Although 12-15 Ctx 
molecules have been characterized, and several exhibit nAChR binding and functional 
subtype selectivity, more will undoubtedly be discovered in the near future, further 
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 contributing to the knowledge of nAChR pharmacology.  It is important to recognize Ctx 
molecules as a new and exciting area for potential SAR discovery, and as new platforms 
for novel drug design.  In fact, several synthetic α-Ctx analogs and mutants have already 
shown improved affinity and selectivity for target nAChR subtypes and several are 
currently are in clinical trials for a variety of medical applications including the treatment 
of neuropathic pain and nAChR-associated disorders (reviewed in Armishaw and 
Alewood 2005, Livett and Khalil 2006).  Despite the inherent problems associated with 
production, purification, formulation and delivery of small peptide molecules the area of 
Ctx research and drug development holds tremendous promise for the production of 
research tools and therapeutics.    
  
Imidacloprid, Neonicotinoids and Guanidine-Containing Nicotine Analogs 
Efforts from the agriculture industry to generate compounds with a high degree of 
selectivity that target the nAChR of insects and crop pests have led to the development of 
a class of insecticides known as neonicotinoids.  The neonicotinoids, derivatives of the 
nitromethylene heterocycle nithiazine, are the most important new class of synthetic 
insecticides discovered in the last three decades.  Related to NIC in structure and 
function, neonicotinoid compounds bind to and function as agonists at insect nAChRs, 
there interrupting normal synaptic transmission leading to persistent stimulation and 
excitotoxicity which ultimately leads to death for the pest.  These compounds have 
considerable improvements over older classes of insecticides and are currently the most 
common group of pesticides in commercial agricultural use worldwide.  They 
demonstrate a high degree of selectivity for the insect nAChR over the mammalian 
nAChR which results in improved toxicity for those handling these pesticide compounds.    
Neonicotinoids, exemplified here by the compound imidacloprid (IMI) (23), are broad 
spectrum insecticides and are highly toxic to a variety of pests and their eggs, yet they 
possess extremely low mammalian affinity and toxicity (Tomizawa and Casida 2005).  In 
[3H]NIC binding experiments to mouse brain nAChR preparations IMI was found to have 
a Ki=806nM compared to Ki=9.5 for house fly nAChR preparations (Chao and Casida 
1997).  This computes to an 85-fold selectivity in binding for insect nAChRs.  The major 
class of insect nAChR which had previously been probed with labeled α-Bgt or MLA is 
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 now routinely investigated with [3H]IMI due to its high selectivity, favorable kinetics, 
and its safety profile (Zhang and Casida 2004).  IMI demonstrates a similar selectivity in 
whole-animal toxicity models and was found to have an oral 24hr LD50 of 450mg/kg in 
rats, and a transdermal 24hr LD50>5g/kg in rats.  Neonicotinoids are thoroughly 
metabolized in the soil and do not persist in soil or in water runoff, and they have little 
effect on soil microbes (reviewed on Extoxnet) making them much healthier for soil 
microenvironments relative to other insecticidal classes like organophosphate 
compounds.  As a note: while nicotinoid and neonicotinoid compounds are similar in that 
they are based on a common NIC-like structure the nominal distinction refers to the 
selectivity properties of the compound.  Where nicotinoids demonstrate preference for 
mammalian nAChRs the neonicotinoids demonstrate selectivity for the insect nAChR 
(reviewed in Tomizawa and Casida 2003).   
  NIC and IMI are remarkably similar compounds when considering the nicotinic 
pharmacophore.  They share the same structural moiety, the same mode of action, and 
essentially the same SAR (Yamamoto and Tomizawa 1998).  Analogs of IMI have been 
synthesized and shown to have the same action as IMI, and several are in wide 
commercial use as pest control agents.  In recent years however, several 6-chloro-3-
pyridyl analogs of NIC and metabolites of IMI were reported to have affinity and 
selectivity for the mammalian nAChR while showing little activity at the insect nAChR.  
Some of these compounds demonstrate a complete reversal of selectivity with only minor 
structural alterations.   
These compounds (now better described as nicotinoid analogs of the 
neonicotinoid IMI) demonstrate selectivity for the mammalian nAChR as high as NIC, 
and possess many of the same physiological properties as NIC, including subtype 
selectivity and functional activity (reviewed in Tomizawa and Casida 2003).  One of 
these well characterized IMI metabolites is the desnitro analog DN-IMI (24).  In binding 
studies using mouse nAChR preparations, DN-IMI demonstrates affinity for the α4β2* 
nAChR of 8nM with an affinity for the insect nAChR of 1530nM (Tomizawa and Casida 
2000).  This equates to a nearly 200-fold binding selectivity.  There is convincing 
evidence that selectivity for insect nAChRs is conferred by the presence of the 
electronegative nitro and cyano substitutions seen in neonicotinoid molecules 
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 (Tomizawa, Zhang and Casida 2003).  This is a dual effect where 1) the electronegative 
atoms interact directly with positively charged amino acids in the binding site (Lys and 
Arg), and 2) these electron-withdrawing functional groups confer a partial positive charge 
on the N-1 atom of the imidazole ring and that this feature interacts strongly with an 
anionic site found in the inset ACh/NIC binding site but not in the mammalian nAChR 
binding site (Tomizawa and Casida 2003).  Analogs of these compounds lacking the 
electronegative group demonstrate a complete reversal of nAChR species’ selectivity and 
activity.  Selected IMI analogs, including 24, have been shown to induce 86Rb+ efflux in 
M10 cells expressing mammalian nAChRs, and have demonstrated potent antinociceptive 
and toxic effects in mice (Tomizawa and Casida 2001).  These effects are also clearly 
blocked by the addition of the channel blocker MEC.   
SAR studies reveal IMI analogs follow similar trends with NIC.  Compounds with 
an imidazolidine as the aliphatic ring heterocycle display the highest affinity upon 
addition of the 2-amino group while larger additions are not well tolerated (Bunnelle 
2004).  As with NIC, addition of small groupings to the 6-pyridyl ring is tolerated while 
replacement of the pyridyl ring with a phenyl ring results in complete loss of affinity 
(Tonder and Olesen 2001).  Positional isomers with additions at the 2’ and 4’ site on the 
pyridine ring demonstrate dramatically lower affinity than the 3’ counterpart.  Ring 
expanded IMI analogs (25) have been reported and it appears that expansion of the ring 
to include 6-membered pyrimidine analogs results in high affinity while rings larger than 
this results in reduced affinity (Chao and Casida 1997).  Also, several ring-opened IMI 
analogs were attempted with and without the electronegative grouping (26), however 
these compounds result in only modest affinity at best and total loss of affinity at worst 
(Chao and Casida 1997, reviewed in Tonder and Olesen 2001).  These results suggest 
simple modifications of the IMI molecule can confer high affinity and selectivity for 
mammalian neuronal nAChRs and that these molecules generally will follow well 
understood SAR patterns seen in NIC drug design.  That generating a series of novel IMI 
analogs can be used to target neuronal nAChRs in a subtype-selective manner. 
IMI analogs selective for the mammalian nAChR feature an amine substituted 
imidazolidine functionality.  Another way of looking at this structure is that of an alkyl 
bridged guanidine functionality bonded to the pyridine ring.  Guanidine-containing 
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 compounds possessing biological activity are common as both natural products and as 
synthetic products.  Featuring a unique diffuse, carbo-cationic, partial positive charge and 
having a relatively high pKa the guanidine group provides a variety of molecules with a 
functionality key to biological activity.  Guanidines are a major focus for molecular 
design in a variety of areas including a variety of drug designs, pesticide design, as 
natural toxins, chemotherapeutic agents, antihypertensive agents, and as peptide mimetics 
(Ekelund and Larsson 2001, reviewed in Berlinck 1999).  One area of interest is the 
promising development of several synthetic antihypertensive agents derived from the 
metabolites of the South American weed plant Verbesina caracasana (reviewed in Botta 
and Monache 2003).  Several compounds have been shown to exert powerful 
antiadrenergic nerve activity and have been linked to both peripheral and central 
mediated mechanisms.  Guanidines from natural sources are popular areas of interest as 
many marine and freshwater aquatic organisms and bacteria produce guanidino 
compounds of physiological interest as possible antibiotics, toxins and regulatory 
compounds (Berlinck 1999).   
One physiologically active guanidine compounds is guanethidine (27), an N-ethyl 
azocane ring-containing guanidine molecule.  This compound has been shown to potently 
and selectively inhibit DMPP (a nAChR agonist) induced whole-cell Ca2+ currents in a 
concentration-dependent manner, while having no effect on K+ induced (non-specific 
Ca2+ channel) depolarization in bovine chromaffin cells (Villarroya 1996).  This indicates 
that this guanidine compound acts to inhibit native nAChRs while leaving other cationic 
channel systems unaltered.  A series of generic chain-lengthened analogs were 
synthesized and evaluated in the same system and it seems a 10 and 11 alkyl chain 
extended guanidine compound successfully inhibited DMPP-induced currents fully 
shoeing that guanidine compounds can affect nAChR activity with a high degree of 
efficacy (Villarroya 1996).      
 It has recently been suggested that a group of Na+ channel blockers may have 
therapeutic potential in a variety of applications such as local anasthetics, antiarrythmics 
and as neuroprotective agents against hypoxic, traumatic and ischemia-induced cell death 
due to neuronal post-insult hyperexcitability (Maillard 1998).  The well known guanidine 
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Figure 2.7  Several neonicotinoid based analogs of nicotine and guanidine-containing NIC analogs. 
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 tetrodotoxin, a marine toxin known to selectively block Na+ channels, has already been 
found to be neuroprotective in ischemia models (Maillard 1998).  CNS 1237 (28) is an 
N,N-disubstituted guanidine compound that has been shown to inhibit Na+ and Ca2+ 
channels governing excitatory NT glutamate release in native brain terminal preparations 
used in ischemic models of brain trauma (Goldin and Magar 1995).  A variety of 
additional diaryl and alkyl-guanidine compounds have been shown to be effective in the 
same manner with EC50s in the low nanomolar range (Maillard 1998).  While SAR 
development for these classes of compounds are in their infancy compared to NIC a great 
deal of interesting biological activity and selectivity have already been demonstrated by 
guanidine containing compounds in a variety of experimental ion channel systems 
suggesting room for development of selective neuronal nAChR active compounds by 
design of NIC analogs around the guanidine moiety. 
 In a recent series of reports the structure of the NIC molecule has been stripped 
down to examine the bare essential elements of high affinity binding.  All compounds 
generated contain a pyridine ring structure with alterations of the 3-pyridine substitutions.  
Open-ring pyrrolidine analogs (or more aptly named aminomethyl pyridine analogs) and 
several imidazole-containing compounds were generated and evaluated for activity in S-(-
)-NIC binding studies (Ferretti and Glennon 2000).  The aminomethylpyridine analogs 
generally resulted in a 10-fold reduction in affinity.  In the imidazole analog series the 
nitrogen bonds of the imidazole moiety are conjugated with the electronegative ring 
theoretically lowering the pKa and (as with the guanidine moiety, generating a more 
diffuse carbo-cationic charge in contrast to the point charge of the quaternary N-
pyrrolidine of NIC.  Azanicotine (29) is the preeminent amidino compound of this group 
and demonstrates good affinity for the α4β2* nAChR (Ki=260nM) while having a 
functional antinociceptive effect in mouse comparable to NIC, 21nM vs. 12nM 
respectively, (Ferretti and Glennon 2000).  From the same report the chain lengthened 
analog homoazanicotine (30) was shown to have even higher affinity (7.8nM) while 
retaining complete potency in the antinociception trials (EC50 19nM), (Ferretti and 
Glennon 2002).  The corresponding homo-analog of NIC was synthesized and evaluated 
in a similar manner and it was found to have lost all high-affinity binding and all 
antinociceptive properties demonstrating that guanidine compounds appear to possess a 
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 degree of flexibility, or tolerability to structural changes that may allow for the 
accommodation of changes that may lead to more desirable subtype-selective molecular 
features in a novel series of guanidine compounds.  A series of homoazanicotine analogs 
were later synthesized and evaluated however, and it was found that they possess an SAR 
quite similar to that of NIC indicating that they interact in a similar manner and 
employing parallel features of molecular recognition (Ferretti and Glennon 2003).  
Additional studies have reported on similar synthetic dihydropiperazino compounds as 
potential insecticidal agents and report similar high affinity for guanidine and amidino 
(and imidazole) containing compounds (Samaritoni and Bruce 2003).  SAR analysis from 
these compounds also indicate tremendous promise in terms of generating compounds 
with high affinity and selectivity for nAChRs            
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 2.6. Specific Research Aims and Hypothesis 
 
 
Specific Aim 1) 
To design and carry out the synthesis of a series of novel guanidine-containing analogs of 
NIC, and to incorporate enough structural diversity into this small library so as to provide 
useful SAR feedback from binding and functional studies.  To apply results from SAR 
analysis to guide synthetic designs for optimization of affinity for novel guanidine 
compounds.    
 
Specific Aim 2) 
To develop methods of an [3H]Ebt assay for initial screening of compounds and for 
characterization of activity at the nAChR.  To assess whether multiple nAChR subtypes 
could be probed using this method and to identify lead high-affinity compounds for 
further testing. 
 
Specific Aim 3) 
To screen and evaluate compounds of interest in the [3H]NIC and [3H]MLA binding 
assays to probe for subtype-selective affinity at major neuronal subtypes.  To further 
characterize leading compounds be carrying out more detailed binding analysis including 
determining Ki for lead compounds and carrying out Schild analysis of binding to 
investigate mechanism of interaction. 
 
Specific Aim 4) 
To evaluate leading compounds in a FLIPR, calcium functional assay to determine 
functional activity in recombinant cell culture expression systems.  To screen compounds 
and evaluate intrinsic activity, inhibitory activity or both for compounds of interest. 
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 Specific Aim 5) 
To develop one or more pharmacophore models in-silico, to investigate and identify key 
molecular features critical to binding interaction of compounds at the nAChR.  To apply 
results from the model to predict a new series of related compounds with improved 
affinity for nAChRs examined. 
 
   
Hypothesis 
The synthesis and evaluation of a novel series of guanidine-containing analogs of NIC 
will reveal high-affinity compounds which demonstrate selectivity and functional activity 
at major neuronal nAChRs.      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Aaron Joseph Haubner 2008  
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Chapter 3: Nicotinoid and Guanidino Compound Design and Synthesis 
 
 
3.1 Drug Design and SAR 
 
 Medicinal Chemistry 
Medicinal chemistry is an interdisciplinary research field that applies chemical 
research techniques (traditional and modern) to the synthesis of pharmaceutical agents.  It 
is rooted in organic chemistry, SAR analysis, molecular modeling and computational 
chemistry.  Although early medicinal chemistry efforts focused almost exclusively on the 
elucidation and synthesis of various medicinal natural products of plants, modern 
medicinal chemistry has expanded to include the rational design and synthesis of novel 
drug compounds.  For the most part investigations into folk remedies, as such, have been 
abandoned and focus has shifted to the development of novel compounds.  Only recently, 
however, medicinal chemists have re-gained interest in uncovering what might have been 
overlooked in the rush to abandon natural product chemistry and pharmacognancy, and 
are now investigating promising natural product treatments and cures as potential 
breakthrough leads.  The field is considered interdisciplinary because medicinal 
chemistry efforts are carried out in conjunction with, and often guided by results from 
biological research.  The biological aspects have added biochemists, molecular biologists 
and enzymologists to medicinal chemistry efforts.  Additionally, medicinal chemists have 
become an integral part in the biological discovery and research process, with biologists 
and pharmacologists providing definitions and descriptions of targets and medicinal 
chemists providing well-designed and active research tools and drug candidates for 
pharmacological development.  The synthetic role is still often filled by a traditionally 
trained organic chemist.  While medicinal chemistry efforts now must account for myriad 
biological data and physiological input, the primary function remains the design and 
discovery of new drugs…only the methods have changed.  The novel product compounds 
that are produced in these efforts serve as valuable tools in elucidating the physiological 
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 roles of targets and provide lead molecules for the development of therapeutically useful 
drugs.     
 nAChR SAR 
Rational drug design and synthesis have fundamentally changed the way drug 
compounds are discovered.  While isolation and subsequent modification of active 
natural products have yielded compounds with expanded application and improved 
therapeutic profiles, this approach is limited in its potential.  The generation and testing 
of large libraries of compounds using high-throughput methods (HTS) is an interesting 
approach that has led to the discovery of some important drug compounds.  HTS methods 
are, by their own scale costly, and the increasing cost of screening compounds makes the 
massive efforts difficult to sustain.  In fact as few as one compound in 25,000 will 
produce a screen hit among random libraries and fewer still make it into the clinic.  By 
beginning the design process with an understanding of underlying biological processes 
and tailoring synthesis to exploit these properties, one can lower costs associated with 
synthesis, improve hit rate and subsequent lead candidate production, and generate a 
more thoughtfully composed molecule in terms of its desired pharmacological properties 
(ADME, specificity, toxicity, etc.).   
One of the most effective ways to begin a rational synthesis approach is through 
examining the molecular structure of the biological target (a receptor in our case).  Using 
this approach molecular distances and chemical features of the binding site or active site 
for enzymes are quantitatively defined.  Using a complex mathematical molecular 
description of the target one can ostensibly “dock” or fit a potential ligand molecule into 
the activated enzyme or receptor binding site and measure it’s “fit” empirically.  In the 
case of the nAChR, as is the case with other membrane-associated receptors, the free 
receptor is not readily soluble in aqueous solution and thus has proven difficult to 
generate useable crystalline structures upon which to carry out X-ray diffraction analysis.  
In lieu of a suitable docking model, structure-activity relationship (SAR) analysis can be 
carried out to develop a model of the binding pocket.  By evaluating 2D and 3D positions 
and physiochemical properties of functional groups on a series of ligands, generalizations 
can be made in terms of what is required for binding and/or activation.  The 
pharmacophore is the arrangement of relevant groups possessing the proper 
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 physiochemical properties that are required of a ligand in order to effectively interact 
with a receptor.  Once the pharmacophoric requirements for binding have been 
established, several common medicinal approaches can be applied to alter the various 
pharmacodynamic and pharmacokinetic properties of a lead compound or lead series.   
 
Common approaches include:  
 
Biosteric replacement of functional groups 
Homologation  
Structural pruning/addition 
Fragmentation (half molecules) 
Rigidification of a molecule 
Changes in feature size 
Duplication/multiplication of important features. 
 
Pharmacophore models of nAChR were developed early in NIC research and 
focused mainly on the internitrogen distance of NIC and structurally-related compounds 
including the natural ligand ACh.  Early models were quick to appreciate the importance 
of a positively centered onium site (Hey 1952).  Later, the model was expanded to 
include a anionic site and believed to exist ~4.9 Å from the onium site (Kier 1968).  The 
first modern, consensus model to gain widespread acceptance was postulated by Beers 
and Reich and was based on Dreidling and CPK space-filling models.  In this dual 
element model they described two common features critical for nAChR binding and 
functional activity 1) a positively charged alkyl-onium moiety (the protonated nitrogen of 
the pyrrolidine ring) and 2) an electronegative H-bond acceptor (the lone pair N-pyridine 
electrons).  These features were believed to have an optimal intramolecular internitrogen 
distance of 5.9Å, from the cationic center to the surface of the hydrogen bond acceptor 
(Beers 1970).  Later, using a distance geometry approach based on the geometries of 
NIC, cytisine, and ferruginine, Sheridan et. al refined the model and helped to define the 
requisite molecular dimensions for active NIC ligands (Sheridan 1986).  The distance 
between functional groups was postulated to be 4.8Å.  Although the general principles 
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 remain sound, recent data has challenged some aspects of this traditional view of the 
nicotinic pharmacophore as new “unusual” compounds have been identified that possess  
 
 
H-bond acceptor 
            (δ-) 
Aryl centroid 
Nicotine
Acetylcholine
5.1Å 
4.75Å Onium group
         (δ+) 
 
 
 
 
 
Figure 3.1  Basic Beers-Reich nicotinic pharmacophore model detailing the critical features as 
demonstrated with the molecules NIC and ACh.  Features include the onium site, the anionic H-bond 
acceptor and the aryl centroid/acetyl methyl group for NIC and ACh respectively.   Later revised models 
include aome other accepted features but the basic model is shown here for simplicity and accuracy.   
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high affinity.  For instance, Ebt appears to have an equivalent internitrogen distance of 
5.5Å.  This distance is longer than that of NIC (4.9Å) and much longer than would be  
considered for an active compound, yet Ebt is the most potent natural nAChR activator 
known.  Glennon recently added to the pharmacophore a restriction on the basic nitrogen 
substituents (Glennon 2004).  Additional reviews and revisions to the model have been 
put forth recently (Tonder 2001, Brejc 2001, Schmitt 2000).           
Given the recent discoveries of the heterogeneity of the neuronal nAChR 
subtypes, and the multiple imagined conformations associated with the various receptor 
activation states, it is no surprise that refinement for this worthwhile model was to be 
expected.  More recently a modified model has been presented featuring four key 
elements 1) interaction between the protonated nitrogen of the pyrrolidine with an anionic 
site in the binding pocket, 2) a H-bond acceptor moiety that corresponds to the pyridine 
nitrogen that interacts with a H-bond donor at the receptor surface, 3) a π-system 
interaction of the ligand with either another π-system or a positively charged residue on 
the receptor, and 4) interaction between a cationic atom in the ligand with a π-system on 
the receptor (trp-149) and relatively nonspecific aliphatic steric interactions of the 
heteroaromatic portions of the ligand with the receptor (Tonder 2001).  Currently it is 
believed that some of the distance issues may be alleviated with the understanding that a 
water bridge may exist to fill the gap between ionically interacting pairs between ligand 
and receptor, even among compounds with interatomic distances outside of the Beers-
Reich-Sheradon norm (Glennon 2004). 
While the defined crystal structure of the nAChR peptide is not currently 
available for reasons discussed earlier, advancements in the structural elucidation of the 
nAChR binding site have recently come about, although from a most unusual source.  
The acetylcholine binding protein (AChBP) is a structural and functional peptide analog 
of the extracellular ligand binding domain of the nAChR isolated from the marine snail 
Lymnaea stagnalis.  Since the AChBP is highly water-soluble crystalline structures of the 
protein were created and used in X-ray diffraction studies to obtain a high-resolution 3D 
structure of the heteromer with specific emphasis on the supposed ligand binding domain.  
It is believed that its natural role is to reside in the cholinergic synapses of the snail and 
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 there, modulate ACh binding and signaling by sequestering excess free ACh.  The 
AChBP structure has become an established model for the ligand binding domain of 
nAChRs and a variety of homology models have been developed upon this hypothesis 
(Smit and Sixma 2006).  Like native nAChRs, AChBPs form homopentamers and their 
primary structure aligns with the corresponding nAChR N-terminal segments as would be 
expected for a peptide containing the ligand binding domain (Brejc and Sixma 2001).  
Without spending too much effort detailing the specific molecular features involved with 
AChBP ligand-peptide interaction, it should be stated that critical molecular features 
predicted by the standard Beers-Reich-Sheridon model are found in the AChBP 
supporting their role in the nAChR (reviewed in Karlin 2004). 
 
 Design of Ligands  
The primary aim of this project was to synthesize novel nicotinic analogs that 
mimic ligands at the NIC pharmacophore by utilizing several drug design approaches to 
synthesis.  While a tremendous number of NIC analogs have been synthesized and tested, 
and several promising guanidine-containing compounds have been identified which 
possess receptor channel activity, there appears to be little work reported in the literature 
on their co-application.  Replacing of the cationic pyrrolidine moiety of NIC with the 
cationic guanidine moiety to generate a small library of compounds designed around the 
functional guanidine group, the potential of this family of compounds can be explored 
and potentially active compounds for the nAChR and its subtypes may be discovered.   
As seen in figure 3-2, the NIC molecule can be broken down into three distinct regions 
viewed as A, B, and C.  Modifications can then be incorporated into each distinct region 
with the aim to design compounds with improved nicotinic activity.  Region A is a 
pyridine ring moiety, and is thought to interact at the nAChR in two ways; 1) the ring 
nitrogen atom is acidic and therefore can interact as a H-bond acceptor and 2) the 
aromatic feature of the pyridine ring is believed to interact with a partially positive site on 
the receptor via a π ring system-cation interaction.  Region B components designate the 
space between the pyridine moiety and the pyrrolidine moiety and thus is critical in 
defining the N-N interatomic distance within the ligand molecule.  Molecular alterations  
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Figure 3-2  Model molecule for guanidine analogs of NIC.  In this depiction region A substitutions take the place of 
the pyridine moiety in NIC.  Region C takes the place of the pyrrolidine moiety in NIC.  Region B modifications 
determine the interatomic distance between the two critical nitrogen atoms in NIC and is varied in this work to examine 
the effects these alterations of the molecule have on ligand affinity and activity. 
 
can be included that extend this distance.  Region C contains the essential onium or 
cationic charge-containing group.  In the case of NIC the pyrrolidine nitrogen is 
protonated at physiological pH and thus in its quaternized state carries a formal charge, 
and the methylene groupings are believed to play a role in binding via non-polar 
hydrophobic interactions with residues in the binding site on the nAChR.   
Although a parallel series of amidino-containing compounds will be introduced in 
a later section, the goal of this synthetic project focuses mainly on guanidino analogs of 
NIC where the pyrrolidine moiety has been replaced with a guanidine or a substituted 
guanidine group.  For Region A several ring substituents were used to generate homologs 
of the NIC pyridine ring.  Positional isomers of pyridine were included (2’, 3’ and 4’ 
aminopyridine and 2’, 3’, and 4’ aminomethyl pyridine) in order to evaluate the effect(s) 
of varying the positional attachment of the cationic moiety within the guanidine series.  
In order to synthesize diguanidine compounds three positional isomers of 
diaminopyridine were employed (2’3’, 3’4’, and 2’6’-diaminopyridine) to explore the 
effects of doubling the guanidine functionality and the effects of varying the position of 
attachment thereof.  2’, 3’ and 4’-methoxybenzylamine was used to examine the effects 
of a partially negative grouping directly off of the pyridine ring and the effects  
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Figure 3-3  List of primary amine compounds used in synthetic procedure as substitutions in the A region of the model 
molecule.  A variety of substituted aromatics were used including pyridines and picolines.  Some pyrrolidines were 
used also to evaluate the effect that the loss of the aromaticity would have on receptor affinity.  All compounds 
contained primary amines and were purchased from commercial sources and used without prior purification.    
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 of varying the ring position.  Various pyrrolidine and substituted pyrrolidine rings were 
employed to examine the effects of doubling the cationic effect of the NIC molecule 
while removing the critical H-bond accepting pyridine moiety.  In order to further 
examine the effects of pyridine ring substitutions on activity compounds were 
synthesized which included a 6-chloro-aminomethylpyridine group in the A region of the 
molecule.  This was done to determine if this guanidine series of compounds reacts in the 
same way other series of compounds react to a 6-chloropyridine; with a similar or 
improved affinity.  2’, 3’, and 4’-picoline was used as an A region substitute because a 
similar series of nAChR antagonists from our lab the picoline moiety seemed to 
contribute to affinity and functional antagonism.  As in the cases above, positional 
isomers at 2’ 3’ and 4’ were used to expand the range and to determine potential 
positional effects on SAR.  As will be seen, additional groups were employed as A region 
substitutions such as 3-(2-aminoethyl)-pyridine and bromo-substituted pyridines to 
explore additional diversity in this series, and will be revealed later in the synthetic 
results.  (Refer to figure 3-3 for a list of substituents discussed).   
For region C, the incorporation of the guanidine group is beneficial to the 
development of active nicotinic compounds in two ways 1) while guanidine carries a 
positive charge, it is a carbo-cationic charge that presents a distinct ionic pair partner 
when compared to the point charge associated with the pyrrolidine group and 2) upon the 
same principle, the charge is stabilized across the two omega nitrogen atoms in a 
resonance form and thus provides a larger surface of potential ionic interaction with 
anionic sites in the binding domain of the receptor.  This may allow for greater flexibility 
in binding and thus, may take advantage of minor differences in the binding domains 
among the nAChR subtypes.  For these reasons, bioisosteric replacement of the NIC 
pyrrolidine with guanidine or a guanidine-like substituent is found in all of the AH series 
of compounds.  In addition to the guanidine group previously mentioned, other N-
substituted guanidines, N,N-disubstituted guanidines, and guanidine-like ring moieties 
were employed.  (Refer to figure 3-4 for the structures associated with synthesis)   
Among the N-substituted guanidines are; N-ethyl, N-propyl, N-butyl, and N-
hexylguanidine.  This series examines the effects that increasing chain length and steric 
bulk has on the activity of the guanidine compounds.  By increasing the length of the  
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 Region C Replacements 
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Figure 3-4  List of guanidine and guanidine-like compounds used in synthetic procedure as substitutions in the C 
region of the model molecule.  The naked thiourea synthon (guanidine), as well as a variety of substituted thioureas and 
ring-containing compounds were used to mimic the guanidine moiety.  All compounds contained primary amines and 
were purchased from commercial sources as thioureas.  All molecules were prepared prior to reaction with 
iodomethane to generate the thiomethyl  “synthon”. 
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 alkyl chain on the guanidine moiety from ethyl through hexyl, differences in the nAChR 
binding domain may be uncovered and exploited.   
Among the N,N-disubstituted guanidines are; N,N-diethyl, N,N-diisopropyl, N,N-
dibutyl and N,N-tetramethyl additions.  Apart from the tetramethyl all of the disubstituted 
guanidine compounds explore the effect of added aliphatic size and steric bulk to the 
terminal ends of the guanidine moiety.  These compounds were developed to probe for 
regions on the receptor that accommodate larger bulky substituents on the ligand 
molecule and to determine the limits of this tolerance by increasing the size of the 
additions throughout the series.  The N,N-N,N-tetramethylguanidine synthesis is designed 
to evaluate the required formal positive charge associated with the covalent 
quaternization of one of the omega nitrogen atoms of the guanidine moiety that in a way 
mimics more closely the pyrrolidine ring of the NIC molecule.     
Among the cyclic guanidine additions are; imidazolidine, pyrimidine and 1,4,5,6-
tetrahydropyrimidine.  The purpose of including these groups is to examine the effects of 
the addition of a closed ring analog in place of the guanidine itself.  These three ring 
systems make it possible to examine the possible effects of both ring expansion and ring 
aromatization/conjugation within the series of guanidine compounds.     
The interatomic N-N distance is determined by the linkage between the two major 
groups (A and C) and is incorporated into the design primarily by the length of the 
connectivity of the primary amine on the A group.  Different A region bioisosteric 
substitutions will result in molecules with differing interatomic nitrogen distances.  Many 
of the common design approaches listed in the SAR section (supra) were addressed in 
this drug design project, and several were employed in order to maximize the potential 
diversity in the small library of compounds that was synthesized.  For all compounds 
synthesized the familiar nitro group that was crucial to the insect selectivity of the IMI 
molecule has been left out.  Since the products are specifically targeted toward 
mammalian nAChRs and insect affinity, it, while not totally undesirable, was to be 
avoided generally due to the higher degree of affinity and subtype selectivity among 
compounds found to be selective for the mammalian nAChRs.  In the other regions 
changes in molecular structure can be seen in the pruning of and reduction in size of 
functional groups and the relative shortening and extension of the atomic bridge between 
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 the two principle groups of the nicotinic ligand.  In some compounds ring chloro groups 
or methyl groups have been added to the pyridine ring and a series of di-guanidine 
containing compounds were synthesized.   
 
 
 
3.2 Guanylation Chemistry: Synthesis Background and Methods 
 
 Synthetic Approaches and Schemes 
A number of pharmacologically active compounds contain guanidine groups.  It is 
found widely in natural products and in numerous synthetic applications (discussed in 
chapter 2.6, reviewed in Yet 1999, and in Orner and Hamilton 2001).  In terms of 
synthesis it presents problems because guanidine moiety is both electron-rich and highly 
basic.  Because of this, bulky protecting groups are often employed in the synthetic route.  
Ideally these protecting groups are relatively non-polar groups that are easily cleaved 
using routine methods that do not present problems for downstream reactions.  There are 
a substantial number of reports in the literature detailing guanylation reactions and 
reactions that generate substituted guanidines (Li and Fan 2003, Linton and Hamilton 
2000).  Although recently a great deal of attention has focused on solid-phase synthesis 
of guanidines from amines and alcohols, the overwhelming majority of papers report on 
more traditional solution-phase methods.   
Currently there exist several rapid and sufficiently simple methods for the 
synthesis of protected and unprotected guanidines and substituted guanidines.  The 
majority of these employ a guanylating reagent of some sort.  Several reported methods 
include the use of cyanamides, carbodiimides, chloroformamidines and 
dichloroisocyanides.  These materials are generally undesirable due to their toxic and 
corrosive properties or because they are highly water sensitive.  Ideally, guanylating 
reagents (synthons) would be cheap and commercially-available or easily and 
inexpensively prepared, result in a high yield, and are easily separated from the product.  
For the most part, successfully employed guanylating reagents are based generally on a 
substituted or protected and activated urea structure.  In application this, more often than 
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 not, takes the form of reacting ammonias or amines with a substituted thiourea because 
they act as a good leaving group when reacted with a primary-substituted amine under 
basic conditions.  As you will see, the term “guanlyation” is preferred here when 
describing the conversion of amines to guanidines, as opposed to the often misused term 
“guanidinylation” which more aptly refers to the addition of a guanidine moiety to a 
parent group.  A select few synthetic routes will be discussed and the advantages and 
disadvantages of each will be examined in the following sections.  
 In many guanylation reactions, as noted above, major synthons often take the 
form of thioureas and protected thioureas.  Numerous methods exist for modifying these 
thioureas into proto-guanidine molecules, and then through processes of cleavage, 
addition, or substitution, the final guanidine product is formed (reviewed in Orner and 
Hamilton 2001).  One such method relies on the attack of sulfonic acid reagents derived 
from N-alkyl substituted thioureas to generate guanidines (Jursic 2000, Maryanoff 1985, 
Maryanoff 1986).  In this case (figure 3-1), a method for preparing mono-substituted 
guanidines is applied where formamidinesulfonic acids are conveniently converted to 
aminoiminomethanesulfonic acid with peracetic acid.  The sulfonic acid readily takes the 
form of the sulfonate anion, a very weak base and very good leaving group.  Under 
normal conditions the synthon is reacted with a primary amine to yield zwitterionic 
guanidines which are commonly isolated in the salt form by treatment with acid (see 
reaction scheme, scheme 1).  This reaction method was considered initially, but because 
of the limitation of this reaction as described in the literature to the synthesis of 
monosubstituted guanidines, the limited commercial availability of prepared mono- and 
di-substituted synthetic reagents, and the low overall yield other reactions were 
investigated.   
A second common, multistep guanylation method involves the use of an 
isothiocyanate reagent (see scheme 3-2).  In this reaction benzoylisothiocyanate is reacted 
with an appropriate amine in order to form the corresponding benzoylthiourea (Zhang 
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Scheme 3-1  A sulfinic acid is conveniently converted to the sulfonic acid in preparation to reaction with a primary 
amine.  The guanylation reaction takes place under basic conditions.  The guanidine product is isolated in the salt form.  
Although a simple method with few synthetic steps, too low a yield among other considerations make this method less 
than ideal.  
 
 
and Li 2001).  The carbamate group increases the reactivity of the isothiocyanate.  From 
here the reaction can proceed in two ways 1) the reagent is deacylated and then reacted 
with an amine or 2) where the carbamoyl thiourea is reacted with amine and then 
deacylated.  In procedure 1, deacylation of the reagent with a strong base, affords the N-
substituted thiourea.  Following treatment, the thiourea must then be N-BOC protected by 
reaction with BOC20 in the presence of a strong base (see Poss 1992).  Only then can the 
actual guanylation reaction take place.  In procedure 2, a second amine is coupled to the 
carbamoyl thiourea to form 1,1- or 1,1,3-substituted thioureas followed by the 
deacylation step.  Although the reported yields are good for these types of reactions, there 
are too many steps for the parallel-type synthesis aimed for in this study.  In either case 
the reaction of the thiourea guanylating reagent with a second amine requires basic 
conditions and the presence of HgCl2 (reviewed in Levallet and Ko 1997).  It was hoped 
that such toxic reagents could be avoided during the synthetic phase of this project.  
Additionally, the handling of large quantities of cyanates and substituted-cyanates in 
order to generate the appropriate synthons was unappealing.  For these reasons, 
alternative methods that did not employ so many synthetic steps and did not require the 
use of potentially toxic reagents were investigated.          
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Scheme 3-2.  Guanidines can be generated by reaction of an isothiocyanate with a primary amine.  The modified 
thiourea can then be reacted with a second amine and deacylated to generate the guanidine or it can be deacylated then 
reacted with a second amine.  Although very useful in other regards, generating a variety of mono-and di-substituted 
guanidine products using this procedure would require too many steps to meet the aim of this project. 
 
 
The synthetic goals of this project require a method that allows for the ability to 
react a variety of amines in parallel with a guanylating reagent(s) to afford products in 
reasonable yields that can be readily purified which also minimizes the use of potentially 
dangerous reagents, and can be carried out in a minimum of reaction steps.  A strategy 
has been reported that employs a non-S-alkylated, BOC-protected thiourea which is then 
reacted with primary and secondary amines, however this process often requires a strong 
base and mercury-containing reagents for improved yields and is thus not optimal for our 
needs (Exposito and Riguera 2001, Yong and Lipton 1996). 
An alternative preparation of a BOC-protected thiourea guanlyating reagent is 
available that makes the reaction with a primary amine more facile and thus does not 
require the use of HgCl2.  In this case the BOC-protected thiourea guanylating reagent is 
treated in a reaction with iodomethane to afford the BOC-protected-S-methyl thiourea 
[N,N’-bis(tert-butoxycarbonyl)-S-methyl-2-thiopseudourea] (see Schemes 3-3 and 3-4)  
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Scheme 3-3.  BOC-protecting the synthons reagent prior to S-methylation.  Di-BOC protected isothiourea is generated 
by reaction of isothiourea with di-tert-butyldicarbonate in chloroform with sodium carbonate for 36 hours.  Product is 
then separated from unreacted thiourea in the organic phase.  Di-BOC product is separated from Mono-BOC product 
via silica column.  Product is further purified via crystallization from hexanes.       
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Scheme 3-4.  Generating the thiomethyl group on the finished synthons.  N,N’-di-(tert-butoxycarbonyl)-thiopseudourea 
is generated by reaction of isothiourea with iodomethane in methanol.  Product is then dried and crystallized upon 
cooling in a small volume of chloroform.  The thiomethyl moiety is an excellent leaving group that can easily be 
removed from reaction mixture by vacuum drying.       
 
(Monache and Carmignani 1993, Baer and Lockwood 1953, Verdini and Giordani 1992).  
Although initial experiments used the commercial reagent later reactions were 
synthesized in the lab and purified according to the method shown in schemes 3-3 and 3-
4).  Treatment of the di-BOC protected thioureas with iodomethane, to afford the S-
methylated guanylation reagent provides a synthon with a very good methyl-mercaptan 
leaving group, thus allowing the nucleophilic-mediated addition to proceed smoothly.  
This treatment not only improves reaction rate and yield, it also circumvents the 
requirement for an Hg-containing reagent.   
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 It is also a common practice to add a protecting group to the thiourea guanylating 
reagent’s terminal amino group in order to help direct the amine addition reaction and to 
avoid undesired products with substitutions on the omega nitrogen atoms on the product 
guanidine.  Since guanidines are highly basic and water-soluble, the common protecting 
group tert-butoxycarbonyl (BOC) is used to improve reactant solubility in common 
organic solvents like THF and DCM, and to facilitate purification away from more water 
soluble reactants for ease of purification.  Additionally, the BOC group also promotes the 
nucleophilic substitution reaction generally.     
In addition to the thiourea synthons proper, additional thiourea-like synthons were 
prepared in a similar manner, using other guanylating reagent starting materials 
(imidazolidines, pyrimidines, and N’-substituted and N,N’-disubstituted thioureas as seen 
in figure 3-4).  We chose this route of synthesis because several affordable, 
commercially-available thioureas were found to be available that could be purchased and 
easily prepared in substantial quantities and employed as synthons in multiple parallel 
reactions in combination with a variety of suitable primary amines.   
 
Synthetic Methods and Materials 
All guanylating reagents were prepared by purchasing the synthon starting 
materials as thioureas or the thiourea analogs (as previously described) from Sigma-
Aldrich Chemicals (St. Louis, MO).  Briefly, thioureas were reacted with a slight molar 
excess (1.1:1) of iodomethane (>99%).  Products were allowed to stir in appropriate 
solvent for up to an overnight period.  Reaction mixtures were placed on a rota-
evaporator to remove solvent and placed under pump vacuum overnight to remove 
residual iodomethane from the reaction mixture.  Products were brought up in a small 
volume of solvent and dissolved under heat and allowed to cool to room temperature.  By 
this method the finished S-methylated synthons were allowed to crystallize to a suitable 
purity.    
In order to accommodate several reactions at the same time, a small semi-
automated, benchtop parallel synthesizer was purchased from Argonaut Technologies.  
The FirstMate unit is proficient in small-scale parallel synthesis, and includes a reactor 
bank, agitator base, automated controller, and temperature variation system.  Agitation is 
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 achieved by vertical oscillation, and is fully adjustable in velocity, upstroke, and 
frequency for optimal flexibility.  Temperature can be adjusted in all reaction vessels 
from -78°C to 130°C, according to reaction requirements.  In this case, the FirstMate 
parallel organic synthesizer apparatus allowed for up to twelve liquid-phase under 
pressurized N2 gas to proceed at a controlled temperature setting using a variable vertical 
stirring mechanism (www.argotech.com/firstmate).      
Several primary amines were reacted with guanylating reagent in parallel using 
the same synthetic route in slightly differing conditions (scheme 4) in order to obtain 
guanidine-containing analogs of NIC.  From two starting materials in each reaction, 
various primary amines correspond to alterations in the A region of the model molecule 
and various synthons correspond to region C of the model molecule (from figure 3-2).  
The primary amine-synthon reaction is the basic synthetic strategy used here to generate 
all guanidine products.   
For clarity, general reaction methods detailing use of each of the synthons will be 
presented in the following section.  All reactions were carried out in some combination of 
common organic solvent (CHCl3, DCM, MeOH, THF, etc.) and allowed to stir at room 
temperature overnight.  With the exception of the BOC-protected guanidine reaction 
product that was isolated as an HCl salt, all reaction products were generated as iodine 
salts.        
 
General reaction 1:   
Unsubstituted guanidine compounds can be prepared by the addition of a slight 
excess of primary amine and guanylating reagent in tetrahydrofuran.  The BOC groups 
are easily cleaved with excess trifluoroacetic acid followed by rota-varopation.  The de-
BOC’ed salt form was separated in the aqueous layer from ether or DCM and treated 
with an excess of hydrochloric acid to form the chloride salt.  The lipophilic BOC groups 
allow for silica column purification away from the unreacted amine and following 
cleavage separation in the aqueous phase allows for similar separation away from the 
unreacted diBOC protected thiourea starting materials.    
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Scheme 3-5.  Reaction of primary amines with diBOC-protected S-methyl-isothiourea guanylating reagent to generate 
the unsubstituted guanidine HCl salt.  Addition of the amine occurs under mildly basic conditions followed by 
treatment with trifluoroacetic acid and separation in the aqueous phase.  Excess hydrochloric acid affords the HCl salt.  
 
 
General reaction 2:   
Nω-Nω’-bridged guanidino compounds [including imidazolidine, pyrimidine and 
tetrahydropyrimidine bridged compounds] (see figure 3-4), are prepared in a manner 
similar to general reaction 1.  Bridged synthons were reacted with primary amines in 
chloroform/methanol (for imidazolidines), in tetrahydrofuran/methanol (for pyrimidines 
and tetrahydropyrimidines).  Reactions were stirred at room temperature for 24-48 hrs.  
Compounds were assayed for purity by thin-layer silica chromatography and 1H-NMR  
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Scheme 3-6.  Reaction of primary amines with S-methyl-bridged thiourea guanylating reagents to generate the N,N’-
bridged guanidino compound.  Addition of the amine occurs under mildly basic conditions followed by rotavaporation 
and column purification. 
 
 
analysis.  If further purification was required compounds were purified via preparative 
silica gel chromatography using an appropriate solvent system; usually employing 
CHCl3/DCM/hexanes with small percentages of MeOH as needed.   
 
 
General reaction 3:   
Nω-Nω’ mono- and di-substituted guanidino compounds [including N’-ethyl, N’-
propyl, N’-butyl, N’-hexyl, N,N’-diethyl, N,N’-tetramethyl, N,N’-diisopropyl, and N,N’-
dibutyl compounds] (see figure 3-4), are prepared in a manner similar to general reactions 
1 and 2.  Alkyl substituted synthons were reacted with primary amines in appropriate 
solvent system: chloroform/methanol or tetrahydrofuran/methanol and stirred at room 
temperature for 24-48 hrs.  Compounds were assayed for purity by thin-layer silica 
chromatography and 1H-NMR analysis.  If further purification was required compounds 
were purified via preparative silica gel chromatography using an appropriate solvent 
system; usually employing CHCl3/DCM/hexanes with small percentages of MeOH as 
needed. 
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Scheme 3-7.  Reaction of primary amines with S-methyl-alkyl-substituted thiourea guanylating reagents to generate the 
N’-mono or N,N’-disubstituted guanidino compound.  Addition of the amine occurs under mildly basic conditions 
followed by rotavaporation and column purification. 
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 3.3 Guanylation Chemistry: Results 
 
 The following includes reaction details for each of the guanidine product 
compounds listed.  Each description follows one of the three general reaction methods 
described previously.   
 
Note: If not further noted, all reagents and chemicals were ordered from Aldrich and 
Acros Chemicals Inc.  Compound purification via flash column chromatography was 
carried out by passing reaction mixtures in an appropriate solvent system through a 
separation column equilibrated with at least 20-fold excess (w/w) ICN Silica-Tech 32–63, 
60Å silica gel in starting solvent.  1H-NMR and 13C-NMR spectra were recorded on a 
Varian 300 MHz instrument in CDCl3, d6-DMSO or D2O NMR solvents, and are reported 
in ppm relative to TMS, DMSO or H20 as internal standard. 
 
AH-1 
   
N NH
N
+
NH2
H
H
Cl
-
1-pyridin-2-ylguanidine hydrochloride
C6H9N4-HCl  F.W.=172.61
 
Reaction was carried out as in general reaction 1.  2-aminopyridine and N,N‘-
(tert-butoxycarbonyl)-S-methyl-isothiopseudourea  were dissolved in tetrahydrofuran and 
stirred 16 hours.  BOC groups were cleaved with TFA.  Hydrochloride salt was formed 
with excess HCl in MeOH.  Product was purified via silica gel column chromatography. 
1H NMR (300MHz, CDCl3): δ 11.61 (broad s, NH), 8.04 (d, J=7.0 Hz, 1H), 7.45 (m, 1H), 6.66 
(m, 1H), 6.54 (dd, J=2.4, J=8.9 Hz), 4.63 (broad s, NH) ppm;  13C NMR (300MHz, d6-D2O) δ 
172.26, 147.28, 130.5, 129.4, 127.3, 126.5 ppm. 
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 AH-2 
   
Cl
-
C6H8N4-HCl  F.W.=172.61
NH
N
+
NH2
H
N
H
1-pyridin-3-ylguanidine hydrochloride
 
Reaction was carried out as in general reaction 1.  3-aminopyridine and N,N‘-
(tert-butoxycarbonyl)-S-methyl-isothiopseudourea were dissolved in tetrahydrofuran and 
stirred 16 hours.  BOC groups were cleaved with TFA.  Hydrochloride salt was formed 
with excess HCl in MeOH.  The product was purified via silica column chromatography. 
1H NMR (300MHz, D2O): δ 8.03 (m, 1H), 7.96 (d, J=7.5 Hz, 1H), 7.73 (m, 1H), 7.67 (d, J=5.4 
Hz, 1H) ppm.  
AH-3 
   
Cl
-
C6H8N4-HCl  F.W.=172.61
NH
N
+
NH2
H
N
H
1-pyridin-4-ylguanidine hydrochloride
 
Reaction was carried out as in general reaction 1.  4-aminopyridine and N,N‘-
(tert-butoxycarbonyl)-S-methyl-isothiopseudourea were dissolved in tetrahydrofuran and 
stirred 16 hours.  BOC groups were cleaved with TFA.  Hydrochloride salt was formed 
with excess HCl in MeOH.  The product was purified via silica column chromatography. 
1H NMR (300MHz, CDCl3): δ 11.61 (broad s, NH), 8.22 (d, J=6.5 Hz, 2H), 6.50 (m, 2H),  4.10 
(broad s, 1H, NH) ppm.  
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 AH-4 
   
Cl
-
C7H10N4-HCl    F.W.=186.64
N
NH
N
+
NH2
H
H
1-(pyridin-2-ylmethyl)guanidine hydrochloride
 
Reaction was carried out as in general reaction 1.  2-aminomethylpyridine and 
N,N‘-(tert-butoxycarbonyl)-S-methyl-isothiopseudourea  were dissolved in 
tetrahydrofuran and stirred 16 hours.  BOC groups were cleaved with TFA.  
Hydrochloride salt was formed with excess HCl in MeOH.  The product was purified via 
silica gel column chromatography.  1H NMR (300MHz, d6-DMSO): δ 8.80 (d, J=5.4 Hz, 1H), 
8.39 (dt, J=6.0, J=20.7 Hz, 1H), 778 (m, 2H), 7.71 (broad s, 2H), 4.81 (d, J=6.1 Hz, 2H) ppm;  
13C NMR (300MHz, d6-DMSO) δ 170.5, 157.53, 153.7, 143.8, 124.8, 123.6, 43.0 ppm. 
 
AH-5 
   
Cl
-
C7H10N4-HCl    F.W.=186.64
1-(pyridin-3-ylmethyl)guanidine hydrochloride
NH
N
+
NH2
H
N
H
 
Reaction was carried out as in general reaction 1.  3-aminomethylpyridine and 
N,N‘-(tert-butoxycarbonyl)-S-methyl-isothiopseudourea were dissolved in 
tetrahydrofuran and stirred 16 hours.  BOC groups were cleaved with TFA.  
Hydrochloride salt was formed with excess HCl in MeOH.  The product was purified via 
silica gel column chromatography.  1H NMR (300MHz, D2O): δ 8.70-8.73 (m, 2H), 8.49 (d, 
J=8.1 Hz, 1H),  8.01 (dd, J=4.5 Hz, J=5.7 Hz, 1H), 4.69 (s, 2H) ppm;  13C NMR (300MHz, d6-
DMSO) δ 157.3, 144.1, 142.9, 141.9, 137.4, 127.6, 42.2, 40.4 ppm. 
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 AH-6 
   
Cl
-
C7H10N4-HCl    F.W.=186.64
1-(pyridin-4-ylmethyl)guanidine hydrochloride
NH
N
+
NH2
H
N
H
 
Reaction was carried out as in general reaction 1.  4-aminomethylpyridine and 
N,N‘-(tert-butoxycarbonyl)-S-methyl-isothiopseudourea were dissolved in 
tetrahydrofuran and stirred 16 hours.  BOC groups were cleaved with TFA.  
Hydrochloride salt was formed with excess HCl in MeOH.  The product was purified via 
silica gel column chromatography.  1H NMR (300MHz, D2O): δ 8.92 (d, J=5.7 Hz, 1H), 8.758 
(t, J=6.3 Hz, 1H), 7.91 (d, J=6.0 Hz, 1H), 7.73 (broad s, and m, 2H, NH), 4.84 (d, J=6.6 Hz) ppm.  
13C NMR (300MHz, DMSO): δ 8.59 (d, J=4.5 Hz, 2H), 7.28 (d, J=5.0 Hz, 2H)), 4.43 (d, J=6.5 
Hz, 2H), 3.61 (s, 4H) ppm. 
AH-7 
   
C7H11N7-HCl  F.W.=266.13
N
+
NH2
H
NH
N NH
N
+
NH2
H
H
H
Cl
-
N,N'''-pyridine-2,3-diyldiguanidine dihydrochloride
Cl
-
 
Reaction was carried out as in general reaction 1.  2,3-diaminopyridine and N,N‘-
(tert-butoxycarbonyl)-S-methyl-isothiopseudourea were dissolved in tetrahydrofuran and 
stirred 16 hours.  BOC groups were cleaved with TFA.  Hydrochloride salt was formed 
with excess HCl in MeOH.  The product was purified via silica column chromatography. 
1H NMR (300MHz, D2O): δ 8.25 (d, J=1.5 Hz, 1H), 8.10 (d, J=18.0 Hz 1H), 7.03 (d, J=6.9 Hz, 
1H) ppm; 13C NMR (300MHz, d6-D2O) δ 156.3, 138.8, 133.9, 118.0, 110.5, 107.8 ppm. 
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 AH-8  
  
Cl
-
C9H10N4O-HCl  F.W.=210.66
N
H
NH
N
+
NH2
H
H
amino(1H-indol-5-ylamino)methaniminium hydrochlride
 
Reaction was carried out as in general reaction 1.  5-aminoindole and N,N‘-(tert-
butoxycarbonyl)-S-methyl-isothiopseudourea were dissolved in tetrahydrofuran and 
stirred 16 hours.  BOC groups were cleaved with TFA.  Hydrochloride salt was formed 
with excess HCl in MeOH.  The product was purified via silica column chromatography. 
 1H NMR (300MHz, DMSO): δ 9.90 (1H, s, broad), 8.10 (2H, s, broad), 8.026 (1H, s) 8.00 (1H, 
d, J=0.044Hz), 7.50 (1H, m, J=0.04Hz), 7.256 (1H, s), 6.928 (1H, m).   
 
AH-13 
   
Cl
-
C9H10N4O-HCl  F.W.=210.66
N
H
NH
N
+
NH2
H
H
amino(1H-indol-5-ylamino)methaniminium hydrochlride
 
Reaction was carried out as in general reaction 1.  4-methoxybenzylamine and N,N‘-(tert-
butoxycarbonyl)-S-methyl-isothiopseudourea were dissolved in tetrahydrofuran and 
stirred 16 hours.  BOC groups were cleaved with TFA.  Hydrochloride salt was formed 
with excess HCl in MeOH.  The product was purified via silica column chromatography. 
1H NMR (300MHz, DMSO): δ 8.60 (broad s, 1H), 7.25 (d, J=8.4 Hz, 2H), 6.94 (d, J=8.4 Hz, 2H), 
4.28 (s, 2H), 3.74 (s, 3H) ppm; 13C NMR (300MHz, d6-DMSO) δ 158.9, 128.9, 128.4, 113.8, 
55.1, 44.9, 42.5 ppm.   
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 AH-14 
   
Cl
-
C8H12N4-HCl    F.W.=200.66
N NH
N
+
NH2
H
H
1-(2-pyridin-2-ylethyl)guanidine hydrochloride
 
Reaction was carried out as in general reaction 1.  2-pyridin-2-ylethanimine and 
N,N‘-(tert-butoxycarbonyl)-S-methyl-isothiopseudourea  were dissolved in 
tetrahydrofuran and stirred 16 hours.  BOC groups were cleaved with TFA.  
Hydrochloride salt was formed with excess HCl in MeOH.  The product was purified via 
silica gel column chromatography.  1H NMR (300MHz, D2O): δ 8.63 (d, J=4.5 Hz, 1H), 8.59 
(t, J=8.1 Hz, 1H), 7.94 (m, 2H), 3.66 (m, 2H), 3.32 (m, 2H) ppm; 13C NMR (300MHz, d6-D2O) δ 
152.9, 147.2, 141.2, 127.8, 125.6, 39.9, 32.7 ppm. 
 
 
AH-15 
   
Cl
-
C7H16N4-HCl    F.W.=192.68
N
NH
N
+
NH2
H
H
1-(2-pyrrolidin-1-ylethyl)guanidine hydrochloride
 
Reaction was carried out as in general reaction 1.  2-pyrrolidin-2-yl)ethanamine 
and N,N‘-(tert-butoxycarbonyl)-S-methyl-isothiopseudourea  were dissolved in 
tetrahydrofuran and stirred 16 hours.  BOC groups were cleaved with TFA.  
Hydrochloride salt was formed with excess HCl in MeOH.  The product was purified via 
silica gel column chromatography. 1H NMR (300MHz, D2O): δ; 4.81 (s, 1H, NH), 3.65 (m, 
2H), 3.58 (t, J=6.0 Hz, 2H), 3.39 (t, J=5.8 Hz, 2H), 3.08 (m, 2H), 2.10 (m, 2H), 1.98 (m, 2H) 
ppm; 13C NMR (300MHz, D2O) δ 162.5, 54.7, 52.9, 37.6, 22.8 ppm.  
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 AH-16 
  
Cl
-
C8H18N4-HCl    F.W.=206.71
1-[2-(1-methylpyrrolidin-2-yl)ethyl]guanidine hydrochloride
N NH
H3C
N
+
NH2
H
H
 
Reaction was carried out as in general reaction 1.  2-(1-methylpyrrolidin-2-
yl)ethanamine and N,N‘-(tert-butoxycarbonyl)-S-methyl-isothiopseudourea  were 
dissolved in tetrahydrofuran and stirred 16 hours.  BOC groups were cleaved with TFA.  
Hydrochloride salt was formed with excess HCl in MeOH.  The product was purified via 
silica gel column chromatography. 1H NMR (300MHz, d6-DMSO): δ 11.1 (broad s, 1H), 4.57 
broad s, 3H), 3.48 (m, 2H), 3.25 (m, 2H), 3.01 (m, 2H), 2.74 (s, 3H), 2.21 (m, 2H), 1.90 (m, 2H) 
ppm; 13C NMR (300MHz, d6-DMSO) δ 156.9, 65.61, 54.924, 38.12, 29.47, 29.24, 21.34 ppm.  
 
 
AH-30 
   
Cl
-
C14H11BrN3O-HCl    F.W.=352.61
NH
N
+
NH2
H
Br
O
H
1-(7-bromo-9-oxo-9H-fluoren-2-yl)guanidine hydrochloride
 
Reaction was carried out as in general reaction 1.  2-amino-7-bromo-fluorenone 
and N,N‘-(tert-butoxycarbonyl)-S-methyl-isothiopseudourea were dissolved in 
tetrahydrofuran and stirred 16 hours.  BOC groups were cleaved with TFA.  
Hydrochloride salt was formed with excess HCl in MeOH.  The product was purified via 
silica gel column chromatography.  1H NMR (300MHz, DMSO): δ 10.65 (broad s, NH), 7.82 
(m, 4H), 7.58 (m, 2H), 3.94 (broad s, NH) ppm.   
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 AH-34 
   
C8H10N4-HI    F.W.=290.10
NH
N
H
N
+
N
H
N-(4,5-dihydro-1H-imidazol-2-yl)pyridin-2-amine 
hydroiodide
-I
 
Reaction was carried out as in general reaction 2.  2-aminopyridine and 2-
methylsulfanyl-4,5-dihydro-1H-imidazole hydroiodide were dissolved in (10:3) 
THF/EtOH and stirred for 16 hours.  Product compound was purified via silica gel 
column chromatography.  1H NMR (300MHz, d6-DMSO): δ 8.34 (broad s, 1H, NH), 7.88 (m, 
1H), 7.37 (m, 1H), 6.45 (m, 2H), 5.94 (broad s, 2H NH), 3.85 (s, 2H), 3.27 (s, 2H) ppm;  
  
 
 
AH-35 
   
C8H10N4-HI    F.W.=290.10
N-(4,5-dihydro-1H-imidazol-2-yl)pyridin-3-amine 
hydroiodide
-I
NH
N
H
N
+
N
H
 
Reaction was carried out as in general reaction 2.  3-aminopyridine and 2-
methylsulfanyl-4,5-dihydro-1H-imidazole hydroiodide were dissolved in tetrahydrofuran 
and stirred for 16 hours.  Product compound was purified via silica gel column 
chromatography.  1H NMR (300MHz, d6-DMSO): δ 7.92 (s, 1H), 7.51 (d, J=3.9 Hz, 1H), 6.99 
(d, J=5.5 Hz, 1H), 6.92 (m 1H), 6.62 (broad s, 1H), 3.85 (s, 4H) ppm.  
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 AH-36 
   
C8H10N4-HI    F.W.=290.10
N-(4,5-dihydro-1H-imidazol-2-yl)pyridin-4-amine 
hydroiodide
-I
NH
N
H
N
+
N
H
 
Reaction was carried out as in general reaction 2.  4-aminopyridine and 2-
methylsulfanyl-4,5-dihydro-1H-imidazole hydroiodide were dissolved in tetrahydrofuran 
and stirred for 16 hours.  Product compound was purified via silica gel column 
chromatography. 1H NMR (300MHz, d6-DMSO): δ 8.11 (d, J=7.2 Hz, 2H), 8.02 (broad s, 2H), 
7.98 (d, J=6.0 Hz, 2H), 3.85 (d, J=3.2 Hz, 2H), 3.25 (s, 2H) ppm. 
 
 
 
AH-37 
  
C9H12N4-HI    F.W.=304.13
NH
N
H
N
+
N
H -I
N-(pyridin-2-ylmethyl)-4,5-dihydro-1H-imidazol-2-amine 
hydroiodide
 
Reaction was carried out as in general reaction 2.  2-aminomethylpyridine and 2-
methylsulfanyl-4,5-dihydro-1H-imidazole hydroiodide were dissolved in (10:3) 
THF/EtOH and stirred for 16 hours.  Product compound was purified via silica gel 
column chromatography.  1H NMR (300MHz, d6-DMSO): δ 8.65 (t, J=6.0 Hz, 1H), 8.58 (m, 
1H), 7.83 (m, 1H), 7.35 (d, J=11.0 Hz, 1H), 4.49 (d, J=6.7 Hz, 2H), 3.62 (s, 4H) ppm.  
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 AH-38 
  
C9H12N4-HI    F.W.=304.13
-I
N-(pyridin-3-ylmethyl)-4,5-dihydro-1H-imidazol-2-amine 
hydroiodide
NH
N
H
N
+
N
H
 
Reaction was carried out as in general reaction 2.  3-aminomethylpyridine and 2-
methylsulfanyl-4,5-dihydro-1H-imidazole hydroiodide were dissolved in (10:3) 
THF/EtOH  and stirred for 16 hours.  Product compound was purified via silica gel 
column chromatography.  1H NMR (300MHz, d6-DMSO): δ 8.52-8.55 (m, 2H), 7.73 (d, J=9.0 
Hz, 1H), 7.43 (d, J=12.0 Hz, 1H), 4.43 (s, 2H), 3.62 (s, 4H) ppm; 13C NMR (300MHz, d6-DMSO) 
δ 159.1, 148.7, 148.5, 135.0, 132.6, 123.6, 43.0, 42.5 ppm. 
 
AH-39 
  
C9H12N4-HI    F.W.=304.13
-I
N-(pyridin-3-ylmethyl)-4,5-dihydro-1H-imidazol-4-amine 
hydroiodide
NH
N
H
N
+
N
H
 
Reaction was carried out as in general reaction 2.  4-aminomethylpyridine and 2-
methylsulfanyl-4,5-dihydro-1H-imidazole hydroiodide were dissolved in (10:3) 
THF/EtOH  and stirred for 16 hours.  Product compound was purified via silica gel 
column chromatography.  1H NMR (300MHz, d6-DMSO): δ 8.59 (d, J=3.0 Hz, 2H), 8.25 
(broad s, 2H), 7.32 (d, J=5.8 Hz, 2H), 4.45 (d, J=6.5 Hz, 2H), 3.61 (s, 4H) ppm; 13C NMR 
(300MHz, d6-DMSO) δ 157.9, 149.6, 144.5, 122.2, 44.6 ppm. 
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AH-41 
   
C11H15N7-2(HI)    F.W.=501.11
NH
N
H
N
+
NNH
N
H
N
+
H
H -I
-I
N,N'-di-4,5-dihydro-1H-imidazol-2-ylpyridine-
2,6-diamine dihydroiodide
 
Reaction was carried out as in general reaction 2.  2,6-diaminopyridine and 2-
methylsulfanyl-4,5-dihydro-1H-imidazole hydroiodide were dissolved in (10:3) 
THF/EtOH and stirred for 16 hours.  Product compound was purified via silica gel 
column chromatography.  NMR (300MHz, d6-DMSO): δ 9.95 (broad, NH), 7.29 (m, 2H), 6.37 
(m, 1H), 3.86 (d J=3.6 Hz, 4H), 2.62 (d, J=3.6 Hz) ppm; 13C NMR (300MHz, d6-DMSO) δ 170.2, 
134.7, 124.2, 45.2, 13.6 ppm. 
 
 
AH-44 
   
-I
C11H15N3O-HI  F.W.=331.17
NH
O
CH3 N
H
N
+
H
N-(4-methoxybenzyl)-4,5-dihydro-
1H-imidazol-2-amine hydroiodide
 
Reaction was carried out as in general reaction 2.  4-methoxybenzylamine and 2-
methylsulfanyl-4,5-dihydro-1H-imidazole hydroiodide were dissolved in (10:3) 
THF/EtOH and stirred 16 hours.  The product was purified via silica column 
chromatography.  NMR (300MHz, d6-DMSO): δ 8.60 (broad, NH), 7.24 (d, J=9.0 Hz 2H), 6.95 
(d, J=8.7 Hz, 2H), 4.28 (s, 2H), 3.74 (m, 4H), 3.60 (s, 3H) ppm; 13C NMR (300MHz, d6-DMSO): 
δ 158.9, 129.5, 128.7, 113.8, 55.1, 44.9, 42.5 ppm.   
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AH-45 
        
C9H18N4-Hl    F.W.=310.18
N
NH
N
H
N
+
H
-I
N-(2-pyrrolidin-1-ylethyl)-4,5-dihydro-
1H-imidazol-2-amine hydroiodide
 
Reaction was carried out as in general reaction 2.  2-pyrrolidin-1-ylethanamine 
and 2-methylsulfanyl-4,5-dihydro-1H-imidazole hydroiodide were dissolved in (10:3) 
THF/EtOH and stirred 16 hours.  BOC groups were cleaved with TFA.  The product was 
purified via silica gel column chromatography.  1H NMR (300MHz, d6-DMSO): δ 8.05 
(broad s, NH), 3.58 (s, 4H), 3.23 (t, J=5.9 Hz, 2H), 2.58 (m, 6H), 1.69 (m, 4H) ppm; 13C NMR 
(300MHz, d6-DMSO): δ 159.20, 54.10, 53.4, 42.5, 41.3, 23.15 ppm. 
 
 
AH-46 
  
C10H20N4-Hl    F.W.=324.20
N NH
H3C
N
H
N
+
H
-I
N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4,5-dihydro-
1H-imidazol-2-amine hydroiodide
 
Reaction was carried out as in general reaction 2.  2-(1-methylpyrrolidin-2-
yl)ethanamine and 2-methylsulfanyl-4,5-dihydro-1H-imidazole hydroiodide were 
dissolved in (10:3) THF/EtOH and stirred 16 hours.  The product was purified via silica 
gel column chromatography.  1H NMR (300MHz, d6-DMSO): δ 8.05 (broad s, NH), 3.58 (s, 
3H), 3.14 (m, 2H), 2.92 (m, 2H), 2.20 (s, 4H), 2.04 (m, 2H), 1.82 (m, 2H), 1.65 (m, 2H), 1.42 (m, 
2H) ppm; 13C NMR (300MHz, d6-DMSO) δ 159.2, 63.0, 56.5, 45.0, 40.35, 39.65, 32.0, 29.8, 21.8 
ppm.  
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 AH-50 
        
C8H10BrN4-HI    F.W.=370.10
NH
N
H
N
+
N
Br H
-I
5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)pyridin-
2-amine hydroiodide
 
Reaction was carried out as in general reaction 2.  2-amino-5-bromopyridine and 
2-methylsulfanyl-4,5-dihydro-1H-imidazole hydroiodide were dissolved in (10:3) 
THF/EtOH and stirred for 16 hours.  Product compound was purified via silica gel 
column chromatography.  1H NMR (300MHz, d6-DMSO): δ 9.99 (broad s, 1H), 7.94 (d, J=4.2 
Hz 1H), 7.49 (dd, J=3.0, J=9.0 Hz, 1H), 6.41 (d, J=14.0 Hz, 1H), 6.16 (broad s, 2H), 3.86 (s, 2H), 
2.621 (s, 2H) ppm; 13C NMR (300MHz, d6-DMSO) δ 170.2, 158.5, 147.7, 139.0, 109.9, 105.0, 
45.2 ppm.   
 
AH-55 
        
C8H10Br2N4-HI    F.W.=449.91
NH
N
H
N
+
N
BrBr H
-I
3,5-dibromo-N-(4,5-dihydro-1H-imidazol-2-yl)pyridin-
2-amine hydroiodide
 
Reaction was carried out as in general reaction 2.  2-amino-3,5-dibromopyridine 
and 2-methylsulfanyl-4,5-dihydro-1H-imidazole hydroiodide were dissolved in (10:3) 
THF/EtOH and stirred for 16 hours.  Product compound was purified via silica gel 
column chromatography.  1H NMR (300MHz, d6-DMSO): δ 9.95 (broad s, H), 8.00 (s, 1H), 
87.95 (s, 1H), 6.47 (broad s, 2H), 3.86 (s, 2H), 2.62 (s, 2H) ppm; 13C NMR (300MHz, d6-DMSO) 
δ 170.1, 155.3, 147.01, 141.1, 104.1, 45.2, 13.6 ppm.   
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 AH-56 
 
NH
N
H
N
+
H
C14H17N3-HI    F.W.=355.22
-I
N-[2-(1H-inden-3-yl)ethyl]-4,5-dihydro-1H-imidazol-2-amine hydroiodide
 
Reaction was carried out as in general reaction 2.  2-(1H-inden-3-yl)ethanamine 
and 2-methylsulfanyl-4,5-dihydro-1H-imidazole hydroiodide were dissolved in (10:3) 
THF/EtOH and stirred for 16 hours.  Product compound was purified via silica gel 
column chromatography.  1H NMR (300MHz, d6-DMSO): δ 10.82 (broad s, NH), 7.53 (t, J=8.5 
Hz, 1H), 7.34 (t, J=6.4 Hz, 1H), 7.15 (d, J=12.0 Hz, 1H), 7.08 (m, 1H), 6.99 (m, 1H), 3.57 (s, 
4H), 3.42 (t, J=7.2 Hz, 2H), 2.82 (m, 2H) ppm; 13C NMR (300MHz, d6-DMSO) δ 159.0, 136.2, 
126.8, 122.7, 120.8, 119.4, 118.1, 111.2, 99.5, 42.9, 42.5, 24.7 ppm. 
 
 
AH-58 
             
C9H8N4-HI    F.W.=300.09
-I
NH
N
N
+
N
H
N-pyridin-3-ylpyrimidin-2-amine
hydroiodide
 
Reaction was carried out as in general reaction 2.  3-aminopyridine and 2-
(methylthio)-pyrimidine hydroiodide were dissolved in MeOH and stirred for 16 hours.  
Product compound was purified via silica gel column chromatography.  1H NMR 
(300MHz, d6-DMSO): δ 8.62 (d, J=5.5 Hz, 1H), 7.91 (m, 1H), 7.25 (m, 1H), 7.04 (m, 2H), 6.92 
(m, 1H), 4.25 (broad s, NH) ppm.  
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 AH-59 
             
C9H8N4-HI    F.W.=300.09
-I
NH
N
N
+
N
H
N-pyridin-4-ylpyrimidin-2-amine
hydroiodide
 
Reaction was carried out as in general reaction 2.  4-aminopyridine and 2-
(methylthio)-pyrimidine hydroiodide were dissolved in MeOH and stirred for 16 hours.  
Product compound was purified via silica gel column chromatography.  1H NMR 
(300MHz, d6-DMSO): δ 8.63 (d, J=4.9 Hz, 2H), 7.97 (d, J=5.4 Hz, 2H), 7.20 (m, 1H), 6.47 (m, 
2H), 6.14 (broad s, NH) ppm; 13C NMR (300MHz, d6-DMSO) δ 161.2, 157.5, 154.5, 148.5, 
116.9, 108.7 ppm. 
 
AH-61 
   
-I
NH
N
N
+
N
H
N-(pyridin-3-ylmethyl)pyrimidin-2-amine 
hydroiodide
C10H10N4-HI    F.W.=314.12
 
Reaction was carried out as in general reaction 2.  3-aminomethylpyridine and 2-
(methylthio)-pyrimidine hydroiodide were dissolved in MeOH and stirred for 16 hours.  
Product compound was purified via silica gel column chromatography.  1H NMR 
(300MHz, d6-DMSO): δ 8.64 (m, 2H), 8.53-8.55 (m, 2H), 8.16 (d, J=9.0 Hz, 1H), 7.65 (m, 1H), 
7.43 (d, J=4.5 Hz, 1H), 4.37 (s, 2H) ppm; 13C NMR (300MHz, d6-DMSO) δ 160.2, 149.7, 149.1, 
148.6, 148.5, 136.4, 134.9, 123.5, 41.3 ppm. 
 
 
 104
  
AH-75 
   
C10H16N4-HI    F.W.=320.19
NH
NH
N
+
CH3
CH3
N
H
1,2-diethyl-3-pyridin-2-ylguanidine 
hydroiodide
-I
 
Reaction was carried out as in general reaction 3.  2-aminopyridine and methyl 
N,N'-diethylimidothiocarbamate hydroiodide were dissolved in (4:1) THF/MeOH and 
stirred for 16 hours.  Product compound was purified via silica gel column 
chromatography.  1H NMR (300MHz, d6-DMSO): δ 8.37 (broad s, NH), 7.87 (m, 1H), 7.37 (m, 
1H), 6.46 (m, 1H), 6.02 (broad s, NH), 2.97 (q, J=1.2 Hz, 4H), 0.96 (t, J=7.2 Hz, 6H) ppm; ; 13C 
NMR (300MHz, d6-DMSO) δ 146.6, 140.5, 137.3, 112.7, 111.6, 108.22, 34.0, 15.8 ppm. 
 
AH-76 
   
C10H16N4-HI    F.W.=320.19
1,2-diethyl-3-pyridin-3-ylguanidine 
hydroiodide
-I
N
NH
NH
N
+
CH3
CH3
H
 
Reaction was carried out as in general reaction 3.  3-aminopyridine and methyl 
N,N'-diethylimidothiocarbamate hydroiodide were dissolved in (4:1) THF/MeOH and 
stirred for 16 hours.  Product compound was purified via silica gel column 
chromatography. 1H NMR (300MHz, d6-DMSO): δ 7.98 (s, 1H), 7.72 (d, J=4.4 Hz, 1H), 7.01 
(m, 1H), 6.93 (m, 1H), 5.74 (broad s, NH), 2.98 (m, 4H), 0.95 (m, 6H) ppm; 13C NMR (300MHz, 
d6-DMSO) δ 144.9, 136.4, 135.8, 127.6, 123.6, 119.8, 34.0, 15.8 ppn. 
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AH-77 
   
C10H16N4-HI    F.W.=320.19
1,2-diethyl-3-pyridin-4-ylguanidine 
hydroiodide
-I
N
NH
NH
N
+
CH3
CH3
H
 
Reaction was carried out as in general reaction 3.  4-aminopyridine and methyl 
N,N'-diethylimidothiocarbamate hydroiodide were dissolved in (4:1) THF/MeOH and 
stirred for 16 hours.  Product compound was purified via silica gel column 
chromatography.  1H NMR (300MHz, d6-DMSO): δ 8.00 (broad s, NH), 7.95 (m, 2H), 6.44 (m, 
2H), 6.01 (broad s, NH), 2.98 (p, J=1.5 Hz, 4H), 0.96 (t, J=7.2 Hz, 6H) ppm; 13C NMR (300MHz, 
d6-DMSO) δ 154.0, 149.0, 143.5, 108.7, 34.0, 15.8 ppm. 
 
AH-79 
   
C11H18N4-HI    F.W.=334.19
-I
1,2-diethyl-3-(pyridin-2-ylmethyl)guanidine 
hydroiodide
NH
NH
N
+
CH3
CH3
H
N
 
Reaction was carried out as in general reaction 3.  3-aminomethylpyridine and 
methyl N,N'-diethylimidothiocarbamate hydroiodide were dissolved in (4:1) THF/MeOH 
and stirred for 16 hours.  Product compound was purified via silica gel column 
chromatography.  1H NMR (300MHz, d6-DMSO): δ 8.66 (s, 1H), 8.59 (d, J=12.0 Hz, 1H), 7.84 
(m, 1H), 7.49 (m, 1H), 4.17 (s, 2H), 3.40 (bs, 2H), 2.972 (m, 4H), 0.958 (t, J=72.0 Hz, 6H) ppm; 
13C NMR (300MHz, d6-DMSO) δ 160.2, 149.8, 148.1, 146.7, 134.3, 123.7, 40.0, 34.0, 15.8 ppm. 
 
 106
  
AH-86 
    
C8H12N4-HI    F.W.=292.12
NH
NH
N
+
CH3
N
H
H
1-ethyl-3-pyridin-2-ylguanidine 
hydroiodide
-I
 
Reaction was carried out as in general reaction 3.  2-aminopyridine and methyl N-
ethylimidothiocarbamate hydroiodide were dissolved in (4:1) THF/MeOH and stirred for 
16 hours.  Product compound was purified via silica gel column chromatography.  1H 
NMR (300MHz, d6-DMSO): δ 8.37 (broad s, NH), 7.87 (m, 1H), 7.42 (m, 1H), 6.49 (m, 2H), 
6.18 (broad s, NH), 2.95 (m, 2H), 0.95 (t, J=8.1 Hz, 3H) ppm; 13C NMR (300MHz, d6-DMSO) δ 
158.5, 145.8, 137.8, 114.4, 111.7, 108.6, 41.5, 15.8 ppm. 
 
AH-87 
         
C8H12N4-HI    F.W.=292.12
1-ethyl-3-pyridin-3-ylguanidine 
hydroiodide
-I
NH
NH
N
+
CH3
H
N
H
 
Reaction was carried out as in general reaction 3.  3-aminopyridine and methyl N-
ethylimidothiocarbamate hydroiodide were dissolved in (4:1) THF/MeOH and stirred for 
16 hours.  Product compound was purified via silica gel column chromatography.  1H 
NMR (300MHz, d6-DMSO): δ 7.92 (m, 1H), 7.73 (m, 1H), 7.70 (m, 1H), 6.95 (M, 1H), 6.92 
(broad s, NH), 5.45 (broad s, NH), 2.95 (m, 2H), 0.95 (t, J=7.5 Hz, 3H) ppm; 13C NMR 
(300MHz, d6-DMSO) δ 148.3, 136.1, 127.6, 123.7, 120.1, 47.5, 15.7 ppm. 
 
 107
  
AH-88 
             
C8H12N4-HI    F.W.=292.12
1-ethyl-3-pyridin-4-ylguanidine 
hydroiodide
-I
NH
NH
N
+
CH3
H
N
H
 
Reaction was carried out as in general reaction 3.  4-aminopyridine and methyl N-
ethylimidothiocarbamate hydroiodide were dissolved in (4:1) THF/MeOH and stirred for 
16 hours.  Product compound was purified via silica gel column chromatography.  1H 
NMR (300MHz, d6-DMSO): δ 8.10 (d, J=6.3 Hz, 2H), 8.02 (broad s, NH), 6.79 (d, J=7.8 Hz, 
2H), 6.23 (broad s, NH), 4.37 (broad s, NH), 2.95 (m, 2H), 0.95 (t, J=7.2 Hz, 3H) ppm; 13C NMR 
(300MHz, d6-DMSO) δ 158.1, 154.7, 148.1, 143.5, 44.4, 15.7 ppm. 
 
AH-90 
   
C9H14N4-HI    F.W.=306.14
1-ethyl-3-(pyridin-3-ylmethyl)guanidine 
hydrochloride
-I
NH
NH
N
+
CH3
H
H
N
    
Reaction was carried out as in general reaction 3.  3-aminomethylpyridine and 
methyl N-ethylimidothiocarbamate hydroiodide were dissolved in (4:1) THF/MeOH and 
stirred for 16 hours.  Product compound was purified via silica gel column 
chromatography.  1H NMR (300MHz, d6-DMSO): δ 8.54 (s, 1H), 8.462 (m, 1H), 7.64 (d, J=6.0 
Hz, 1H), 4.23 (d, J=7.0 Hz, 2H), 3.18 (m, 2H), 1.00 (dq, J=30.9 Hz, J=6.0 Hz, 3H) ppm; 13C 
NMR (300MHz, d6-DMSO) δ 160.5, 149.3, 148.9, 148.4, 134.7, 123.3, 40.7, 34.1, 16.0 ppm. 
 
 108
 AH-96 
        
C9H12N4-HI    F.W.=304.13
-I
NH
N
H
N
+
N
H
N-pyridin-2-yl-1,4,5,6-tetrahydropyrimidin-
2-amine hydroiodide
 
Reaction was carried out as in general reaction 2.  2aminopyridine and 2-
(methylsulfanyl)-1,4,5,6-tetrahydropyrimidine hydroiodide were dissolved in THF: 
MeOH and stirred for 16 hours.  Product compound was purified via silica gel column 
chromatography.  1H NMR (300MHz, d6-DMSO): δ 9.60 (broad s, NH), 7.88 (m, 1H), 7.35 (m, 
1H), 6.44 (m, 2H), 5.91 (broad s, NH), 3.37 (t, J=5.7 Hz, 4H), 1.89 (m, 2H) ppm; 13C NMR 
(300MHz, d6-DMSO) δ 159.2, 147.2, 136.9, 111.6, 107.9, 40.3, 18.3 ppm.  
 
AH-97 
        
C9H12N4-HI    F.W.=304.13
-I
NH
N
H
N
+
N
H
N-pyridin-3-yl-1,4,5,6-tetrahydropyrimidin-2-amine 
hydroiodide
 
Reaction was carried out as in general reaction 2.  3-aminopyridine and 2-
(methylsulfanyl)-1,4,5,6-tetrahydropyrimidine hydroiodide were dissolved in THF: 
MeOH and stirred for 16 hours.  Product compound was purified via silica gel column 
chromatography.  1H NMR (300MHz, d6-DMSO): δ 9.57 (broad s, NH), 7.91 (d, J=3.9 Hz, 1H), 
7.72 (d, J=6.9 Hz, 1H), 7.00 (m, 1H), 6.9 (m, 1H), 5.25 (broad s, NH), 3.37 (m, 4H), 1.88 (m, 2H) 
ppm; 13C NMR (300MHz, d6-DMSO) δ 162.8, 144.6, 136.6, 136.1, 123.5, 119.5, 40.35, 18.10 
ppm. 
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 AH-98 
        
C9H12N4-HI    F.W.=304.13
-I
NH
N
H
N
+
N
H
N-pyridin-4-yl-1,4,5,6-tetrahydropyrimidin-2-amine 
hydroiodide
 
Reaction was carried out as in general reaction 2.  4-aminopyridine and 2-
(methylsulfanyl)-1,4,5,6-tetrahydropyrimidine hydroiodide were dissolved in THF: 
MeOH and stirred for 16 hours.  Product compound was purified via silica gel column 
chromatography.  1H NMR (300MHz, d6-DMSO): δ 8.05 (dd, J=5.4, J=18.0 Hz, 1H), 8.02 
(broad s, NH), 6.47 (dd, J=4.5, J=4.9 Hz, 2H), 6.20 (broad s, NH), 6.08 (broad s, NH), 3.07 (m, 
4H), 1.67 (p, J=5.5 Hz, 2H) ppm; 13C NMR (300MHz, d6-DMSO) δ 158.1, 154.6, 143.5, 109.1, 
44.3, 21.5 ppm. 
 
AH-100 
      
C10H14N4-HI    F.W.=318.16
-I
NH
N
H
N
+
N
H
N-(pyridin-4-ylmethyl)-1,4,5,6-tetrahydropyrimidin-2-amine hydroiodide
 
Reaction was carried out as in general reaction 2.  3-aminomethylpyridine and 2-
(methylsulfanyl)-1,4,5,6-tetrahydropyrimidine hydroiodide were dissolved in THF: 
MeOH and stirred for 16 hours.  Product compound was purified via silica gel column 
chromatography.  1H NMR (300MHz, d6-DMSO): δ  8.63 (s, (1H), 8.43 (d, J=4.8 Hz, 1H), 7.76 
(d, J=6.9 Hz, 1H), 7.35 (m, 1H), 4.84 (s, 2H), 3.77 (t, J=5.5 Hz, 4H), 1.57 (m, 2H) ppm; 13C 
NMR (300MHz, d6-DMSO) δ  157.5, 148.7, 147.6, 134.9, 123.3, 61.4, 42.6 ppm. 
 
 
 110
 AH-106 
       
C10H17N4-I    F.W.=320.17
NH
N
N
+
N
CH3
CH3
CH3
CH3
-I
N-[(dimethylamino)(pyridin-2-ylamino)methylidene]
-N-methylmethanaminium iodide
 
Reaction was carried out as in general reaction 3.  2-aminopyridine and N-
[(dimethylamino)(methylsulfanyl)methylidene]-N-methylmethanaminium iodide were 
dissolved in (4:1) THF/MeOH and stirred for 16 hours.  Product compound was purified 
via silica gel column chromatography. 1H NMR (300MHz, d6-DMSO): δ 7.88 (d, J=5.1 Hz, 
1H), 7.46 (m, 1H), 6.52 (m, 2H), 6.32 (broad s, NH), 3.10 (s, 6H), 2.67 (s, 2H), 2.55 (s, 2H) ppm; 
13C NMR (300MHz, d6-DMSO) δ 158.2, 144.9, 138.3, 111.7, 109.0, 54.2, 34.5 ppm. 
 
AH-107 
  
C10H17N4-I    F.W.=320.17
-I
N-[(dimethylamino)(pyridin-3-ylamino)methylidene]
-N-methylmethanaminium iodide
NH
N
N
+
CH3
CH3
CH3
CH3
N
 
Reaction was carried out as in general reaction 3.  3-aminopyridine and N-
[(dimethylamino)(methylsulfanyl)methylidene]-N-methylmethanaminium iodide were 
dissolved in (4:1) THF/MeOH and stirred for 16 hours.  Product compound was purified 
via silica gel column chromatography.  1H NMR (300MHz, d6-DMSO): δ  7.93 (d, J=2.4 Hz, 
1H), 7.75 (d, J=4.5 1H), 7.08 (m, 1H), 7.00 (m, 1H) ppm; 13C NMR (300MHz, d6-DMSO) δ 
154.1, 135.5, 134.7, 123.9, 120.7, 47.5, 38.2 ppm. 
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 AH-108 
  
C10H17N4-I    F.W.=320.17
-I
N-[(dimethylamino)(pyridin-4-ylamino)methylidene]
-N-methylmethanaminium iodide
NH
N
N
+
CH3
CH3
CH3
CH3
N
 
Reaction was carried out as in general reaction 3.  4-aminopyridine and N-
[(dimethylamino)(methylsulfanyl)methylidene]-N-methylmethanaminium iodide were 
dissolved in (4:1) THF/MeOH and stirred for 16 hours.  Product compound was purified 
via silica gel column chromatography.  1H NMR (300MHz, d6-DMSO): δ  8.00 (d, J=4.1 Hz, 
2H), 6.551 (m, 2H), 3.11 (s, 6H), 2.68 (s, 6H) ppm. 
 
 
AH-114 
  
C11H19N4-I    F.W.=334.17
NH
N
N
+
N
CH3
CH3
CH3
CH3
CH3
-I
N-{(dimethylamino)[(5-methylpyridin-2-yl)amino]methylidene}-
N-methylmethanaminium iodide
 
Reaction was carried out as in general reaction 3.  2-amino-5-picoline and N-
[(dimethylamino)(methylsulfanyl)methylidene]-N-methylmethanaminium iodide were 
dissolved in (4:1) THF/MeOH and stirred for 16 hours.  Product compound was purified 
via silica gel column chromatography.  1H NMR (300MHz, d6-DMSO): δ 7.72 (d, J=0.6 Hz, 
1H), 7.36 (d, J=9.0 Hz, 1H), 6.51 (d, J=8.7 Hz, 1H), 6.25 (broad s, NH), 3.10 (s, 3H), 2.09 (s, 
(CH3)4) ppm; 13C NMR (300MHz, d6-DMSO) δ 156.1, 143.2, 139.9, 120.2, 109.1, 16.8 ppm.   
 
 112
 AH-132 
   
C13H22ClN4-HI    F.W.=396.69
-I
NH
NH
N
+
N
CH3
CH3
CH3
CH3Cl
H
1-[(6-chloropyridin-3-yl)methyl]-2,3-bis(1-
methylethyl)guanidine hydroiodide
 
Reaction was carried out as in general reaction 2.  2-chloro-5-
aminomethylpyridine and methyl N'-isopropyl-N-isopropylideneimidothiocarbamate 
hydroiodide were dissolved in (4:1) THF/MeOH and stirred for 16 hours.  Product 
compound was purified via silica gel column chromatography.  1H NMR (300MHz, d6-
DMSO): δ 8.47 (s, 1H), 7.73 (d, J=9.0 Hz, 1H), 7.61 (d, J=9.0 Hz, 1H), 7.48 (m, 1H), 5.49 (d, 
J=12.0 Hz, 2H), 3.56-3.68 (m, 2H), 0.99 (d, J=5.1 Hz, 12H) ppm; 13C NMR (300MHz, d6-
DMSO) δ 153.5, 149.1, 138.8, 137.9, 132.2, 123.9, 41.9, 36.1, 14.2 ppm. 
 
AH-133 
C14H24N4-HI    F.W.=396.69
-I
NH
NH
N
+
N
CH3
CH3
CH3
CH3
CH3
H
1,2-bis(1-methylethyl)-3-[(5-methylpyridin-3-yl)methyl]guanidine hydroiodide
 
Reaction was carried out as in general reaction 2.  3-aminomethyl-5-picoline and 
methyl N'-isopropyl-N-isopropylideneimidothiocarbamate hydroiodide were dissolved in 
(4:1) THF/MeOH and stirred for 16 hours.  Product compound was purified via silica gel 
column chromatography.1H NMR (300MHz, d6-DMSO): δ  8.15 (broad s, NH), 7.17 (d, J=1.5 
Hz, 1H), 7.21 (d, J=6.9 Hz, 1H), 6.39 (d, J=8.1 Hz, 1H), 5.49 (d, J=5.2 Hz, 1H), 3.64 (m, 2H), 
0.99 (t, J=3.2, 12H) ppm. 13C NMR (300MHz, d6-DMSO) δ 156.8, 145.6, 143.9, 138.3, 108.0, 
40.66, 23.32 ppm.  
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 AH-141 
   
C13H22ClN4-HI    F.W.=362.25
-I
NH
NH
N
+
N
CH3
CH3
CH3
CH3
H
1,2-bis(1-methylethyl)-3-(pyridin-3-ylmethyl)
guanidine hydroiodide
 
Reaction was carried out as in general reaction 2.  3-aminomethylpyridine and 
methyl N'-isopropyl-N-isopropylideneimidothiocarbamate hydroiodide were dissolved in 
(4:1) THF/MeOH and stirred for 16 hours.  Product compound was purified via silica gel 
column chromatography.  1H NMR (300MHz, d6-DMSO): δ 8.65 (m, 1H), 8.58 (m, 1H), 7.90 
(m, 1H), 7.49 (m, 1H), 5.50 (d J=7.8 Hz, 2H), 3.66 (m, 2H), 1.00 (m, 12H) ppm; . 13C NMR 
(300MHz, d6-DMSO) δ 156.6, 149.9, 149.8, 146.5, 136.6, 123.5, 49.1, 23.3 ppm. 
 
 
 
AH-148 
  
C11H15N3    F.W.=189.25
N
N
N CH3
3-[(1-ethyl-4,5-dihydro-1H-imidazol-2-yl)methyl]pyridine
 
Ethyl-3-pyridylacetate and N-ethylethane-1,2diamine were dissolved in 
tetrahydrofuran and stirred with LAH at reflux for 4 hours.  Product compound was 
purified via silica gel column chromatography.  1H NMR (300MHz, d6-DMSO): δ 8.44 
(broad s, 2H), 8.42 (d, J=5.1 Hz, 1H), 8.20 (m, 1H), 7.65 (d, J=7.5 Hz, 1H), 7.31 (m, 1H), 3.44 (s, 
2H), 3.12 (q, J=6.0 Hz, 2H), 2.55 (m, 4H), 0.98 (t, J=6.9 Hz, 3H) ppm; 13C NMR (300MHz, d6-
DMSO) δ  
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 AH-149 
  
-Cl
NH
NH2
N
+
NCl
H
H
1-[(6-chloropyridin-3-yl)methyl]guanidine hydrochloride
C7H9ClN4-HCl    F.W.=221.08
 
Reaction was carried out as in general reaction 1.  2-chloro-5-
aminomethylpyridine and N,N‘-(tert-butoxycarbonyl)-S-methyl-isothiopseudourea were 
dissolved in tetrahydrofuran and stirred 16 hours.  BOC groups were cleaved with TFA in 
water.  Hydrochloride salt was formed with excess HCl in MeOH.  Purified via silica 
column chromatography.  1H NMR (300MHz, d6-DMSO): δ 8.60 (bs, 2H), 8.38-8.43 (m, 1H), 
7.82 (d, J=9.0 Hz, 1H), 7.55 (d, J=9.0 Hz, 1H), 7.49 (bs, 3H), 4.45 (d, J=6.0 Hz, 2H) ppm; 13C 
NMR (300MHz, d6-DMSO) δ 157.1, 149.2, 147.8, 138.7, 132.7, 124.2, 40.8 ppm. 
 
AH-150 
   
C9H13ClN4-HI    F.W.=340.59
-I
NH
NH
N
+
CH3
H
NCl
H
1-[(6-chloropyridin-3-yl)methyl]-3-ethylguanidine 
hydroiodide
    
Reaction was carried out as in general reaction 3.  2-chloro-5-
aminomethylpyridine and methyl N-ethylimidothiocarbamate hydroiodide were dissolved 
in (4:1) THF/MeOH and stirred for 16 hours.  Product compound was purified via silica 
gel column chromatography.  1H NMR (300MHz, d6-DMSO): δ 8.38 (d, J=2.7 Hz, 1H), 7.85 
(dd, J=2.4, J=7.8 Hz, 1H), 7.50 (d, J=8.4 Hz, 1H), 4.42 (s, 2H), 3.81 (broad s, 2H), 3.15 (m, 2H), 
1.08 (t, J=7.5 Hz, 3H) ppm; 13C NMR (300MHz, d6-DMSO) δ 155.1, 149.2, 139.0, 136.5, 132.6, 
123.8, 41.4, 36.1, 14.5 ppm.    
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 AH-151 
   
C11H17ClN4-HI    F.W.=368.64
-I
NH
NH
N
+
CH3
CH3
NCl
H
1-[(6-chloropyridin-3-yl)methyl]-2,3-diethylguanidine 
hydroiodide
 
Reaction was carried out as in general reaction 3.  2-chloro-5-
aminomethylpyridine and methyl N,N'-diethylimidothiocarbamate hydroiodide were 
dissolved in (4:1) THF/MeOH and stirred for 16 hours.  Product compound was purified 
via silica gel column chromatography.  1H NMR (300MHz, d6-DMSO): δ 8.36 (s, 1H), 7.81 
(m, 1H), 7.50 (dd, J=8.1, J=26.1 Hz, 1H), 4.48 (s, 2H), 3.20 (m, 4H), 1.08 (t, J=7.2 Hz, 6H) ppm; 
13C NMR (300MHz, d6-DMSO) δ 153.4, 148.9, 138.8, 132.5, 124.0, 41.9, 36.1, 14.3 ppm. 
 
 
AH-153 
           
C10H13ClN4-HI    F.W.=352.60
-I
NH
N
H
N
+
NCl
H
N-[(6-chloropyridin-3-yl)methyl]-1,4,5,6-tetrahydropyrimidin-
2-amine hydroiodide
 
Reaction was carried out as in general reaction 2.  2-chloro-5-
aminomethylpyridine and 2-(methylsulfanyl)-1,4,5,6-tetrahydropyrimidine hydroiodide 
were dissolved in THF: MeOH and stirred for 16 hours.  Product compound was purified 
via silica gel column chromatography.  1H NMR (300MHz, d6-DMSO): δ 8.36 (s, 1H), 7.84 
(d, J=9.0 Hz, 1H), 7.46 (d, J=12.0 Hz, 1H), 4.36 (s, 2H), 3.24 (t, J=6.0 Hz, 4H), 1.80 (m, 2H) 
ppm. 13C NMR (300MHz, d6-DMSO) δ 152.3, 148.5, 138.7, 137.6, 132.5, 123.4, 42.8, 38.1, 19.4 
ppm. 
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 AH-154 
   
C9H10N4-HI    F.W.=348.57
-I
NH
N
N
+
NCl
H
N-[(6-chloropyridin-3-yl)methyl]pyrimidin-2-amine
hydroiodide
 
Reaction was carried out as in general reaction 2.  2-chloro-5-
aminomethylpyridine and 2-(methylthio)-pyrimidine hydroiodide were dissolved in 
THF:MeOH and stirred for 16 hours.  Product compound was purified via silica gel 
column chromatography.  1H NMR (300MHz, d6-DMSO): δ 8.64 (d, J=4.8Hz, 2H), 8.61 (broad 
s, 3H), 8.43 (d, J=4.5, 1H), 8.23 (dd, J=4.4, 7.9, 1H), 8.58 (m, 1H), 7.21 (t, J=6.0), 4.84 (s, 2H) 
ppm.   
 
AH-155 
   
C10H15ClN4-HI    F.W.=354.61
-I
NH
NH
N
+
H
NCl
CH3
H
1-[(6-chloropyridin-3-yl)methyl]-3-propylguanidine
hydroiodide
    
Reaction was carried out as in general reaction 3.  2-chloro-5-
aminomethylpyridine and methyl N-propylimidothiocarbamate hydroiodide were 
dissolved in (4:1) THF/MeOH and stirred for 16 hours.  Product compound was purified 
via silica gel column chromatography.  1H NMR (300MHz, d6-DMSO): δ 8.36 (s, 1H), 7.81 
(m, 1H), 7.52 (dd, J=8.4, J=27.6 Hz, 1H), 4.44 (s, 2H), 3.10 (t, J=7.2 Hz, 2H), 1.48 (m, 2H), 
0.844 (t, J=7.45, 3H) ppm; 13C NMR (300MHz, d6-DMSO) δ 155.2, 148.6, 138.9, 137.3, 132.5, 
123.7, 42.6, 41.7, 21.8, 11.0 ppm. 
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 AH-156 
   
C11H17ClN4-HI    F.W.=368.64
-I
NH
NH
N
+
H
NCl
CH3
H
1-butyl-3-[(6-chloropyridin-3-yl)methyl]guanidine
hydroiodide
    
Reaction was carried out as in general reaction 3.  2-chloro-5-
aminomethylpyridine and methyl N-butylimidothiocarbamate hydroiodide were dissolved 
in (4:1) THF/MeOH and stirred for 16 hours.  Product compound was purified via silica 
gel column chromatography. 1H NMR (300MHz, d6-DMSO): δ 8.37 (s, 1H), 7.78 (d, J=8.4 
Hz), 7.57 (d, J=8.4 Hz, 1H), 7.46 (broad s, 2H), 4.44 (s, 2H), 3.13 (m, 2H), 1.44 (m, 2H), 1.25 
(m, 2H), 0.86 (t, J=7.2 Hz, 3H) ppm; 13C NMR (300MHz, d6-DMSO) δ 155.5, 149.1, 148.7, 
138.8, 132.5, 124.2, 41.1, 40.7, 30.4, 19.3, 13.6 ppm. 
 
AH-157 
   
C15H25ClN4-HI    F.W.=424.75
-I
NH
NH
N
+
NCl
CH3
CH3
H
1,2-dibutyl-3-[(6-chloropyridin-3-yl)methyl]guanidine
hydroiodide
    
Reaction was carried out as in general reaction 3.  2-chloro-5-
aminomethylpyridine and methyl N,N-dibutylimidothiocarbamate hydroiodide were 
dissolved in (4:1) THF/MeOH and stirred for 16 hours.  Product compound was purified 
via silica gel column chromatography.  1H NMR (300MHz, d6-DMSO): δ 8.355 (t, J=2.4, 1H), 
7.95 (broad s, 1H), 7.77 (dt, J=3.0, J=11.1, 1H), 7.56 (dd, J=2.7, J=9.2, 1H), 7.48 (broad s, 3H), 
4.47 (d, J=3.3 2H), 3.16 (m, 4H), 1.41 (t, J=6.0, 4H), 1.19 (broad s, 4H), 0.83 (t, J=7.2, 4H) ppm;  
13C NMR (300MHz, d6-DMSO) δ 153.8, 149.2, 148.6, 138.7, 132.6, 124.1, 40.9, 38.7, 30.5, 19.3, 
13.6 ppm. 
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 AH-158 
   
C12H22ClN4-HI    F.W.=396.69
-I
NH
NH
N
+
H
NCl
H
CH3
1-butyl-3-[(6-chloropyridin-3-yl)methyl]guanidine
hydroiodide
    
Reaction was carried out as in general reaction 3.  2-chloro-5-
aminomethylpyridine and methyl N-hexylimidothiocarbamate hydroiodide were 
dissolved in (4:1) THF/MeOH and stirred for 16 hours.  Product compound was purified 
via silica gel column chromatography.  1H NMR (300MHz, d6-DMSO): δ 8.35 (s, 1H), 7.83 
(dd, J=2.1, J=7.8 Hz, 1H), 7.45 (d, J=8.4 Hz, 1H), 4.43 (s, 2H), 3.12 (t, J=6.0 Hz, 2H), 1.44 (m, 
2H), 1.22 (d, J=3.6 Hz, 2H), 1.01 (m, 2H), 0.85 (t, J=6.90, 3H) ppm. 
 
 
AH-159 
   
C9H11ClN4-HI    F.W .=338.57
-I
NH
N
H
N
+
NCl
H
N-[(6-chloropyridin-3-yl)m ethyl]-4,5-dihydro-
1H-im idazol-2-am ine hydroiodide
 
Reaction was carried out as in general reaction 2.  2-chloro-5-
aminomethylpyridine and 2-methylsulfanyl-4,5-dihydro-1H-imidazole hydroiodide were 
dissolved in tetrahydrofuran and stirred for 16 hours.  Product compound was purified via 
silica gel column chromatography.  1H NMR (300MHz, d6-DMSO): δ 8.38 (s, 1H), 7.86 (dd, 
J=9.0 Hz, J=3.0 Hz, H), 7.54 (dd, J=9.0 Hz, J=21.0 Hz, 1H), 4.42 (s, 2H), 3.83 (s, 2H), 3.61 (s, 
2H) ppm. 13C NMR (300MHz, d6-DMSO) δ 159.2, 149.0, 139.1, 132.2, 124.3, 123.7, 42.6, 42.3, 
41.3 ppm. 
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Results 
Over 140 synthetic reactions were carried out and initial products were confirmed 
by thin layer silica chromatography and spot identification.  Compounds found to be of 
sufficient quantity and purity were screened for nAChR binding affinity in the [3H]Ebt 
binding assay.  Being a facile reaction between the amine starting material and the 
synthon, all but a handful of planned reactions gave a major product.  All reaction 
products that could be confirmed by TLC analysis against the reactants were then held for 
a quick, initial “first look” 1H-NMR analysis.  Because the broad aim of the project was 
to carry out a scaled-up drug design project (employing the use of parallel synthetic 
techniques), and not a purely synthetic project (employing more complicated chemistry), 
often times prior to screening, a crude reaction mixture would be evaluated by TLC to 
simply confirm the disappearance of starting materials and to confirm the presence of a 
predicted major product.  In all only ~60 AH compounds are described here in any detail 
because while all AH compounds were evaluated in screen experiments only a select few 
compounds were later tested in the subtype-selective nAChR binding assays.  Although 
many of the reaction processes yielded compounds of high purity that required no 
additional purification (>95% for many of the guanidine-HCl salts), several compounds 
were screened as components of their respective reaction mixtures if a major product 
could be verified.  Reaction mixtures of >80% were generally considered acceptable 
candidates for initial one and two point screening efforts.   
Since the initial screening in the [3H]Ebt binding assay evaluated the test 
compounds at very high concentrations, a loss of efficacy due to a less than idea product 
composition would, theoretically not interfere with efforts to simply identify active 
compounds.  This strategy was employed to make synthetic progress more efficient by 
foregoing complicated, and often times lengthy silica gel column purification, preparative 
silica chromatographic separation, and additional purification procedures such as time-
consuming re-crystallization.  A few compounds proved to be water-insoluble even as 
hydrochloride and iodide salts, and were thus not further purified, characterized or 
reported on.  In short, advanced purification and characterization was reserved for many 
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 of the more interesting compounds that would later produce a positive result in the initial 
nAChR activity screen.    
As noted earlier in the reaction methods section, most reactions were carried out 
at room temperature, although for slow reactions reactants were sometimes warmed to 
45OC to speed reaction progress.  These reactions were usually carried out in the 
FirstMate parallel synthesizer in batches of 10-12 reactions at a time and were also TLC 
analyzed in small batches to monitor the course of the reaction and to confirm the 
disappearance of reactants and to visualize the appearance of product spots.  Since all of 
the reactions involve the evolution of volatile methylmercaptan, which can be an 
unpleasant irritant, reactions with S-methyl synthons were always carried out in the fume 
hood with the protective sash pulled down to an appropriate height.   
Other synthetic routes to generate novel guanidino compounds were attempted 
during the course of this project.  None of the three alternative synthetic efforts that were 
attempted during the course of this study will be discussed or reviewed here, despite the 
fact that a great deal of time and energy went into developing these methods, and in at 
least one case more than two dozen starting materials were synthesized.  This is added as 
a side note by the author’s simply for those who may remember other synthetic efforts 
that were undertaken that should seemingly be included in a dissertation on this project.  
It is also added here because the author needed to have a little something to write about 
for all those long-forgotten months of work.      
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 3.4 Amidine Chemistry: Synthesis Background and Methods 
 
Background 
In addition to the guanidine containing AH-series of compounds a second series 
of compounds was synthesized and evaluated for nAChR activity.  As noted earlier in the 
SAR background several aminomethylpyridine, quinuclidine, aminomethylthiophene, 
and pyrimidine and amidino-containing nicotinic compounds exist that demonstrate high 
affinity and selectivity among neuronal subtypes (refer to azanicotine and 
homoazanicotine analogs).  The synthesis and characterization data of these various 
aminomethylpyridine, quinuclidine, aminomethylthiophene, and pyrimidine and amidino-
containing analogs is described here briefly.  All JC-compounds were evaluated at greater 
than 90% purity.    
 
 Methods and Materials 
Note: If not further noted, all reagents and chemicals were ordered from Aldrich and 
Acros Chemicals Inc.  Compound purification via flash column chromatography was 
carried out by passing reaction mixtures in an appropriate solvent system through a 
separation column equilibrated with at least 20 fold excess (w/w) ICN Silica-Tech 32–63, 
60Å silica gel in starting solvent.  Melting points were determined with a Fisher-Johns 
melting point apparatus and are reported here as uncorrected values. 1H-NMR and 13C-
NMR spectra were recorded on a Varian 300 MHz instrument and are reported in ppm 
relative to TMS as internal standard. 
  
JC compounds were synthesized and analyzed for composition and purity by Dr. 
Jianhong Chen, a post-doctoral researcher in Dr. Crooks’ laboratory.  Analytical data for 
several compounds were provided upon request and are included here at the time of 
publication.  This includes data for compounds JC 2-25, JC 2-31, JC 3-2 and JC 3-9. 
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 General Method   
Trimethylaluminum (2M solution in toluene) was cooled to 40C in an ice bath, an 
appropriate diamine was added and slowly stirred in drop wise.  The mixture was stirred 
at room temperature for one hour then cooled again.  0.66molar equivalents of methyl 
nicotinate in toluene were added.  The reaction was heated to reflux.  After 3 hours it was 
cooled again and left to stir overnight.  A (1:1:20) mixture of methanol, water and 
chloroform were added and the reaction mixed.  The organic phase was separated and 
dried with anhydrous sodium sulfate.  After removal of solvent the product was purified 
over silica gel column (chloroform/methanol 50:1) to afford purified product compound. 
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3.4 Amidine Chemistry: Results 
 
JC 1-27 
 
N
NH
N
CH3
.HCl
8-methyl-N-(pyridin-3-ylmethyl)-8-azabicyclo[3.2.1]octan-3-amine hydrochloride
C14H21N3-HCl    F.W.=267.79  
 
 
 
JC 1-31 
  
.2TsOH.2H2O
C27H39N3O8S2    F.W.=597.75
N
NH
N
N-(pyridin-3-ylmethyl)quinuclidin-3-amine ditoluenesulfonate
 
 
 
 
JC 1-41B 
  
.2TsOH.2H2O
C28H41N3O8S2    F.W.=611.77
N
NH N
N-(2-pyridin-3-ylethyl)quinuclidin-3-amine ditoluenesulfonate
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 JC 1-80 
 
  
.2TsOH.2H2O
C24H28N4O8    F.W.=500.48
N
NH
N
N
N,1-bis(pyridin-3-ylmethyl)pyrrolidin-3-amine ditoluenesulfonate
 
 
 
 
JC 1-93 
  
.2TsOH.2H2O
C15H20N2S2  -2TsOH.2H2O  F.W.=500.48
N
NH
S
S
N,1-bis(thiophen-2-ylmethyl)piperidin-4-amine ditoluenesulfonate
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 JC 2-25 
  
.3HCl
C9H11N3 -3HCl    F.W.=270.59
N
N
H
N
2-pyridin-3-yl-1,4,5,6-tetrahydropyrimidine trihydroiodide
 
1H NMR (300MHz, D2O): δ 2.10-2.19 (m, 2H), 3.61-3.68 (m, 4H), 8.20 (m, 1H), 8.80 (m, 
1H), 9.10 (m, 1H), 9.20 (m, 1H). 13C NMR (300MHz, D2O) δ 17.4, 39.6(two carbons), 
128.0, 128.5, 141.7, 144.9, 146.1, 156.1 ppm.  Mp 225-228°C.   
 
 
 
JC 2-31 
  
.3HCl
C9H11N3 -3HCl    F.W.=270.60
N
N
N
CH3
3-(1-methyl-4,5-dihydro-1H-imidazol-2-yl)pyridine trichloride 
 
1H NMR (300MHz, D2O): δ 3.00 (s, 3H), 3.90-4.10 (m, 4H), 8.05 (m, 1H), 8.58 (m, 1H), 
8.92 (m, 1H), 9.00 (m, 1H) ppm. 13C NMR (300MHz, D2O) δ 13CNMR (D2O, 300MHz) δ 
34.0, 43.7, 52.9, 122.6, 128.0, 142.8, 145.6, 146.8, 161.5 ppm. 
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 JC 2-33A 
     
.3HCl
C12H15N3 -3HCl    F.W.=201.27
N
N
N
H
(3aS,7aR)-2-pyridin-3-yl-3a,4,5,6,7,7a-hexahydro-1H-benzimidazole trihydrochloride
 
 
 
 
JC 2-46B 
        
.3HCl
C13H17N3 -3HCl    F.W.=324.68
N
N
N
H
(3aS,7aR)-2-(pyridin-3-ylmethyl)-3a,4,5,6,7,7a-
hexahydro-1H-benzimidazole trihydrochloride
 
 
 
 
JC 2-48 
  
.3HCl
C10H13N3 -3HCl    F.W.=284.62
N
N
N
CH3
3-(1-ethyl-4,5-dihydro-1H-imidazol-2-yl)pyridine trichloride
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 JC 2-66 
 
  
.2CO2H
-
CO2H
C8H10N2S-2(C2H2O4)    F.W.=284.62
N
N
CH3S
1-methyl-2-(3-thienyl)-4,5-dihydro-1H-imidazole dioxalate
 
 
 
 
JC 2-67 
  
.2CO2H
-
CO2H
C8H10N2S-2(C2H2O4)    F.W.=284.62
1-methyl-2-(2-thienyl)-4,5-dihydro-1H-imidazole dioxalate
S
N
N
CH3
 
 
 
 
JC 2-77 
 
        
C13H17N3O -2(CO2H)    F.W.=385.33
N
N
H
CH3
CH3
N
OCH3 .2CO2H
-
CO2H
(3aS,7aR)-3a,7a-dimethyl-2-(5-methylisoxazol-3-yl)-
3a,4,5,6,7,7a-hexahydro-1H-benzimidazole dioxalate
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 JC 2-78 
       
 
C9H13N3O -2(CO2H)    F.W.=269.25
N
OCH3
N
N
CH3
.2CO2H
-
CO2H
1-methyl-2-(5-methylisoxazol-3-yl)-1,4,5,6-tetrahydropyrimidine dioxalate
 
 
 
 
JC 3-2 
  
C9H10ClN3 -2(CO2H)    F.W.=375.72
N
N
N
CH3Cl
2-chloro-5-(1-methyl-4,5-dihydro-1H-imidazol-2-yl)pyridine dioxalate
.2CO2H
-
CO2H
 
1H NMR (300MHz, CD3OD): δ 3.18 (s, 3H), 4.00-4.21 (m, 4H), 5.10 (brs, 1H), 7.75(m, 
1H), 8.19 (m, 1H), 8.70 (m, 1H) ppm. 13C NMR (300MHz, CD3OD) δ 34.9, 44.7, 53.9, 
120.2, 126.2, 141.1, 150.7, 156.7(two carbons), 165.0, 166.7. ppm.  Mp 211-213°C.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 129
 JC 3-9 
 
C10H12ClN3 -2(CO2H)    F.W.=375.72
N
N
N
CH3Cl
.2CO2H
-
CO2H
2-(6-chloropyridin-3-yl)-1-methyl-1,4,5,6-tetrahydropyrimidine dioxalate
 
1H NMR (300MHz, d6-DMSO): δ 1.95-1.98 (m, 2H), 3.48-3.52 (m, 4H), 7.76 (m, 1H), 8.20 
(m, 1H), 8.77 (m, 1H), 9.85 (brs, 1H)ppm. 13C NMR (300MHz, d6-DMSO) δ 17.6, 39.0(two 
carbons), 124.3, 124.4, 139.2, 148.9, 153.8, 156.5(two carbons), 164.7 ppm.  Mp 207-
209°C 
 
 
 
 Results 
A small library of amidino-containing JC compounds were provided for screening 
by Dr. Jianhong Chen and sixteen are profiled here.  Structures of the JC compounds 
provided for nicotinic receptor testing range from bridged ring and quinuclidine 
containing compounds (1-27, 1-31, and 1-41B), to di-substituted amidino compounds (1-
80, 1-93), and simple 2-ring amidino compounds (2-25, 2-31, 2-48, 3-2, and 3-9).  These 
compounds were provided in sufficient quantities and in suitable salt forms for screening.  
Synthesis of compounds was carried out in single batch reactions and all were TLC spot 
tested for purity.  All compounds were >85% pure and nearly all JC compounds were 
>90% pure in salt form.  All JC compounds were readily soluble in water and buffer. 
 
Discussion 
 In this chapter the synthesis of two groups of nicotinic analogs was described.  
This synthetic work meets the first specific aim of this doctoral project by successfully 
generating a small library of compounds that is suitable for testing in one of several 
nicotinic receptor binding and functional assays.  Nearly all compounds were generated 
in sufficient quantities (>15mg) as to allow for testing beyond any initial screen, and 
most were generated on a much larger scale providing >100mg of each compound.  All 
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 compounds were monitored during synthesis by small plate TLC spotting to measure the 
disappearance of starting material and also to monitor the evolution of new product spots.  
Compounds were finished as either HCl salts or iodide salts for AH compounds, or as 
HCl, succinate or tosylate salts for JC compounds.  Compounds were evaluated for 
product compound content and purity primarily by 1H-NMR and 13C-NMR spectroscopy. 
 The compound library that was synthesized was primarily an exploration around 
the core structure of the neonicotinoid analog DN-IMI.  While a variety of structural 
changes were considered based on rational design potential of this molecule the final 
structural changes mostly comprised of substitutions of the A region ring and the C 
region N,N substitutions.  The resulting compounds faithfully imitated the key features of 
the parent DN-IMI compound while adding structural diversity in key positions.  AH 
compounds were generated that included structural diversity in regions A, B, and C of the 
model platform:  Region A features include unsubstituted and halogen substituted 
pyridine rings, pyrrolidine rings, quiniline rings, methoxybenzylamines and picoline 
rings.  Region B features include a variety of bridge lengths including direct attachment 
utilizing aminopyridines, a methylene bridge, an ethylene bridge, and diaminopyridine 
di-substitutions.  Region C features include a variety of N- and N,N substitutions to the 
guanidine moiety including unsubstituted guanidines, imidazolidine rings, a 
tetrahydropyridine ring, a pyrimidine ring, N-ethyl, N,N-diethyl, tetramethyl, diisopropyl, 
N-propyl, N-butyl, N,N-dibutyl, and n-hexyl additions.  See complete AH compound 
product list in appendix (a).  The AH series provides for sufficient structural similarity 
and variation among a core group of compounds for a practical pharmacophore model 
development test series that will be used to define a single binding site. 
 One notable shortcoming of the AH series of compounds is the fact that relative to 
the parent molecule, DN-IMI, AH compounds have the substitutions shifted to the 
terminal nitrogen atoms in the guanidine moiety.  This generally introduces a structural 
shift among AH compounds, whereby the alkyl and bridge (ring) additions are effectively 
more distant from the pyridine ring nitrogen.  This could help to explain the shift in 
affinity when compared to the high affinity of the neonicotinoids, especially in the light 
of the importance of the N-N distance in the NIC molecule.  On the other hand the real 
influence of this change may be far more subtle and more complex given the fact that the 
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 6-chloro-N-ethyl substitutions of AH-150 should be able to adopt a conformation that 
would mimic that of DN-IMI very closely.  In this case, however, we see a large drop off 
in affinity between DN-IMI and AH-150 leaving the answer to be better addressed in 
future synthetic design work. 
 Another issue that could be addressed in future work would be to design more 
compounds with a 6-chloro addition on the pyridine ring of the molecule to simulate DN-
IMI even better.  Although several AH compounds, and some of the most active at that, 
possess a 6-chlorine not all of the N,N substitution series possess a 6-chloro analog and 
this also should be considered since a more complete synthetic exploration may find 
something useful in regards to this feature.  Additionally, one or more guanidine-N-nitro 
containing AH compounds might have been synthesized and evaluated in the insect 
screening assay.  Exploring the effect of this minor addition, so critical to conferring 
insect affinity, could have given important insight into how these AH compounds interact 
with the nAChR and whether or not the addition in this series would result in a reversal to 
insect affinity as would be expected in the classical neonicotinoid series.  Larger ring 
structures on the guanidine group (n=7 and n=8) could have also been explored since 
several natural product spider toxins and synthetic anti-hypertension mimetics have been 
looked at with this structural feature.  Although several starting materials were generated 
to carry out synthesis of bis-guanidine compounds using isothiocyanate reactive groups, 
none of these synthetic projects were completed and no di-guanidine or bis-guanidines 
were synthesized.  This is an interesting structural trend from the Crooks’ lab that has 
been shown to result in some powerful subtype selective nAChR antagonists.  Finally 
none of the AH compounds synthesized possessed a bridged ring system like those seen 
in well known, high affinity nAChR compounds like Ebt,Cyt, or Mec.  Again, this could 
be a very productive area of exploration for future synthetic efforts, and may yield 
positive results in the search for high affinity compounds with subtype selectivity at 
major neuronal nicotinic receptors.  Overall the methods and results detailed in this 
chapter were successful in satisfying the goal of specific aim #1.            
 
Copyright © Aaron Joseph Haubner 2008  
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   Chapter 4: [3H]Epibatidine Binding Assay  
 
 
4.1  [3H]Epibatidine Binding Background 
 
 Compounds synthesized as described in the previous chapter were evaluated in a 
nAChR activity screen.  Initial testing involved screening these compounds for their 
ability to interact with the nAChR.  One of the most efficient and reliable ways of testing 
this is by measuring if the compound binds to the receptor protein (nAChR binding 
theory reviewed in Grutter and Changeux 2004).  Since no pharmacologically relevant 
response can occur without initial binding, all compounds that are found not to bind are 
generally considered inactive and no further work is carried out on them.  While 
biochemical methods provide literally dozens of ways to measure intermolecular 
interactions, only classical pharmacological methods provide the ability to examine and 
measure the specificity, the mechanism, and the strength of the interaction that takes 
place at the receptor’s ligand binding site.  Applying these fundamental principles, 
compounds are evaluated for their ability to displace a radiolabeled form of a known 
ligand (in the case of this chapter this compound is epibatidine) from the receptor 
binding site.  These classical binding methods can be used to rapidly assay a large 
number of compounds and are thus a preferred method for a rapid screen.  
 
 nAChR Binding Background 
 The use of radiolabeled ligands to analyze nAChRs was first carried out by Lee 
and Tseng in 1967.  In their experiments they used [131I]-α-Bgt to label nAChRs in rat 
diaphragm before and after denervation (Lee and Tseng 1967).  The first quantitative 
analysis employing radioligand binding was carried out by Miledi and Potter (Miledi and 
Potter 1971).  Once again α-Bgt was used to label and quantitate the receptors in the 
tissue.  In the same series of experiments they also showed for the first time that 
pretreatment with curare could block α-Bgt binding.  This result demonstrated that 
binding of multiple compounds at the nAChR could be mutually exclusive and thus 
demonstrated compounds competed for the same binding site.  Later studies used 
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 solubilized and homogenized membrane preparations.  In this manner tissue samples 
could be distributed more evenly in an experimental procedure and in a sense, made the 
receptor source an experimental reagent.  This provided for larger scale binding 
experiments and made binding experiments more robust and consistent between 
experiments. 
Ligand binding displacement studies have been used to help understand and 
characterize the nature of the drug-receptor interaction at the nAChR since the early 
1980s.  In principle the binding experiment is carried out in a series of  steps: 1) tissue 
homogenates containing either a natural or artificially enriched source of receptor is 
homogenized, 2)  an appropriate concentration of radiolabeled ligand is allowed to 
equilibrate in solution with the receptor for a prescribed length of time, 3) when solution 
equilibrium conditions are achieved the test compound is added into the solution and 
allowed to incubate, 4) in time, equilibrium states and mass action will allow the two 
compounds to “compete” for the binding site on the receptor, and depending on the 
compound’s affinity for the binding site, will allow the test compound to effectively 
displace none, some, or all of the control ligand depending on the affinity that compound 
has for the receptor is, 5) the contents of the solution phase (unbound) are washed off of 
the tissue homogenate portion of the reaction mixture and the remaining sample is rinsed 
to remove excess labeled compound, 6) the remaining label is measured to determine 
how much remains “bound” and thus a relative measure of the test compound’s affinity 
for the receptor can be determined.  In this case the ability of a compound to displace a 
nicotinic ligand such as Ebt is truly a measure of its binding affinity for the nAChR.  By 
this process the classically understood pharmacological constants (maximal binding, 
specific binding, Ka, and Kd, etc.) are determined.  Although a detailed background on 
receptor binding dynamics is without the scope of this thesis the topic has been well 
reviewed (Lippiello and Fernandes 1987, Kenakin 1993, Borea and Gilli 2004, Rang and 
Dale’s Pharmacology 2007).  These measures of the specific physiochemical interaction 
between ligand and receptor become the signature of the specific ligand-receptor system.   
 The binding of S-(-)-NIC to the nAChR in rodent brain has been exhaustively 
studied and there exists an extensive literature covering the subject which will not be 
reviewed here at any length.  Early binding studies were, and to a great extend still are, 
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 simple “grind and bind” procedures (Waud 1988).  Binding experiments using brain 
homogenates have indicated that the binding of the nicotine molecule to the receptor is 
reversible, stereo-selective, and involves a single site of high-affinity nAChR binding 
(Romano and Goldstein 1980, Abood 1983, Lippiello and Fernandes (and references 
cited within), 1987).  While NIC and other compounds may bind to the same site, not all 
compounds that bind to the nAChR bind to only one site on a single nAChR subtype.  
Numerous compounds have been described in the literature that bind multiple nAChRs or 
to distinct sites on the nAChR.  In fact compounds that interact with a single subtype in a 
selective manner are the exception as most nicotinic ligands bind to multiple subtypes.  
As stated here before, in different ways, this can make for a very confusing 
pharmacological picture.  Fortunately the arsenal of compounds that are selective for 
distinct nAChR subtypes has grown over the last decade and researchers are now able to 
use selective compounds to probe individual subtypes to a greater degree. 
 
 Epibatidine Binding 
 Epibatidine (Ebt) is a naturally occurring, structurally novel nicotinic agonist that 
was originally isolated from a South American tree frog toxin.  Until the discovery and 
characterization of Ebt in the early 1990s, NIC possessed the highest affinity of any 
compound for the nAChR (Spande and Daly 1992).  Attempts to alter the NIC structure 
almost always resulted in a reduction in affinity and efficacy (reviewed in Dukat and 
Glennon 2002).  Compared to high affinity NIC binding (Ki=1-3nM), Ebt high affinity 
binding (20-100pM) was a revelation.  Ebt binds to nAChRs in the brain with high 
affinity (Ki= mid pM-low nM for various neuronal nAChR subtypes), competes for the 
same binding site as NIC, is 150-fold more potent than NIC in releasing DA from rat 
striatal slices, is a more potent agonist of the nAChR than NIC, and among other 
impressive qualities in a potent analgesic that acts via a CNS-mediated and MEC-
sensitive mechanism (Spande and Daly 1992, Badio and Daly 1994, Sullivan 1994, 
London and Kellar 1995, Dukat and Glennon 2002).  Following its characterization, 
numerous analogs of Ebt were synthesized and evaluated for all kinds of binding and 
functional effects.  Although it has been evaluated in numerous clinical trials for nAChR-
related conditions Ebt was always found to have too many side effects owing to the fact 
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 that it is relatively non-selective among the many nAChR subtypes and that it is a potent 
agonist at peripheral and ganglionic subtypes which can lead to serious unwanted effects 
(Arneric and Brioni 1999).  While the synthesis of novel compounds based on Ebt SAR is 
ongoing, Ebt continues to be a hugely useful compound in a research tool capacity.  It is 
commonly used as [3H]Ebt for use in nAChR binding studies as well as being used 
extensively in functional studies for its ability to elicit a maximal nAChR-mediated 
response.   
  
[3H]Ebt binding assay 
 Several nAChR ligands were used in validating the [3H]Ebt binding assay.  These 
include compounds that have been discussed in previous sections (NIC, Ebt, MLA, 
DHβE, α-Bgt and Cyt) in addition to the selective, high-affinity nicotinic antagonist 
Lobeline (Lob, Ki=16nM), the α7*-selective agonist PNU-282987 (PNU, Ki=27nM) was 
used (Damaj 1997, Bodnar 2004, Hajos and Groppi 2004). 
A few considerations must be made when using Ebt for any study, and especially 
for binding applications.  First of all Ebt is extremely toxic and can enter the body 
through the skin rapidly so good lab protection should be used and extra care taken when 
handling the compound.  Secondly, when used in binding experiments, a long incubation 
period is required (2-4hrs for Ebt versus 1hr for NIC) because of its extremely slow 
receptor dissociation or “off” rate.  This increases the length of time to reach equilibrium 
state at room temperature.  Additionally since it is so potent, small amounts must be 
weighed with care and then from stock solutions multiple serial dilutions are needed to 
make test solutions down to the pM and sub-pM concentration range needed.  This thesis 
chapter will describe 1) the characterization and validation of [3H]Ebt binding to rat 
whole brain and hippocampus, 2) the screening procedure developed to evaluate AH and 
JC compounds for nAChR affinity, and 3) the concentration-response (CR) type 
experiments carried out to determine the compound’s ability to displace NIC and the 
compound’s affinity for the nAChR (Ki).   
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  Methods and Materials 
 All chemicals and reagents (Tris base and buffer salts) were ACS reagent grade 
and were purchased from Sigma-Aldrich Chemical Co. (St. Louis, Mo.) or Fisher 
Scientific.  S-(-)-NIC was purchased from Research Biochemicals Inc. (RBI, Natick, 
Ma.).  Radiolabeled compounds were purchased from New England Nuclear-Perkin 
Elmer Inc. (Waltham, Ma.).   
 Adult male Sprague-Dawley rats (225-250g) were housed two per cage with free 
access to food and water and held at the, then, Tobacco Health and Research Institute, 
University of Kentucky Campus.  Animals were held at least three days after delivery 
prior to harvesting.  Experimental protocols involving animal use were in strict 
compliance with NIH and institutional animal care guidelines.  Before tissue harvesting, 
the animals were incapacitated by brief exposure to CO2 gas in the cage and were then 
decapitated to obtain brain tissue.   
 
 Membrane Tissue Homogenate 
Following decapitation, cerebral membranes were pulled away and removed and 
excess vasculature was removed to reduce non-specific binding.  Brain tissues were 
removed and stored in ice cold membrane preparation buffer (50mM Tris-HCl, 120mM 
NaCl, 5mM KCl, 1mM MgCl2.7H2O, 2mM CaCl2 pH adjusted to 7.4 with NaOH and 
HCl).  Tissue was homogenized by first chopping tissue into a rough chopped mix with a 
razor blade and homogenized properly using a teflon mortar and pestle style manual 
tissue homogenizer (15-20 reps each preparation).  Tissue is homogenized in 10ml 
membrane buffer per brain sample.  Crude homogenate is then divided into two Beckman 
25ml polypropylene centrifuge tubes.  Samples are spun in a Beckman TI-60 rotor head 
at 49,000g for 30 minutes at 40C.  After centrifugation the supernatant is discarded and 
the pellet is resuspended in 15ml fresh, ice cold buffer and mixed well until a suspension 
is achieved.  Tissue is then re-homogenized 5-7 reps using Teflon homogenizer, this is 
the first wash step.  The suspension is again centrifuged as above without further 
homogenization, and repeated again for a total of three wash/centrifugation steps.  
Following final wash, the pellet is stored in 10 volumes of buffer (w/v) and stored in 
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 pellet form in -800C freezer until sample is thawed and resuspended for use.  A 0.1ml 
aliquot is reserved for protein determination.   
 
Protein Determination 
Protein content for the brain tissue homogenate was determined either following 
membrane preparation or day of experiment after thawing.  Protein content was 
determined using standard Lowry Method using Folin reagents (Lowry and Rosebrough 
1951).  Lowry reagent is made by combining 50ml Solution A (60g of Na2CO3, 12g 
NaOH, 600mg NaK tartrate dissolved in ddH2O up to 3.0 liters) with 1ml Solution B (5g 
CuSO4.5H2O in 1 liter ddH2O)  made immediately prior to use and allowed to stand at RT 
for 20 minutes.  Folin reagent is made by dilution of 2 parts commercially-available Folin 
solution (Sigma product #P5656) with 1 part 1N NaOH and mixed.  Standard protein was 
purchased commercially and stock solutions made in ddH2O.  Protein standard dilutions 
were made at 0.0, 5, 10, 15, 20 and 25µg in duplicate.  Membrane samples were diluted 
1:10, 1:20, 1:50, and 1:100 in water.  20µl of 1.0M NaOH was added to 100µl of samples 
and standards and were then incubated at 450C for 1hr.  100µl of Folin reagent was added 
to each sample and incubated for 30 minutes at RT.  Measurements were made in a table-
top spectrophotomer with UV.  Absorbance at 660λ was measured and a best-fit standard 
curve was generated to determine protein standards.  Protein content was determined as 
compared to the standard and was expressed in µg total protein/ml homogenate reagent.   
 
[3H]Ebt Binding General Procedure 
 The general procedure is a variation of that described earlier by Houghtling and 
Kellar 1995). Tissue samples were thawed and brought up to volume so that final protein 
concentration is 150µg/well total protein.  Homogenates were well mixed to ensure 
proper suspension and mixed by repeated pipeting periodically throughout the dispensing 
procedure to ensure equal distribution across the plate, and temporally throughout the 
plating.  All procedures are performed at RT unless otherwise noted.  Test compounds are 
brought up o make a stock solution of 3mM in binding buffer (50mM Tris-HCl, 120mM 
NaCl, 5mM KCl, 1mM MgCl2.7H2O, 2mM CaCl2 pH adjusted to 7.4 with NaOH and 
HCl) and dilutions were made from this stock.  When compounds were found to be 
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 insoluble in binding buffer a second weighed sample of compound was brought up in a 
small volume of 100% dimethylsulfoxide (DMSO) and then diluted in binding buffer.  
All buffer-insoluble test compounds were brought up into a more concentrated 100mM 
stock solution.  Dilutions were made such that final DMSO concentrations were <0.1%.  
It has been reported that DMSO concentrations <0.1% have no adverse affect in nAChR 
binding assays (Eaton and Eterovic 1997).   All test compounds were diluted to a working 
(3x) concentration prior to addition to the plate.  All binding experiments were carried 
out in a final volume of 300µl in 96-well plates (96F MicroWell plate, Nunc-Nalgene).  
[3H]Ebt was determined to have a Ki value of 71pM in this experimental procedure.  
Although it is common to evaluate displacement of a ligand at its Ki Ebt presents a small 
problem.  Because it binds with such a high affinity nAChR binding experiments using 
the Ki concentrations were found to yield counts that were so low that the topcounter 
results would often contain a high degree of variability.  To correct for this [3H]Ebt was 
used in all binding experiments at the concentration of 177pM or roughly 2.5-fold greater 
concentration than it’s previously established Ki.  Affinity values of competitors were 
correspondingly adjusted by compensation through Cheng-Prusoff calculations (see data 
analysis section for details).  Radioligand (100µl) and test compound (100µl) were added 
to the plate and allowed to equilibrate for 60 minutes undisturbed.  Binding displacement 
reactions were initiated by addition of membrane homogenate (100µl) to each well.  
Plates were then allowed to incubate at room temperature for 180 minutes.  Following 
incubation binding reactions were rapidly terminated by vacuum filtration (using a 
Packard Harvester Filtermate 196) of reaction volume through a 96-well filter plate 
(0.65µm Unifilter 96 GF/B, Packard) separating the tissue homogenate and bound 
Radioligand from the liquid portion of the reaction mixture.  Filter plates were soaked in 
0.1% polyethylamine for at least two hours prior to filtration in order to reduce retention 
of unbound [3H]Ebt during the filtration and wash steps.  Once the sample was bound on 
the filter plate each well was washed rapidly three times with 350µl of ice cold Tris 
buffer (50mM Tris, pH 7.4).  Plates were left to dry in a dark cabinet for at least 2hrs, but 
often times plates were let to dry overnight.  Following drying, plates were bottom sealed 
and 35µl of MicroScint scintillation cocktail was added to each well.  Plates were then 
top sealed and the sample was left at RT for 60 minutes in the dark where samples were 
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 left to mix with the detection fluid.  Radioactivity was measured on a Packard TopCount 
NTX (2 detector system) scintillation counter for 5 minutes per well or until threshold 
sigma value was achieved.  Counts were converted from CPM to DPM depending on the 
instruments’ counting efficiency, as determined according to the factory programmed 
quench curve.  For all experiments specific binding is measured by subtracting [3H]Ebt 
binding in the presence of excess NIC (100µM) from total [3H]Ebt binding in the absence 
of competitor.  Unless otherwise noted individual experimental measurements were 
carried out in at least triplicate for each experiment. 
 
Data Analysis 
For all experiments data were plotted and processed using the current version of 
the GraphPad Prism, graphical and statistical software package (GraphPad Software Inc., 
San Diego, Cal).  Curves were fit according to the method described in each of the 
following sections and were fit by an uninterrupted iterative process.  The best fit curve 
was defined as the fit that minimized the absolute squared distance (Y2) from each data 
point to the curve.  All binding curves were fit with a non-linear regression, sigmoidal 
dose-response curve with each Y value as a single data point.  The basic equation is as 
follows: 
Y= bottom + ((top-bottom)) / (1+10^(x-logIC50)) 
 
Curve fits were generated without artificial weighting of values.  Competitor drug 
concentrations were input as X (ordinate) values in logarithm notation.  For all curves an 
F test was made between two models, the standard fixed slope and the variable slope fit.  
If the slope of the best fit curve was not significantly different from the standard slope 
than it was applied.  In either case the equation with the fewer variables was chosen 
unless the p value was less than the threshold p value (<0.05).  Unlimited iterations were 
allowed until the row change of the sum of the squares changed less than 0.01% upon 
additional rounds.  Top values for the curves were determined automatically by analyzing 
the several maximal binding values.  If too few top values exist to set a calculated top 
value then the maximal values from the corresponding control was used as the top value 
for the curve.  Bottom values for the curves were determined automatically by analyzing 
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 the several minimum binding values.  If too few bottom values exist to set a calculated 
top value then the minimum values from the corresponding control was used as the top 
value for the curve.  In the case of inhibition binding curves the maximal inhibitory 
values minus the non-specific value gave the minimum. EC50 values were automatically 
calculated as the X value that corresponds to the point on the curve halfway between 
maximal and minimal specific binding.    
 The affinity, as measured as (Ki), was derived from the calculated EC50 value.  
Calculations were made according to the Cheng-Prusoff equation: 
 
Ki = IC50 / (1 + ([ligand] / Kd)) 
 
Note: for this series of experiments Ki values may appear to not align very well with IC50 
values as seen on the inhibition curves since there is a 3.5-fold difference between IC50 
and Ki.  This difference is due to the Cheng-Prusoff conversion because [3H]Ebt was used 
at a concentration 2.5-fold greater than its Ki in order to generate sufficient counts for 
scintillation measurement. 
 
[3H]Ebt Binding Optimization and Validation Experiments 
Prior to testing compounds in a binding displacement assay experiment the 
procedure needed to first be tested in a validation experiment to make sure that output 
from this experimental design matched previously published results and that the results 
generally supported predictions that could be made regarding the experiments.  The main 
objectives of this experimental section was to 1) determine a Ki for Ebt and NIC and 
determine if the values obtained agreed with known values, 2) to evaluate a series of 
known nAChR ligands in the assay and compare the rank order of the experimental 
affinity values with those reported widely in the literature, and 3) using known α7* 
nAChR ligands, to attempt to determine the α7* nAChR subtype component of [3H]Ebt 
binding. 
In the first set of experiments, five known nAChR ligands (NIC, Ebt, DHβE, 
LOB, and HEX) were evaluated for their ability to displace [3H]Ebt at 177pM.  
Displacement curves were used to determine an affinity value for each.  [3H]Ebt and 
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 serial dilutions were prepared from stock solution (300µM).  NIC and other test 
compounds, and serial dilutions of each, were freshly prepared from stock solutions (10 
µM).  Membrane suspensions were brought up to final protein concentration of 
150µg/well from frozen concentrates.  Final concentration of [3H]Ebt was adjusted and 
verified for each experiment by counting a 100µl sample in 2.5ml MicroScint cocktail for 
5 minute counts on a TriCarb Packard liquid scintillation analyzer.  Compounds were 
added with membrane homogenates and incubated at RT for 60 minutes.  [3H]Ebt was 
added and the reaction was allowed to incubate in the plate for an additional 180 minutes 
until equilibrium conditions were achieved.  The reaction was terminated and tissue 
washed as described previously and counted.  The purpose of this experiment was to 
verify that the method assays for high-affinity nAChR binding by comparing 
experimental results against published results.  
In the second set of experiments, several known α7* nAChR ligands (NIC control 
and MLA, α–Bgt, and PNU-282987) were evaluated for their ability to displace [3H]Ebt 
across a broad concentration range in order to determine what component of the total 
[3H]Ebt binding could be attributed to the α7* nAChR subtype compared to the α4β2* 
high affinity subtype.  It is well known that Ebt binds to several known nAChRs and 
through selective labeling experiments has revealed previously unknown subtypes 
(Whiteaker and Marks 2000).  Compounds were assayed for their ability to displace 
[3H]Ebt in two tissue preparations.  Whole brain binding assessment (whole brain minus 
cerebellum) was carried out in order to characterize the subtype component associated 
with the preparations used in the initial characterization (experiment 1) and in the 
screening experiments (below).  Assay conditions were carried out as described above in 
the general method.  Specific α7*-associated displacement was measured as the amount 
of total binding displacement at a concentration 10-fold each compound’s α7* Ki.  At this 
concentration α7* binding should be near the maximally achievable level and total 
inhibition should provide a good indication if there is significant α7* binding interfering 
with the high-affinity [3H]Ebt binding.  If binding levels are sufficiently large it would be 
possible to use this assay to conduct high-throughput screening using a single membrane 
preparation and a single ligand ([3H]Ebt) to carry out an initial screen of both α7* and 
α4β2* nAChR subtypes 
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 [3H]Ebt binding displacement experiments using α7* ligands as described above 
in whole brain were also carried out using enriched, hippocampal P2-tissue fractions.  It 
is well-established in the literature that the hippocampal tissues express a higher level of 
α7* nAChR relative to whole brain (Barrantes and Wonnacott 1994, Albuquerque and 
Maelicke 1997, Davies and Wonnacott 1999).  Additionally hippocampal homogenates 
are fractionated via centrifugation through sucrose cushions in order to enrich the nAChR 
component of the membrane preparation (P2 fraction).  The P2 fraction is a nAChR-
enriched membrane fraction and is used in the hippocampal preparations to improve α7*/ 
α4β2* signal as well as to improve signal to noise and decrease non-specific binding 
levels in order to facilitate the identification and measurement of the minor α7* binding 
component.   
Generation of P2 fraction membranes is carried out as follows.  Hippocampal 
tissues were dissected from decapitated rats as described above.  Tissues were 
homogenized in a 50mM Tris-acetate buffer (5mM Tri-acetate, 320mM sucrose, pH 
adjusted to 7.4).  This crude homogenate was centrifuged for 10 minutes at 4°C and 2800 
rpm in a Sorvall RC 26 Plus centrifuge, after which the supernatant was saved and the 
procedure was repeated with the pellet dissolved into cold buffer with sucrose. The 
combined supernatants were then centrifuged for 20 minutes at 4°C and 20,500 rpm on 
the same instrument. The supernatant was decanted, and the pellet retained and 
resuspended in 50 mM Tris-acetate buffer at pH 7.4, without sucrose. Samples were 
incubated on ice for 60 minutes.  Another 20-minute centrifugation was performed on the 
resuspended pellet with the above parameters, and two additional 10-minute washings at 
20,500rpm, with the pellet retained between each. After these washings, the membrane 
was again suspended in the above buffer without sucrose, and the protein concentration 
determined using Lowry as described above. Aliquots of 2.5ml of the concentrated P2 
membrane preparation were dispensed into cryo-tubes, and stored at -80°C. Final protein 
concentration was adjusted to 150µg/100µL buffer by the addition of sufficient 50 mM 
Tris-acetate buffer at pH 7.4 to bring the total solution volume to 15 ml per 96-well plate.  
This procedure was carried out in order to better dissect out any α7* subtype associated 
inhibition that may be taking place in the [3H]Ebt binding assay. 
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 [3H]Ebt Binding Screen  
Compounds were evaluated initially in a [3H]Ebt binding displacement screen 
where compounds were tested for their ability to displace [3H]Ebt at its previously 
determined Ki (71pM) at one of two concentrations 100nM (low concentration) and 
100µM (high concentration).    Since a variety of compound libraries including the JR-
series and SN-series of benzylamine, guanidines and polyamine analogs were also tested 
in the initial nAChR screen, daily multi-plate experiments were carried out.  In order to 
scale up the throughput, the liquid handling and incubation was automated using a 
Packard Multiprobe HT-II automated liquid handler.  The general procedure remains the 
same as described except all pipeting and liquid transfer was carried out using the multi-
channel (8-tip) robotic platform.   
 Inhibition was analyzed for each test compound and those found to inhibit 
specific [3H]Ebt binding by more than 20% of the total were considered positive screen 
hits.  These compounds were evaluated for inhibitory binding ability across a full 
concentration range. 
  
[3H]Ebt Concentration-Response Experiments for Binding Screen Hits 
 Compounds that were found to displace, or inhibit more than 20% of total [3H]Ebt 
binding in the screen were evaluated in a concentration-response (CRC) binding 
experiment in order to determine nAChR affinity.  The general binding procedure 
remains unchanged from the general method described above.  Inhibition data were 
plotted and fit to sigmoidal dose-response curves.  IC50 and Ki values were determined 
for each compound as described above. 
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 4.2  [3H]Epibatidine Binding Validation Experiment Results 
 
Assay Validation 
This study was carried out with the goal of determining if a [3H]Ebt binding 
displacement assay in the hands of the author could yield results that were consistent with 
those that would be predicted for a nAChR binding assay.  Initial experiments examine 
the high-affinity compounds NIC and Cyt for ability to inhibit [3H]Ebt binding.  The 
binding curves for both compounds followed a one-site, sigmoidal dose-response model 
and Hill coefficients were not significantly different from unity (slope other than -1).   
 
Assay Validation Results: Inhibition of [3H]Ebt Binding NIC and Cyt 
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Figure 4-1.  Inhibition of total [3H]Ebt binding by unlabeled NIC and Cyt.  Data are not normalized and are 
fit to a one-site, sigmoidal dose-response curve.  Control is binding with 177pM [3H]Ebt without inhibitor, 
and N/S=non-specific binding measured in the presence of 100µM NIC.    
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 Uninhibited [3H]Ebt at 177pM was taken as the top value (or 100% maximal binding) 
and non-specific binding was measured as 177pM [3H]Ebt binding in the presence of 
100µM NIC. 
GraphPad software was used to calculate IC50 values based on the inhibition 
curves and from those inhibitory affinity constants for each test compound was 
calculated.  Binding data shown in figure 4-1.  Curves fit the data well for NIC (R2=.967) 
and CYT (R2=.962) with a Hill slope not different than unity.  IC50 values were 24.4nM 
for NIC and 18.3nM for CYT.  Ki values were calculated for NIC at 6.8nM and Cyt at 
5.5nM.  It is important to note that both NIC and Cyt inhibited nearly 100% of specific 
[3H]Ebt binding and that the affinity values calculated for NIC and Cyt in these 
experiments match with published values and with results previously obtained in this lab.     
 
 Assay Validation Results: Inhibition of [3H]Ebt Binding 
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Figure 4-2.  Inhibition of total [3H]Ebt binding by several nAChR ligands for validation of assay.  Data are 
normalized to each experimental control (total binding) and fit to a one-site sigmoidal dose response curve.  
Total binding is measured as binding with 177pM [3H]Ebt without inhibitor, and N/S=non-specific binding 
measured in the presence of 100µM NIC. 
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Additional experiments were carried out to determine if the assay probes the high-
affinity nAChR only.  Test compounds Ebt (unlabeled), NIC, DHβE, Lob, and Hex were 
evaluated for their ability to displace [3H]Ebt binding to rat whole brain membrane 
preparations and their inhibition curves are shown in Figure 4-2. All binding curves 
followed a one-site model and Hill coefficients were not significantly different from unity 
(slope other than -1).  Uninhibited [3H]Ebt at 177pM was taken as the top value (or 100% 
maximal binding) and non-specific binding was measured as 177pM [3H]Ebt binding in 
the presence of 100µM NIC.  For this experiment inhibition curves were normalized to 
the total specific binding of the control for graphical purposes.     
 GraphPad software was used to calculate IC50 values based on the inhibition 
curves and from those inhibitory affinity constants for each test compound was 
calculated.  Test compound affinities are shown in Figure 4-3.  Data values are compared 
to similar experimental results from binding studies published in the literature and 
references are given in the figure caption.  The results obtained were very promising and 
agreed well with the published data.  Rank order of binding affinity in this assay system 
was: Ebt>NIC>Lob> DHβE>Hex.  This trend was identical to the same trend from the 
reported values: Ebt>NIC>Lob> DHβE>Hex.   
While some of the values differed slightly from published data these differences 
were generally small and all affinity values fell within a 3-fold range of the 
corresponding published value.  It is important to note that in these types of binding 
studies different labs and different binding systems will often yield slightly different 
results which tend to vary to some small degree.  This does not invalidate the results in 
any way as individual data and groups of data must be considered on their own.   
The most important result of this straight forward study is the fact that the binding 
data agree reasonably well with data generated from multiple labs and that the general 
trend of affinity matched the published data.  All of the published data were from binding 
experiments that probe the high-affinity (α4β2*) nAChR.  Additionally, [3H]Ebt is known 
to bind to multiple nAChR subtypes, with 20-100pM including the high affinity 
α4β2*subtype.  Hexamethonium was chosen to obtain binding data for a low-affinity, 
non-competitive antagonist; a situation very different from the other compounds 
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 evaluated.  In this case the very low value that was expected reflects the fact that the high 
affinity nAChR subtype is what is being probed in this assay.   
It was noted that the affinity value obtained for NIC is lower than would be 
expected for typical α4β2* binding.  As described earlier, [3H]Ebt is a relatively non-
selective nAChR ligand with affinities ranging from mid-picomolar to the mid-
micromolar range.  Given the fact that NIC shares a similar binding profile (multiple 
affinity values for various nAChR subunit combinations) the small decrease in apparent 
affinity may be due to the displacement of [3H]Ebt from other lower-affinity nAChR 
subtypes.  Since whole brain contains a variety of nAChR subtypes some lower-affinity 
binding may be getting incorporated into the higher end of the binding displacement 
curve.  This effect could theoretically result in a slightly shallower curve that gives an 
artificially lower affinity value for NIC.  Although the curve fit did not significantly 
differ from a single site model, these changes may be great enough to alter the IC50 value 
slightly without drastically changing the model used to fit the data.   
 
 
nAChR High-affinity Binding for Selected Ligands   
 
 
Compound IC50 (curve) Ki (calculated) Ki (reference) 
Epibatidine (Ebt) 235pM 67 pM ± 7 50pm  a 
Nicotine (NIC) 10nM 2.9 nM ± 1.6 1.0-5.0nM  b 
Cytisine 17nM 5.5nM ± 1.2 1.0-5.0nM  a 
Lobeline (Lob) 98nM 27 nM ± 7 16nM  c 
DHβE 209nM 59 nM ± 5 35nM  d 
Hexamethonium 
(Hex) 
1.0 mM >100 μM 322 µM  e 
 
 
Figure 4-3.  Table of IC50 and Ki for test compounds in [3H]Ebt binding assay validation experiments.  
Affinity values are computed from IC50 determinations according to Cheng-Prusoff method.  Experimental 
affinity values are compared side-by-side with published values for the same compound. 
a Sharples 2001, b Bunnelle 2004, c Terry and Pauly 1998, d Alkondon 1993, e Loiacono 1993. 
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  Discussion 
 The current study indicates that, as reported in the literature, a steady-state 
radioligand binding assay using tritiated Ebt can be used to evaluate the affinity of 
compounds for the nAChR in whole rat brain homogenates.  Two high affinity ligands at 
the nAChR were tested and gave affinity values that matched well with reports from the 
literature as well as those obtained previously in the Littleton lab (unreported data).  
Additionally the rank order of the known compounds that evaluated for affinity in the 
assay agreed well with published data, and furthermore the affinity values themselves 
compared favorably with previously published values in experiments using multiple high-
affinity nAChR ligands as the label including Ebt, Cyt, and NIC.  The fact that the data 
agree with several published results from more than one experimental system indicates 
that high-affinity nAChR binding is what is being targeted.  This being the case, the study 
could then continue to determine if an additional nAChR subtype component is 
associated with the Ebt binding.  A reasonable validation of the assay is important prior 
to proceeding with experiments to screen and then further evaluate AH and JC 
compounds.             
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 4.3  [3H]Epibatidine α4β2* / α7* Binding Component: Experiment Results 
 
 Whole brain minus cerebellum  
Four experiments (n=4) were carried out using NIC and three α7*-selective 
compounds, with each experiment having an n=2 for each data point.  Since inhibition 
was not robust, binding curves were fit using either a one-site standard slope or a one-site 
variable slope sigmoidal dose response model.  Error bars represent the standard error of 
the mean for each value.  Hill coefficients for non-standard fits deviated from unity and 
variable slope fits were applied.   
 
Results: nAChR Subtype Examination of [3H]Ebt Binding in Whole Brain 
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Figure 4-4.  Inhibition of total [3H]Ebt binding by several α7*-selective nAChR ligands.  Data are 
normalized to each experimental control (total binding) and fit to a one-site sigmoidal dose response curve.  
Control is binding with 177pM [3H]Ebt without inhibitor, and N/S=non-specific binding measured in the 
presence of 100µM NIC. 
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 Uninhibited [3H]Ebt at 177pM was taken as the top value (or 100% maximal binding) 
and non-specific binding was measured as 177pM [3H]Ebt binding in the presence of 
100µM NIC (data not on graph).      
IC50 values could not be calculated based on the inhibition curves that were 
generated from the data since maximal inhibition for the test compounds never exceeded 
15% for any individual experiment in the concentration range examined (~10-fold Ki).  
Greater inhibition was observed at the highest concentrations for all compounds as can be 
seen on the results graph.  This however could be explained by non-specific binding 
effects at concentrations that are far higher than the test compounds’ known affinity 
constants.  Test compound inhibition curves are shown in Figure 4-3.   
 In these experiments the NIC control was good and was found to inhibit [3H]Ebt 
binding with a Ki of 9.7nM which agrees well with previous experiments.  Total binding 
at low NIC concentrations did not differ significantly from uninhibited total binding and 
non-specific binding in the presence of 100µM NIC was <15% total.  In order to 
determine what portion of total specific binding in this assay, if any, is attributable to an 
α7* nAChR subtype, compounds were evaluated for their ability to displace [3H]Ebt at 
the concentration 10-fold their literature-reported α7* Ki value.  This is done for two 
reasons 1) to determine the theoretical maximum inhibitory ability of these compounds 
since inhibition at ten times the Ki concentration should reveal maximal, or near maximal 
inhibitory ability in a standard model and 2) to prevent including random and non-
specific binding inhibition effects that is commonly seen amongst nicotinic ligands, even 
highly selective ones at very high concentrations.  For each compound “maximal specific 
inhibition” was determined by measuring the % inhibition that corresponds to the point 
on the curve that is associated with the Ki via Cheng-Prusoff conversion.  In this case the 
Ki value for each compound is converted to the corresponding IC50 by multiplying it by a 
factor of 3.5 (Cheng-Prusoff conversion factor for these experiments).  The point on the 
inhibition curve that then corresponds to this IC50 value is then taken as the measure of 
inhibition.   
 MLA was found to have only modest inhibitory ability even at the maximal 
measured value of 52.5nM (1.5nM)x(3.5)x(10), corresponding to -7.27 on the log scale.  
The mean inhibitory value for the combined four experiments was 3.75%.  α-Bgt was 
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 found to have inhibited binding at 70nM (2nM)x(3.5)x(10), corresponding to -7.15 on the 
log scale by only 2.0%.  Similarly, PNU was found to have inhibited binding at 840nM 
(24nM)x(3.5)x(10), corresponding to -6.08 on the log scale by 1.5%.  Due to the modest 
scale of the inhibition, the combined data tended to have higher than usual errors 
associated with them.  This compounds the fact that even the highest inhibition by MLA 
was not significant (p>0.05).  Taken together the data indicate that at the values tested 
[3H]Ebt can not be used as an effective probe for the α7* in whole brain preparations but 
rather seems to selectively label the high-affinity nAChR subtype. 
 
 P2, hippocampal preparations 
While the prior results seem to show that the whole-brain [3H]Ebt  binding assay  
is a measure of the high-affinity nAChR there may be potential to develop the assay as a 
“one-stop” multi-subtype binding screen.  To this end, in the next series of experiments, 
the same test conditions were carried out in an α7*-enriched, P2 hippocampal membrane 
preparation in order to improve potential α7* binding signal.     
As in the whole brain experiment, four experiments (n=4) were carried out using 
NIC and three α7*-selective compounds, with each experiment having an n=2 for each 
data point.  Since inhibition was not robust, binding curves were fit using either a one-site 
standard slope or a one-site variable slope sigmoidal dose response model.  Error bars 
represent the standard error of the mean for each value.  Hill coefficients for non-standard 
fits deviated from unity and variable slope fits were applied.  Uninhibited [3H]Ebt at 
177pM was taken as the top value (or 100% maximal binding) and non-specific binding 
was measured as 177pM [3H]Ebt binding in the presence of 100µM NIC 
IC50 values could not be calculated based on the inhibition curves that were 
generated from the data since maximal inhibition for the test compounds never exceeded 
15% for any individual experiment in the concentration range examined (~10-fold Ki).  
Greater inhibition was observed at the highest concentrations for all compounds as can be 
seen on the results graph.  This however could be explained by non-specific binding 
effects at concentrations that are far higher than the test compounds’ known affinity 
constants.  Test compound inhibition curves are shown in Figure 4-4. 
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 Results: nAChR Subtype [3H]Ebt Binding in Hippocampal P2 Membrane 
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Figure 4-5.  Inhibition of total [3H]Ebt binding in hippocampal P2 membrane preparations by several α7*-
selective nAChR ligands for validation of assay.  Data are not normalized.  Data are fit to a one-site 
sigmoidal dose response curve.  Control is binding with 177pM [3H]Ebt without inhibitor, and N/S=non-
specific binding measured in the presence of 100µM NIC. 
   
 
The NIC control was good and was found to inhibit [3H]Ebt binding with a Ki of 
9.7nM which agrees well with previous experiments.  Total binding at low NIC 
concentrations did not differ significantly from uninhibited total binding and non-specific 
binding in the presence of 100µM NIC was <15% total.  In order to determine what 
portion of total specific binding in this assay, if any, is attributable to an α7* nAChR 
subtype, compounds were evaluated for their ability to displace [3H]Ebt at the 
concentration 10-fold their literature-reported α7* Ki value. 
MLA was again found to have only modest inhibitory ability even at the maximal 
measured value of 52.5nM (1.5nM)x(3.5)x(10), corresponding to -7.27 on the log scale.  
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 The mean inhibitory value for the combined four experiments was 5.9%.  α-Bgt was 
found to have inhibited binding at 70nM (2nM)x(3.5)x(10), corresponding to -7.15 on the 
log scale by only 9.6%.  Similarly, PNU was found to have inhibited binding at 840nM 
(24nM)x(3.5)x(10), corresponding to -6.08 on the log scale by 6.5%.  Due to the modest 
scale of the inhibition, the combined data tended to have higher than usual errors 
associated with them.  This compounds the fact that even the highest inhibition by MLA 
was not significant (p>0.05).   
Taken together the data indicate that at the values tested [3H]Ebt can not be used 
as an effective probe for the α7* even in enriched hippocampal preparations but rather 
seems to selectively label the high-affinity nAChR subtype.  While there did appear to be 
an increase in α7* binding inhibition in the P2 hippocampal membranes, as expected, 
these results are modest and represent a portion of the total binding so small that 
attempting to screen for α7*-inhibitors by using this assay would not be practical.  While 
this is still theoretically possible by increasing the concentration of [3H]Ebt in the assay 
to hit lower affinity nAChRs the procedure would require additional α4β2*-selective 
ligands to block the high-affinity binding component of the measure.  These additional 
steps would complicate the method beyond the simple single procedure that we had 
hoped to validate and carry out.  In order to evaluate the test compounds for affinity at 
additional non-α4β2* nAChR subtypes additional subtype selective screens will have to 
be carried out.   
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 4.4  [3H]Epibatidine Screening Results: AH Compounds 
 
 
Screening experiments were carried out in triplicate on 96-well plates.  Binding data 
are displayed as a single column for each compound with error bars representing the 
standard error of the mean for each.  Since the data are compiled on a single graph from 
several experiments, data values were separately transformed as a percent total of control 
binding for each experiment and then combined.  Uninhibited [3H]Ebt binding at 177pM 
was taken as 100% total binding control and non-specific binding was measured as 
177pM [3H]Ebt binding in the presence of 100µM NIC (data not on graphs).  For all 
experiments the non-specific binding was remarkably consistent and ranged from 12-16%  
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Figure 4-6.  Screen Results:  Inhibition of total [3H]Ebt binding for active AH compounds at 100µM.  
Response is normalized to 100% experimental control.  Control is binding with 177pM [3H]Ebt without 
inhibitor, and N/S=non-specific binding (not shown) is measured in the presence of 100µM NIC. 
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Inhibition of Specific [3H]Ebt Binding: Screen Results  
 
Compound  
Code 
Structure  % Specific Binding 
at 100µM 
AH-2  Cl-
NH
N
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NH2
H
N
H
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Figure 4-7.  Screen Results:  Specific binding of total [3H]Ebt in the presence of AH compounds at 
100µM.  Inhibition response is normalized to 100% of each experimental control.  Control is binding with 
177pM [3H]Ebt without inhibitor non-specific binding was measured in the presence of 100µM NIC. 
 
 
of total.  Compounds that inhibited total [3H]Ebt binding to a value ≤ 80% of control 
were considered screen hits.    
Among all AH compounds screened only 16 were found to inhibit [3H]Ebt 
binding by more than 20% of total.  The inhibitory ability of the active compounds in 
order: 90>79>38>91=110>35>114>111>2>80>37>109>6>107>61.  Overall the results 
were quite promising in that of the ~150 AH compounds screened over 10% resulted in 
some inhibitory activity (>20% inhibition) and several compounds resulted in nearly 
100% inhibition.  The vast majority of compounds that do not contain a pyridine ring in 
their structure were found to be inactive.  This matches well with SAR reports in the 
literature that finds the pyridine ring element crucial for high-affinity binding.  Upon 
further analysis the data suggest some strong SAR trend among the compounds found to 
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 be the most active.  Five of the six compounds with the highest inhibitory ability were 3’-
pyridine-(aminomethyl)-guanidino analogs.  In all cases, the 2’ and 4’-pyridyl analogs 
were not very active.  For each bioisosteric (guanidine) group the 3’-pyridyl analog 
demonstrated greater inhibitory activity than both its 2’ and 4’-pyridyl counterpart.  In 
terms of productivity the two families that generated the most hits were the unsubstituted 
guanidine analogs, the imidazolidine analogs, and the tetramethyl-substituted guanidine 
analogs with multiple hits from each group.  For all three of these groups the 3-
aminomethylpyridine analog (3-AMP) of each gave the best result, with AH-5 giving a 
near 100% inhibition of binding.  Among the pyrimidine substituted compounds, the lone 
active was the familiar 3-AMP analog (AH-61) with all others giving negative results.  
The 3-AMP diethyl substituted guanidine compound (AH-79) also resulted n near 100% 
inhibition while the 4’ analog (AH-80) was significantly less potent.  The monoethyl 
substituted series gave a near identical result as the diethyl, with the 3-AMP (AH-90) and 
4-AMP (AH-91) analog coming up active.  Again, the 3-AMP compound was the far 
more active of the two resulting in 100% inhibition at 100µM.  The lone non-pyridine 
containing compound that resulted in a positive screen result was the 2-amino-5-picoline, 
tetramethyl analog (AH-114) which resulted in a fairly robust inhibition (80%) of 
specific binding.   
Interestingly enough, none of the tetrahydropyrimidine analogs (AH-96 through 
AH-100) elicited a positive result, including the 3-aminopyridine and 3-
aminomethylpyridine analogs, despite the fact that it represents a small change from the 
5-membered ring of the imidazolidine grouping to the 6-membered ring of the 
tetrahydropyrimidine.  It appears among the more extensive series of guanidine analogs 
synthesized that multiple ring halogen substitutions (AH-50 and AH-55), pyrrolidine ring 
substitutions (AH-15, AH-16, AH-45, AH-46), and other multiple ring systems (AH-8, 
AH-30, AH-56) are not well-tolerated at all.  Additionally, among the several di-
substituted (2,3 3,4 and 2,6) pyridine analogs (AH-7, AH-41, etc.) none were found to be 
active, suggesting that multiple cationic centers are not tolerated in the high-affinity 
nAChR binding pharmacophore.  A more detailed and specific SAR discussion will be 
included in following chapters when more useful and information-rich binding and 
functional data are presented, rather than the simple screening results presented here.     
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 Because the synthesis of compounds was ongoing throughout the testing 
procedure, none of the AH compounds beyond AH-115 were available for testing in the 
initial screening.  These several compounds were however, later tested in concentration 
response experiments along with the screen experiment hits and will be reported in 
following chapters.               
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 4.5  [3H]Epibatidine Screening Results: JC Compounds 
 
 Screening experiments were carried out in triplicate on 96-well plates.  Binding 
data are displayed as a single column for each compound with error bars representing the 
standard error of the mean for each.  Since the data are compiled on a single graph from 
several experiments, data values were separately transformed as a percent total of control 
binding for each experiment and then combined.  Uninhibited [3H]Ebt binding at 177pM 
was taken as 100% total binding control and non-specific binding was measured as 
177pM [3H]Ebt binding in the presence of 100µM NIC (data not on graph).  For all  
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Figure 4-8.  Screen Results:  Inhibition of total [3H]Ebt binding for active JC compounds at 100µM.  
Response is normalized to 100% experimental control.  Control is binding with 177pM [3H]Ebt without 
inhibitor, and N/S=non-specific binding (not shown) is measured in the presence of 100µM NIC. 
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  Inhibition of Specific [3H]Ebt Binding: Screen Results 
 
 
Compound  
Code 
Structure  % Specific Binding 
at 100µM 
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Figure 4-9.  Screen Results:  Specific binding of total [3H]Ebt in the presence of JC compounds at 100µM.  
Inhibition response is normalized to 100% of each experimental control.  Control is binding with 177pM 
[3H]Ebt without inhibitor and non-specific binding was measured in the presence of 100µM NIC. 
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 experiments the non-specific binding was remarkably consistent and, again, ranged from 
12-16% of total.  Compounds that inhibited total [3H]Ebt binding to a value ≤ 80% of 
control were considered screen hits.  The inhibitory ability of the active compounds in 
order:  2-48>2-25>2-46B>2-31>1-27>2-66>2-67>1-41>2-33A>1-80.  Overall the results 
were quite promising in that of the ~40 JC-compounds screened 10 were found to have 
some inhibitory ability (>20%) at 100µM.  This resulted in a hit rate of ~25% which is 
outstanding for a group of novel compounds, even those generated through rational drug 
design methods.   
 In this series also there was a strong trend favoring 3-aminopyridine and 3-
aminomethylpyridine compounds.  Eight of the ten compounds positive in the screen 
were e3’-substituted compounds with only a single 2’analog and a single disubstituted 
compound making the cut.  Unlike in the AH series, there appears to be less selectivity 
between 3-amino (3-A) and 3-aminomethyl (3-AM) compounds.  JC compounds 
featuring an amidino moiety in the form of an imidazolidine or a pyrimidine tolerate a 3-
aminopyridine molecule where the 3-aminomethylpyridine was preferred among AH 
compounds.  Compounds in this series also seem to tolerate larger bicyclic substitutions 
and even a di-substituted compound.   
 The 3A-N-ethyl substituted imidazolidine molecule (2-48) gave the highest 
inhibition at ~94%, with the 3A-N-tetrahydropyrimidine analog (2-25) close behind with 
93% inhibition.  The 3AMP-benzimidazole (2-46) and the 3AMP-azabicyclic compound 
(1-27) were the next highest affinities at 80% and 70% respectively at 100µM.  The 
imidazolidine substituted thionyl compounds (2-66) and (2-67) gave an unexpected result 
with binding inhibition of 59% and 52% respectively.  Although not a common molecular 
feature among nicotinics, the thionyl ring structure has featured prominently in some 
nicotinic ligands as described in the thionyl analogs of the imidacloprid molecule 
discussed earlier.  In this light it is less of a surprise than initially thought and may hold 
promise for future synthesis of high-affinity nAChR ligands.  Rounding out the hits are 
the lone quinuclidino compound (1-41) and the di-pyridyl substituted pyrrolidine 
molecule (1-80) which resulted in lower but noteworthy inhibition of 45% and 39% 
respectively.  Interestingly, none of the methylisoxazole compounds (2-77, 2-78) 
demonstrated activity in the screen.  Also, while the disubstituted pyrrolidine compound 
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 (1-80) gave a meager but significant inhibitory effect, its piperidine analog (1-93) 
resulted in a total loss of activity even at 100µM.  This appears to be a SAR limitation for 
only the di-substituted hits as several of the mono-substituted compounds featured six-
membered rings in the form of pyridine and pyrimidine that appeared to be well tolerated.   
Although it was touched on earlier, there appears to be significant differences 
between the AH and JC series, despite their seemingly common molecular features.  
While the amidino and various guanidino bioisosteric replacements may look similar at 
first glance they actually present distinct electronic features to the nAChR binding 
domain with which to interact.  The guanidino analogs present a more cationic, 
resonance-stabilized feature than the amidinos of the JC series.  Also, the larger bicyclic 
additions appear to be better tolerated in the JC series indicating that larger steric groups 
fit in better in the way the JC compounds interact with the nAChR allowing for more 
diversity and structural features to be added to the JC motif.  This could possibly lead to 
compounds with greater selectivity among these libraries of compounds. 
As with the AH series of compounds, the synthesis of JC compounds was ongoing 
throughout the testing procedure and none of the JC compounds beyond 2-78 were 
available for testing in the initial screening.  Similarly, these additional compounds (3-
series compounds) were later tested in concentration response experiments along with the 
screen experiment hits and will be reported in following chapters.               
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 4.6 [3H]Epibatidine Binding: Concentration-Response Experiments for  
AH Screen Hit Compounds 
 
 
Concentration-response (CR) of binding inhibition experiments were carried out 
with a minimum n=3 in 96-well plates.  Binding data are displayed as a single column set 
of data points with error bars representing the standard error of the mean for each data 
point.  Inhibition curves were fit to a one-site sigmoidal dose-response curve and all 
derivations and calculations were carried out as described in detail in the methods 
section.  Since the data are compiled on a single graph from several experiments, data 
values were separately transformed as a percent total of control binding for each 
experiment and then combined.  Uninhibited [3H]Ebt binding at 177pM was taken as  
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Figure 4-10.  Concentration-response results:  Specific binding inhibition of total [3H]Ebt in the presence 
of varying concentrations of AH screen compound hits.  Inhibition response is normalized to 100% of each 
plate’s experimental control.  Control is binding with 177pM [3H]Ebt without inhibitor and non-specific 
binding was measured in the presence of 100µM NIC. 
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 [3H]Ebt Binding Inhibition Data: AH concentration-Response Experiments 
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Figure 4-11.  Binding Data:  Binding affinity of screen hit compounds determined as Ki derived from IC50 
from [3H]Ebt binding inhibition curve fit.  Additional data include goodness of curve fit (R2) value along 
with curve model applied for final analysis.  Hill slope of curves for each AH-compound is included.  
Control for binding is determined with 177pM [3H]Ebt without inhibitor and non-specific binding was 
measured in the presence of 100µM NIC. 
 
 
100% total binding control and non-specific binding was measured as 177pM [3H]Ebt 
binding in the presence of 100µM NIC (data not on graph).   
 
 CRC Experimental Results 
For all experiments the non-specific binding was consistent and ranged from 9-
15% of total.  For each data set a best fit binding inhibition curve was fit and tested to one 
of two models, a fixed slope of unity or a variable slope model.  From the curve fit the 
IC50 was automatically determined and a Ki was calculated.  The goodness of the curve 
fit to the data is reflected as measured with the R2 value for each data set and was 
generally very good.  R2 values ranged from 0.940-0.989, with the average being 0.971.  
Hill slope values varied greatly among the screen hits and ranged from -0.44 to -1.98.   
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 All curves that could be fit to a preferential standard slope model was fit, but for 
curves with slopes significantly different than unity, a less stringent variable slope model 
was fit.  All compounds demonstrated rather good efficacy in displacing specific [3H]Ebt 
binding at the highest concentrations.  For curve fits of the compounds where a true 
bottom value could be determined, it was found that these compounds inhibited [3H]Ebt 
binding by at least 85% and often by as much as 95% (see figure 4-10).  This indicates 
that this family of compounds possesses good efficacy in displacing [3H]Ebt at the high-
affinity nAChR binding site.  Several non-active (non-hit) compounds were also 
evaluated as controls and validation of the screen assay and revealed very poor nAChR 
affinity in CR experiments (data not presented), indicating that the screening experiment 
works well to weed out non-active compounds from further analysis. 
Compound AH-114 was the revelation of the group giving an unexpected result to 
be certain.  While the screening data ranked it 8th most active by inhibiting [3H]Ebt 
binding by 79% at 100µM in the screen, CR experiments reveal it to have a Ki of 117nM, 
making it the compound with the highest affinity.  Compounds AH-79, 90, 5, 38, and 110 
were all in the top third of the compounds evaluated (with Ki values of 238nm, 368nM, 
557nM, 902nM, and 1.5µM respectively), and are remarkably well-placed according to 
where the screening experiments would predict.  In the screen they represent 5 of the top 
6 hits, and here they make up 5 of the top 7 compounds as measured by affinity.  This 
result would indicate that the screen is rather effective at selecting compounds that 
possess a high affinity for the target.  Compounds AH-107, 2, 35, 37, and 80 also appear 
to follow the trend predicted in the screen.  These five compounds fell in the range of 7-
15 in rank order in the screen and for the most part occupy the middle third of the 
distribution.  Their screen inhibition effects (49%, 73%, 80%, 66%, 68% respectively) 
correlate well with their affinity measures (with Ki values of 2 µM, 4.0µM, 4.1µM, 
7.5µM, and 8.6µM respectively).  Results for compounds AH-91 and AH-111 were 
disappointing as these two compounds were ranked in the top half of the hits with 
inhibition values of 85% and 70% respectively, but failed to yield a high affinity result in 
the CR experiments (Ki=12.3µM and 13.7µM respectively).  Compounds AH-109 and 
AH-6 behaved just as the screen results predicted with these compounds resulting in the 
two lowest affinity values at 14.2µM and 15µM respectively.  Finally, from the screen 
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 data, AH-61 was expected to have the lowest affinity of all hits (inhibition of only 39% at 
100µM).  The CR experiments reveal a much more promising activity for this compound 
however, with a Ki of 985nM.  At the experimental concentration used in the screening 
experiments 100 µM, (~100-fold higher than the calculated Ki for this compound) AH-61 
should have resulted in a maximal inhibition instead of the modest inhibitory activity 
seen in the screening data.  This was not observed.     
Despite the apparent hit-and-miss relationship between the screening data and the 
CR data, the SAR trend continues between results from the screen CR binding data.  
Once again 6 of the 7 compounds with the highest affinity values were the 3-
aminomethylpyridine analog.  We also witness a dramatic drop in affinity for all 2’ and 
4’ analogs in each series compared to the 3’ analog.  Overall, six of the sixteen 
compounds gave affinity values <1.0µM.  Not surprisingly the 3-aminomethyl 
compounds were the highest affinity compounds with the lone exception the 2-amino-5-
picoline compound, AH-114.  Relative affinity values for the nAChR among these 
compounds were less than what was hoped for, with the best compound being AH-114 at 
117nm.  Additionally only 5 compounds possess a Ki affinity in the nanomolar range, 
which might be considered a bare minimum requirement for a lead compound 
identification for a high-affinity drug/research tool/therapeutic.  All compounds were 
found to be 100% or nearly 100% efficacious at displacing [3H]Ebt at the highest values, 
with the only exceptions being those few compounds with IC50 values so high that the 
experimental range did not challenge their maximal inhibitions.  The most surprising 
result is compound AH-114 which was rated low in the first screening rank order and 
was expected to demonstrate lower affinity but appears to have a very good affinity for 
the high affinity nAChR at 117nM.   
 
Screen-to-CRC Comparison 
In order to evaluate the ability of the one-point screen to predict activity in CR 
experiments, a quick analysis was carried out where the rank order of the data from the 
screening experiments were compared to the rank order of the CRC experiments.  The 
goal was to measure the ability of the screen to predict the relative potency of the test  
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  [3H]Ebt Binding: Comparison Between Screen and CRC  
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Figure 4-12.  Binding Data:  Rank order comparison data analysis between rank order of AH compounds 
according to maximal inhibition of [3H]Ebt binding inhibition in the single concentration screen assay 
(ordinate axis) and the rank order of binding affinity determined in concentration-response experiments 
(abscissa).  Data were compared using linear regression analysis and a best-fit line is presented with 95% 
confidence interval.  Line slope is 0.547±0.223 with an R2 of 0.299.  Linearity test reveals significance 
(F=5.979 and p=0.028) with a significant deviation from zero.    
 
 
compound hits.  In this study a correlation was determined between the rank orders from 
the screen and rank orders from the CR experiments, and standard statistical analysis 
reveals a mixed result (see figure 4-12).  Data were assigned values 1-16 depending on 
their rank order and plotted on the X,Y graph (figure 4-12).  A standard linear regression 
analysis was performed on the data.  Results reveal a relationship with a slope of 
0.547±0.22 and an R2 value for the regression of 0.299 indicating that the relationship 
was not significant.  The data was tested for linearity and was found to fit very well to a 
linear model (F=5.979 and p=0.028) indicating that there  
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 is a commonality throughout the dataset, but if a trend exists it is a weak one and not 
significant.  Eight points lie above the regression line and eight below with the runs test  
value of 0.2145.  Only slightly more than half the data points lie within the 95% CI range 
along the graph which does not speak well for the screens ability to predict relative 
compound activity.  On the other hand the screen data was able to accurately predict 4 of 
the top 5 compounds with the highest affinity, possibly demonstrating a small preference 
for predicting activity among high-affinity compounds.  Overall the resulting analysis 
reveals the fact that the [3H]Ebt screen does not appear to predict nAChR activity beyond 
the simple act of selecting for hit compounds to be retained for further testing. 
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 4.7  [3H]Epibatidine Binding: Concentration-Response Experiments for  
JC Screen Hit Compounds 
 
 
Concentration-response (CR) of binding inhibition experiments were carried out with 
a minimum n=3 in 96-well plates.  Binding data are displayed as a single column set of 
data points with error bars representing the standard error of the mean for each data point.  
Inhibition curves were fit to a one-site sigmoidal dose-response curve and all derivations 
and calculations were carried out as described in detail in the methods section.  Since the 
data are compiled on a single graph from several experiments, data values were 
separately transformed as a percent total of control binding for each  
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Figure 4-13.  Concentration-response results:  Specific binding inhibition of total [3H]Ebt in the presence 
of varying concentrations of JC screen compound hits.  Inhibition response is normalized to 100% of each 
plate’s experimental control.  Control is binding with 177pM [3H]Ebt without inhibitor and non-specific 
binding was measured in the presence of 100µM NIC. 
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[3H]Ebt Binding Inhibition Data: AH concentration-Response Experiments 
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N/A 
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Figure 4-14.  Binding Data:  Binding affinity of JC-screen hit compounds determined as Ki derived from 
IC50 from [3H]Ebt binding inhibition curve fit.  Additional data include goodness of curve fit (R2) value 
along with curve model applied for final analysis.  Hill slope of curves for each JC-compound is included.  
Control for binding is determined with 177pM [3H]Ebt without inhibitor and non-specific binding was 
measured in the presence of 100µM NIC. 
 
 
experiment and then combined.  Uninhibited [3H]Ebt binding at 177pM was taken as 
100% total binding control and non-specific binding was measured as 177pM [3H]Ebt 
binding in the presence of 100µM NIC (data not on graph).   
 
 CRC Experimental Results 
For all experiments the non-specific binding was consistent and ranged from 9-
15% of total.  For each data set a best fit binding inhibition curve was fit and tested to one 
of two models, a fixed slope of unity (standard model) or a variable slope model.  From 
the curve fit the IC50 was automatically determined and a Ki was calculated.  The 
goodness of the curve fit to the data is reflected as measured with the R2 value for each 
data set and was generally very good for data that were able to be fit to a curve.  R2 
values ranged from 0.975-0.997, with the average being 0.989.  Hill slope values ranged 
from -0.80 to -1.45.  All curves that could be fit to a preferential standard slope model 
were, but curves with slopes significantly different than unity, the less stringent variable 
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 slope model was fit.  Compounds demonstrated good efficacy in displacing specific 
[3H]Ebt binding at the highest concentrations for compounds where a bottom could be 
established on the curve.  For curve fits of the compounds where a true bottom value 
could be determined, it was found that these compounds inhibited [3H]Ebt binding by at 
least 85% and often by as much as 95% (see figure 4-10).  This indicates that this family 
of compounds possesses good efficacy in displacing [3H]Ebt at the high-affinity nAChR 
binding site.  Several non-active (non-hit) compounds were also evaluated as controls and 
validation of the screen assay and revealed very poor nAChR affinity in CR experiments 
(data not presented), indicating that the screening experiment works well to weed out 
non-active compounds from further analysis. 
SAR analysis reveals only three JC compounds with high affinity (Ki <100nM) 
with nine JC compounds giving a low affinity (Ki >100nM).  The rank order of affinity 
was 3-9>2-25>3-2>2-31>1-80>1-27>1-41>2-66>2-67>2-33A>2-46B>2-48.  Generally 
the results from the CR experiments matched the screening results well with a few 
remarkable exceptions.  Four compounds (2-48, 2-46B, 2-33A, 1-67) showed such low 
affinity that the data could not be fit to an inhibition curve.  For these compounds a 
provisional Ki of >100 µM was assigned.  The results for compound 2-48 were a surprise.  
While it gave the highest apparent inhibitory ability in the screen (94% inhibition at 100 
µM), rank order comparison from CR experiments reveal that it possesses among the 
lowest affinity values (>100 µM).  Compound 2-46B was another screening failure as it 
also revealed poor affinity after testing very well in the screen at 3rd out of the 10 JC hits 
presented.  Compounds 2-33A and 2-67, however were no surprise as they tested 
relatively weakly in the screen (43% and 51% inhibition at 100µM) and were found to 
have very low affinity in the CR experiments.  Compounds 1-41 and 2-66 had poor 
affinity values but resulted in sufficient inhibition to fit a curve to the data and determine 
an actual Ki value (Ki= 11.3µM and 25.1µM respectively).  Compounds 2-31, 1-80 and 
1-27 gave a more promising result with Ki values between 1.0 and 10µM (1.3 µM, 3.0 
µM, and 3.1 µM respectively).  The compound with the highest affinity that was 
evaluated in the screen was 2-25.  JC 2-25 gave a very good result in the screen and was 
also found to have a high affinity in the CRC tests (2nd in screen rank order at 93% 
inhibition compared to Ki=141nM in the CR experiments).  Two compounds were 
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 synthesized only after the screening experiments were carried out were evaluated in CR 
experiments; JC 3-2 and JC 3-9.  These two compounds were among the few with sub-
micromolar affinity values (Ki values of 205nM and 29nM respectively).  With 
nanomolar affinities, compounds 3-2, 2-25, and 3-9 represent a real success in the 
amidino series since the aim was to design and synthesize amidino-containing 
compounds that possess high affinity for the nAChR. 
SAR analysis reveals a lot of structures that were not found to be leading 
templates for further high-affinity nAChR drug development.  The two benzimidazole 
compounds that were synthesized, JC 2-46B and 1-33A, were both abject failures with 
pitifully low affinity, revealing this structure platform to be not of interest for further 
testing.  The two thionly-containing compounds JC 2-67 and JC 2-66 produced a 
similarly poor result, revealing a structure not amenable to high-affinity nAChR binding.  
Additionally the quinuclidine moiety of JC 1-41 did not appear to confer any particular 
affinity and was deemed a not very successful strategy from an SAR perspective.  
Compounds JC 1-80 and JC 1-27 both gave a similar result with an affinity value around 
3µM.  In the case of 1-80 this represents an unexpected result since it is a bis-
methylpyridine substituted pyrrolidino compound.  Previous work revealed poor affinity 
among all pyrrolidino and bis-substituted nicotinics and represents a structural motif that 
may warrant further examination.  JC 1-27 was a less than surprising result, as 3-
aminomethylpyridine compounds have been found to be a preferred structure among 
compounds possessing high affinity at the nAChR.  The larger azabicyclo-octan ring is an 
unusual feature as most nicotinics mimic the smaller bicyclo ring system of Ebt or the 
quinuclidine ring system while few results in the literature reveal success with larger ring 
systems.  This result suggests some possibly room for improvement in this area.  The 
story with the imidazolidine compounds, however, is a little more complex with one 
imidazolidine compound giving a poor result, one a greatly improved result, and a third 
imidazolidine compound providing one of the highest affinity compounds in the series.  
All of these imidazolidine compounds were 3-aminopyridine analogs, however the 
difference between JC 2-48 (Ki>100µM) and JC 2-31 (Ki=~1µM) is dramatic.  From the 
structure one can see that the only difference between these two compounds is the 
reduction of the imidazolidino substituent from an ethyl (2-48) to an ethyl (2-31); a very 
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 small change with a dramatic result.  That would suggest that among 3-aminopyridine 
amidino analogs imidazolidine substitution selection is a critical feature for high affinity 
nAChR binding.  This trend for dramatic shifts in affinity with minor structural 
alterations is continued with compound JC 3-2.  3-2 is identical to 2-31 with a 6-chloro 
addition on the pyridine ring.  Though minor, this change improves binding affinity in the 
series by a further 6.5-fold (Ki=200nM) and results in one of the most promising of all 
the JC compounds.  The best results were returned following testing of 2-25 and 3-9.  As 
might be expected, these two compounds share a common base structure as seen in the 
imidazolidine series above.  Just as with the previous series, the structures are built 
around a 3-aminopyridine core but the ring component is the larger 6-membered 
tetrahydropyrimidine (THP) moiety.  For both 3-2 and 3-9 the THP ring appears to be 
essential for high affinity binding.  JC 3-9 is identical to JC 3-2 except for two 
modifications: a 6-chloro addition and a single 1-N-methyl addition to the THP ring 
structure.  These two differences are enough to confer a nearly 5-fold improvement in 
affinity from 141nM to 29nM.  At first glance these results appear to bolster some of the 
SAR trends continued from the imidazolidine series: 1) that in the amidino series a 3-
aminopyridine ring additions are preferred over thionyl and even 3-aminomethyl groups 
and seem to be required for high affinity, 2) that single ring structures are (IM and THP) 
are preferred to larger bis-substitutions, bicyclo, and linked benzimidazole groups, 3) that 
among highly active compounds small changes to the amidino ring appear to confer large 
changes in activity, and finally 4) that the 6-membered ring system may be favored over 
smaller 5-membered ring systems that confer high affinity.   
 
Screen-to-CRC Comparison 
In order to evaluate the ability of the one-point screen to predict activity in CR 
experiments, a quick analysis was carried out where the rank order of the data from the 
screening experiments were compared to the rank order of the CR experiments.  The goal 
was to measure the ability of the screen to predict the relative potency of the test  
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Figure 4-15.  Binding Data:  Rank order comparison data analysis between rank order of JC compounds 
according to maximal inhibition of [3H]Ebt binding inhibition in the single concentration screen assay 
(ordinate axis) and the rank order of binding affinity determined in concentration-response experiments 
(abscissa).  Data were compared using linear regression analysis and a best-fit line is presented with 95% 
confidence interval.  Line slope is -0.103±0.35 with an R2 of 0.010.  Linearity test reveals significance 
(F=0.085 and p=0.777) with a non-significant deviation from zero.    
 
 
compound hits.  In this study a correlation was determined between the rank orders form 
screen and CR experiments, and standard statistical analysis reveals a mixed result (see 
figure 26).  Data were assigned values 1-10 depending on their rank order and plotted on 
the X,Y graph (figure 4-15).  A standard linear regression analysis was performed on the 
data.  Results reveal a relationship with a slope of -0.103±0.35 and an R2 value for the 
regression of 0.010 indicating that the relationship was not significant.  The data was 
tested for deviation from zero and was found to fit be non-significant (F=0.085 and 
p=0.777) indicating that there in no trend in the dataset that can be distinguished from 
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 random.  Five points lie above the regression line and five below with the runs test value 
of 0.205.  Most of the data points lie within the 95% CI range along the graph but it is 
only because of the extremely large range that this occurs.  This data does not indicate 
any ability to predict relative compound activity in the CR experiment from preliminary 
screen data at all.   
 
Discussion 
A [3H]epibatidine binding inhibition assay was characterized and validated.  The 
parameters for running the assay were clearly established and the pharmacological 
significance was backed-up by rank-order analysis of known control compounds.  
Furthermore, the experimentally determined binding affinity value of known compounds 
closely matched published results for the same compounds as demonstrated in the 
literature.  These data were consistent even when compared to results from multiple 
sources.  The affinity values determined from binding match the values for these 
compounds assayed in high-affinity systems and therefore indicate that the [3H]Ebt 
binding assay probes the high-affinity α4β2* nAChR subtype.   
Binding experiments in whole brain fractions demonstrated a nearly complete 
lack of α7* nAChR binding activity for the tissue selections that were used, and at the 
concentrations of radioligand evaluated in this assay protocol.  Even enriched 
hippocampal P2 membrane preparations which are known to express a high level of α7* 
nAChR revealed poor α7* binding selectivity, confirming that under the conditions 
described here the α4β2* nAChR appears to be the major subtype probed in this assay. 
Experiments screening compounds at a single, high-concentration were carried 
out and revealed several compounds that resulted in significant binding inhibition relative 
to experimental controls.  These compounds were considered active “hits” and were 
carried over for further evaluation, while no further work on inactive compounds was 
carried out.  A screening procedure to evaluate compounds was successfully established 
allowing for selection among newly-synthesized compounds based on binding activity.  
Several compounds from both the AH and JC series were identified and selected as 
having activity at the high-affinity nAChR subtype using the screening method.   
 178
 Concentration-response experiments (CR) were successfully carried out in order 
to determine the maximal inhibitory efficacy and the affinity of screen hit compounds.  
The data revealed that several compounds found to be active in the screen were inactive 
in the CR experiments.  This is likely due to the low stringency of the screen, where test 
compounds were evaluated at a very high concentration (100µM) and may have some 
significant non-specific interactions that could affect the measure of displacement.  
Predictably, this led to the selection of several compounds with marginal or poor affinity 
that was later more clearly revealed in the CR data.  This approach is in fact the more 
desirable screening strategy since the experiment is designed to increase false positives in 
order to avoid false negatives since these can be weeded out in later testing.  
Additionally, numerous high affinity AH and JC compounds were confirmed in the Ebt 
binding CR experiments.  Further testing was later carried out on these compounds to 
better characterize the mechanism of interaction and particular activities of these 
compounds.  For these reasons the CR experiments served their purpose in revealing false 
positives as real negatives carried over from the screening assay, and revealed much 
about the binding interaction for active compounds. 
The correlation of measures between the screening assay and the CR assay were 
evaluated by a simple rank-order comparison in both the AH and JC series.  While there 
appears to be a general trend in activity between the two methods among AH compounds 
there seems to be little real power in predictability from screen to binding affinity.  
Compounds that demonstrated the highest inhibitory ability in the screen did correlate 
more closely between the two experiments than the whole group for each series.  In this 
manner the screen does serve the purpose of simply identifying compounds with the 
highest affinity among a library of unknown nicotinic analogs.  Based on these results it 
can be concluded that the screen assay must always be followed up by the CR assay in 
order to confirm a positive result and to better define the magnitude of the binding 
interaction for the test compounds.  Overall the methods and results detailed in this 
chapter were successful in satisfying the goal of specific aim #2.       
 
Copyright © Aaron Joseph Haubner 2008  
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   Chapter 5: nAChR Subtype-Selective Binding Analysis 
 
5.1  Background 
 
AH and JC compounds that were synthesized as described in previous chapters 
were evaluated in a nAChR subtype-selective binding screen.  While they were earlier 
screened and evaluated for binding activity in the [3H]Ebt assay, it was found that no 
distinction could be made between the high affinity subtype and non-α4β2* subtypes.  
Since both the α4β2* and α7* nAChR subtypes represent interesting potential drug 
targets AH and JC guanidino and amidino compounds were also evaluated for their 
ability to interact with either or both of the two major neuronal nAChR subtypes.  For 
these experiments subtype selective, radiolabeled compounds were used in binding 
inhibition studies to first screen, then determine the affinity of these compounds for 
either of the two major neuronal subtypes.     
 
[3H] Nicotine and [3H] Methyllycaconitine Binding 
S-(-)-NIC is the major alkaloid product in tobacco and binds selectively to α4β2* 
vs. α7* nAChRs with a 100 to 1000-fold preference for the α4β2* subtype (Daly 2005).  
NIC activates α4β2* receptors at about 1µM while requiring around 500 times higher 
concentration to activate neuronal α7* nAChRs, making S-(-)-NIC selective for high-
affinity nAChRs in binding and functional studies where NIC concentrations are held 
below 50nM (reviewed in Sharples 2001).  This concentration-dependent selectivity or 
subtype-selectivity window is important in understanding how a compound that binds all 
subtypes can be used in an experiment to probe a single subtype.  This is accomplished 
by incubating the receptor population with the ligand only within the concentration range 
where it exists as a selective agent.  nAChR subunit composition is an important factor 
that determines the relative affinity of nAChR antagonists at the S-(-)-[3H]nicotine 
binding site (Harvey and Luetje, 1996; Harvey et al., 1996; Chavez-Noriega et al., 1997).   
The α4β2* subtype is the predominant nAChR in the CNS and is commonly the 
target for high affinity S-(-)-[3H]NIC binding studies.  Binding of S-(-)-[3H]nicotine to 
nAChRs in homogenates of rodent brain is reversible and stereospecific, and represents a 
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 single class of high-affinity sites located at the interface of the α4β2* subunits (Lippiello 
et al., 1987; Reavill et al., 1988; Zhang and Nordberg, 1993).  The 7* nAChR subtype is 
sensitive to inhibition by -bungarotoxin and methyllycaconitine (MLA) (Schoepfer et 
al., 1990; Orr-Urtreger et al., 1997; Davies et al., 1999).  MLA is a natural plant product 
Erythrinia alkaloid which was found to selectively inhibit [125I]α-bgt from as early as 
1988 (Macallan 1988, Albuquerque, 1988, Ward and Wonnacott 1990).  Later studies 
found MLA to be a functional inhibitor of hippocampal nAChR currents (Alkondon and 
Albuquerque 1992), although as with most compounds MLA’s functional inhibitory 
activity is greater than its binding affinity.  By 1996 studies had linked MLA binding and 
function to the putative α7* nAChR (Palma and Bertrand 1996, Yum and Chiappinelli 
1996), and shortly after the first reported use of [3H]MLA as a radioligand for binding 
studies it was reported to be a useful radioligand for probing this nAChR subtype (Davies 
et al., 1999).  It has been thoroughly established in the research literature that [3H]MLA 
binds selectively to the α7* nAChR and can alter its function.  As described in chapter 3 
MLA has high affinity for α7* nAChR (Ki=1-3nM) while having a 1000-fold lower 
affinity for the α4β2* subtype (Jensen 2004), and unlike the well known α7*-selective 
peptide ligand α-Bgt, MLA discriminates between neuronal α7* and muscle-type 
nAChRs (Whiteaker and Wonnacott 1999).  It is a potent and selective antagonist at 
neuronal nAChRs in both native and expressed systems (Alkondon 1992, Davies 1999) 
inhibiting functional responses in the low nanomolar range.  
In the work described herein, S-(-)-[3H]NIC and [3H]MLA were used in binding 
displacement experiments to probe a common pool of neuronal nicotinic receptors in the 
form of whole rat brain homogenates (much like binding procedures described in 
preceding chapters).  These two compounds have both been well established as selective 
at their Ki concentrations to probe selectively the α4β2* and α7* nAChR subtypes 
respectively.  This, along with their ease of purchase in pure form and their affordability 
is why they were chosen as radioligands in these binding experiments.  
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 5.2  Materials and Methods 
 
Materials 
 HEPES, Tris hydrochloride (Trizma HCl), Tris aminomethane base (Trizma), and 
polyethylenimine (PEI) were purchased from Sigma/RBI (Natick, MA). S-(-)-
[3H]nicotine [N-methyl-3H]; specific activity, 80 Ci/mmol and (±)-[3H]methyl-
lycaconitine specific activity, 25.4 Ci/mmol; [3H]MLA) were purchased from New 
England Nuclear-PerkinElmer Life Sciences (Boston, MA) and Tocris Cookson Ltd. 
(Bristol, U.K.), respectively. Scintillation cocktail 3a70B was purchased from Research 
Products International Corp. (Mt. Prospect, IL). Remaining chemicals used in the buffers 
were obtained from Fisher Scientific (Pittsburgh, PA).  All chemicals and reagents (Tris 
base and buffer salts included) were reagent grade and were purchased from Sigma-
Aldrich Chemical Co. (St. Louis, Mo.) or Fisher Scientific.  S-(-)-NIC was purchased 
from Research Biochemicals Inc. (RBI, Natick, MA) and Cyt was purchased from 
Sigma-Aldrich Chemical Co. (St. Louis, MO).  The known, reference inhibitor DN-IMI 
(5mg) was obtained as a gift from Dr. John E. Casida (UC Berkeley). 
 Adult male Sprague-Dawley rats (225-250g) were housed two per cage with free 
access to food and water and held at the University of Kentucky, Biomedical Biological 
Sciences Research Building Animal Care Facility.  Animals were held at least three days 
after delivery prior to tissue harvesting.  Experimental protocols involving animal use 
were in strict compliance with the NIH “Guide for the Care and Use of Laboratory 
Animals” and institutional animal care guidelines, and were approved by the Institutional 
Animal Care and Use Committee at the University of Kentucky   
 
 Membrane Tissue Homogenate 
Following decapitation, cerebral membranes were pulled away and removed and 
excess vasculature was removed to reduce non-specific binding.  Brain tissues were 
removed and stored in ice cold membrane preparation buffer Krebs-HEPES buffer 
(20 mM HEPES, 118 mM NaCl, 4.8 mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, pH 7.5).  
Tissue was homogenized by first chopping tissue into a rough chopped mix with a razor 
blade and homogenized properly using a Tekmar Polytron in 10 volumes of ice-cold 
modified Krebs-HEPES buffer (20 mM HEPES, 118 mM NaCl, 4.8 mM KCl, 2.5 mM 
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 CaCl2, 1.2 mM MgSO4, pH 7.5). Homogenates were incubated (5 min at 37°C) and 
centrifuged (29,000g for 20 min at 4°C). Tissue pellets were resuspended in 10 volumes 
of ice-cold Milli-Q water (Millipore Corp., Bedford, MA), incubated (5 min at 37°C), and 
centrifuged (29,000g for 20 min at 4°C). The tissue pellets were again resuspended in 
10 volumes of ice-cold 10% Krebs-HEPES buffer, then incubated and centrifuged as 
described. Final tissue pellets were stored at -20°C in fresh 10% Krebs-HEPES buffer 
until use. Upon assay, pellets were resuspended in 0.1x Krebs-HEPES buffer, incubated.  
A 0.1ml aliquot is reserved for protein determination.  The amount of protein was 
determined for each membrane sample according to previously published method 
(Bradford, 1976) using the BioRad reagent in a clear 96-well plate format.  Plates were 
measured for absorbance at 595nM and protein amounts were calculated from standard 
curves made using dilutions of BSA as the protein standard.   
 
[3H]NIC and [3H]MLA Binding: General Procedure 
 Interaction of nicotine analogs with nAChR subtypes probed by S-(-)-[3H]NIC 
binding (α4β2*) and [3H]MLA binding (α7*) to rat brain membranes was determined to 
assess the nAChR subtype selectivity of compounds as described previously (Sumithran, 
2005).  Binding assays were performed using homogenates of whole rat brain, excluding 
cortex and cerebellum. Membranes from adult male Sprague-Dawley rats were prepared 
using a modification of the general procedure previously described (Chen 2006) and 
suspended in dilute buffer solution so as to give final concentration ~110 μg protein per 
100μl.  Homogenates were well mixed to ensure proper suspension, and also mixed by 
repeated pipeting periodically throughout the dispensing procedure to ensure equal 
distribution across the plate, and temporally throughout the plating process.  All 
procedures are performed at RT unless otherwise noted.  Briefly, whole brain was 
homogenized in 20vol of ice-cold buffer (in mM: 20 HEPES, 118 NaCl, 4.8 KCl, 2.5 
CaCl2 and 1.2 MgSO4, pH 7.5). 96-well plates (96F plate, Nalgene-Nunc Int.) were used 
with a final volume of 250μL.  All test compounds were diluted to a working (5x) 
concentration prior to addition to the plate.  Reactions include 50μL of compound or 
water for control, 50μL of 9nM [3H]NIC or 9nM [3H]MLA, 50μL of buffer (2x) and 
100μL membrane suspension. Each well contained 100-150μg protein per well, with 
counts being performed for each experiment immediately following final incubation.  
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 [3H] ligands were diluted from fresh stock solutions and scintillation measurements 
counted as described.  Ligand solution counts were adjusted with 1x Krebs-Hepes buffer 
to a final of 28,000 DPM for NIC and 8,000 DPM for MLA for a final concentration of 
9nM each according to the specific activity provided by the manufacturer for each 
compound.  For displacement binding experiments inhibitors and ligands in buffer were 
allowed to incubate for one half hour followed by the addition of membrane suspension.  
When compounds were found to be insoluble in binding buffer a second weighed sample 
of compound was brought up in a small volume of 100% dimethylsulfoxide (DMSO) and 
then diluted in binding buffer. When needed, dilutions were made such that final DMSO 
concentrations were <0.1.  Total binding was in the absence of analogue while non-
specific binding was determined in the presence of 10μM cytisine for S-(-)-[3H]NIC 
binding and 10μM NIC for [3H]MLA binding.  
After 60 minutes of moderate shaking at ambient temperature, incubation was 
terminated by rapid filtration.  96-well glass-fiber filter plates (0.65µm, Unifilter 96 
GF/B, Packard) presoaked at least two hours in 0.5% polyethylenimine, were used in a 
plate harvester (Packard Harvester Filtermate 96™) to collect the incubate.  After 
washing 5 times with 350μL ice-cold assay buffer, filter plates were dried for 60 minutes 
at ambient temperature, bottom-sealed, filled with Packard’s MicroScint 20™ cocktail 
(40μL/well) and top sealed. After 30 minutes resting, radioactivity was determined via 
scintillation counting. Counting was performed for 2 minutes per well in a Packard 
TopCount NTX™ 6-detector, 96-well microplate scintillation counter.  Counts were 
converted from CPM to DPM depending on the instruments counting efficiency, as 
determined according to pre-programmed quench curve.  For all experiments specific 
binding is measured by subtracting [3H]ligand binding in the presence of CYT (100µM) 
for NIC binding and NIC (100µM) for MLA binding from total binding in the absence of 
competitor.  Unless otherwise noted individual experimental measurements were carried 
out in at least triplicate for each experiment. 
 
[3H]NIC and  [3H]MLA  Binding Screen Procedure  
Compounds were evaluated initially in a [3H]NIC and [3H]MLA binding 
displacement screen, where compounds were tested for their ability to displace ligand at 
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 its previously determined Ki (3nM for both NIC and MLA) at 1µM.  Binding 
experiments with both radioligands were carried out in tandem for each experiment on 
the same plate.  Inhibition was analyzed for each test compound and those that inhibited 
specific [3H]ligand binding by more than 25% of the total at the highest concentration 
were considered positive screen hits when this value was measured to be a statistically 
significant lower value than the binding controls as measured in by t test.  These 
compounds were then evaluated for their ability to inhibit subtype-selective binding 
across a concentration range. 
   
[3H]NIC and [3H]NIC Concentration-Response Experiments  
 Compounds that were found to displace, or inhibit more than 25% of total [3H]Ebt 
binding in the screen were evaluated in a concentration-response (CRC) binding 
experiment in order to determine nAChR affinity.  The general binding procedure 
remains unchanged from the general method described above.  Compounds 
concentrations were made from an initial stock of 3mM in water and serial dilutions were 
made for each compound across the experimental concentration range.  Most experiments 
examined binding concentration ranges of 10pm-100µM with a minimum of seven data 
points for inhibition curve fittings.  Inhibition data were plotted and fit to sigmoidal dose-
response curves.  IC50 and Ki values were determined for each compound as described 
above. 
 
Data Analysis 
For all experiments, data were plotted and processed by non-linear least squares 
analysis using the current version of the GraphPad Prism, graphical and statistical 
software package (GraphPad Software Inc., San Diego, Cal).  In screening experiments 
data were measured as specific binding in DPM.  Specific binding was calculated as total 
uninhibited binding minus non-specific binding values.  A total and non-specific value 
was calculated for each plate and experiment.  Data are represented as the mean and SEM 
of the individual data values compiled from multiple experiments.  Graphs which are 
presented as composites of multiple experiments show data normalized to each 
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 experiments total control binding value.   For screening experiments data were plotted in 
column bar graphs.   
For concentration-response experiments, curves were fit according to the method 
described in each of the following sections and were fit by an uninterrupted iterative 
process.  The best fit curve was defined as the fit that minimized the absolute squared 
distance (Y2) from each data point to the curve.  All binding curves were fit with a non-
linear regression, sigmoidal dose-response curve with each Y value as a single data point.  
The basic equation is as follows: 
 
Y= bottom + ((top-bottom)) / (1+10^(x-logIC50)) 
 
Curve fits were generated without artificial weighting of values.  Competitor drug 
concentrations were input as X (ordinate) values in logarithm notation.  For all curves an 
F test was made between two models, the standard fixed slope and the variable slope fit.  
If the slope of the best fit curve was not significantly different from the standard slope 
than it was applied.  In either case the equation with the fewer variables was chosen 
unless the p value was less than the threshold p value (<0.05).  Unlimited iterations were 
allowed until the row change of the sum of the squares changed less than 0.01% upon 
additional rounds.  Top values for the curves were determined automatically by analyzing 
the several maximal binding values.  If too few top values exist to set a calculated top 
value then the maximal value from the corresponding control was used as the top value 
for the curve.  Bottom values for the curves were determined automatically by analyzing 
the several minimum binding values.  If too few bottom values exist to set a calculated 
bottom value then the minimum values from the corresponding control was used as the 
bottom value for the curve.  In the case of inhibition binding curves the maximal 
inhibitory values minus the non-specific value gave the minimum. EC50 values were 
automatically calculated as the concentration value on the curve that corresponds to the 
point on the curve halfway between maximal and minimal specific binding.  For 
competition binding experiments the IC50 values were calculated using: 
 
Θ = 1/[(1 + ([L]nH/IC50)] 
 186
  
Where Θ is the amount of [3H]NIC bound in the presence of inhibitor [L] compared to 
the amount of [3H]NIC bound in the absence of inhibitor (total binding).  IC50 is the 
ligand concentration at which Θ = 0.5 (50% bound).  
The affinity, measured as (Ki) was derived (same as described in Chapter 4) from 
the calculated EC50 value.  Calculations were made according to the Cheng-Prusoff 
equation:   
Ki = IC50 / (1 + ([ligand] / Kd)) 
 
 
5.3  [3H]NIC and [3H]MLA Binding Screen Results 
 
Cyt and Nic Control Binding Results 
This experiment was carried out in order to assess the inhibitory ability of the two 
known inhibitors Cyt and NIC on the specific binding of [3H]NIC and [3H]MLA 
respectively.  Initial control experiments examine the high-affinity compounds Cyt and 
NIC for ability to inhibit [3H]NIC and [3H]NIC binding respectively.  The binding curves 
for both compounds fit a one-site, sigmoidal dose-response model and the Hill 
coefficients of the curves were not found to be significantly different from unity (slope 
other than -1).  Uninhibited binding of radioligand at a concentration of 3nM for both was 
taken as the top value (or 100% maximal binding), and all data points were calculated as  
a percentage of this maximal binding value.  Non-specific binding was measured as 
binding in the presence of 10µM competitor.   
GraphPad software was used to calculate IC50 values based on the inhibition 
curves and the inhibitory affinity constant (Ki) for each test compound was calculated.  
The data were found to generate a Hill slope not significantly different from unity and 
were found to fit a one-site non-variable slope model best.  Binding curve fits modeled 
the data well for both Cyt inhibition (R2=.967) and NIC inhibition (R2=.990).  IC50 values 
were 3.8nM for Cyt and 6.2nM for NIC.  Ki values were calculated for Cyt at 1.9nM and 
3.1nM for NIC.  It is important to note that both NIC and Cyt inhibited nearly 100% of 
specific [3H]Ebt binding and that the affinity values calculated for NIC and Cyt in these  
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Figure 5-1.  Inhibition of total [3H]NIC binding by Cyt (closed circles) and inhibition of total [3H]Cyt 
binding by NIC (closed triangles).  Data are normalized to 100% total binding in absence of inhibitor, and 
are fit to a one-site, sigmoidal dose-response curve.  Control is binding with 177pM [3H]Ebt without 
inhibitor, and N/S=non-specific binding measured in the presence of 10µM NIC.    
 
experiments match published values (Daly 2005) as well as with results previously 
obtained in the Dwoskin lab.     
 
[3H]NIC Screen Assay Results 
[3H]NIC screening experiments were carried out in triplicate on 96-well plates.  
Binding data are displayed as a single column for each compound with error bars 
representing the standard error of the mean for each data set.  Since the data are compiled 
on a single graph from several experiments, data values were separately transformed as a 
percent total of control binding for each experiment and then combined and analyzed.  
Uninhibited [3H]NIC binding at 3nM was used as 100% total binding control and non- 
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[3H]NIC Screen: Single Plate Result 
 
 
Figure 5-2.  Single experiment screen results:  Screens were carried out to measure inhibition of total 
[3H]NIC binding for AH and JC compounds at 1µM.  Each screen was carried out in duplicate (one light 
and one dark bar for each compound), with n=3 for each set.  Total binding is 3nM [3H]NIC without 
inhibitor, and non-specific binding is measured in the presence of unlabeled 10µM Cyt. 
 
specific binding was measured as 3nM [3H]NIC binding in the presence of 100µM Cyt.  
For all experiments the non-specific binding was consistent and ranged from 12-16% of  
total.  Compounds that inhibited total [3H]Ebt binding to a value ≤ 75% of control were 
considered screen hits.    
In this study nearly all of the AH-guanidino compounds described in chapter 3 
were used in subtype-selective screening experiments.  A few of the compounds were not 
made in sufficient quantities for further testing however, and others were found to be 
either insoluble or inactive during the [3H]Ebt binding assays, and were thus left out.  In 
total 53 AH compounds were screened for their ability to inhibit [3H]NIC binding.  
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 Compounds were screened at a single high concentration of 1µM.  Among all AH 
compounds screened 12 were found to inhibit [3H]NIC binding by more than 25% of 
total.  The inhibitory ability of the active compounds in order: 
159>141=14>132>79>149>61 >90>38>110>5>156.  As with the [3H]Ebt screening 
experiment, the results were promising in that of the 53 AH-compounds screened 23% 
resulted in inhibitory activity (>25% inhibition) and three compounds resulted in an 
apparent 100% inhibition level.  Several promising JC compounds were also screened 
and it was found that two inhibited binding by at least 25%.  
Structure-activity analysis confirms most of the major findings from Ebt binding 
studies.  The 3’pyridine moiety again appeared to be absolutely crucial for high affinity 
binding and all of the compounds were found to contain a methylene bridge between the 
pyridine and the cationic group.   
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Figure 5-3.  Screen Results:  Inhibition of total [3H]NIC binding for active AH and JC compounds at 1µM.  
Responses are normalized to 100% experimental control.  Control is binding with 3nM [3H]NIC without 
inhibitor, and non-specific binding (not shown) is measured in the presence of 10µM Cyt. 
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 These results confirm that guanidine-containing nicotinic analogs, much like the 
traditional pyrrolidine-containing analogs of NIC, appear to require a 3’substituted 
pyridine group as a core structural high-affinity binding requirement.  Further analysis 
suggests some strong SAR trends among the compounds found to be the most active.  For 
all of the pyridine-containing AH compounds screened the 2’ and 4’-pyridyl analogs 
were found to be inactive.  For each bioisosteric (guanidine) group the 3’-pyridyl analog 
demonstrated greater inhibitory activity than both its 2’ and 4’-pyridyl counterpart.   
 Structure analysis reveals a seemingly complicated situation.  For the 
unsubstituted 3-pyridine guanidine analogs AH-5 and AH-149 the addition of the 6-
chlorine atom resulted in improved affinity of nearly 3-fold.  This is expected as the 
general trend for nicotinics is either no change or an improvement in affinity upon 
addition of a 6-chlorine for molecules that are otherwise identical.  Providing a slightly 
different result is the affinity values of AH-141 compared to AH-132.  These two 
compounds are identical N,N-diisopropyl substituted pyridines except AH-132 has an 
added 6-chlorine.  Both compounds give a similar result which would indicate no change 
but since both compounds result in near maximal inhibition, these two compounds could 
have different affinity values that will require a concentration-response (CR) analysis of 
binding to reveal their differences in affinity.  We would naturally expect that AH-132 
would reveal a higher affinity when we look at the binding concentration response (CR) 
analysis in the next section.  Surprisingly there was no such obvious trend among the 
mono-substituted, di-substituted, or the ring-containing AH-compounds.      
 Overall, there appears to be little difference between the top candidates identified 
with the [3H]NIC vs. the [3H]Ebt biding screen assay.  Both assays were able to identify 
active AH compounds; 90, 79, 38, 110 and 5 among AH compounds tested.  These 
results provide further confirmatory evidence that these two ligands probe the same 
nAChR combination, presumably the high-affinity α4β2*subtype.  All AH-compounds 
found to be active in the screen were investigated in CR binding experiments.      
Several select JC-compounds were screened for activity in the [3H]NIC binding 
assay, including JC 2-25, 3-9, 2-31 and 3-2.  Among these JC 3-9 and JC 2-25 were 
both found to inhibit 100% of specific binding and were deemed candidates for further 
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 testing in high-affinity nAChR CR experiments.  So few JC compounds were evaluated 
that little could be gleaned from an SAR perspective given so few positive assay results.    
 
[3H]MLA Screen Assay Results 
[3H]MLA screening experiments were carried out in the same manner, using the 
same general procedure as the previously described [3H]NIC screening assay.  The 
experimental design and data analysis for these two experiments, executed in tandem on 
the same plate, were identical.  Uninhibited [3H]MLA binding at 3nM was used as 100% 
total binding control and non-specific binding was measured as 3nM [3H]MLA binding in  
 
[3H]NIC Inhibition Screen Single Plate Result 
 
Figure 5-4.  Single experiment screen results:  Screens were carried out to measure inhibition of total 
[3H]MLA binding for AH and JC compounds at 1µM.  Each screen was carried out in duplicate (light and 
dark bar for each compound), with n=3 for each set.  Total binding is 3nM [3H]MLA without inhibitor, and 
non-specific binding is measured in the presence of unlabeled 10µM NIC. 
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 the presence of 100µM NIC.  For all experiments the non-specific binding was consistent 
and, once again, ranged from 14-17% of total.  Compounds that inhibited specific 
[3H]MLA binding to a value ≤ 75% of control were considered screen hits. All of the 
previously described AH compounds a these select few JC compounds were once again 
evaluated for their ability to inhibit binding at 1µM.   
Unlike in the [3H]NIC and [3H]Ebt inhibition experiments, only 4 AH compounds 
were found to inhibit [3H]MLA binding by more than 20% of total.  This result would 
indicate that the common structural features that resulted in a high percentage of α4β2* 
binding hits does not translate to a similar affinity for the α7* nAChR.  The inhibitory 
ability of the active compounds in order: 132>55>110>159.  Not a single AH compounds 
was found to maximally inhibit [3H]MLA binding indicating that none of the AH 
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Figure 5-5.  Inhibition of total [3H]MLA binding for active AH and JC compounds at 1µM.  Responses are 
normalized to 100% experimental control.  Control is binding with 3nM [3H]MLA without inhibitor, and 
non-specific binding is measured in the presence of 10µM NIC. 
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 compounds evaluated as hits in the screen will demonstrate high Ki values as determined 
in the CR experiments.  Additionally, two JC-compounds, JC 2-25 and JC 3-9 both 
demonstrated maximal or near maximal inhibition of [3H]MLA binding, indicating a high 
(nM) affinity for the α7* nAChR.  Since there were only a few compounds providing 
positive screen results only a crude structure-activity analysis can be attempted.  One 
trend that is easily observed however, is that the compounds with the highest inhibitory 
response in the [3H]NIC assay also give the highest inhibition values in the [3H]MLA 
assay.  This would indicate that among the compounds tested (guanidino or amidino-
containing) there may exist a common binding motif that provides high affinity while 
sacrificing selectivity.  Of course little can be stated definitively until CR experiments 
reveal the actual affinity values for these compounds.  Again, with the exception of AH-
55, the AH compounds that result in a hit were 3-aminomethyl substituted pyridine 
compounds which holds with previous findings.  Once again, for the JC compounds, it 
appears that the 3-pyridyl-pyrimidino moiety provides high affinity while providing little 
in the way of α4β2*/α7* selectivity.  Of course additional analysis will reveal a great deal 
more about the actual affinity of the screen compounds and the nature of the interaction 
with the nAChR subtypes probed.    
 
Subtype Selective Binding Screen Results  
 
 
Compound  
Code 
 
 
Structure 
% Specific  
[3H]NIC 
Binding 
Inhibition 
at 1µM 
% Specific  
[3H]MLA  
Binding 
Inhibition 
at 1µM 
 
JC 2-25  
.3HCl
N
N
H
N  
97.3 
 
88.5 
 
JC 3-9 
N
N
N
CH3Cl
.2CO2H
-
CO2H
 
76.3 
 
97.4 
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AH-5  
Cl
-
NH
N
+
NH2
H
N
H
 
44.5 
 
----- 
 
 
AH-14  
N
N
H
NH
N
Cl
 
 
87.1 
 
----- 
 
AH-38  
-I
NH
N
H
N
+
N
H  
54.5 
 
----- 
 
AH-55  
N N
HI N
N
Br Br  
----- 
 
43.2 
 
AH-61  
-I
NH
N
N
+
N
H  
63.3 
 
----- 
 
AH-79 
-I
NH
NH
N
+
CH3
CH3
H
N
 
73.4 
 
----- 
 
AH-90 
-I
NH
NH
N
+
CH3
H
H
N
 
59.6 
 
----- 
 
 
AH-110 
-I
NH
N
N
+
CH3
CH3
CH3
CH3
N
 
 
49.3 
 
 
32.3 
 
AH-132 
N
N
H
HI HN
N
Cl
 
86.4 
 
58.2 
 
AH-141 
N
N
H
HI HN
N  
87.1 
 
----- 
 
AH-149 
N
N
H
HI NH2
NH
Cl
 
69.4 
 
----- 
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AH-156 
N
N
H
HI NH
NH
Cl
 
30.6 
 
----- 
 
AH-159 
N
N
H
HI HN
N
Cl
 
91.6 
 
21.8 
 
 
Cyt N
NH
O
H
H
 
 
91.4 
 
 
----- 
 
 
NIC N
+
CH3
H
N
 
 
----- 
 
 
97.1 
 
Figure 5-6.  [3H]NIC and [3H]MLA Screen Results:  Compound number, structure and inhibition data (% 
total) for all compounds found to inhibit a minimum of 25% in either assay.  Responses are normalized to 
100% experimental control.  Control is binding with 3nM [3H]NIC or [3H]MLA without inhibitor, and non-
specific binding is measured in the presence of 10µM competitor Cyt for NIC and NIC for MLA binding.  
Binding inhibition values for controls Cyt and NIC are shown. 
 
5.4  [3H]NIC and [3H]MLA Binding Concentration-Response Results 
 
[3H]NIC Inhibition CR Assay 
Concentration-response (CR) of binding inhibition experiments were carried out 
with a minimum n=3 in 96-well plates.  CR binding was carried out according to the 
general method described above.  Binding data are displayed as a single data point with 
error bars representing the standard error of the mean for each concentration.  Inhibition 
curves were fit to a one-site sigmoidal dose-response curve and all derivations and 
calculations were carried out as described in detail in the methods section.  Since the data 
are compiled on a single graph from several experiments, data values were separately 
transformed as a percent total of control binding for each individual experiment and then 
combined for graphical and statistical analysis.  Uninhibited [3H]NIC binding at 3nM was 
used as 100% total binding control.  Non-specific binding was measured as 3nM [3H]NIC 
binding in the presence of 10µM Cyt and used to calculate specific binding. 
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 For all experiments the non-specific binding was consistent and ranged from 5-
25% of total.  For each data set a best fit binding inhibition curve was fit and tested to one 
of two models, a fixed slope of unity or a variable slope model.  From the curve fit the 
IC50 was automatically determined and a Ki was calculated.  The goodness of the curve 
fit to the data is reflected as measured with the R2 value for each data set and was 
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Figure 5-7.  Concentration-response results:  Specific binding inhibition of total [3H]NIC in the presence of 
varying concentrations of AH and JC compound (screen hits).  Inhibition response is normalized to 100% 
of each plate’s experimental control.  Control is binding with 3nM [3H]NIC without inhibitor and non-
specific binding was measured in the presence of 10µM Cyt. 
 
generally very good.  R2 values ranged from 0.750-0.969, with the average being 0.915.  
Hill slope values varied greatly among the screen hits and ranged from -0.75 to -1.10 
where the variable slope fit was preferred.  Compounds demonstrated good efficacy in 
displacing specific [3H]NIC binding at the highest concentrations.  All compounds 
evaluated, where an affinity value could be determined, inhibited [3H]NIC binding by at 
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 least 75% and often by as much as 95% (see figure 5-7).  This indicates that active AH 
and JC compounds possess good efficacy in displacing [3H]NIC from the high-affinity 
nAChR binding site.  Several non-active (non-hit) compounds were also evaluated as 
controls and validation of the screen assay and revealed very poor nAChR affinity in CR 
experiments (data not presented), indicating that the screening experiment works well to 
weed out non-active compounds from further analysis. 
In this study the positive control and guanidino model compound DN-IMI 
(described in chapter 3) was evaluated for the first time in a high-affinity nAChR binding 
assay.  DN-IMI was found to have a Ki value of 13.5nM in this assay method.  This is 
very similar to the value of 8-9nM previously published by Casida, et.al, the group that 
synthesized the compound originally.  This result indicates that our experimental model 
examines a similar target as those previously published and accepted.  The other 
experimental control was Cyt which gave an affinity value of ~5nM.  This also indicates 
that the assay is selectively probing high-affinity neuronal nAChRs since Cyt is a known 
selective ligand with a published affinity value of 1-5nM in various high-affinity α4β2* 
nAChR systems (Sharples, 2001, reviewed in chapter 3).    
Compounds were classified as either high-affinity (<100nM), medium-affinity 
(100-1000nM), or low-affinity (>1000nM).  Unfortunately only two AH compounds, 
AH-132 and AH-153 were found to possess high-affinity binding in these experiments, 
with Ki values of 27nM and 81nM respectively.  These represent the highest-affinity AH 
compounds found in the α4β2* nAChR binding experiments.  The other 8 AH 
compounds all fell in the medium-affinity range.  Rank order of AH compounds was 
found to be 132 >153 >149 >159 >90 >79 >5 >61 >110 >38.  One potential indicator of a 
screening success is the fact that only a single (low-affinity) false-positive compound was 
selected for CR studies from the screening.  Because only two AH compounds possess 
high affinity for the α4β2* nAChR little can be learned from structure-activity analysis in 
terms of selecting high-affinity compounds.  Some informative trends can be found by 
examining some common features among the compounds tested.  For instance, the top 
four compounds all contain a 6-chloro pyridine ring addition.  This continues to be a 
common molecular feature that appears to be required for generating high-affinity 
guanidines like those described in this work.  Changing the unsubstituted guanidino 
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 compounds AH-5 to AH-149 by the addition of a 6-chlorine results in a modest ~3-fold 
improvement in affinity.  A similar improvement is seen with the conversion of the 
imidazolidine ring containing compounds AH-38 to AH-159.  In this case the addition of 
a 6-chloro again results in a modest but significant ~3.5-fold improvement in affinity.  
For the complimentary N,N diisopropyl substituted compounds AH-141 and AH-132, 
however, the addition of a 6-chloro group to the compound appears to make all the 
difference in the world since AH-132 is the highest affinity AH-compound tested, while 
the des-chloro compound AH-141 resulted in poor affinity (>1µM) for the high-affinity 
nAChR.  This was a surprising result though since AH-141 appeared to have significant 
activity as measured in the screen experiment.     
Another interesting result came with the N-ethyl substituted guanidino compound 
AH-90 which demonstrated moderate affinity (Ki~400nM) whereas its 6-chloro 
counterpart (AH-150) did not even make it past the screening stage.  The tetramethyl-
substituted compound AH-110 again fails to result in high-affinity binding despite what 
would be considered a high-affinity molecular feature in the quaternary nitrogen.  
Additional SAR analysis of N,N-substitution patterns reveal a poor tolerance for long 
alkyl chains and bulky N-substitutions (propyl, dibutyl, hexyl, etc) as demonstrated in the 
compounds AH-155 through AH-158.  These compounds seemingly help to define a 
limit in the binding pocket that surrounds the part of the nicotinic molecule that carries 
the positive charge.  All-in-all, there is only a small amount of helpful high-affinity SAR 
information that can be used from these results since only two AH compounds were 
found to bind to the α4β2* with <100nM affinity. 
The few JC compounds evaluated in the screen performed remarkably well, with 
three compounds having high-affinity for the α4β2* nAChR.  Affinity values of 30nM 
for JC 2-25, 70nM for JC 3-2, and a very respectable 11nM for JC 3-9 were discovered.  
The two highest affinity compounds in this group are both 3’-pyrimidino groupings with 
a direct bond to the pyridine ring.  Distinctive from the AH series of compounds, the 6’-
chloro group does not seem to be a requirement for high affinity binding in the JC series, 
as JC 2-25 appears to couple tightly to the nAChR binding site without this common 
molecular feature, although clearly more compounds in this series need to be evaluated 
before any conclusive SAR can be established.  As with the AH series, none of the non-
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 pyridine containing JC compounds were found to inhibit binding with any affinity at all, 
revealing the critical need for a pyridine ring for affinity in this series.    
 
[3H]NIC Binding: Screen-to-Binding Results  
In order to evaluate the ability of the one-point screen to predict activity in CRC 
experiments, a quick (and highly speculative) analysis was carried out where the rank 
order of the data from the screening experiments were compared to the rank order of the 
CR experiments.  The goal was to measure the ability of the screen to predict the relative 
potency of the test compound hits.  In this study a correlation was determined between 
the rank orders and  
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Figure 5-8.  Comparison of data between rank order of AH and JC compounds according to maximal 
inhibition of [3H]NIC binding inhibition in the single concentration screen assay (ordinate axis) and the 
rank order of binding affinity determined in concentration-response experiments (abscissa).  Data were 
compared using linear regression analysis and a best-fit line is presented with 95% confidence interval.  
Line slope is 0.401 ±0.245 with an R2 of 0.154.  Linearity test reveals significance (F=2.197 and p=0.616) 
with a significant deviation from zero.  Reassign affinity data NIC CR experiment according to the Table 
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standard statistical analysis reveals a less than promising result.  Data were assigned 
values 1-16 depending on their rank order and plotted on the X,Y graph (figure 5-8).  A 
standard linear regression analysis was performed on the data.  Results reveal a 
relationship with a slope of 0.40 ±0.245 and an R2 value for the regression of 0.154, 
indicating that the relationship between the data were scattered and that the best-fit line 
was a poor representative measure of the data.  The best-fit line was tested for  
linearity and was found to fit a linear model well (P=0.616) indicating that the line does 
not significantly deviate from linearity.  10 of the 14 data points lie within the 
95% CI range along the graph, which does not speak well for the screen’s ability to 
predict relative compound affinity.  The screen data was not able to be used to accurately 
predict compounds with the highest affinity, although it appears that the lower affinity 
compounds followed the trend more closely.  On a promising note, twelve of the fourteen 
compounds identified as hits in the screen resulted in affinity values in the nanomolar 
range reinforcing the reasonable reliability in a small scale single point screen to identify 
compounds that bind the receptor target with high-affinity.  Overall the resulting analysis 
reveals the fact that the [3H]NIC screen unfortunately does not appear to provide any 
predictive power for nAChR activity beyond the simple act of identifying compounds 
either as screen hits or not and for hit compounds to be retained for further testing. 
 
[3H]MLA Inhibition CRC Assay 
[3H]MLA binding inhibition screen experiments were carried out in tandem alongside 
[3H]NIC binding experiments.  All experimental procedures and data analysis is identical 
to the method described in the preceding section.  Concentration-response (CR) of 
binding inhibition experiments were carried out with a minimum n=3 in 96-well plates.  
CR binding was carried out according to the general method described above.   
Since the data are compiled on a single graph from several experiments, data values were 
separately transformed as a percent total of control binding for each individual 
experiment and then combined for graphical and statistical analysis.  Uninhibited 
[3H]MLA binding at 3nM was taken as 100% total binding control.  Non-specific binding  
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 [3H]MLA inhibition CRC assay results 
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Figure 5-9.  Concentration-response results:  Specific binding inhibition of total [3H]MLA in the presence 
of varying concentrations of AH and JC compound (screen hits).  Inhibition response is normalized to 
100% of each plate’s experimental control.  Control is binding with 3nM [3H]MLA without inhibitor and 
non-specific binding was measured in the presence of 10µM NIC.   
 
was measured as 3nM [3H]MLA binding in the presence of 10µM NIC and subtracted 
from total binding to calculate specific binding.   
For the few compounds that were evaluated in CR experiments the non-specific 
binding was consistent and ranged from 12%-16% of total.  The goodness of the curve fit 
to the data as measured with the R2 value for each data set and was generally very good.  
R2 values ranged from 0.853 to 0.981, with the average being 0.901.  All curves were 
tested against two models and most were fit to the preferred standard slope model.  Hill 
slope values varied greatly among the screen hits and ranged from -2.65 to -0.850 for 
curve fits where the variable slope method was preferred.  For curve fits of the 
compounds where a true bottom value could be determined, it was found that the 
compounds inhibited [3H]MLA binding by at least 90% and as much as 100% 
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 theoretically, (see figure 5-9).  This indicates that these families of compounds possesses 
good efficacy in displacing [3H]MLA from the nicotine binding site of the α7* nAChR.  
Several non-active (non-hit) compounds were also evaluated as controls and validation of 
the screen assay and revealed very poor nAChR affinity in CRC experiments (data not 
presented), indicating that the screening experiment works well to weed out non-active 
compounds from further analysis. 
The JC compounds were clearly the group of compounds with higher-affinity in 
the assay.  The only two compounds that had affinity for the α7* nAChR at or less than 
250nM were JC 3-9 and JC 2-25, with Ki values of 118nM and 250nM respectively.  
This higher affinity might possibly have something to do with the same pyrimidine 
substitution on the pyridine ring composition that affords the high affinity in the α4β2* 
[3H]MLA assay.  Among the AH compounds tested only AH-132 has an affinity in the 
nanomolar range at ~650nM, with the other AH compounds 110 and 159 having Ki 
values in the high micromolar range.  In a side note, it seems that AH-110 continues to 
provide consistently mediocre binding results in every experimental method, coming in 
with an affinity value measured here at 10µM.  AH-55 was the most disappointing result 
to come out of this study as it appeared to perform as well as all of the other AH 
compounds in the screen with >50% inhibition at 1µM, while giving absolutely no result 
in the CR experiment.  This result can likely be explained as some sort of contamination 
event that took place during the screening experiment.  For reporting, we consider AH-55 
to have an affinity >100µM.  The experimental result of DN-IMI (~4µM) was again 
consistent with literature reports for α7* binding affinity and compared favorably with 
the published value of 7-10 µM (Davies and Wonnacott 1999, Sharples 2001, Daly 
1999).  DN-IMI served a dual role as a published control and as an experimental control 
since it had never been evaluated in our lab.  It was reassuring to find this result, and 
coupled with the agreeable result for DN-IMI in the [3H]NIC binding assay this result 
lends extra support to the validity of the work that was carried out in this section.  Results 
for NIC were consistent with previous findings, and with a Ki of ~400nM served its role 
as a positive control.  As reported earlier in the [3H]MLA screen section, so few 
compounds were found to have activity that arriving at any meaningful SAR analysis is 
difficult.  Some trends that appear significant, however is the fact that 1) the ring-
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 containing JC compounds appear to have high affinity in both major neuronal nAChR 
binding assays tested here, 2) few AH compounds appear to have any molecular features 
amenable to high-affinity α7* nAChR binding and should therefore likely not be pursued 
aggressively for this application, 3) the earlier SAR findings from the [3H]Ebt assay  
 
Subtype Selective Binding CR Results  
Compound 
Code 
 
Structure  
[3H]NIC 
Binding 
Ki (nM) 
[3H]MLA 
Binding 
Ki(µM) 
 
DN-IMI 
Cl
N N
NH
H
 
13.5 ± 2.5 
 
3.3 ± 0.3 
 
JC 2-25  
.3HCl
N
N
H
N  
29.9 ± 3.6 
 
0.3 ± 0.04 
 
JC 3-2 
N
N
N
CH3Cl
.2CO2H
-
CO2H
 
69.1 ± 14 
 
1.7 ± 0.2 
 
JC 3-9 
N
N
N
CH3Cl
.2CO2H
-
CO2H
 
10.5 ± 1.5 
 
0.12 ± 0.02 
 
 
AH-5 
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NH
N
+
NH2
H
N
H
 
410 ± 33 
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NH
N
H
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+
N
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945 ± 113 
 
>100 
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N N
HI N
N
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NH
N
N
+
N
H  
433 ± 52 
 
>10 
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Cl
 
287 ± 45 
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H
 
4.9 ± 0.3 
 
----- 
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+
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H
N
 
----- 
 
400 ± 28 
  
Figure 5-10.  Binding affinity of screen hit compounds determined as Ki derived from IC50 from [3H]NIC 
and [3H]MLA  binding inhibition curve fits.  Only compounds found to perform in the respective screening 
experiments were tested in CR experiments, hence the blank spaces for some compounds in one result 
column or the other.  Cells with (---) indicate that the experiment was not carried out (see CR graph). 
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 appear to hold true in that a 3’-substituted pyridine ring system is required for high 
affinity binding, not only for α4β2* binding but for α7* binding as well.  Finally, among 
JC compounds, the existence of a 6-chloro addition does not appear to confer higher 
affinity for the α7* nAChR as evidenced by the JC compound’s SAR. 
 
[3H]NIC vs. [3H]MLA Binding:  Subtype Selectivity Analysis  
 
 
 
 
 
 
 
 
 
 
     Compound  [3H]Nicotine             [3H]MLA  
             #              binding (Ki, nM)     binding (Ki, µM)     Selectivity 
 
•      AH-5         410         >100         >250          
•      AH-38         945         >100         >105 
•      AH-61         433           >10            >23 
•      AH-79         394             32             81 
•      AH-90         387           >10           >26 
•      AH-110         611    10    16 
•      AH-132           27                      0.65             24 
•      AH-149         119                      41           341 
•      AH-153                81                      >100       >1200 
•      AH-159              287                    100           348 
•      JC 3-9   11          0.12             11 
•      JC 2-25   30          0.25               9 
•      JC 3-2   69            1.7     25 
•      DN-IMI   14   3.3   250 
•      NIC   ----           0.80   ----  
•      Cyt     5   ----   ----  
Figure 5-11.  nAChR binding selectivity chart of active AH and JC compounds.  Affinity values for 
[3H]NIC and [3H]MLA binding are presented for each compound.  The selectivity measure is the Ki value 
of the compound in the [3H]MLA (in nM) assay divided by the Ki value of the compound in the [3H]NIC 
(in nM), and is used to measure relative selectivity. 
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  Subtype Selectivity Analysis 
 As discussed briefly in the preceding two sections, there is a clear and 
unmistakable trend where the compounds evaluated in this study possess a preferential  
affinity for the α4β2* nAChR versus the α7* nAChR.  This data was scattered throughout 
the previous binding screen and CR experimental results sections but is presented here in 
a more condensed form (figure 5-12).  The rank order for compounds with selectivity 
values >100-fold is:  153>>149=159>5>61, with the remainder being less than two  
 
 [3H]NIC/[3H]MLA Binding:  Subtype Selectivity Analysis  
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Figure 5-12.  Comparison of binding affinity values for compounds in the two nAChR subtypes examined.  
Experimental values for AH and JC  test compounds were plotted with [3H]NIC affinity on the ordinate 
axis and [3H]MLA affinity on the abscissa.  Colored lines extending bi-directionally from the center line 
each represent an order of magnitude of nAChR selectivity.  All compounds evaluated were found to 
possess some degree of preferential selectivity for the α4β2* nAChR, represented by the data points 
graphing to the upper left of the graph.     
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 orders of magnitude selectivity.  Surprisingly, in looking at the compounds with 
progressively lower selectivity, one could reasonably expect to find a more normalized 
distribution where at least some of the compounds would, if only by chance or standard 
error display some selectivity for the α7* nAChR, no matter how slight.  This was not 
observed however, confirming a strong SAR trend for α4β2* nAChR selectivity among 
all AH and JC compounds.  Clearly AH-153 is the star in this group with a selectivity 
index of >1200.  The real selectivity is, in fact greater than this value and was only not 
properly determined because higher concentrations could not be reasonably evaluated in 
the α7* CR assay and represents an experimental limit.  In fact, the real selectivity for 
this compound is certainly greater than 1200-fold.  The JC compounds were all 
consistently selective for the α4β2* nAChR but only slightly.  The AH class of 
compounds, however, with the high degree of selectivity may provide important data in a 
more detailed study of selectivity and may serve as a promising design template in future 
efforts to exploit α4β2* nAChR selectivity in drug design efforts.  
 
 
 
5.5  Schild Analysis of Binding: AH-132 and JC 3-9 
 
 Radioligand Binding Study Background 
 So far the studies of this project have focused on the binding of the various 
radiolabeled ligands (Ebt, NIC, and MLA) to a population of nAChRs in brain tissues.  
Radiolabeled ligands are added to the binding mixture and allowed to equilibrate in 
solution such that stable receptor occupancy is reached.  Test compounds (binding 
competitors) are evaluated for their ability to displace the labeled ligands by adding them 
in varying concentrations to the reaction mixture, and once equilibrium is reached the 
membrane samples with the bound compounds (solid-phase) are separated from the 
unbound radiolabeled ligand and test compounds that remain in the solution (liquid-
phase) by rapid filtration of the sample followed by repeated rinsing.  Naturally the 
amount of radioligand bound to the receptors in the presence of test compound will 
decrease in a manner proportional to the affinity and concentration of the test compound.  
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 A lower count of radioligand in the membrane sample indicates that the test compound 
successfully “competed” for the binding site on the receptor and thus prevented a full 
amount of radioligand to remain bound.  As radiolabel is displaced, either through the 
addition of test compounds with higher affinity (how strong the test compound binds to 
the receptor) or through an increase in concentration to overwhelm the radioligand (by 
mass action) one can determine the strength of the interaction of the test compound with 
the receptor.  This is the essential experimental protocol for competition binding (Waud 
1988, Kilbourn and Zalutsky 1985, Martin and Aceto 1981).  While these experimental 
methods are well-suited and easily adapted to rapid screening and basic concentration-
response methods that allow the researcher to determine pharmacological properties of 
the test compounds such as IC50 and Ki, these binding methods can determine very little 
about the nature of the binding interaction itself.  For this study more complicated 
analysis of measures is required.  
 Evaluating and measuring the interaction of a compound with its receptor is 
central to understanding receptor pharmacology as well as in developing ligands that 
have characteristics that are desirable.  Often this means little more than determining if 
the compound binds to the receptor and if so, determining if the compounds acts as either 
an agonist or an antagonist.  This last determination is critical to the development of 
subtype selective ligands that are useful as research tools and therapeutic agents.  
Determining if a compound is an agonist involves little more than activating a system and 
determining the maximal activation and the concentration of compound that activates 
50% of the maximum response.  This value is the EC50 and is commonly used as a 
measure of agonist potency.   The method for the investigation of antagonist action is a 
little more complicated.  The method first described, and commonly applied to 
characterize an antagonist was proposed by Schild in 1949 and allowed the determination 
of the equilibrium constant for competitive antagonism.  This method (Schild analysis) 
has been used as the gold standard for determination of antagonism for most of the last 50 
years and has been employed in the pharmacological characterization of numerous drugs 
(Colquhoun 2006, Wyllie and Chen 2007).   
The experimental procedure for a Schild analysis can be deconstructed into two 
simple steps, 1) determination of an agonist-induced response curve for a physiological 
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 system from zero response to maximal response in the absence of inhibitor, and 2) 
determination of a response curve in the presence of several concentrations of inhibitor.  
Since it binds the receptor, the inhibitor will then theoretically interfere with the agonist-
induced response in a concentration-dependent manner.  If the agonist and antagonist are 
exerting their actions at the same site on the receptor (and presumably acting via the same 
mechanism) then the change in concentration response will be reflective of this 
interaction whereby an increase in inhibitor will lead to a corresponding decrease in 
concentration response for the agonist.  In an equilibrium state, the laws of mass action 
dictate that a decrease in agonist response will be proportional to the concentration of 
antagonist in the system and this will be reflected in a rightward shift in the 
concentration-response curves for the system.   
In Schild analysis the magnitude of this inhibitor-dependent shift can be used to 
determine the mechanism of interaction (for a good review of drug receptor interactions 
see Tallarida 2007 and Kenakin 2003).  In a purely competitive system a regular and 
incremental increase in the concentration of inhibitor will lead to a corresponding regular 
and incremental decrease in relative response at the same concentration of agonist.  In 
experiments over several concentrations of inhibitor, a dose-response value can be 
established that measures this inhibition.  This value is usually the measure of the 
rightward shift in the response curve as measured at the curved IC50.  For a complete 
review of Schild analysis background, methods and interpretation see following 
references: Arunlakshana and Schild 1959, Kenakin 1993, Wylie and Chen 2007. 
In experiments described in this chapter Schild analysis is carried out on binding 
saturation as opposed to the classical Schild analysis application of functional response.  
In an effort to better understand the nature of the interaction of binding of AH and JC test 
compounds to the high affinity neuronal nAChRs (competitive vs. non-competitive), 
saturation binding experiments were carried out and Schild-type analysis was performed 
with S-(-)-NIC as the agonist and AH and JC compounds substituted as the antagonists.  
Traditionally functional response values (EC50) and binding affinity values (Ki) often 
correlate poorly (or at least unevenly) with each other and usually differs by orders of 
magnitude.  This is especially true of high-affinity nAChR binding, as was described 
earlier.  Investigations into the nature of the ligand-receptor interaction at the binding site 
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 of the nAChR have been carried out previously (Wilkins 2002, Arias 2006) yielding 
useful results.  Carrying out this type of analysis on the high affinity nAChR presents a 
complicated pharmacological picture, however, and therefore the results may need 
special consideration.  These considerations will be more fully explained in the 
discussion section.  Pharmacological analysis in this manner can be meaningful and 
useful, especially in a drug design effort where knowledge of the binding interaction can 
be helpful in the ongoing design of novel nAChR ligands.   
 
Materials and Methods 
All materials and general binding methods were carried out according to the 
general methods described in the S-(-)-[3H]NIC concentration-response experiments 
described in section 5.4 above. 
 
Schild Analysis Binding Procedure 
 Briefly, for S-(-)-[3H]NIC saturation binding experiments, whole rat brain was 
prepared as previously described and binding was carried out according to the general 
procedure described above in this chapter.  Saturation binding of S-(-)-[3H]NIC was 
performed in triplicate in a final volume of 250µl of Krebs-HEPES (pH 7.4). Reactions 
were initiated by addition of 100µl of membrane suspension to tubes containing 50µl of 
Krebs-HEPES buffer and 50µl of S-(-)-[3H]NIC (0.02–200 nM, final concentration). 
Nonspecific binding at each S-(-)-[3H]NIC concentration was determined in duplicate in 
the presence of 100µM CYT. Following 60 min of moderate shaking at ambient 
temperature incubation was terminated by rapid filtration.  96-well glass-fiber filter plates 
(0.65µm, Unifilter 96 GF/B, Packard) presoaked in 0.5% polyethylenimine, were used in 
a plate harvester (Packard Harvester Filtermate 196™) to collect the incubate.  
Scintillation counting was carried out according to the general procedure. 
Saturation of specific S-(-)-[3H]NIC binding was determined in the absence and 
presence of three concentrations of AH-132 or JC 3-9. Reactions were initiated by 
addition of 100 µl of membrane suspension to tubes containing 50µl S-(-)-[3H]NIC 
(0.02–20 nM, final concentration) and 50 µl of Krebs-HEPES buffer (control, i.e., 
absence of analog) or one of three concentrations of AH-132 or JC 3-9. Concentrations of 
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 inhibitor compounds were chosen based on results obtained from the inhibition 
experiments carried out earlier.  S-(-)-[3H]NIC assay buffer solutions for each experiment 
was made by serial dilution in buffer from manufacturer stock ethanol solution and 
adjusted and verified by scintillation counting described above.  Following incubation (60 
min at RT), reactions were terminated and filters processed as previously described.  
Scintillation counting was carried out according to the general procedure. 
 
Data Analysis 
The general method for plotting and curve fitting of binding data are the same as 
described above (section 5.2).  The mechanism of analog interaction with high-affinity S-
(-)-[3H]nicotine binding sites was assessed via Schild analysis experiments. Saturation 
binding of S-(-)-[3H]nicotine was assessed in the absence and presence of three 
concentrations of test ligand (AH-132 and JC 3-9). Minimum binding was held constant 
at a value of zero, and simple slope sigmoid fits were used since the F statistic revealed 
that the variable slope did not provide a significantly better fit to the data.  For each 
analog, the saturation isotherms were assessed for parallelism by comparing simple and 
variable slope sigmoid curve fit using GraphPad Prism software package.   
The one-site exponential saturation binding representations (non-linear 
regressions of the saturation binding experiments) were generated by fitting the data to a 
one-site hyperbolic binding equation: 
 
y = (Bmax (X)) / Kd +(X) 
 
This equation describes the equilibrium binding of a ligand to a receptor as a function of 
increasing ligand concentration, where X is the concentration of the ligand, Y is the 
specific binding, Bmax is the maximum binding, and Kd is the equilibrium dissociation 
constant. 
To determine the mechanism of analog interaction with high affinity S-(-)-
[3H]nicotine binding sites, the binding affinities derived from saturation analyses in the 
absence and presence of three concentrations of competitor were negative log 
transformed (-log Kd) and plotted as a function of concentration.  Three nonlinear 
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 regression models were fit to the data.  In the presence of a competitor the IC50 will 
increase by a factor equal to 1+[B]/Kb where B is the competitor, or in the case here, the 
experimental analog displacing the radioligand, is described as the dose ratio.  If the 
antagonist is competitive, the dose ratio equals one plus the ratio of the concentration of 
antagonist divided by its Kd for the receptor.  The equation used for the Schild plot:  
 
log(dose ratio-1) = log ([A’]) – log([A]) 
 
was used, where [A’] = concentration of  S-(-)-[3H]NIC required for the same fractional 
occupancy in the presence of inhibitor, and [A] =  concentration of  S-(-)-[3H]NIC 
required for reference fractional occupancy in the absence of inhibitor.  Experiments 
performed with increasing concentrations of competitor were arranged on a graph with 
log(antagonist) on the X-axis, and log(dose ratio -1) on the Y-axis.  This was used to 
create the Clarke Plot, or more commonly referred to Schild plot graph.  Values were 
determined independently for each data point from the (n) repeats.  Each value carried its 
own standard error of the mean and does not reflect the error of the Schild plot linear 
regression best-fit line.  Inhibition binding curves were plotted on a log [M] scale of S-(-
)-[3H]NIC and each was evaluated across the linear portion and were evaluated for 
parallel slope.  Dose-ratios values for each curve were determined based on a reference 
fractional occupancy point determined within the linear portion of the inhibition curves.    
 
 Schild Analysis for AH-132 Results 
 For Schild analysis of AH-132, saturation binding of S-(-)-[3H]NIC to rat whole 
brain membranes was found to be saturable and specific (see figure 5-13).  Non-specific 
binding was low and represented less than 15% of total binding at the Kd value.  A simple 
one-site hyperbolic curve fit the data best.  This result indicates that the saturable 
equilibrium binding of S-(-)-[3H]NIC represents a predominant single nAChR population.  
This makes sense in light of the fact that prior chapters found that the membrane 
preparations used in these binding experiments are primarily high-affinity α4β2* 
preparations.  Values for affinity and for maximal binding were found to be Bmax = 49.3 ± 
2.86 fmol/mg and Kd = 2.93 ± 0.830 nM.  The curve fit the data closely (R2 = 0.915) and  
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Figure 5-13.  Specific saturation binding of S-(-)-[3H]NIC to rat whole brain membrane preparations in the 
absence and presence of three concentrations of AH-132 fit to a one-site hyperbolic binding curve.  Data 
(in fmol/mg) represent the mean ± SEM of at least three independent determinations.   
 
provides a good representation of the saturable binding.  Clearly the addition of AH-132 
in higher concentrations drives the observed Kd values higher (6.90 ± 1.97, 14.44 ± 3.95, 
and 27.04 ± 7.43) for the three concentrations of AH-132 (5.4nM, 27nM, and 132nM) 
respectively.  These three data sets fit a one-site hyperbolic curve very well also with R2 
values of 0.923, 0.947, and 0.926 in the same order.  The Bmax values remained relatively 
unchanged for all three data sets at 47.5, 52.7, and 50.3 with very low SEM values for all 
data sets.   
In order to better visualize the degree of parallel of the curve shifts, sigmoidal 
concentration-response curves of specific S-(-)-[3H]NIC binding were fit to the data.  
Comparisons were made between either a simple fixed slope fit or a variable slope fit and 
all curve fits were found to not be significantly different from a fixed slope of 1, and are  
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Figure 5-14.  Specific saturation binding of S-(-)-[3H]NIC to rat whole brain membrane preparations in the 
absence and presence of three concentrations of AH-132 fit to a one-site sigmoidal concentration-response 
curve.  Data (in specific DPM) represent the mean ± SEM of at least three independent determinations.   
 
thus represented in this manner.  This suggests a simple, one-site interaction across the 
linear concentration range of AH-132.  Since all curves fit the standard model, slopes 
were fixed to unity for IC50 determination purposes.  Maximal binding of specific S-(-)-
[3H]NIC again occurred at a concentration of around 200nM.  In the presence of all three 
values of AH-132 maximal binding comparable to control was achieved.  The Ki for the 
uninhibited S-(-)-[3H]NIC control was 1.60nM ± 0.146.  The curve fit the data closely (R2 
= 0.919) and provides a good representation of the saturable binding relative to the 
concentration of S-(-)-[3H]NIC in the incubation reaction.  The addition of AH-132 in 
higher concentrations drives the observed Ki values higher (4.98 ± 0.116, 7.61 ± 1.38, 
and 15.66 ± 1.37) for the three concentrations of AH-132 (5.4nM, 27nM, and 132nM) 
respectively.  These values generally agree with those derived from the hyperbolic 
binding plot, however the hyperbolic curves generate an easy-to-read representation of 
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 maximal binding, whereas the classic sigmoidal concentration-response curves are better 
suited to providing a clear representation of the “rightward-shift” effect, the parallel 
nature of the curves, and the relative EC50 values.  These three data sets fit a one-site 
sigmoidal concentration response curve very well with R2 values of 0.947, 0.929, and 
0.932 in the same order.  The theoretical Bmax values were not found to be statistically 
different among the three data sets.     
 Inhibition of S-(-)-[3H]NIC saturation binding data were used to generate a Schild 
plot.  Here the dose responses derived from the rightward shift in the binding curves are 
measured and plotted on a linear graph.  The data sets from three independent 
experiments were used to generate each data point and agreed very well with the standard 
error of each less than 20% of the experimental value.  The Schild plot of saturation 
binding fit the data well (R2=0.91), and was tested for linearity and found to not deviate 
from linearity across the data set, with the runs test (P=1.00) indicating a non-significant 
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Figure 5-15.  Specific saturation binding of S-(-)-[3H]NIC to rat whole brain membrane preparations in the 
absence and presence of three concentrations of AH-132 fit to a one-site sigmoidal concentration-response 
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deviation from linearity.  This suggests a single mechanism of interaction or a single site 
of interaction at the α4β2* subtype.  The Schild plot afforded a non-standard slope (0.384 
± 0.053) that is significantly different from unity (theoretical curve).  These results 
usually indicate non-equilibrium binding states or multiple receptor interactions in 
addition to a possible non-competitive mechanism.  S-(-)-[3H]NIC binding 
thermodynamics, however, are well characterized, and because at 3nM, S-(-)-[3H]NIC is 
believed to selectively probe a single nAChR subtype (α4β2*), these results would appear 
to indicate a non-competitive mechanism of interaction between AH-132 and S-(-)-
[3H]NIC at the high affinity ligand binding site on the nAChR.  Although there is more 
than one interpretation, however, and a more thorough analysis of this result is contained 
in the discussion section.       
 
Schild Analysis of JC 3-9Results 
For Schild analysis of JC 3-9, saturation binding of S-(-)-[3H]NIC to rat whole 
brain membranes was found to be saturable and specific (see figure 5-16).  Non-specific 
binding was low and represented less than 12% of total binding at the Kd value.  A simple 
one-site hyperbolic curve fit the data best.  This result indicates that the saturable 
equilibrium binding of S-(-)-[3H]NIC represents a predominant single nAChR population.  
This makes sense in light of the fact that prior chapters found that the membrane 
preparations used in these binding experiments are primarily high-affinity α4β2* 
preparations and that the JC compounds generally displaced S-(-)-[3H]NIC binding nearly 
completely and with high-affinity.  Values for affinity and for maximal S-(-)-[3H]NIC 
binding were found to be Bmax = 58.1nM ± 9.24 and Kd = 7.40 ± 5.14.  The curve fit the 
data (R2 = 0.770) and provides a good visual representation of the saturable, binding.  
Clearly the addition of JC 3-9 in higher concentrations drives the observed Kd values 
higher (19.0 ± 13.54, 24.1 ± 13.02, and 36.9 ± 12.27) for the three concentrations of JC 
3-9 (11nM, 55nM, and 275nM) respectively.  These three data sets fit a one-site 
hyperbolic curve with R2 values of 0.75, 0.850, and 0.890 in the same order.  The Bmax 
values remained relatively unchanged among the data sets at 59.1, 59.7, and 52.4 with 
very low SEM values for all data sets.   
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Figure 5-16.  Specific saturation binding of S-(-)-[3H]NIC to rat whole brain membrane preparations in the 
absence and presence of three concentrations of JC 3-9 fit to a one-site hyperbolic binding curve.  Data (in 
fmol/mg) represent the mean ± SEM of at least three independent determinations.   
 
 Sigmoidal concentration-response curves of specific S-(-)-[3H]NIC binding were 
fit to the data (figure 5-17).  Comparisons were made between either a simple fixed slope 
fit or a variable slope fit and all curve fits were found to not be significantly different 
from a fixed slope of 1, and are thus represented in this manner.  This suggests a simple, 
one-site interaction across the linear concentration range of JC 3-9.  Since all curves fit 
the standard model best slopes were fixed to unity for IC50 determination purposes.  
Results are similar to the hyperbolic curve fit generally.  Maximal binding of specific S-(-
)-[3H]NIC again occurred at a concentration around 200nM.  In the presence of all three 
values of JC 3-9 maximal binding comparable to control was achieved.  The Ki for the  
 
 
 
 218
 JC 3-9 Dose-response Curves 
-11 -10 -9 -8 -7 -6
0
250
500
750
1000
1250
1500
[3H] S-(-)-Nicotine
NIC + 11nM
NIC + 55nM
NIC + 275nM
[3H] S-(-)-Nicotine log(M)
Sp
ec
ifi
c 
B
in
di
ng
 (D
PM
)
 
Figure 5-17.  Specific saturation binding of S-(-)-[3H]NIC to rat whole brain membrane preparations in the 
absence and presence of three concentrations of JC 3-9 fit to a one-site sigmoidal concentration-response 
curve.  Data (in specific DPM) represent the mean ± SEM of at least three independent determinations.   
 
uninhibited S-(-)-[3H]NIC control was 4.03  ± 0.208.  The curve fit the data closely (R2 = 
0.850) and provides a good representation of the saturable binding relative to the  
concentration of S-(-)-[3H]NIC in the incubation reaction.  The addition of JC 3-9 in 
higher concentrations drives the observed Ki values higher (6.30 ± 0.20, 9.80 ± 0.180, 
and 22.01 ± 2.07) for the three concentrations of JC 3-9 (11nM, 55nM, and 275nM) 
respectively.  These values generally agree with those derived from the hyperbolic  
binding plot.  These three data sets fit a one-site sigmoidal concentration response curve 
with R2 values of 0.860, 0.880, and 0.870 in the same order.  The Bmax values were not 
found to be statistically different among the three data sets.     
 Inhibition of S-(-)-[3H]NIC saturation binding data were used to generate a Schild 
plot.  Here the dose responses derived from the rightward shift in the binding curves are 
measured and plotted on a linear graph.  The data sets from three independent  
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Figure 5-18.  Specific saturation binding of S-(-)-[3H]NIC to rat whole brain membrane preparations in the 
absence and presence of three concentrations of JC 3-9 fit to a one-site sigmoidal concentration-response 
 
experiments were used to generate each data point and agreed very well with the standard 
error of each less than 20% of the experimental value.  The Schild plot of saturation 
binding fit the data well (R2=0.898), and was found to not deviate from linearity across 
the data set, with the runs test (P=1.00) indicating a non-significant deviation from 
linearity.  This suggests a single mechanism of interaction or a single site of interaction at 
the α4β2* subtype.  The Schild plot afforded a non-standard slope (0.372 ± 0.045) that is 
significantly different from unity (theoretical curve).  These results usually indicate non-
equilibrium binding states or multiple receptor interactions in addition to a possible non-
competitive mechanism.  S-(-)-[3H]NIC binding thermodynamics, however, are well 
characterized, and because at 3nM, S-(-)-[3H]NIC is believed to selectively probe a single 
nAChR subtype (α4β2*), these results would, for most receptor systems, indicate a non-
competitive mechanism of interaction between JC 3-9 and S-(-)-[3H]NIC at the high 
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 affinity ligand binding site on the nAChR.  This conclusion, however, will be more 
thoroughly examined in the discussion section following.       
 
 
5.6 Discussion 
 
 Subtype-selective nAChR binding assays were carried out as described in 
previous reports (Chen 2006) in Dr. Linda Dwoskin’s lab(s).  These assays were 
modified to screen AH and JC compounds for binding activity using a single high-
concentration of drug, and measuring the compounds’ ability to displace a known 
concentration of subtype-selective radioligand from nAChRs in whole-brain membrane 
preparations.  In these studies S-(-)-[3H]NIC at 3nM was used to selectively probe the 
α4β2* subtype and [3H]MLA at 3nM was used to selectively probe the α7* subtype.  
Control experiments yielded affinity values for NIC and Cyt that agreed with published 
literature values (Daly 1999, Wilkins 2004, Chen 2006) and were in-line with previous 
findings from the lab.  Non-specific binding for these experiments varied only slightly 
from experiment to experiment and typically ranged from 12-16% of total binding.  
Control binding results were consistent between plates and the error for data points with 
at least n=3 repeats was small across all data points.  Given the fact that this, and similar 
methods are well established and have been used commonly in Dr. Dwoskin’s lab an 
extensive validation was deemed unnecessary and simple controls with NIC and MLA 
were deemed sufficient for validating the assay.   
 A single concentration screen was used to identify compounds to be evaluated in 
the subtype-selective concentration-response (CR) experiments.  The aims of this 
experiments was to 1) confirm activity results from the screen and 2) determine binding 
parameters for test compounds such as Ki, Hillslope, maximal inhibition, etc. that are 
described in results section.  The screening efforts were successful in identifying several 
high-affinity compounds while selecting out the majority of compounds evaluated.  A 
total of ~53 compounds were screened in both assays and only 14 were found to displace 
NIC binding and 6 in the MLA assay.   
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  CR experiments were carried out on all of the screen hits and on several non-
screen hits.  From these experiments it was found that several AH and JC compounds 
were found which display high affinity for the two nAChR subtypes.  AH-132 and AH-
153 were the two guanidine compounds with the highest α4β2* affinity, while JC 2-25, 
JC 3-2, and JC 3-9 from the amidino series were found to bind with high-affinity 
(<100nM).  It was found that AH-132 had a Ki of 27nM while the best from the JC 
series, JC 3-9 had a Ki of 11nM.  Several other AH series compounds were found to 
possess a more modest affinity for the α4β2* nAChR with Ki values from 119nM-
945nM.  All active compounds displaced S-(-)-[3H]NIC in a concentration-dependent 
manner and all compounds displaced nearly 100% of S-(-)-[3H]NIC at the highest 
concentrations.  All of the binding data fit a single-site inhibition curve with Hillslope 
values for the highest affinity compounds around 1.0 across the concentration range(s), 
indicating a single orthosteric binding site on the nAChR.  
 Analysis of screen-to-binding comparison reveals a poor correlation between 
rank-order of %inhibition in the single concentration screen vs. rank-order of affinity in 
the CR experiments.  On the other hand, the screen did select for the highest affinity 
compounds with few false positives, and all non-hits evaluated in CR experiments (at 
least 5 for each subtype assay) were found to be inactive, confirming that the screen did a 
good job of selecting out inactive test compounds.   
 There appears to be a strong general trend among the compounds tested toward 
α4β2* affinity vs. α7* affinity.  Among active compounds (Ki <1000nM) AH series 
compounds appear to possess a stronger α4β2* affinity than the JC series.  However, just 
as the highest affinity guanidine compound AH-132 has one of the lowest selectivity 
values (24-fold) so do the highest affinity JC compounds (11, 9, and 25-fold).  This 
appears to be a common theme among high-affinity AH and JC compounds, and since all 
of the active JC compounds have high affinity values (<100nM) this may explain the 
difference between the two groups.  The one exception to the “high affinity equals lower 
selectivity” trend is AH-153.  With a Ki value of 81nM and a selectivity index value of 
>1200 it is somewhat of an anomaly and should be looked at carefully as a possible basis 
for subtype-selective, high-affinity ligand design.   
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  In terms of SAR analysis a few strong trends should be noted.  The four highest-
affinity AH compounds (132, 153, 149, 159) all possess a 6-chloro addition on the 
pyridine ring.  Additionally, short-chain and bulky N,N-substitutions and N,N-bridged 
compounds seem to result in improved affinity vs. longer chains (N-butyl, N-hexyl, and 
N,N-dibutyl). 
 Schild analysis of binding was carried out using similar binding conditions as 
described in the screen and CR experiments.  These experiments were aimed at 
measuring S-(-)-[3H]NIC saturation binding parameters in the absence and presence of 
several concentrations of inhibitor.  The highest affinity compound from each series was 
chosen for these experiments (AH-132 and JC 3-9).  Through classic Schild analysis 
dose-response ratio values were derived from the sigmoidal concentration-response 
curves and plotted into a Schild plot.  The best-fit linear regression line displayed a very 
straight fit line with a similar slope for both AH-132 and JC 3-9 (~0.38) indicating a non-
competitive mechanism of interaction with the high-affinity α4β2* nAChR.  
Theoretically, this result indicates non-equilibrium binding states or multiple receptor 
interactions in addition to a non-competitive mechanism.  S-(-)-[3H]NIC binding 
thermodynamics, however, are well characterized, and at 3nM, S-(-)-[3H]NIC is believed 
to selectively probe a single nAChR subtype.  Assuming we are probing a single receptor 
type and equilibrium state has been reached in the incubation, these results at first suggest 
a non-competitive interaction.   
As stated earlier, however, this receptor system (α4β2) is unusual in that the 
radioligand used to probe the receptor binds in the active site of the receptor in the high 
affinity conformation…or more appropriately, binding of the high affinity ligand drives 
the receptor conformation into the high affinity desensitized state.  In this inactivated 
state, binding performance is not so straight forward, since the desensitized state is likely 
forced into its conformation by powerful allosteric and possibly regulatory influences.  
This opens the door for alternative hypotheses to explain the Schild result that indicates a 
non-competitive binding interaction.  Possible explanations include desensitized state 
changes in the conformation of the binding site leading to non-linear binding kinetics 
across saturating concentrations of NIC ligand.  These conditions would lead to a 
complex picture of binding that is not easily interpretable.  Intracellular phosphorylation 
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 signaling events following high affinity shift may cause changes in the protein tertiary 
structure, or other intramolecular interactions within the plasma membrane portion of the 
receptor following conversion to the desensitized state.  These and other potential 
confounding factors must be considered when analyzing a Schild analysis of the high 
affinity nAChR subtype.  The complex model of the high affinity nAChR desensitized 
state (reviewed in chapter 2), therefore, may not represent a straight forward experimental 
system for determining the mechanism of binding since the forces governing the free 
ligand-open receptor dynamics (mass action and affinity) may not be the major, forcing 
factors that drive competitor-induced rightward shifts in saturation binding.  As Dr. 
Roger Papke had related previously, the desensitized high affinity nAChR represents a 
moving target for Schild analysis of binding and therefore makes any definitive 
conclusions hard to support.  As of publication, these issues have not been further 
investigated or resolved.                       
 On a more positive note, compounds which demonstrate selectivity for the α4β2 
nAChR subtype have come to the fore recently in terms of drug development, drawing 
attention as smoking cessation aids and as cognitive and Alzheimer’s therapies.  Selective 
Compounds like Varenicline (Chantix) have recently been approved as a smoking 
cessation aid in the US, while the α4β2 selective natural product agonist cytisine has been 
sold in European markets under the brand name (Tabex) for years as a smoking aid.  
Additional late-phase clinical trials are also being carried out with other promising, 
highly selective compounds like TC-1734 (Targacept) for cognitive therapy.  This bodes 
well for some of the more selective AH compounds evaluated since one day these 
compounds, or their better refined analogs, may find themselves as potential lead drug 
candidates and/or as future models for further synthetic design and synthesis.  Overall the 
methods and results detailed in this chapter were successful in satisfying the goal of 
specific aim #3.          
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  Chapter 6: nAChR Subtype-Selective Functional Analysis 
 
6.1  Background 
 
 There are numerous ways to examine neuronal nAChR functional activity.  Today 
studies can be performed examining neuronal nAChR activity in every biological 
preparation conceivable, from large intact tissue slices, as in neurotransmitter release, all 
the way to examining functional response of a single receptor using patch-clamp 
methods.  Some of the more widely used experimental systems to evaluate functional 
nAChR response include methods using synaptosomal preparations and brain tissue slices 
to evaluate nAChR-mediated neurotransmitter release (Grinevich 2003, Wonnacott 
2006), radioisotopic ion flux experiments using synaptosome preparations (Lukas 1988, 
Wilkins 2006), as well as voltage-sensitive dyes (Fitch 2003) used to detect 
depolarization activity and calcium-sensitive dyes (Grynkiewicz 1985, Minta 1989) to 
detect cation influx in intact cells expressing both native and recombinant nAChRs 
(reviewed in Dunlop 2007).  One of the most common established methods is voltage-
clamp functional experiments using receptors expressed in receptor-deficient, 
recombinant oocytes expression systems (Papke).  More recently, however, higher-
throughput methods using calcium-sensitive fluorescence in mammalian cells have begun 
to replace this and other methods in order to screen and evaluate a larger number of 
compounds in whole-cell functional assays (Dunlop 2007).  This, of course, makes a 
great deal of sense because functional nAChR response in a mammalian cell provides a 
great deal more usable information than screening by traditional radioligand binding, and 
can be used in a much higher throughput than electrophysiology methods for measuring 
function (Molecular Devices Application Notes for FLIPR).  Additionally, measuring the 
function of expressed nAChRs in mammalian cell lines is generally preferred to 
expression in amphibian oocyte because the mammalian system better models the native 
human receptor microenvironment.  Naturally, each method has its advantages and 
drawbacks, but keeping that in mind, whole-cell fluorescent measurement experiments 
have attracted a growing amount of attention in the last several years (Sullivan 1999, 
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 Fitch 2003, Smart 2001, Alt 2004).  This method of experimentation has expanded 
mainly due to the increased capacity, reliability and availability of automated fluorescent 
plate reading systems.  Whole-cell fluorescence methods are currently being used 
successfully in both native and recombinant systems for functional HTS experiments as 
well as in more complex pharmacology protocols.   
 The Fluorescent Imaging Plate Reader (FLIPR) device (Molecular Devices) was 
recently developed to perform high-throughput measurements of functional agonism and 
antagonism in whole-cell samples.  Ionized calcium plays a major role in the regulation 
of intracellular signal transduction and regulation of cellular processes.  This is certainly 
true for nAChR activation as the main function of nAChR activation is to facilitate cation 
influx across cellular membranes via nAChR opening.  Measurement of changes in 
intracellular calcium levels in whole-cells has become a common application for the 
FLIPR device and has been used to examine a variety of pharmacological targets.  Some 
of the more common targets include G-protein coupled receptors (Coward 1999), 
voltage-gated channels (Vickery 2004), kainate receptors (Dravid 2003), and nAChRs to 
name a few (Craig 2004, Lansdell 2005).  Practically any physiological response that can 
be measured by a fluorescent reporter can find a useful FLIPR application.  FLIPR 
experiments have been carried out in 96, 384 and 1536-well assay formats (Hodder 2004, 
Coward 1998, Lansdell 2005), using a variety of cell lines and recombinant systems, 
while providing high-quality data on receptor function.   
   The FLIPR work described in this chapter was carried out as the result of a 
University of Kentucky Graduate School, Dissertation Enhancement Award used for 
research travel in July 2005.  Work was carried out in the lab of Dr. Neil Millar at 
University College London, (London, UK) where he generously allowed the use of his 
materials, laboratory and expertise in nAChR expression, functional response, and FLIPR 
device operation.  Dr. Millar’s research group has a well established record of work with 
nAChR subunit transfection and expression in mammalian systems (Cooper 1999, 
Harkness 2002), expertise in nAChR subunit composition, function and subtype 
pharmacology (Millar 2003), and a documented history of developing successful FLIPR 
methodologies for the investigation of major nAChR subunit combinations (Gee 2007).  
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 6.2  Materials and Methods 
 
 FLIPR materials 
 All plate readings were carried out using a 96-well fluorescence imaging plate 
reader (FLIPR-96) system (Molecular Devices).  This device is a cellular assay system 
which provides real-time kinetic data using a multi-well plate format.  The FLIPR uses 
confocal laser scanning microscopy and an integrated dual scanning monochromator to 
measure in-well fluorescence and is optimized to assay excitation and emission 
wavelengths.  Time resolution during functional response periods was set at 1 
measure/second.  The flourophore dye (Fluo-4) has an excitation optimum at 488nm and 
calcium binding affinity of ~345nM, generating a subsequent >100-fold fluorescence 
increase (Molecular Devices, Application Notes).  All cell culture media (HBSS, DMEM, 
trypsin EDTA, Glutamax) was purchased from Gibco and all supplements (pen/strep 
solutions, FBS) were purchased from Sigma Life Sciences.  Pluronic F-127 acid and 
Fluo-4 were purchased from Invitrogen and Molecular Probes, respectively.  The 
Effectine™ transfection kit and reagents were purchased form Qiagen.    
  
FLIPR:  cDNAs, cell culture and transfections 
Rat α4, β2, α3 and β4 subunit cDNAs were provided by Jim Patrick (Baylor 
College of Medicine, TX). All subunit cDNAs were subcloned into plasmid expression 
vector pRK5 as previously described (Cooper 1999).  TSA201 cells, a derivative of the 
HEK 293 cell line, which expresses the simian virus 40 large T-antigen, were obtained 
from Dr. William Greene (University of Chicago, USA).  TSA201 cells were cultured in 
Dulbecco’s Modified Eagles Medium (Gibco #61965-026) containing 10% heat-
inactivated fetal calf serum (Sigma), penicillin (100U/ml) and streptomycin (100U/ml) 
(Sigma), 4.5g/l glucose, +glutamax, +pyruvate.  Cells were maintained in a humidified 
incubator (Scientific Laboratory Supplies, Galaxy R Incubator) at 5% CO2, at 370C, and 
transfected using Effectene™ reagent (Qiagen) according to manufacturer’s instructions 
using a total of 600ng (300ng of each subunit) of cDNA per 10cm plate (Corning). Cells 
were transfected two days prior to FLIPR reading with nAChR genes cloned into PRK5 
expression plasmids.  PRK5 is a single-stranded plasmid DNA which contains a strong 
CMV promoter sequence and a multiple cloning region where the nAChR subunits were 
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 cloned into.  Cells were split 1:5 at 40% confluence into 10cm plates.  Cells were 
incubated overnight and prepared for transfer to FLIPR plates the next day.  Two 10cm 
plates were harvested for each FLIPR plate seeded.  24 hours later media was removed, 
cells were rinsed with PBS, and the cells (60-65% confluent) were detached from the 
plate with a brief incubation in a 50% diluted trypsin solution exposure and re-plated at a 
density of 5 x 105 cells/ml.   
 
FLIPR:  Intracellular calcium reading 
Transfected TSA201 cells were grown ~65% confluence and re-plated onto poly-
L-lysine-coated, black-walled, 96-well assay plates (Marathon Labs, London, UK) 
approximately 18hrs post-transfection.  Approximately 24 hours later, culture medium 
was removed and plated cells were incubated for 60 minutes with 50µl of 1µM Fluo-4 
acetoxymethylester (Invitrogen) and 0.02% pluronic F-127 (Molecular Probes) in Hanks’ 
Balanced Salt Solution (HBSS).  Cells were rinsed twice with 160µl assay buffer (HBSS 
+ 18.8mM CaCl2, 8.8mM sucrose, 6.3mM HEPES) and assayed in an initial 120µl assay 
buffer final volume using the fluorometric imaging plate reader (FLIPR) system 
(Molecular Devices, Winnersh, UK).  Wells were excited by 488nM wavelength light 
from a 4W argon-ion laser and the emitted fluorescence passed through a 510-570nM 
bandpass interference filter prior to detection with a cooled, charge-coupled device 
camera (Princeton Instruments).  The 96-well instrument that was used had an integrated 
fluid handling apparatus that allowed for addition of drug solutions to the plate during the 
acquisition of signal.  All drug solutions were prepared in serial dilutions from a 10mM 
stock solutions in high calcium FLIPR assay buffer, and added at 40µl/well from a 
separate 96-well plate.  Drug dilutions were applied to the FLIPR plate at 4x final assay 
concentration during agonist addition (40µl drug into 120µl) while agonist was added at 
5x concentration (40µl drug into 160µl) due to the increasing well volumes associated 
with multiple dug additions to the plate.  All data collection and FLIPR fluorescent traces 
were carried out as previously described (Lansdell 2005).  Parameters for drug addition to 
the FLIPR plate were programmed and delivered via the automated liquid handler.  
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 Fluorescence data was gathered during a brief 24 second baseline measurement 
followed by addition of drug(s) in series.  For antagonist-agonist dual activity 
experiments cells were measured at baseline then test drug was added.  Fluorescence 
measurements were taken once every second for two minutes during the agonist response 
period followed by an eight minute equilibration period where measurements were taken 
once every ten seconds.  Following this equilibration period Ebt was added to measure 
potential antagonist activity at which time measurements were once again taken once 
every second for an additional 2 minute period.  Step-by-step: 1) cells were allowed to 
equilibrate in the dark for 5 minutes, 2) 24 second baseline measurements were taken in 
buffer, 3) test drug was added and agonist fluorescence measurements were recorded for 
2 minutes, 4) cells were allowed to incubate undisturbed in drug solution for an 
additional 8 minutes, 5) agonist solution (Ebt) was added and fluorescence recording 
continued for an additional 2 minutes to measure potential antagonist effect.  Using this 
experimental protocol allowed for the assessment of both agonist and antagonist activity 
in a single well in the same experiment.  Compounds were screened at 100µM 
concentration and cells were challenged with 1µM Ebt.  All control agonist responses 
were carried out also using 1µM Ebt.  All compound stock solutions were kept stored at 
4oC and reused for no longer than a week before fresh stock solutions were made.   
 
 FLIPR:  Data analysis 
All data are reported as peak height measured in relative fluorescent units.  The 
FLIPR device reports plate/well fluorescence in a relative, unit-less fluorescence value 
that can differ from plate to plate.  Response values are normalized relative to baseline 
values collected just prior to addition of drug.  Only a single calculation is required for 
this method since response is simply relative peak height minus baseline (1.0).  Unless 
otherwise stated, each data point represents at least four independent determinations of 
functional response.  Processed peak response data values were transferred to a GraphPad 
Prism worksheet (column, +SEM) and analyzed using an ANOVA function with Tukey’s 
post hoc tests to measure differences in response between each pair of drug concentration 
conditions.   
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 6.3  Whole-cell FLIPR Results 
 
 Agonist Control Response Experiments 
 The functional properties of TSA201 cells transiently transfected with nAChR 
subunit combinations were initially evaluated for response to the nAChR agonist 
epibatidine (Ebt).  Following baseline measurements of 25 seconds plated cells were 
exposed to Ebt dilutions in buffer, and responses were measured for an additional 90 
seconds.  Similar to previous Ebt agonist response experiments carried out in the lab 
(data not presented) a clear, time-resolved, concentration-dependent fluorescence 
response was demonstrated.  The standard Ebt agonist response had been established 
previously in the Millar lab at an optimum of 1µM so this experiment was less oriented 
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Figure 6-1.  TSA201 cells expressing α3 and β4 nAChR subunits were exposed to increasing Ebt 
concentrations (1nM-10µM) in FLIPR plates to determine appropriate agonist concentrations for 
subsequent experiments.  Baseline measurements were taken for 25 seconds prior to agonist addition and 
response measurements continued for 90 seconds following exposure to agonist.  Measurement values are 
calculated in relation to normalized baseline fluorescence.    
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 toward optimizing the Ebt response from the ground-up than simply establishing a clear 
signal window that can be used for agonist measurements.   
The target agonist concentration is the lowest Ebt concentration that yields a near 
maximal response.  In this way the response will be large enough so that agonists and 
antagonist responses can be detected while using the minimal concentration of Ebt also 
so no agonist will be present in excess concentration for a potential antagonist to have to 
overcome.  This condition would unnecessarily skew antagonist responses to the right on 
a concentration response graph.  Experiments were carried out for both α3β4 and α4β2 
nAChR subunit combinations.  In both cases a clear concentration response was observed 
with little difference between the two subtypes in this regard.  Both subtype responses 
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Figure 6-2.  TSA201 cells expressing α4 and β2 nAChR subunits were exposed to increasing Ebt 
concentrations (1nM-10µM) in FLIPR plates to determine appropriate agonist concentrations for 
subsequent experiments.  Baseline measurements were taken for 24 seconds prior to agonist addition and 
response measurements continued for 90 seconds following exposure to agonist.  Measurement values are 
calculated in relation to baseline fluorescence.    
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 showed a similar sensitivity to Ebt and both peak responses occurred at or near 10 
seconds post Ebt application.  The one notable difference in the two subtype responses is 
the magnitude of the response with α3β4 giving a larger maximal response of ~0.35 
relative to α4β2 which gave a slightly more modest maximal response of ~0.18.  Both 
subtypes showed an initial response in the 10-100nM range with robust, near maximal 
response at 1uM.  Responses are in agreement with previously published reports from the 
Millar lab (Lansdell 2005).  Both responses as plotted were of the same general scale, 
curve shape, and response duration as previously published results for the same expressed 
nAChR subunit combinations (Lansdell 2005, Sharples 2002).  Control cells transfected 
with vector alone produced no Ebt-induced calcium signal at any concentration (data not 
shown). 
 
Agonist-Antagonist (Ag/Ant) Experiments    
Having successfully reproduced the Ebt standard responses for nAChRs 
expressed in TSA201 cells, the aim of the FLIPR study was then directed at testing a 
method for screening the test compounds.  A method was worked out whereby, 
theoretically at least, both agonist and antagonist response could be screened for in a 
single well, during a single experiment by the stepwise addition of drug/Ebt solution to 
the wells.  The method calls for a collection of baseline response followed immediately 
by exposure to the test compound.  If the test compound functions as an agonist it will 
produce a measured response upon addition and will be seen as a peak in the first half of 
the graph.  If the drug has no intrinsic activity at the nAChR subtype, however, no 
response will be detected.  This first response is described as the agonist response period.  
The drug was then allowed to incubate in the reaction solution for an additional 8 minutes 
to allow for a short solution phase equilibration/diffusion prior to challenge with agonist.  
Next, Ebt solution (1µM) was added to the wells and agonist response data was collected 
for an additional 2 minutes.  If test compounds possessed any antagonist activity this will 
be revealed with a diminished peak height following Ebt addition.  This second response 
is described to as the antagonist response period.  Responses for agonist and antagonist 
evaluations were measured by peak height determinations relative to the adjusted 
baseline value for each response.        
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  Ag/Ant Controls Experiments 
Before screening experiments could be carried out control response experiments needed 
to be performed using Ebt to elicit an agonist response.  In this experiment plated cells 
were challenged with either Ebt or buffer in the initial agonist response period.  Each of 
these conditions was followed again by either Ebt or buffer in the “antagonist” response 
period.  In this way 1) a buffer control for both periods could be visualized, 2) Ebt 
responses could be compared between the first and second period to measure any 
potential changes in Ebt response due to time across the experiment, and 3) the effect of 
double agonist exposure could be determined.  The double agonist exposure control was 
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Figure 6-6.  TSA201 cells expressing α3 and β4 nAChR subunits were exposed to either Ebt or buffer in 
each of two time periods in order to determine baseline and normal responses in each of two exposure 
periods “antagonist” and “agonist” period.  Four conditions were tested, each with two separate drug 
exposure periods:  1) Buff-Buff dual buffer control, 2) buff-Ebt second half agonist response, 3) Ebt-buff 
first half agonist response, and 4) Ebt-Ebt first and second half agonist response to determine response 
during repeated agonist exposure.  Data values are calculated in relation to baseline fluorescence.    
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 particularly important in establishing a normal response in the second period following an 
agonist exposure in the first period.  As expected there was a clear and stable, static 
baseline response for both nAChR subtypes tested when buffer solution was added to the 
plate (buffer-buffer).  This stable baseline begins through the first half of the time-course 
and continues through the second, indicating that the expressed nAChRs do not 
negatively respond in a significant way to multiple solution additions throughout the 
assay process.  The first period Ebt exposure condition (Ebt-buffer) resulted in a clear 
signal that reached a maximum ~10 seconds post-addition which then begins to stabilize 
and level off around 75 seconds post addition.  As expected the following buffer 
treatment produced no response in the second half.  The second period Ebt exposure  
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Figure 6-7.  TSA201 cells expressing α4 and β2 nAChR subunits were exposed to either Ebt or buffer in 
each of two time periods in order to determine baseline and normal responses in each of two exposure 
periods “antagonist” and “agonist” period.  Four conditions were tested, each with two separate drug 
exposure periods:  1) Buff-Buff dual buffer control, 2) buff-Ebt second half agonist response, 3) Ebt-buff 
first half agonist response, and 4) Ebt-Ebt first and second half agonist response to determine response 
during repeated agonist exposure.  Data values are calculated in relation to baseline fluorescence.    
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 condition (buffer-Ebt) resulted in an unresponsive first period followed by a robust Ebt 
response in the second.  No difference could be determined between a first period and a 
second period Ebt response for either nAChR subtype tested as inter-period Ebt responses 
were nearly identical for both subtypes indicating that there is no time-dependent effect 
on agonist response across the assay time course.  The double agonist exposure condition 
(Ebt-Ebt) produced a clear and robust signal in the first period followed by a normal 
gradually declining equilibration period response.  During the second period Ebt 
challenge, however, no response could be detected in either nAChR subtype tested.  This 
could be due to exhaustion of intracellular calcium mobilization activity leading to a 
diminished signal, desensitization of functionally active cell surface nAChRs, or an 
undefined mechanism of receptor response down-regulation particular to the expression 
system used here.  Either way, this result makes it clear that a second agonist exposure 
does not result in a detectable response in this assay system and that a hallmark of first 
period agonist response in this experimental system is an abolished second period agonist 
response even in the presence of high concentration of agonist.  Otherwise the control 
response experiments went as expected with no difference detected between a first period 
and a second period naïve response in the same nAChR subtype.   
  
 Agonist-Antagonist Response Experiments 
 For ag/ant screening experiments compounds were tested for functional activity at 
100µM concentration in duplicate on a single plate.  For ag/ant concentration-response 
experiments compounds were tested in triplicate on each plate and each experiment was 
repeated for a total n=3.  Data values for each time point were averaged to yield the 
concentration-response traces presented.  In all 19 AH and JC compounds were screened 
using this method.   
 Results from these studies revealed several compounds to be active as potential 
agonists and antagonists at both major nAChR subtypes (α3β4 and α4β2).  Selection 
(positive response) was simply an agonist response of 0.1 above baseline for the α3β4 
subtype and 0.02 at the α4β2 nAChR subtype, and an antagonist inhibition of either 0.1 at 
for the α3β4 subtype and 0.05 at the α4β2 nAChR subtype.  These values represent ~20% 
maximal agonist and antagonist response for both subtypes.  Among all 19 screened 7 
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 Agonist-Antagonist Screen Results 
      
    Compound  
                       α3β4   
     Agonist           Antagonist 
                    α4β2 
   Agonist            Antagonist 
JC 2-25 - - - - 
JC 2-31 - - - - 
JC 3-9 + - + - 
AH-3 - - - - 
AH-5 - - - - 
AH-6 - - - - 
AH-37 - - - - 
AH-38 - - - - 
AH-39 - - - - 
AH-79 + - + - 
AH-90 - - - - 
AH-106 - - + - 
AH-107 + - + - 
AH-110 + - + - 
AH-114 - - - - 
AH-115 + - + - 
AH-132 + - - + 
AH-133 - + - - 
AH-134 - - - - 
 
Figure 6-8.  Results for AH and JC compounds screened for agonist and antagonist activity at both α3β4 
and α4β2 nAChR subtypes.  FLIPR experiments tested 100µM compound for agonist and antagonist 
response.  A negative (-) screen response indicates no significant agonist or antagonist response over 
baseline.  A positive (+) screen response indicates either a significant agonist or antagonist response.   
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 compounds were found to display either agonist or antagonist activity in the screens.  
These results are shown in figure 6-5. 
 Some notable screen results include the fact that while seven compounds were 
found to be active at each subtype 6 of these were common between the two with only 
AH-106 and AH-133 being selective for one.  While AH-132 was active in both screens 
it appears as an agonist at the α3β4 nAChR while exhibiting antagonist activity at α4β2 
nAChR subtype.  A final note is the fact that while several of the N,N-tetramethyl 
substituted compounds (AH-106 through AH-115) appeared to be agonists at both 
subtypes, the responses elicited by these compounds all appeared unusual in that the 
calcium response peaked rapidly (as expected for an agonist) but did not diminish over 
time.  In fact, the agonist response for every N,N-tetramethyl compound remained 
maximal for the duration of the experiment suggesting some sort of supra-physiological 
or non-receptor mediated event.  A representative response for these compounds is 
presented in the response section.  All compounds with measured responses from 
screening experiments were used to conduct concentration-response (CR) experiments. 
 
AH-132 Ag-Ant Concentration Response Results 
 The 6-chloro, N,N-diisopropyl substituted 3-aminomethylpyridine compound AH-
132 was first evaluated in CR experiments at the α3β4 nAChR because of its agonist 
response in the screening assay.  These experiments were carried out in the same manner 
as the screen experiments (evaluation of both agonist and antagonist response in the same 
run) except that multiple concentrations of AH-132 were tested to produce response data 
over a concentration range.  First the raw trace data is presented so that the response can 
be observed as the data were measured on the FLIPR device.  Next the data are presented 
in a simple column graph with each column representing the mean peak height for the 
response at each concentration with simple t-test analysis to determine significant 
deviation from minimum control values.  Finally the data were fit to a sigmoidal dose-
response curve in an attempt to calculate an EC50 for the agonist activity.  While this last 
analysis of the data was not expected to yield any useable data given the relatively small 
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Figure 6-9.  TSA201 cells expressing α3 and β4 nAChR subunits were exposed to varying concentrations 
of AH-132 in the ag/ant CR experiment.  Top: complete time-course response of FLIPR experiment.  
Bottom: bar graph representation of agonist response derived from trace data showing a maximal response 
peak height that differs significantly from both baseline and control agonist response indicating some sort 
of partial agonist activity for AH-132.      
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 concentration range of drug evaluated this analysis was attempted anyway in hopes of 
better defining the agonist activity response of the drug.    Data analysis reveals that the 
agonist response has an EC50 of 137nM while only reaching a maximal response of ~67% 
of Ebt-induced maximal response.  The data were tested against a standard slope model 
and a variable slope model, with the variable slope model being preferred (Hillslope= 3.5 
and R2=0.894).  A significant difference was calculated between the maximal response 
points (200nM, 2µM, and 20µM) and both the baseline control and the maximal Ebt-
induced control.  With an EC50 of only 137nM, these results indicate that AH-132 is a 
potent activator of the α3β4 nAChR subtype.  The fact that the activation at the highest 
concentration only provided a ~66% maximal response (20µM AH-132 versus 1µM Ebt) 
indicates that however AH-132 engages the nAChR to initiate activation, it is acting in 
some manner as a partial agonist.  One point of interest is that data analysis reveals a  
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6-10.  AH-132 data from ag/ant experiments in TSA201 cells expressing α3 and β4 subunits.  Data were fit 
to sigmoidal dose-response curve to reveal maximal agonist response of ~0.25 over baseline and a 
calculated EC50 value of 137nM.  
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 dramatic response between the 20nM and the 200nM concentrations.  This apparent 
response of around 80% of maximal response over a little more than a 10-fold 
concentration increase is certainly larger than would be expected if acting at a single 
orthosteric site (native nicotinic binding site) on the nAChR tested.  While additional 
experiments with more data points in this narrow range may help to elucidate and better 
define the actual agonist response a little better, it is clear enough that even with 
additional work the response data would still reflect a sharp concentration dependent 
response that is likely due to a non-orthosteric or synergistic mechanism that remains 
undefined and unexplored between AH-132 and the α3β4 nAChR.  
 
AH-132 α4β2 Ag-Ant Response 
 AH-132 was next evaluated in the same way at the α4β2 nAChR.  Again, multiple 
concentrations of AH-132 were tested to produce response data over a concentration 
range.  First the raw trace data is presented so that the response can be observed as the 
data were measured on the FLIPR device.  Next the data are presented in a simple 
column graph with each column representing the mean peak height for the response at 
each concentration with simple t-test analysis to determine significant deviation from 
control values.  Finally the data were fit to a sigmoidal dose-response curve in an attempt 
to calculate an IC50 for the agonist activity.   
Data analysis reveals that the antagonist response has an IC50 of 506nM while 
maximally inhibiting Ebt-induced.  The data were tested against a standard slope model 
and a variable slope model, with the variable slope model being preferred (Hillslope= 2.4 
and R2=0.862).  No significant difference was calculated between the maximal inhibition 
values and those of the vector control and buffer control values.  With an IC50 of 506nM 
AH-132 appears to be a potent and efficacious inhibitor of the α4β2 subtype.  This is 
somewhat unexpected though considering that it is a well established principle in 
pharmacology that for a group of compounds the antagonist activity often occurs at a 
lower concentration than the corresponding agonist activity.  It seems this principle 
should hold true if this compound was interacting at the same NIC-binding site for both 
of these subtypes, but since this principle does not seem to apply it can be hypothesized 
that it may, in fact, be acting at two distinct sites on these two subtypes.  This, of course 
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Figure 6-11.  TSA201 cells expressing α4 and β2 nAChR subunits were exposed to varying concentrations 
of AH-132 in the ag/ant CR experiment.  Top: complete time-course response of FLIPR experiment.  
Bottom: bar graph representation of antagonist response derived from trace data showing a maximal 
inhibition at 2µM.   AH-132 was able to fully inhibit Ebt agonist response indicating efficacious antagonist 
activity.      
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Figure 6-12.  AH-132 data from ag/ant experiments in TSA201 cells expressing α4 and β2 subunits.  Data 
were fit to sigmoidal dose-response curve to reveal complete inhibition of agonist response and a calculated 
IC50 value of 506nM.  
 
is merely speculation.  The fact that AH-132 appears to be selective between the α3β4 
and α4β2 nAChR subtypes is somewhat unusual in that it appears to be a potent partial 
agonist at one subtype and a full antagonist at the other.  As with the AH-132 agonist  
response at the α3β4 subtype, the antagonist response was more sharply concentration-
dependent that would be expected, going from no inhibition to maximal inhibition in just 
over a 10-fold concentration increase.  This result supports the idea of a non-orthosteric 
site of interaction, or a multi-site or synergistic concentration effect at the nAChR.  The 
mixed response of AH-132 between these two major subtypes is something that should 
be examined in more depth from an SAR perspective, but until other data from similar 
experiments are presented little can be gleaned from the two responses presented here.   
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 JC 3-9 α3β4 Ag-Ant Response 
The 6-chloro, N,N-tetrahydropyrimidino ring substituted 3-aminopyridine 
compound JC 3-9 was evaluated in the same way as above at the α3β4 nAChR subtype.  
Again, multiple concentrations of JC 3-9 were tested to produce response data over a 
concentration range.  First the raw trace data is presented so that the response can be 
observed as the data were measured on the FLIPR device.  Next the data are presented in 
a simple column graph with each column representing the mean peak height for the  
response at each concentration with simple t-test analysis to determine significant 
deviation from control values.  Finally the data were fit to a sigmoidal dose-response 
curve in an attempt to calculate an EC50 for the agonist activity.   
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Figure 6-13.  TSA201 cells expressing α3 and β4 nAChR subunits were exposed to varying concentrations 
of JC 3-9 in the ag/ant CR experiment.  Complete time-course response of FLIPR experiment.   
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Figure 6-14.  TSA201 cells expressing α3 and β4 nAChR subunits were exposed to varying concentrations 
of JC 3-9 in the ag/ant CR experiment.  Top:  bar graph representation of agonist response derived from 
trace data showing a maximal activation at 2µM.   JC 3-9 was able to fully activate the α3β4 nAChR to a 
level comparable with the control Ebt agonist response.  Bottom: Data were fit to sigmoidal dose-response 
curve to reveal maximal agonist response and a calculated EC50 value of 147nM. 
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 Data analysis reveals that the JC 3-9 agonist response has an EC50 of 147nM 
while activating the receptors maximally.  The data were tested against a standard slope 
model and a variable slope model, with the variable slope model being preferred 
(Hillslope= 0.48 and R2=0.775).  No significant difference could be calculated between  
the maximal JC 3-9 activation values and those of the Ebt agonist control values.  With 
an EC50 of 147nM, JC 3-9 appears to be a potent and efficacious activator of the α3β4 
subtype.  As with the preceding analyses, the slope differs significantly from unity 
although in this case the slope is shallow rather than steep.  As with any whole-cell 
functional assay these FLIPR experiments possesses some error that could contribute to 
the unusual slope, and while additional experiments may help to refine the definition of  
the response (especially in light of the seemingly devious response at the 200nM data 
point) it does appear that the general trend among these compounds is a response that 
does not fit the traditional one-site, 2 orders-of-magnitude functional response.   
 
JC 3-9 α4β2 Ag-Ant Response 
JC 3-9 was evaluated in the same way as above at the α4β2 nAChR subtype.  
Multiple concentrations of JC 3-9 were tested to produce response data over a 
concentration range.  First the raw trace data is presented so that the response can 
 be observed as the data were measured on the FLIPR device.  Next the data are presented 
in a simple column graph with each column representing the mean peak height for the 
response at each concentration with simple paired t-test analysis to determine significant 
deviation from control values.  Finally the data were fit to a sigmoidal dose-response 
curve in an attempt to calculate an EC50 for the agonist activity.   
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Figure 6-15.  TSA201 cells expressing α4 and β2 nAChR subunits were exposed to varying concentrations 
of JC 3-9 in the ag/ant CR experiment: complete time-course response of FLIPR experiment.   
 
Data analysis reveals that the JC 3-9 agonist response has an EC50 of 4.12µM 
maximal while activating the receptors maximally.  The data were tested against a 
standard slope model and a variable slope model, with the standard slope model being 
preferred (Hillslope= 1.03 and R2=0.91).  No significant difference could be calculated 
between the maximal JC 3-9 activation values and those of the Ebt agonist control values.  
On the other hand, maximal agonist responses at 20µM and 200µM were highly 
significantly different than negative vector control values with no measured response 
(p<0.001).  With an EC50 of 4.12µM JC 3-9 appears to be a less potent but still highly 
efficacious activator of the α4β2 subtype versus the α3β4 subtype.  As opposed to the 
preceding compounds, the slope of this particular response does not differ significantly 
from unity.  This can be interpreted as an indication of a single-site interaction at the 
α4β2 nAChR.  While there is some variation of response at the lower concentrations, 
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Figure 6-16.  JC 3-9 data from ag/ant experiments in TSA201 cells expressing α4 and β2 subunits.  Top: 
bar graph representation of agonist response derived from trace data showing a maximal activation at 
20µM.   JC 3-9 was able to fully activate the α4β2 nAChR to a level comparable with the control Ebt 
agonist response.  Bottom:  Data were fit to sigmoidal dose-response curve to reveal maximal agonist 
response and a calculated EC50 value of 4.12µM. 
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 particularly with the 20nM data point, additional experiments would almost certainly help 
to refine the definition of the agonist response presented here.  It appears certain that JC 
3-9 functions as a potent and highly efficacious, non-selective activator for both α3β4 and 
α4β2 subtypes.  Little can be stated regarding SAR analysis of this compound, however 
while it appears that the most of the responses observed so far involve an unusual 
response (steep slope, shallow slope, and sub-maximal activity) there appears to be a 
general trend for potent responses with these compounds. 
 
 AH-133 α3β4 Ag-Ant Response 
The N,N-diisopropyl substituted 2-amino-5-picoline compound, AH-133 was 
evaluated in the same way as the compounds above at the α3β4 nAChR subtype.  
Multiple concentrations of AH-133 were tested to produce response data over a 
concentration range.  First the raw trace data is presented so that the response can be 
observed as the data were measured on the FLIPR device.  The data were fit to a 
sigmoidal dose-response curve in an attempt to calculate an IC50 for the antagonist 
activity.   
 Data analysis reveals a less than ideal inhibition of Ebt-induced response by AH-
133.  A variable slope model best fit to the data with modest results.  The curve fit 
revealed a shallow slope significantly lower than unity, and an R2 value for the fit of 
0.475.  While an IC50 value of 167nM was calculated by the computer model, the 
antagonist response was not-robust with a maximal inhibition of only ~55% at 20µM.  
From the data it is pretty clear that maximal inhibitory response at concentrations higher 
than 20µM will not lead to significantly improved inhibition and while the IC50 appears 
to be quite potent it seems that AH-133 is a partial antagonist at the α3β4 nAChR.  The 
compound was evaluated in the α4β2 subtype  
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Figure 6-17.  Top:  TSA201 cells expressing α3 and β4 nAChR subunits were exposed to varying 
concentrations of AH-133 in the ag/ant CR experiment: complete time-course response of FLIPR 
experiment.  Bottom:  bar graph representation of antagonist response showing a sub-maximal inhibition at 
2µM.   
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Figure 6-18.  AH-133 ag/ant response experiment results.  Data were fit to sigmoidal dose-response curve 
to reveal sub-maximal antagonist response and a calculated IC50 value of 167nM. 
 
 
 N,N-tetramethyl Compounds:  ag/ant Responses   
 N,N-tetramethyl substituted pyrimidine compounds (AH-106 through AH-115) 
that were revealed in the screening experiments as being activators at both α3β4 and α4β2 
nAChRs were examined in CR ag/ant experiments just as the previous compounds were.  
While the CR experiments backed up the initial findings with a positive agonist response, 
an unusual response characteristic was noted with all of the test compounds that 
contained N,N-tetramethyl guanidine substitutions.  Regardless of any other structural 
modifications, all of the active tetramethyl compounds gave robust and persistent 
signaling responses throughout the duration of the assay.  These responses were 
uncharacteristically high and did not result in a return to baseline over time.  While some 
previous FLIPR results of compounds at the highest concentrations do appear to result in 
a slower return to baseline, this only occurred at the highest concentration (usually in the 
upper micromolar range) and was likely due to a surplus of compound in solution that 
may have some unwanted effects.  These results were of minor concern since every assay 
has an effective signal window and normal operation range where some data points on 
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 the end of the scale will often result in a slightly skewed response.  The response noted 
here however was something completely different in that even the smallest response 
would result in abnormal and persistent signaling throughout the assay period.  While the 
magnitude of the response was concentration-dependent it appears that some sort of non-
nicotinic, or possibly supra-physiological process may be in play because even at the 
highest concentrations of agonist, responses from all previous compounds evaluated  
 
AH-110  α3β4 Ag-Ant Response 
 
 
Figure 6-19.  TSA201 cells expressing α3 and β4 nAChR subunits were exposed to varying concentrations 
of  AH-110 in the ag/ant CR experiment: complete time-course response of FLIPR experiment.   
 
resulted in a characteristic peak followed by a gentle and gradual return toward baseline 
through the assay time course.  No such characteristic was observed for any of the 
tetramethyl substituted compounds.  A representative FLIPR ag/ant concentration 
response experiment is presented.  The high-level fluorescence can be clearly seen at all 
concentrations tested. 
Although AH-79 appeared to result in an agonist response in the screen 
experiments, later CR experiments revealed no functional activity at all…even at the 
highest concentrations evaluated (data not shown).  This compound, despite its promising 
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 screen activity appeared to possess no functional activation whatsoever at either nAChR 
subtype relegating it to the only false-positive detected in the screen for this series of 
experiments.  A possible explanation for this result could be nothing more than a cross-
contamination event with either Ebt or NIC from the first experiments carried out where.  
These experiments looked to determine which of the two agonists would be most useful 
as the control agonist and while both gave robust and clear agonist responses (data not 
shown) Ebt was chosen for its higher potency and its lower functional selectivity among 
the nAChR subtypes evaluated in this experimental series.   
FLIPR experiments were also carried out to screen and evaluate compound 
concentration response at the major α7 neuronal nAChR.  Unfortunately, the α7 subtype 
is a notoriously difficult subunit combination to express for functional studies in cell 
culture systems.  Unmodified α7 nAChR subunit cDNA was transfected into cells 
without success, followed by an attempt at transfection of the previously reported 
functional α7/5-HT3 chimera (Craig and Broad 2004).  Both transfected cell plates failed 
to produce a nAChR-mediated response in either the first or second response period.  
While this result was a disappointment because of the importance of the α7 nAChR in 
terms of drug discovery potential, later experiments carried out in the Papke lab did allow 
for at least a snapshot of α7 activity for a few of the leading compounds evaluated 
although these results will not be discussed in this work.     
 
 
6.4  Discussion 
 
Several AH and JC compounds were found to act as nAChR agonists and 
antagonists.  AH compounds were found to elicit agonist and antagonist responses in both 
subtypes evaluated in the FLIPR experiments, while JC compounds were found to be 
potent and efficacious agonists at each subtype evaluated.   
According to the FLIPR data AH-132 appears to be a partial agonist at the α3β4 
subtype, while displaying properties of a complete antagonist at the α4β2 subtype.  
Clearly more work needs to be carried out on AH-132 to confirm these findings in other 
functional native or artificial expression systems in order to better characterize and more 
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 precisely define the functional responses of AH-132 at various nAChR subtypes.  Despite 
its relative high nanomolar potency, AH-132 does not appear to be very selective 
between the major high affinity receptor subtype and the ganglionic subtype tested.  At 
first glance this result would indicate that AH-132 might not be useful as a drug 
candidate since α3β4 “ganglionic” activity is certainly considered an undesirable property 
when developing neuronal nAChR drug molecules.  On one hand unwanted side effects 
caused by activation of the nAChRs at the autonomic ganglia can limit the potential 
therapeutic value of a compound.  On the other hand there is considerable interest 
surrounding partial agonists at neuronal subtypes these days, as will be discussed more a 
little later.  Selective partial agonists and compounds displaying mixed subtype 
pharmacology are currently being explored as a new paradigm in nicotinic drug discovery 
and while the results for AH-132 shown here may not obviously lend themselves to drug 
development the potential may exist for exploitation of a unique and interesting 
pharmacology that has yet to be more precisely defined.  Importantly, however, the 
molecular structure of this compound has demonstrated some manifestation of subtype-
selectivity and functional promiscuity that should be explored further since this multiple-
subtype/multiple-receptor “mixed” functional pharmacology is unusual and certainly 
interesting.   
Despite its positive screening result, AH-79 appears to possess no functional 
activity of any kind among the nAChR subtypes tested here.  This result should be 
considered a false positive that was picked up in the one and two point screen assays.  A 
possible explanation for this result is a simple contamination with functionally active NIC 
or Ebt, or otherwise a simple error in pipeting that may occur when preparing dozens of 
96-well plates in parallel.  In any event the hope in a screening assay like this is to 
identify some false positives rather than wonder about the missed opportunities of false 
negatives.   
AH-133 appears to act as a α3β4 subtype-selective antagonist.  Once again, 
ganglionic activity is clearly not a desirable quality to possess when developing drug 
molecules to be used as CNS therapies, and since there was no activity at either of the 
major neuronal subtypes, it might be concluded that further design and development of 
and around the structure of AH-133 should not be pursued.  This may be true, but then 
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 again there may be room for investigation focused on development of these drugs as 
ganglionic receptor modulators.  The autonomic ganglia (as reviewed in chapter 2) are 
critical regulatory factors in the control of blood pressure, heart rate, GI motility, body 
temperature and a number of other normal involuntary regulatory functions in the body.  
Additionally, autonomic neurons express a wide array of nAChR subtypes with the α3β4 
subtype playing a dominant functional role in many peripheral systems.  When 
considering this, potential exists for the development of these compounds as ganglionic 
drugs for treatment of IBS, motion sickness, overactive bladder syndrome, COPD 
respiratory disorders, anti-arrhythmics and blood pressure medicines.      
The N,N-tetramethyl substituted compounds all appear to be involved in some 
unusual process that results in super robust, persistent cellular calcium signaling that is 
currently hypothesized to be a non-nAChR mediated, supra-physiological process (data 
not shown).  It is suspected that this result may involve an undefined cellular mechanism 
causing calcium dumping, increased membrane calcium permeability, membrane 
leakage, or a powerful physiochemical reaction that leads to rapid cell death and release 
of cellular contents.  While all of these possibilities are merely speculation what is for 
certain is that the tetramethyl-substituted guanidines gave clear and consistently abnormal 
results that were not reflective of any physiological action that this project was interested 
in pursuing at the time.  
Functional FLIPR experimental results reveal JC 3-9 to be a potent and 
efficacious, non-selective agonist among the nAChR subtypes tested.  While it does have 
the highest affinity of all compounds tested, it was previously shown to have poor 
binding selectivity and these results hinted that the same trend might continue in the 
functional analysis.  These results combine to make JC 3-9 the least selective, and 
functionally promiscuous nicotinic compound evaluated in this work.  While this 
compound does not appear to be a good candidate for continued drug development due to 
its glaring non-selectivity, continuing SAR analysis and design based around the JC 3-9 
molecule should be carried out to exploit its desirable properties of high affinity and 
potency.  Functionally JC 3-9 does not appear all that different from NIC in its relatively 
high affinity and non-selective agonist activity.  It was recently stated, “with this 
molecule you have really just re-invented nicotine”.  In one sense this is a true statement.  
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 With the relatively high affinity and low selectivity this compound should not have a 
whole lot more luck than NIC as a therapeutic compound.  With a high functional activity 
and a low therapeutic window JC 3-9 would make a less than ideal drug candidate.  In 
another sense, however, the whole point of novel drug design and drug screening efforts 
is to exploit new molecular structures in order to better understand and take advantage of 
naturally occurring, and usually frustratingly subtle, differences in subtype 
pharmacology.  By testing novel compounds and identifying promising hits additional 
compound design and synthesis can progress in a way so as to yield compounds with 
ever-improving biological properties.  The first step isn’t necessarily to find a blockbuster 
the first time out, but rather to develop the drug design idea and improve as part of the 
drug discovery process.  In this way, there may yet be more to these series’ of compounds 
than just being nicotine reinvented.     
While the FLIPR method, and more generally, receptor expression in cell lines for 
testing in functional assays have been widely accepted for decades, there remain some 
important considerations that should be addressed here.  First of all, the nAChRs 
transfected and expressed in this work were derived from rat cDNAs and therefore will 
not always be comparable to the response from a primate nAChR, much less that of a 
human.  It is well known that some subtype expression and functional differences, exist 
among the experimental systems used.  For instance, in rat systems there has been little 
success in developing a functional β3 subunit combination while the subunit is known to 
play an important functional role in primate neuronal nAChR subtypes.  Additionally, the 
FLIPR studies carried out in this work uses cells, cloned and sub-cloned from lines 
known to express other receptors, such as 5-HT3, excitatory amino acid neurotransmitter 
receptors, imidazolidine receptors, and other GPCRs that could influence the functional 
response peak height and sensitivity to drug molecules, and influences from these 
systems can not be ruled out altogether.  In one since this was minimized with the use of 
a selective compound like Ebt versus the use of endogenous and/or less selective 
compounds such as Ach which may activate metabotropic cholinergic receptors, or NIC 
which has been shown to interact with other receptor systems.  Additional studies that 
ideally should have been carried out include nAChR selective activation with agonists 
like DMPP, inhibition of potential cholinergic GPCRs with atropine and other 
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 compounds, inhibition of possible imidazolidine receptor interactions, NMDA receptor 
interactions and other calcium cahnnel activation interactions, and other controls.  These 
studies, however, were limited in time to simply screening and characterization, while 
sacrificing any number of experiments that could have been carried out in order to satisfy 
the criticisms that appropriate controls were not carried out.  While these may be valid 
concerns and caveats to the method, and while these experimental results, again, should 
be reproduced and verified, the entire method (cDNAs, functional controls, expression 
controls, FLIPR method, and data analysis methods) has been published more than once, 
and the data examined here were clear, while the interpretations derived were neither 
unnecessarily complicated nor exotic enough to warrant serious condemnation of the 
work.  As with all experiments, those carried out here have limitations, special 
considerations and caveats that must be accepted.  In any experimental situation there are 
constraints (time, money, equipment, supplies) and limits to the extent of the work that 
can be carried out, and at some point the data must be allowed to stand on its own, 
caveats and all.   
With demonstrated agonist and antagonist responses in the nanomolar range 
selected compounds from both the AH and JC series of compounds (and guanidine and 
pyrimidino compounds in general) appear to hold some potential as versatile molecular 
modifiers of function at multiple nAChR subtypes, including the major α4β2 neuronal 
nAChR subtype.  Overall the methods and results detailed in this chapter were successful 
in satisfying the goal of specific aim #4.     
 
 
 
 
 
 
 
 
Copyright © Aaron Joseph Haubner 2008  
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 Chapter 7: Molecular Modeling of the High-Affinity  
nAChR Binding Pharmacophore 
 
7.1  Background 
  
 Molecular Modeling 
 Rational drug design and biological testing allows for the identification of the 
most promising compounds from a synthetic library.  The results from the testing phase 
of the drug discovery process contain a great deal more information than merely which 
compounds are active, potent, selective and efficacious.  There remains buried in the data 
a tremendous amount of information that can be applied to conduct structure-activity 
relationship (SAR) analysis.  This information can be imagined to reside in a hidden layer 
of the results and has less to do with major biological effects and more to do with specific 
and distinct molecular features and their direct or indirect influence on the activity of 
their parent compound.  By carefully extracting and analyzing this information, important 
molecular features critical for a drug activity (in this particular case, the ability to bind to 
a particular nicotinic receptor subtype) can be identified.   
Once identified, a compilation of these data can be used to identify structural 
trends among the molecules tested, and then applied in the form of a mathematical model 
that can be used to estimate the activity of additional novel compounds before they are 
made.  By developing a mathematical model of a structure-activity relationship the 
potential of new compounds can be evaluated without having to undertake the costly and 
time consuming process of synthesis.  In this way, once a working model is established, 
compounds can be screened for activity so that those without the critical molecular 
features presumably needed for activity can be disregarded while additional attention and 
effort can be applied to more promising compounds that are predicted to have greater 
activity.  A pleasant secondary result of ligand-based model building is the custom 
definition of structural elements that often times lead to key insights into the mechanism 
of interaction being examined, and for these and many other reasons molecular modeling 
has proven to be invaluable in a modern drug discovery effort (Dror 2004).   
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  While a great deal is known about the structure of the nicotinic receptor in 
general, and the nicotine binding site specifically (Brejc 2001, LeNovere 2002, Karlin 
2002, Schapira 2002), it is not such a simple task to identify which structural features 
contribute to make a compound bind with high affinity, or what molecular features confer 
functional activity on a particular structure.  Answers to these questions can be revealed, 
however, by breaking down the molecules being examined and analyzing their numerous 
describable molecular features.  This process is exceedingly complex, and today relies on 
the use of powerful computers to generate complex and seemingly cryptic mathematical 
descriptions of the structure.    
 A variety of mathematical regression models have been developed to describe the 
relationship between the structural and physiochemical properties of compounds and their 
influence on a biological activity.  Computer-assisted molecular modeling techniques 
have been useful in revealing structural information of active compounds in a variety of 
applications (Hattotuwagama 2006).  This biological activity often depends on more than 
a single chemical property, and often is best modeled by including dozens of factors 
within a single model.  The multi-dimensional nature of complex modeling methods can 
account for large data sets and multiple independent factors, rationalized over a broad 
parameter space.  To deal with these complexities advanced statistical methods and 
computational tools have been developed in the field of QSAR and CAMD (Olsson 
2006).  These modern methods provide for the reliable prediction of biological properties 
for compounds that have not yet been synthesized or evaluated, commonly by means of 
multivariate analysis and artificial neural network analysis (Bohm 1996, Matter 2001 
Mitchell 1990).   
In general terms, compounds with similar physiochemical properties 
(lipophilicity, electronegativity, volume, mass, electronic features, etc.) will behave in a 
similar manner.  It is a common observation for compounds that are similar in these and 
other features to generally give a similar result in a biological system.  The tools used to 
measure and simulate these molecular properties are provided for by computational 
chemistry.  The idea behind quantitative structure-activity relationship (QSAR) analysis 
is the simple fact that a compound’s combined physiochemical properties underlies all of 
its biological activity (Mekenyan 2002).  The numerous describable physical properties 
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 of a molecule combine to define its solubility, reactivity, stability, lipophilicity, and its 
interaction with other biomolecules in addition to other measurable features.  Through 
different interactions these same properties also dictate more specific characteristics like 
how well the same molecule fits into an active site or interacts with a receptor binding 
site.  Closely matched molecular interactions between drug and receptor define how 
effective the molecule is at, for example, inducing a conformational change in a receptor 
or enzyme, thus resulting in function.  These and other biological properties can be 
ascribed to the sum collection of chemical variations that the molecule presents.   
A number of possible approaches exist in the realm of molecular modeling, but in 
terms of ligand development two approaches are most common, receptor-based (or 
structure-based) and ligand-based (or pharmacophore model) approaches.  When the 
target structure is well-defined, receptor based methods using the pre-defined coordinates 
and molecular features of the active site or binding site are preferred.  Great strides have 
been made to develop structure-based models of the nAChR, especially in terms of ligand 
design (Klebe 2000, Bisson 2005).  While efforts continue to carefully map the binding 
site of the various nAChR subtypes in an attempt to conduct meaningful and productive 
receptor based and docking modeling, 3-D mapping is still hindered by the lack of a 
precise definition of the subunit composition of many of the most influential nAChR 
subtypes, and as a consequence, a lack of structural details of the binding sites on the 
various native nAChR subtypes.  Ligand-based and pharmacophore building modeling 
efforts, on the other hand have already proven successful in identifying novel agonists 
and antagonists for the nAChR (Schmitt 2000, Nicolotti 2002, Dror 2004).   
Structure-based molecular design methods have proven successful, but when the 
biological target is unknown or poorly defined the strategy shifts from structure-based 
design to ligand-based pharmacophore development.  The ligand-based model (or 
pharmacophore model) goes about developing a model of ligand-receptor interaction 
around a set of test compounds that are known to bind or otherwise interact with the 
receptor.  By using SAR information derived from a set of compounds with activity, a 
framework model of the binding site interaction can be developed around a mathematical 
composite, or overlay, of the key features of the numerous compounds, while paying 
particular attention to those molecular features most tightly correlated with activity.  In 
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 this case, the pharmacophore is a three-dimensional representation of the most influential 
structures and functionalities contained within the composite test compound group.  All 
supposed interactions are accounted for and all critical features of the active molecules 
are precisely defined.  This mathematical model, once defined, can be used to search 
among new compounds recorded in databases in order to identify favorable interaction 
potentials and thus result in lead candidate compound identification.  A valid and 
successful pharmacophore-based model requires a common method whereby 
experimental data are derived, a common or related molecular structure(s) is examined, 
and an understanding that the experimentally defined differences among the compounds 
are related to the physiochemical properties being examined.  Because of these reasons 
compounds of a related series (congeners) are usually the target for ligand-based 
pharmacophore models.   
 Although the systematic variation of substituents in a template molecule is now 
routinely carried out (Glennon 2000, Ferretti 2000), the selection of appropriate structural 
variability is not a simple task.  Selection of a representative subset of substituents that 
adequately covers the multidimensional parameter space is a challenge, and often is 
carried out by identifying relevant molecular descriptors and selecting the most 
significant using statistical techniques in order to assemble a model through rational input 
selection.       
 
Model Development  
In the early seventies Beers and Reich, using Dreiding and CPK space-filling 
models to identify common structural features necessary for nicotinic-cholinergic 
activity, made the first systemic effort to identify key common structural features within a 
small set of conformationally-restricted nAChR agonists and antagonists of the nAChR 
(Beers and Reich 1970, reviewed in Nicolotti 2004).  This pharmacophore model 
identified three requirements 1) an onium moiety, 2) a hydrogen bond acceptor, and 3) a 
distance of ~5.9 angstroms separating these features.  In a series of well published works, 
Sheridan et al, refined this model using a distance geometry approach and included an 
additional factor, the existence of either a ring centroid or electronegative group as seen 
in cytisine (Sheridan 1986).  While quite simple in its primary form, the basic 
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 assumptions of this model have proven to be sound, and after years of testing the vast 
majority of nAChR ligands fit this model surprisingly well, even among totally custom 
synthetic libraries of compounds (see Tonder and Olesen 2001).   
Through the following years, models of the nAChR pharmacophore have evolved 
out of simple linear, 2-D and distance geometry approaches, to more complex analysis of 
surface molecule properties, 3-D molecular approaches (COMFA), and then advanced 
PLS, MLR, and ANN models (among others) used to handle and make sense of the 
thousands of molecular descriptors available to modelers today (Nicolotti 2004). 
Qantitative structure-activity relationships (QSAR) analysis describes the area of 
drug discovery that attempts to define, understand, and correlate physiochemical 
properties with a biological activity.  Hansch et al, (Hansch and Fujita 1964) were 
pioneers in this area.  QSAR began with analysis of structurally similar compound sets by 
mathematically describing a relationship between activity and molecular properties such 
as electronegativity and lipophilicity using Hammett parameters and partition coefficients 
as correlated molecular descriptors.  The key to modern computer-driven QSAR analysis, 
however, is the translation of molecular features into simple arithmetic terms that can 
easily be weighted, scored, normalized, or otherwise processed, and then applied to a 
mathematical model.  These are referred to molecular descriptors, or simply as 
descriptors.   
The type of descriptors and the influence these descriptors have on the 
experimentally measured values is crucial for the development of a good QSAR model.  
There are numerous commercially-available software packages available for generating 
upwards of 3000 descriptors for a molecule set (Putta 2007, Consonni 2002).  These can 
generally be characterized as belonging to one of several classes of descriptors such as 
physical properties, geometric features, topological features, distance measurements, 3-D 
regional and global features, functional group features, energetic and orbital features, and 
a variety of custom-defined features just to name several.  Of course with so many 
descriptors, many do not apply well to all molecule sets and many will correlate strongly 
with others.  In order to exclude non-applicable or repetitive descriptors, statistical 
analysis must be carefully carried out and multiple descriptors that measure essentially 
the same attribute must be reduced to a single meaningful data set, otherwise features 
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 described by these related descriptors would compile to bestow an artificially inflated 
mathematical weight in the final regression model.    
For many modeling methods data from the descriptor values must be scaled and 
centered so as not to make any single factor artificially influential.  In an equation using 
un-scaled values, descriptors with small absolute values would be less influential and 
those with larger absolute values will become excessively important.  For this process the 
software usually can account for these differences and normalize the input values by 
means of an autoscaling function where each factor is normalized and mean centered 
variance scaled prior to model calculations. 
The primary goal of preparing QSAR models of the sort utilized here is for use in 
predicting biological activities of new molecules.  In this case the various computer 
models (MLR, PLS, and ANN) were each developed using data from a small library of 
44 AH compounds.  These compounds were previously evaluated for activity in the high-
affinity (α4β2*) S-(-)-[3H]NIC binding assay and the measured affinity (Ki) values were 
used as the measure of biological activity.  Although other nAChR subtypes may present 
potentially more interesting targets, the high-affinity nAChR subtype probed by S-(-)-
[3H]NIC binding was the only subtype examined where a sufficiently large number of 
compounds gave a measurable result, and thus provided a sufficiently large set of 
quantitative and qualitative data on which to develop a ligand-based pharmacophore 
model.   
 Following the development and validation of the various models a small set of 52 
novel theoretical compounds were designed in-silico to be evaluated for high-affinity 
binding activity using the model outputs from the various models executed.  Appropriate 
descriptor values for these imaginary novel compounds were assigned and each was 
evaluated for binding affinity in hopes of identifying new promising compounds as a 
conclusion to this modest drug discovery project.  Although a number of promising 
compounds have been identified through the work described in this thesis so far, there is 
certainly a great deal of room for refinement.  While the high-affinity compounds 
evaluated in this study certainly represent promising starting points, additional drug 
design work will almost certainly lead to improvements in many important 
 262
 pharmacological characteristics like potency, efficacy and selectivity.  This modeling 
work is the natural extension and result of this primary goal. 
 
 
Computer-Assisted Drug Design Scheme  
 
Synthetic Literature Known
Library Data Ligands
Pharmacophore Models
(PLS, MLR, ANN, etc)
In-Silico Novel Compound Screening
De-Novo Design
Structural Optimization and Synthesis
Experimental Testing
 
 
Figure 7-1.  Flow chart of the molecular modeling-assisted drug design and discovery process.  Novel and 
improved lead compounds are generated by model predictions and screening leading to improved activity 
for compounds that are synthesized following rational drug design based on output from pharmacophore 
models. 
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  MLR Model  
 A Multiple Linear Regression, (MLR) is a natural extension of a single factor 
regression analysis extended to multiple dimensions (Duleba 1996).  In its simplest form 
a QSAR model will describe the relationship between molecular descriptors and a 
measured biological response for the compounds being examined.  If a close relationship 
(correlation) exists between the two then the data will fit a regression or best-fit line.  
From that close relationship a predictive mathematical model emerges where new 
compounds can be evaluated for their theoretical biological activity simply by 
determining its descriptor value(s) and calculating its theoretical activity using the 
mathematical formula describing the relationship.   
 A description of the MLR model, or ordinary least squares model, was described 
in 1978 and it was quickly recognized as a powerful tool in QSAR analysis and it remains 
a widely used modeling platform. In fact, until very recently MLR analysis has been the 
obvious choice to establish a relationship between X and Y, where X is of full rank and 
where Y values are measured with little error.  In MLR modeling the descriptor inputs are 
assessed to be independent terms and the residuals are assumed to be randomly 
distributed.  The algebraic equation describing the basic model: 
 
y=Ao + A1X1 + A2X2, + A3X3 …+ e 
 
where A’s are unknown constants, X’s represent regression coefficients, and e represents 
error, and where the goal of the analysis is to define these constants for particular sets of 
variables (descriptors).  While for many applications MLR methods have been replaced 
with the more powerful PLS model, MLR models can provide adequate predictive power 
when the factors are few in number, are not significantly collinear, and have a well 
understood relationship to the responses. 
 
 PLS Model  
 Partial least squares (PLS) analysis was first introduced in the 70’s by Wald et al 
and represents a true multivariate regression method.  The difference between MLR and 
PLS is the PLS models can detect latent relationships between X and Y values not 
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 explicit in individual descriptor data values.  It also serves as a more appropriate model 
for highly correlated variables and for systems with a larger number of variables to begin 
with.  This method has been found to improve predictability over MLR in most 
applications, while revealing little in regards to the underlying relationship between 
variables (vcclab 2006, Geladi 1986).  
 PLS is based on the transition from using a large data set of original variables to a 
smaller data set of more meaningful latent (orthogonal) values that more precisely define 
the relationship and often result in optimized predictability over other, more direct 
multiple linear regression models.  These latent variables are entirely new inputs that are 
independent linear combinations derived from original descriptors.  Since this method 
relies on complex mathematical treatment of the descriptor values they must be more 
carefully screened such that descriptors with a large range and high variability for the 
molecule set being examined are excluded, while more information rich descriptors are 
applied.  Subsequently the PLS method tends to rely on only a few powerful relationships 
for predictability, thus the inclusion of too many descriptors in the PLS model will result 
in a more MLR-like model (vcclab 2006).  While PLS does work well with numerous 
factors, it relies on latent vectors to relate observation to predicted outcomes, thus too 
many factors will cause the model to fit the test sample data too well while losing real 
predictability.  This is referred to as over-fitting the model, and occurs when more 
powerful latent variables get diluted by less powerful relationship vectors.  The main idea 
behind building a PLS model is to distill the model down to only those factors that 
account for most of the variability in the model.  In PLS the X and Y scores are chosen so 
that the relationship is as strong as possible through each round of model building.  
       
 ANN Model  
 The artificial neural network model (ANN) analysis method is radically different 
from the traditional algorithm-based computer methods.  Instead of relying on a set of 
commands to solve a problem ANN methods applies a large number of highly 
interconnected processing nodes (neurones) working in parallel to solve a problem.  
Functioning much like a human brain, neural networks cannot be programmed to perform 
a specific task rather they process data and learn by example (Stergiou 2004).  The 
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 advantage of an ANN model is that every computational process does not need to be 
known in advance and programmed first.  ANN models generally operate by pattern 
recognition and are usually implemented via a feed-forward network that has been trained 
appropriately.  Training occurs when the network is taught to associate outputs with input 
patterns.  Once the training is established and the model fixed, a pattern that has no 
output associated with it can be used as an input and the model will give an output that 
most closely corresponds to a taught input pattern.  In this way ANNs are powerful 
predictive tools and as such have enjoyed success when used in ligand and drug design 
applications (Winkler 2004, Aoyama 1990, Kovesdi 1999)       
 Like the MLR and PLS models introduced above, ANN models rely on a similar 
set of molecular descriptors derived from the physiochemical properties of the 
compounds being examined.  The major differences begin during data processing.  The 
ANN model uses feed-forward and back propagation programming to allow bi-
directional inter-neurone processing.  These feedback loops are dynamic and their state 
changes dramatically until an equilibrium state is achieved.  Data is input into the input 
layer which is connected to a “hidden” layer.  Here additional pattern recognition 
processing takes place which probes beyond what can be correlated using traditional 
multivariate analytical methods.  This hidden layer is then connected to an output layer.  
The output depends on the activity of the hidden layer and the weights between the 
hidden and output layer. 
 The main idea behind the ANN approach is to extract hidden relationships 
between data input and output that would not otherwise be possible with multivariate-
regression analysis.  This unique approach makes ANN a powerful tool in the application 
of computational QSAR methods for drug discovery. 
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 7.2  Methods 
 
Molecular Library Construction 
A total of 44 compounds were included in the training sets for each of the three 
pharmacophore models developed.  A total of 43 of these were AH compounds that were 
synthesized as described (chapter 3), and a single compound (DN-IMI) was added since it 
was the parent molecule that these AH-compounds analogs were designed after.  DN-IMI 
also served as an additional, well characterized, “model” high-affinity guanidino-
containing compound.  Only 44 total compounds were included because no additional 
AH compounds were found to demonstrate measurable binding activity at the high-
affinity nAChR subtype, as measured by (S)-(-)-[3H]NIC binding displacement.   
All compounds were constructed and modeled using Sybyl discovery software 
7.0, using a Silicone Graphics (SGI) Octane workstation.  Once the molecules were 
constructed the Sybyl software was used to carry out energy minimizations (geometrical 
optimizations) for each molecule.  The optimization (energy minimization) was first 
performed by using the molecular mechanics (MM) method with the Tripos force field 
and the default convergence criterion.  Several structural conformations, each associated 
with local minima on the corresponding potential energy surface, were evaluated using 
the RANDOMSEARCH function in the Sybyl program.  Each compound was examined 
with a net charge of +1 associated with the guanidine function.  All of the conformations 
obtained from the molecular mechanics method and minimized locally were examined 
further by conducting semi-emperical molecular orbital (MOPAC) energy calculations at 
the PM3 level.  The molecular confirmation with the lowest energy found from the PM3 
analysis was considered the most stable confirmation, and this conformation was used for 
each molecule to compute molecular descriptors.    
 
Molecular Descriptors 
For each of the AH-series of compounds examined, a set 313 molecular 
descriptors (variables) was generated by using the DRAGON 3.0 (2003) program.  
DRAGON software is a commercially available software package which is an application 
for the calculation of molecular descriptors (Milano Chemometrics).  These variables 
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 consisted of zero-dimensional (simplest atom type) descriptors, one-dimensional 
descriptors (empirical and physical descriptors as well as functional group indications), 
fragment counts, two-dimensional (topological and geometrical) descriptors, and three-
dimensional (WHIM) descriptors. Descriptors were generated and saved as MOL2 files.  
A small series of custom-defined descriptors were generated using the molecular builder 
application of the Sybyl discovery software.  After molecule library construction several 
descriptors were manually defined and measured/calculated: 1)  HoF: heat of formation 
for the molecule, 2) IP: ionization potential, 3) HOMO: absolute Eigenvalue of the 
highest occupied molecular orbital, 4) LUMO: absolute Eigenvalue of the lowest 
occupied molecular orbital, 5) TOR: torsion angle of the pyridine-guanidine N-to-N 
bonds, 6) N-N: molecular intra-nitrogen distance, 7) C-N: intramolecular distance 
between the guanidine nitrogen and the centroid point of the pyridine ring.  These later 
descriptors were custom built to account for some very specific molecular properties and 
features that are understood to be important in nicotinic-specific SAR.   
The descriptors for every compound were then transferred to a Microsoft Excel 
database along with the corresponding Ki values of each molecule.   A value for the 
correlation of each descriptor to the Ki value of each compound was generated using the 
CORREL function, and the descriptors with the best correlation were selected to be 
further examined, while those with constant, near-constant and extremely low correlation 
values were discarded.  For example, for the 44 compounds examined, gunidino 
compounds examined, only the 110 descriptors with a CORREL function absolute value 
of greater than 0.2 were examined.   
 
PLS Model 
The PLS model was the first QSAR (pharmacophore) model developed for 
binding activity of the selected AH compounds at the high-affinity nAChR and was 
constructed in the general manner described previously (Zheng 2007).  Following 
generation and pruning of the descriptor library to only those descriptors that correlate 
sufficiently with affinity and are not highly correlated with other descriptors (redundant), 
the model was developed.  Partial least squares analysis was carried out using the QSAR 
modeling module of the SYBYL 7.0 program, and the NIPALS algorithm was used to 
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 extract the original variables into PLS components.  All variables were initially auto-
scaled to zero mean and unit variance.  The process of developing the model is a 
wearisome and painstaking affair that requires initial selection of top candidate 
descriptors with high correlation values to be added first.  Additional descriptors were 
added stepwise, and statistical measures of the model (R2, C.V., Rcv2, and S.E) were 
calculated.  For each new descriptor combination as many as 100 additional descriptors 
were evaluated in order to compare which of the descriptors would be included next.  
Descriptors that added the most value to the model at each step, by improving the R2 and 
Rcv2 values and lowering the S.E. value of the model were retained, while those that 
failed to improve these measures were not incorporated.  The process of adding 
descriptors continued until additional descriptors failed to improve the predictive ability 
of the model.  At this point additional descriptors would only add variability and error to 
the model without contributing significantly to the predictive power of the model.  This 
method is good for developing a model when using strongly correlated and/or noisy data 
as the independent variables.  The final output was compared to the experimentally 
determined Ki value which was generated in the leave-one-out cross-validation employed 
in the modeling, and the validity of each model was evaluated based on the discrepancy 
of the set of output values and the set of experimental values. The model assessment was 
based on Pearson correlation coefficient (R) measurements, the root mean square 
deviation (RMSD) measurement, and the predictive coefficient (r
cv
) value. 
  
MLR Model 
The MLR model was the second QSAR (pharmacophore) model developed for 
binding activity of the selected AH compounds at the high-affinity nAChR, and again, 
general procedures followed those described previously (Zheng 2006).  Again, following 
generation and pruning of the descriptor library to only those descriptors that correlate 
sufficiently with affinity and are not highly correlated with other descriptors (redundant), 
the model was developed.  The MLR model was constructed in much the same manner as 
the PLS model.  The most highly correlated variables were used to begin with and 
additional descriptors were added stepwise.  Hundreds of iterations and optimizations 
were carried out to improve the models predictive ability and additional models were 
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 generated until an optimized correlation coefficient value was achieved.  The final output 
was compared to the experimentally determined Ki value which was generated in the 
leave-one-out cross validation employed in the modeling, and the validity of each model 
was evaluated based on the discrepancy of the set of output values and the set of 
experimental values. The model assessment was based on Pearson correlation coefficient 
(R) measurements, the root mean square deviation (RMSD) measurement, and the 
predictive coefficient (Rcv) value. 
   
ANN Model 
 Using the descriptors derived from the best MLS model, an artificial neural 
network model was developed.  Using the general methods described previously (Zheng 
2006), a feed-forward, back-propagation of error neural network model was constructed 
using a neural network C program.  The sigmoidal function was chosen as the transfer 
function that generates the output of a neuron from the weighted sum of inputs from the 
preceding layer.  The input vector was the variables determined from the MLS model and 
all descriptors were normalized to the [0,1] interval.  The final output from the output 
layer was compared to the experimentally determined Ki value which was generated in 
the leave-one-out cross validation employed in the modeling, and the validity of each 
model was evaluated based on the discrepancy of the set of output values and the set of 
experimental values.  Calculations were made using a Linux VM-ware workstation, 
Redhat OS.   
In order to determine the optimal configurations for the ANN model, parameters 
were modified while training and cross-validating the network in an effort to obtain the 
best predictive final model.  Through repeated iterations and testing of various 
parameters an optimal learning rate, momentum rate, and max iterations for the model 
were pinned down.  Again, through tedious repetition, the ANN model was tested 
following changes to each of these three parameters until an optimum learning model was 
established.   The parameters that were modified were the number of nodes in the hidden 
layer (from 1 to 4), and the number of total training cycles (varying from 10,000 to 
100,000).  Each model was trained The model assessment was based on Pearson 
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 correlation coefficient (R) measurements, the root mean square deviation (RMSD) 
measurement, and the predictive coefficient (r
cv
) value. 
 
 
7.3  Results  
 
PLS Model 
The PLS pharmacophore model was developed in order to provide a tool to guide 
future synthesis of guanidino-containing compounds.  The model will provide a means 
where future molecular designs can be evaluated for high-affinity nAChR binding prior 
to synthesis and purification.  The model was developed based around the activity of 44 
AH/guanidine-containing nicotine analogs and focused mainly on pyridine ring-
containing, N-substituted guanidine compounds.  The compounds used presented a 
focused group of structurally-related compounds that possessed a wide range of binding 
activity from low nanomolar to high micromolar values.  This range of activity is 
important in order for the model to select and define with clarity absolute differences 
between high-affinity and low-affinity structures in defining the series’ SAR.   
Descriptors were added to the model one at a time and the cross-validated rcv2 
value was used to assess the output from the model for each step.  The rcv2 was defined: 
 
rcv2 = (SD-PRESS) / (SD) 
 
where SD is the sum of the squared deviations of each measured Ki value from its mean 
and PRESS is the predictive sum of squared differences between the actual and predicted 
values.  The first descriptor added to the model was the Mor04v descriptor.  This 
descriptor generally describes the atomic volume features of the training set molecules 
and of all the descriptors was the most highly correlated with the measured Ki at the high-
affinity nAChR subtype.  Mor04v alone provided an rcv2 value of 0.233 for the model.  
MoR12m was determined to provide the best improvement with a 2-model rcv2 value of 
0.446.  Adding Rtv+ improves the model’s rcv2 value to 0.536.  A value >0.5 is generally 
considered to provide a reliable model for high predictive ability (Schneider 2004) and it 
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 was good to see that this threshold was met after only three descriptors were added.  The 
ionization potential, or IP, is a Sybyl-determined descriptor and was added fourth to 
improve the rcv2 of the model to 0.592.  Addition of the fifth descriptor, MoR13m, 
provided only a slight improvement resulting in rcv2 value of 0.611.  At this point in the 
model construction it did not look like any amount of additional descriptors was going to 
result in a predictive model with an rcv2 value greater than or equal to 0.7, which is 
generally considered the threshold for a model with powerful and reliable predictive 
ability, but construction continued all the same.  Adding the R2p variable improved the 
measure to 0.658, R3u to 0.662, and the fragment measures C-008 and C-028 improved 
the correlation value to 0.668 and 0.678 respectively.  Addition of the custom-defined C-
N descriptor measuring the all-to-critical distance between the centroid of the ring system  
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Figure 7-2.  PLS training set descriptors (1-11) and the optimized improvements in rcv2 value each 
contributed to the final model. The final rcv2 value for the 11 descriptor model was 0.696. 
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 to the positive-charge carrying nitrogen atom improved the value to 0.691, and finally 
MoR09m improved the rcv2 value to 0.696.  It was found that inclusion of additional 
descriptors failed to improve the power of the model, while adding error and variability.  
In fact after only two additional descriptors the predictive power of the model began to 
decline.         
After this best-component, 11-variable PLS model with 3 latent variables was 
constructed using these descriptors, statistical analysis of the model correlation was 
carried out.  The model in its final version gave an R2 value of 0.799, a CV value of 
0.222, a SE value of 1.025, and a highly-significant F statistic of 14.28.  These data 
reveal that the model is highly correlated to the descriptor combination used, is non-zero 
in its correlation slope, and should provide a powerful predictability for high-affinity 
binding based on the 11 descriptors used to generate the training set.   
 
1. MoR04v  - 3D-MoRSE signal 4, weighted by atomic van der Waals volumes. 
2. MoR12m - 3D-MoRSE signal 12, weighted by atomic masses. 
3. Rtv+        - Rmax index.  Weighted by atomic van der Waals volumes. 
4. IP             - Ionization potential of the molecule. 
5. MoR13m  - 3D-MoRSE signal 13, weighted by atomic masses. 
6. R2p          - Autocorrel of lag2, weighted by atomic polarizability, Getaway. 
7. R3u          - Autocorrel of lag3, unweighted, Getaway. 
8. C-008       - CHR-2X.  Atom-centered fragments. 
9. C-028       - R…CR…X.  Atom-centered fragments. 
10. C-N          - Distance between guanidine-N and pyridine ring centroid.  
11. MoR09m - 3D-MoRSE signal 9, weighted by atomic masses. 
 
The equation describing the final PLS model includes that 11 descriptors in a single, 
multi-linear variable equation, and is: 
 
Log Ki = (-3.343) + (0.225)x(Mor09m) + (0.288)x(MoR12m) + (2.422)x(MoR04v) +  
(1.635)x(MoR15v) – (0.708)x(R3u) – (18.496)x(RTV+) – (1.176)x(R2P) –  
(0.461)x(C-008) + (0.569)x(C-028) + (0.134)x(IP) – (0.08)x(C-N) 
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 The weight for each descriptor was calculated using the determination of the predicted Ki 
value. Weights were determined based on standard deviation of the descriptors as a 
group, and then multiplying by the factor from the model-generated regression equation. 
Each one of these products was then divided by the sum of the eleven product values and 
multiplied by 100 to generate a percentage weight for each.  The descriptors that make up 
the equation for the PLS model and the input values of each descriptor for the compounds 
that comprise the training set are listed in figure 7-3.    
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 PLS Training Set Compounds and Descriptor Values 
 
 
Desc:  Mor 
4v 
Mor 
12m RTv+ IP 
Mor 
15v R2p R3u 
C-
008 
C-
028 CN 
Mor 
09m 
AH-1 -0.29 0.52 0.10 13.2 0.40 0.49 1.28 0 0 5.08 -0.64
AH-2 -0.10 0.64 0.07 13.2 0.33 0.61 1.24 0 0 4.95 -1.08
AH-3 -0.16 0.59 0.07 13.3 0.34 0.61 1.20 0 0 5.09 -0.98
AH-4 -0.58 0.45 0.07 13.1 0.36 0.68 1.40 0 0 4.93 -0.82
AH-5 0.26 0.38 0.06 12.5 0.35 0.68 1.39 0 0 ------ -1.31
AH-6 0.01 0.56 0.05 12.9 0.37 0.63 1.27 0 0 4.87 -1.00
AH-7 -0.18 0.66 0.06 13.0 0.33 0.64 1.22 0 1 4.93 -1.09
AH-13 -0.22 0.69 0.05 12.1 0.45 0.64 1.51 0 0 5.28 -0.91
AH-14 -0.06 -0.06 0.05 12.7 0.31 0.70 1.53 2 1 5.09 -0.50
AH-15 -0.63 -0.41 0.09 12.3 0.44 0.84 1.78 2 0 5.50 -0.32
AH-16 0.02 0.55 0.05 12.6 0.35 0.63 1.27 0 0 4.88 -1.01
AH-30 -0.27 0.39 0.07 12.8 0.43 0.67 1.67 0 1 5.73 -0.78
AH-34 0.13 0.06 0.07 13.2 0.39 0.73 1.71 0 0 3.86 -1.08
AH-37 -0.29 -0.03 0.11 12.5 0.31 0.73 1.54 0 0 5.22 -0.55
AH-38 -0.39 0.02 0.05 12.7 0.26 0.67 2.10 0 0 ------ -0.40
AH-39 0.02 0.16 0.09 12.4 0.33 0.80 1.71 0 0 5.40 -0.57
AH-42 -0.13 -0.27 0.08 12.3 0.28 0.80 1.74 0 0 5.37 -0.70
AH-44 -0.32 -0.08 0.10 12.3 0.30 0.88 2.03 0 0 5.39 -0.46
AH-47 -0.27 0.43 0.10 12.2 0.65 0.86 1.68 0 0 5.02 -0.69
AH-50 0.21 0.11 0.08 12.4 0.27 0.83 1.85 0 0 5.35 -0.58
AH-55 0.00 -0.17 0.07 12.4 0.29 0.83 1.87 0 0 5.39 -0.49
AH-61 0.75 -0.38 0.07 12.4 0.08 0.92 2.07 0 0 5.44 -0.85
AH-79 0.49 -0.23 0.07 12.4 0.20 0.84 1.91 0 0 5.39 -0.65
AH-80 -0.42 0.01 0.10 12.4 0.50 0.86 1.88 0 0 5.34 -0.77
AH-106 -0.39 0.63 0.06 11.7 0.31 0.54 1.32 0 0 ------ -0.60
AH-107 -0.34 0.49 0.07 13.6 0.50 0.58 1.42 0 0 5.02 -0.68
AH-108 -0.31 0.49 0.07 13.6 0.49 0.57 1.39 0 0 5.10 -0.68
AH-110 -0.47 1.42 0.07 11.9 1.43 0.84 1.54 0 0 ------ -1.39
AH-114 -0.28 0.38 0.06 13.1 0.61 0.63 1.84 0 0 5.08 -0.80
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AH-115 -0.17 0.27 0.07 13.2 0.56 0.76 1.96 0 1 5.29 -0.95
AH-133 -0.49 0.34 0.08 13.3 0.46 0.79 1.91 0 0 5.23 -1.00
AH-131 0.08 0.21 0.07 12.9 0.59 0.71 1.82 0 0 6.04 -0.94
AH-132 -0.22 0.34 0.07 13.2 0.51 0.60 1.52 0 1 3.96 -0.69
AH-149 -0.38 0.40 0.06 16.3 0.52 0.79 2.00 0 0 ------ -1.04
AH-150 -0.24 0.51 0.06 12.2 0.65 0.77 1.80 0 0 5.36 -1.09
AH-151 -0.09 0.06 0.07 12.8 0.47 0.67 1.80 0 0 5.08 -0.84
AH-155 -0.42 0.44 0.08 13.4 0.27 0.66 1.59 0 0 5.26 -0.75
AH-156 0.02 0.64 0.10 12.9 0.75 0.73 1.80 0 0 3.85 -0.40
AH-157 0.17 0.56 0.10 12.9 0.92 0.79 1.74 0 0 ------ -0.46
AH-158 -0.38 0.37 0.07 12.9 0.36 0.66 1.55 0 0 6.04 -0.67
AH-153 -0.66 0.72 0.08 13.4 0.43 0.79 1.70 0 0 3.88 -1.10
AH-154 -0.16 -0.03 0.07 13.2 0.24 0.77 1.80 0 0 5.37 -0.93
AH-159 0.40 0.28 0.07 13.1 0.45 0.72 1.68 0 0 5.37 -1.23
DN-IMI -0.26 -0.22 0.04 16.6 0.18 0.69 2.20 1 0 ------ -0.13
Figure 63.  Table of compounds used in the PLS training set and the names and values of the descriptors 
for each compound used in the model training set. 
 
 The final PLS model was cross-validated using the ‘leave-one-out’ (LOO) 
method.  In this approach the model is internally validated by comparing how well the 
model predicts the observed Ki value of each of the training set compounds after 
generating a sample model where each of the predicted compounds are left out of the 
model equation.  This method amounts to validating the model by using the 44 compound 
training set as a de facto external validation set by simply leaving each one out and 
repeating that 43 times.  The correlation between the observed and the LOO prediction 
was plotted and statistical analysis was performed on the correlation between the two 
measures.  The results from the LOO validation are presented in Figure 7-4 below.  In 
general the correlation between the predicted and the observed was modest with an R2  
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Figure 7-4.  Results from the PLS LOO validation.  Predicted vs. observed Ki values for the compounds in 
the PLS model 
 
value around 0.7.  The correlation was found to be significant with a p<0.05 and a highly 
non-linear slope.   
 The final validation was carried out where each of the compounds from the 
training set were re-evaluated using the completed model to calculate a Ki value for each.  
This “training set” validation is the final validation for this model and serves as substitute 
for validation on an external set of compounds.  These predicted Ki values were 
compared to experimental results and plotted on a graph for comparison.  The results 
from this validation can be seen in figure 7-5.  In general the correlation between the 
predicted and the observed was high with an R2 value around 0.73.  The correlation was 
found to be significant with a p<0.05 and a highly non-linear slope.  This appears to be an 
improvement over the LOO validation, and while the best-fit correlation appears to 
provide a better fit to the group it also appears that the slope of the final training set 
validation deviates from the 1:1 ideal a little more than the LOO validation result.   
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Figure 7-5.  Results from the PLS training set validation.  Observed vs. predicted Ki values for the training 
set compounds generated by applying the final PLS model. 
 
This is mitigated by the fact that the divergence seems to be more pronounced only on the 
lower affinity portion of the scale while the high-affinity compounds (Ki< 1.0 
micromolar) appear to fit the ideal correlation relationship nicely.   
  
MLR Model 
 The MLR model was developed in a similar manner to PLS model system.  The 
same set of structurally-related guanidine-containing analogs, (AH-series of compounds) 
were used, and although most of the descriptors were different for the MLR model the 
descriptors were drawn from the same pool.  The same types of statistical measures were 
carried out and similar LOO and training set validation was performed.   
As described above, descriptors were added to the model one at a time and the 
cross-validated rcv2 value was used to assess the output from the model for each step.  As 
with the PLS model the MLR model was constructed by tedious stepwise addition and 
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 subtraction/substitution of descriptors in order to improve the model by selecting the 
most influential and highly correlated descriptors, while disregarding those that did not 
contribute in a significant way to improve the model.   Initially, it was found that twelve 
descriptors could be added that contributed to the model.  These descriptors and their 
relative contribution to the final rcv2 value of the model are shown in figure 7-6 below.  
The final descriptors that were added included descriptors MoR4u, MoR15v, RTV+, 
MoR29v, MoR27u, HATS1v, DISPe, IC2, R4u, C-N, IP, in the order shown in the graph.  
Following selection of the descriptors that would be included in the initial model an 
optimization was carried out to determine the optimal order these descriptors would be 
added in.  Unlike the PLS model, which can accept descriptors in a more-or-less random  
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Figure 7-6.  MLR training set descriptors (1-12) and the rcv2 value each contributed to the initial model. 
The final rcv2 value for the 12 descriptor model was ~0.71. 
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 order and find more complex relationships through the latent vectors generated by the 
model, the MLR model is a much more linear component-driven model and therefore it 
helps to have optimization of the variables so the most influential and highly-correlated 
variables are added in order with the most highly correlated added first.  This leads to the 
optimization and ranking of the descriptors for the MLR model.  In the same manner that 
the descriptor combinations were pieced together earlier, the same descriptors were 
optimized in a “try every possible combination”, factorial-like method.  The optimized 
order resulted in the graphic representation seen in figure 7-7.  Although similar to the 
previous graph, the optimized graph is generally smoother, indicating a more ordered 
improvement in the model across the descriptor additions, and the rcv2 value for the  
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Figure 7-7.  MLR training set descriptors (1-12) and the optimized improvements in rcv2 value each 
contributed to the initial model. The final rcv2 value for the 12 descriptor model was ~0.72. 
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 optimized set of descriptors reached the critical 0.7 value threshold after only 7 
descriptors while the first attempt did not reach the 0.7 mark until the final, twelfth 
descriptor in the series.  This indicates that the proper weighting-order was achieved.  
Another purpose of this exercise is to rank the descriptors so that the variable set can be 
trimmed to accommodate the MLR process.  The MLR model is not as good at handling 
larger number of variables as the PLS model and it is thus beneficial to minimize the 
model inputs to as few as possible.  In this case descriptor limit was determined when the 
inclusion of additional descriptors led to a diminished return in terms of improving the 
model.  Also additional descriptors that provided modest yet non-significant 
contributions to the model were excluded based on the fact that although they may 
contribute fractionally to the power of the model the additional error associated with the 
extra factor makes the model less effective overall, despite the modestly improved rcv2 
value.  As a result the first 6 descriptors were chosen as the complete set of variables for 
the refined and optimized MLR model that was to be used in later predicting steps.  The 
final MLR model descriptors are listed below and the final 6 descriptor-rcv2 relationship 
can be seen in figure 7-8.   
 
1. MoR04v  - 3D-MoRSE signal 4, weighted by atomic van der Waals volumes. 
2. MoR15m - 3D-MoRSE signal 15, weighted by atomic van der Waals volumes. 
3. Rtv+        - Rmax index.  Weighted by atomic van der Waals volumes. 
4. MoR29v  - 3D-MoRSE signal 29, weighted by atomic van der Waals volumes. 
5. MoR27u  - 3D-MoRSE signal 27, unweighted. 
6. HATS1v  - Leverage-weighted autocorrelation of lag1. 
 
The first descriptor added to the model was the Mor04u descriptor.  This descriptor 
along with all of the MORSE-derived descriptors, generally describes the weighted or 
unweighted atomic masses or van der Waals volumes.  Of all the descriptors this one was 
the most highly correlated with the measured Ki at the high-affinity nAChR subtype.  
Mor04u alone provided an rcv2 value of 0.23 for the model.  MoR15v was determined to 
provide the best improvement with a 2-descriptor rcv2 value of 0.355.  Adding Rtv+ 
improves the model’s rcv2 value to 0.52.  Again, a value >0.5 is generally considered to 
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 provide a reliable model for high predictive ability (Schneider 2004) and it was good to 
see that this threshold was met after only three descriptors were added.  The MoR29v 
descriptor was added fourth to improve the rcv2 of the model to 0.61.  Fifth was MoR27u 
and finally Hats1v was added to finalize the set of variables that was used to compose 
this model.  At this point the model had a final rcv2 value of 0.69, and while falling a bit 
short of the 0.7 value that we would have liked to have seen the model development was 
halted here as this 6-variable model provided an optimum balance between high 
predictive activity and low error.   
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Figure 7-8.  Optimized MLR training set descriptors (1-6) and the optimized improvements in rcv2 value 
each contributed to the initial model. The final rcv2 value for the 6 descriptor model was ~0.69. 
The equation describing the final MLR model includes 6 descriptors in a single, multi-
linear variable equation, and is: 
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 Log Ki = (-4.239) + (1.922)x(Mor27u) + (2.382)x(MoR04u) + (2.121)x(MoR15v) +  
(4.431)x(MoR29v) + (23.31)x(Hats1v) – (46.29)x(RTV+) 
 
The weight for each descriptor was calculated using the determination of the predicted Ki 
value. Weights were determined based on standard deviation of the descriptors as a 
group, and then multiplying by the factor from the model-generated regression equation. 
Each one of these products was then divided by the sum of the eleven product values and 
multiplied by 100 to generate a percentage weight for each.  The descriptors that make up 
the equation for the MLR model and the input values of each descriptor for the 
compounds that comprise the training set are listed in figure 7-9. 
 
 
Descriptor:  Mor04v Mor15v RTv+ Mor29v Mor27u HATS1v 
AH-1 -0.289 0.399 0.104 0.095 -0.333 0.159
AH-2 -0.099 0.326 0.073 0.108 0.018 0.089
AH-3 -0.161 0.34 0.069 0.162 -0.2 0.089
AH-4 -0.58 0.362 0.074 -0.041 -0.136 0.086
AH-5 0.261 0.349 0.059 -0.102 -0.158 0.084
AH-6 0.006 0.367 0.047 0.021 -0.081 0.074
AH-7 -0.179 0.327 0.056 0.074 0.054 0.083
AH-13 -0.22 0.448 0.05 0.087 -0.392 0.082
AH-14 -0.064 0.308 0.05 -0.11 0.131 0.08
AH-15 -0.631 0.442 0.085 -0.164 0.067 0.094
AH-16 0.022 0.354 0.047 0.035 -0.041 0.074
AH-30 -0.272 0.43 0.07 0.029 -0.454 0.097
AH-34 0.127 0.391 0.067 -0.091 -0.233 0.1
AH-37 -0.29 0.31 0.111 0.086 -0.435 0.126
AH-38 -0.393 0.255 0.049 -0.156 -0.081 0.076
AH-39 0.017 0.333 0.091 0.041 -0.368 0.114
AH-42 -0.134 0.28 0.078 -0.013 -0.224 0.1
AH-44 -0.32 0.298 0.101 -0.022 -0.533 0.12
AH-47 -0.27 0.645 0.1 0.101 -0.55 0.14
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AH-50 0.213 0.267 0.082 -0.054 -0.284 0.104
AH-55 0.001 0.29 0.072 0.004 -0.322 0.096
AH-61 0.749 0.081 0.071 -0.146 -0.119 0.088
AH-79 0.493 0.196 0.069 -0.036 -0.324 0.09
AH-80 -0.419 0.499 0.102 -0.011 -0.098 0.127
AH-106 -0.394 0.309 0.062 0.037 -0.226 0.088
AH-107 -0.342 0.504 0.073 0.107 -0.213 0.112
AH-108 -0.308 0.492 0.072 0.118 -0.195 0.111
AH-110 -0.473 1.427 0.074 0.07 -0.5 0.098
AH-114 -0.282 0.608 0.06 0.00 -0.081 0.082
AH-115 -0.167 0.563 0.071 -0.014 -0.212 0.102
AH-133 -0.486 0.461 0.077 -0.069 -0.241 0.114
AH-131 0.081 0.59 0.069 -0.027 -0.129 0.103
AH-132 -0.224 0.51 0.072 0.146 -0.18 0.096
AH-149 -0.38 0.521 0.06 -0.152 0.005 0.092
AH-150 -0.242 0.653 0.055 -0.078 -0.113 0.088
AH-151 -0.09 0.467 0.072 -0.052 -0.138 0.091
AH-155 -0.416 0.272 0.076 0.132 -0.317 0.109
AH-156 0.02 0.75 0.095 0.068 -0.089 0.096
AH-157 0.174 0.919 0.096 -0.025 -0.144 0.109
AH-158 -0.377 0.359 0.072 0.112 -0.378 0.111
AH-153 -0.664 0.429 0.077 0.081 -0.298 0.13
AH-154 -0.16 0.241 0.072 0.017 -0.295 0.099
AH-159 0.396 0.446 0.069 -0.033 -0.056 0.095
DN-IMI -0.264 0.183 0.044 -0.247 0.382 0.069
 
 
 
 
 
 
 
 
 
 
 
Figure 7-9.  Table of compounds used in the MLR training set and the names and values of the descriptors 
for each compound used in the model training set. 
 
As seen with the PLS model, the descriptors used to generate the MLR model were 
heavily weighted toward MORSE-derived molecular mass and volume descriptors, with 
RTv+ also making a contribution in the output calculation.     
The final MLR model was cross-validated using the ‘leave-one-out’ (LOO) 
method.  The correlation between the observed and the LOO prediction was plotted and 
statistical analysis was performed on the correlation between the two measures.  The 
results from the LOO validation are presented in Figure 7-10 below.  In general the  
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Figure 7-10.  Results from the MLR LOO validation.  Predicted vs. observed Ki values for the training set 
compounds in the MLR model 
 
correlation between the predicted and the observed was quite similar to that seen with the 
PLS model, with an R2 value of 0.682.  The correlation was found to be significant with a 
p<0.05 with a highly non-linear slope.   
The final validation step was carried out where each of the compounds from the 
training set were re-evaluated using the completed model to calculate a Ki value for each.  
This “training set” validation is the final validation for this model and serves as substitute 
for validation on an external set of compounds.  These predicted Ki values were 
compared to experimental results and plotted on a graph for comparison.  The results 
from this validation can be seen in figure 7-11 below.  In general the correlation between 
the predicted and the observed was high with an R2 value of 0.73.  The correlation was 
found to be significant with a p<0.05 and a highly non-linear slope.  This appears to be an 
improvement over the MLR LOO validation results.  Additionally this validation for the 
MLR model appears to be an improvement over the same validation method in the PLS  
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Figure 7-11.  Results from the training set validation.  Observed vs. predicted Ki values for the training set 
compounds generated by applying the final MLR model. 
 
model.  In addition, the slope of the best-fit line not only fit the data better, but that 
correlation line lies much closer to the desired 1:1 slope that indicates a tight relationship 
between predicted and observed.   
 
PLS -. MLR Correlation 
 In order to gauge how the validation outputs from the two multivariate models 
looked at so far compared with each other, a quick analysis was performed.  The output 
from the two LOO and training set validation correlations were themselves correlated to 
see how well the predicted values from the validation analysis of the two compared.  
Predicted Ki values were plotted on a graph with the values from the PLS model output 
on the ordinate and those from the MLR model output from the abscissa, seen in figure 7-
12 below.   
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 PLS vs. MLR Validation Results Comparison 
-9 -8 -7 -6 -5 -4 -3
-9
-8
-7
-6
-5
-4
-3
R2=0.800
p<0.01
PLS pred [log Ki]
M
LR
 p
re
d 
[lo
g 
K
i]
 
-9 -8 -7 -6 -5 -4 -3
-9
-8
-7
-6
-5
-4
-3
R2=0.852
p<0.01
PLS pred [log Ki]
M
LR
 p
re
d 
[lo
g 
K
i]
 
 
Figure 7-12.  Results from two tests measuring the correlation between the predicted Ki values generated 
by the two model validation steps (LOO and training validation) are shown.  The top graph compares the 
LOO validation results and the bottom compares the training set validation results. 
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  The LOO validation results correlation was measured to have and R2 value of 
0.80, while the training set validation results yielded an R2 value of 0.85.  Obviously, the 
results from this comparison demonstrate a tight correlation between the results of the 
two models.  In fact the higher correlation of the two is between the training set data 
which is in fact most like the actual prediction results used later on to analyze compounds 
in-silico, so the output from the two models seem to be very similar indeed.   
In comparing the two models further it is clear that while both models have 
reached a final rcv2 value of right around 0.7, there are some real differences between the 
two that should be taken into consideration before proceeding further.  While the 
validation data set from the MLR model presented nearly identical results as the PLS 
model, the MLR validation data set aligned much closely with the 1:1 line (predicted 
versus observed) indicating a better match between prediction and observation.  
Additionally, the MLR model basically generated the same predictive measures using 
fewer variables.  This is an advantage when developing a model based on a small set of 
similar compounds since only the more powerful descriptors are used to generate 
predictions based on structure, and inherently the use of additional descriptors in a model 
system introduces additional error to the model.  For these reasons the descriptor set that 
was used to construct the MLR was also used to generate the artificial neural network 
model.        
 
 ANN Model 
Various configurations were used to train, cross-validate, and test the artificial 
neural network (ANN) model in order to select the model with the best predictive ability.  
Using the top descriptors from the optimized, six-variable MLR model as the input, 
multiple configurations were attempted.  It was determined that the optimal learning rate 
(LR) was 0.01, the optimal momentum rate (MR) was α=0.05, and the maximum 
iterations (training cycles) tested to provide the best output was 100,000.  The unknown 
parameters included the number of input neurons and the umber of hidden layers.  
Additionally, a number of models needed to be tested using a variety of training cycles in 
order to fully optimize the model configuration to maximize predictive ability.  At each 
step new model configurations were evaluated primarily on the basis of the LOO 
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 correlation and the root-mean-square deviation (RMDS) between the output values and 
the target values.  The number of descriptors used to train an ANN model should 
generally be held to the fewest possible, and while additional descriptors from the MLR 
model could have been added to make slight improvements in the output correlation R2 
value, the corresponding drop in standard error would ultimately lower the predictive 
ability of the model.  For this reason only the top six descriptors from the MLR 
optimization were used.  Using each combination of parameter variables, models were 
generated and evaluated based on root-mean square deviation (RMSD).   
 
OUTPUT   
Layer Nodes  RMSD 
1 0  0.592 
1 1  0.126 
1 2  0.129 
1 3  0.104 
2 0,1  0.590 
2 1,1  0.127 
2 1,2  0.127 
2 1,3  0.130 
2 2,1  0.128 
`2 2,1  0.130 
2 2,3  0.136 
 
Figure 7-13.  Results from testing ANN model parameters; hidden layers and nodes, and the error 
associated with each new combination was used to select top model candidates for further evaluation. 
 
Before optimizing any parameter further, the basic design of the model needed to 
be established.  To determine this, the various combinations of hidden layers and nodes 
associated with each hidden layer were tested and the error associated with each was 
measured.  Calculated values for the various models are shown in figure 7-13.  Three 
model configurations can be seen to have the lowest error associated with them.  Model 
NN-631 (RMSD=0.104), NN-6211 (RMSD=0.127), and NN-6221 (RMSD=0.127) had 
the lowest error of those tested and were thus selected as the three best model 
configurations to further evaluate.  Additional 3-hidden layer model configurations were 
also evaluated and resulted in higher error than any of those presented.  In the end it 
appeared that maximum statistical power had been reached with the three top model 
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 candidates and thus exhaustive testing of more exotic layer/node configurations was not 
continued. 
In the next phase of model development, leave-one-out (LOO) cross-validation 
analysis was carried out on each of the model candidates in addition to testing for the 
optimum training cycles needed for each model to develop.  In addition to measuring an 
RMSD value for each model candidate for each of the iterations examined, each model’s 
LOO output was compared against the observed value of binding and an R2 value was 
determined for each.  This final validation method would then be used to select the 
optimum model to be used in the prediction of new guanidine-containing analogs.  
Results from the analysis can be seen in figure 7-14 below. 
 
 6-descriptor ANN Model  
Configuration LR MR Cycles R R2 RMSD 
NN-631 0.01 0.05 1000 0.015 0.001 1.137
NN-631 0.01 0.05 10000 0.826 0.678 0.646
NN-631 0.01 0.05 20000 0.834 0.695 0.628
NN-631 0.01 0.05 30000 0.835 0.696 0.627
NN-631 0.01 0.05 40000 0.835 0.695 0.628
NN-631 0.01 0.05 50000 0.834 0.694 0.630
NN-631 0.01 0.05 60000 0.832 0.690 0.633
NN-631 0.01 0.05 75000 0.829 0.684 0.639
NN-631 0.01 0.05 100000 0.826 0.678 0.646
NN-6211 0.01 0.05 1000 0.010 0.001 1.215
NN-6211 0.01 0.05 10000 0.809 0.652 0.671
NN-6211 0.01 0.05 30000 0.822 0.672 0.651
NN-6211 0.01 0.05 40000 0.821 0.670 0.654
NN-6211 0.01 0.05 50000 0.819 0.666 0.657
NN-6211 0.01 0.05 60000 0.818 0.665 0.659
NN-6211 0.01 0.05 75000 0.817 0.663 0.660
NN-6211 0.01 0.05 100000 0.817 0.662 0.661
NN-6221 0.01 0.05 30000 0.754 0.566 0.749
NN-6221 0.01 0.05 40000 0.824 0.676 0.647
NN-6221 0.01 0.05 50000 0.825 0.646 0.678
NN-6221 0.01 0.05 60000 0.821 0.670 0.653
NN-6221 0.01 0.05 70000 0.814 0.656 0.666
 
Figure 7-14.  Results from testing ANN model parameters; the optimum number of cycles was determined 
for each of the three candidates by examining the LOO correlation value of each configuration of model-
cycle number. 
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 The results from the LOO validation and training cycle optimization analysis 
demonstrate that all three models tend to generate similar values.  Examination of the table in 
figure 7-14 closely reveals that all three model candidates generate a good LOO correlation 
R2, with values ranging from 0.672 to 0.696.  Interestingly the top correlation values for all 
three models are achieved at or around the 30,000 iteration mark.  This may be due more to 
the small number and/or quality of the descriptor set and less to do with any similarities 
among the learning processes of the models being examined. The data analysis presents a 
clear top candidate in NN-631.  This is the 6-descriptor model developed with 1 hidden 
layer and 3 nodes.  This model set results in the highest LOO correlation value (0.695) 
and also, surprisingly, carries the least error (RMSD=0.627) of the three top candidates 
tested.  Finally training set validation was carried out on the NN-631 measure the 
finished model.  Final analysis reveals a R2 value of 0.901 and an RMSE of 0.493.   
This model should be able to be used to make a good prediction of the high-
affinity nAChR binding Ki value of any compound with the general guanidine-
containing, DN-IMI/nicotine structure, however there may be some structural features 
which impact site binding that have not yet been introduced into this model, and would 
create unexpected divergences from the current model predictions. Therefore, the 
continual addition of more molecular structures would lead to a beneficial refining and 
retraining of the current model, making it more accurate and reducing the number of 
outlying points for any particular structural group.    
 
 
7.4  In-Silico Screening 
 
 in-silico Screening of Novel Library 
 In order to use the three models to predict the binding affinity of a theoretical set 
of guanidine-containing compounds, a small library of 52 novel (pAH) compounds were 
designed and constructed. Molecule construction was carried out on an SGI Octane 
computer, using the Sybyl software described earlier in the chapter.  The compound 
design was focused around the structural features most critical for high affinity nAChR 
binding as was discussed at length in chapters 4 and 5.  Briefly the small library was 
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 designed such that all molecules contained 1) a pyridine ring to provide critical pi-cation 
ring interaction, 2) a guanidine group situated off of the 3’-position of the pyridine ring to 
serve as the positively charged molecular feature, 3) an aminomethyl bridge between the 
ring and guanidine group since this linker appears to provide the optimum length in this 
series of compounds, 4) various N,N-ring and short aliphatic chain additions to generate 
guanidine group structural diversity in hopes of improving on the previously seen affinity 
improvements witnessed with short, bulky and lipophilic substitutions.  
  
Screening Results from PLS, MLR and ANN Model Outputs 
 
 Name 
 
        Structure PLS 
log  pKi 
MLR 
log pKi 
ANN 
log pKi 
pAH-1 
N
NH
NH
NH CH3 -5.2 -5.2 -5.0
pAH-2 
N
NH
NH
NH CH3
Cl -7.9 -8.0 -8.1
pAH-3 
N
NH
NH
NH
CH3
CH3
-7.8 -7.4 -8.0
pAH-4 
N
NH
NH
NH
Cl CH3
CH3
-8.5 -8.3 -8.3
pAH-5 
N
NH
NH
N CH3
CH3 -6.3 -5.9 -5.9
pAH-6 
N
NH
NH
N CH3
CH3
Cl -8.7 -9.9 -8.4
pAH-7 
N
NH
NH
NH CH3 -6.1 -6.2 -6.3
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 pAH-8 
N
NH
NH
NH CH3Cl -6.9 -7.4 -7.7
pAH-9 
N
NH
NH
NH
-5.4 -5.4 -5.1
pAH-10 
N
NH
NH
NH
Cl -6.3 -6.9 -6.8
pAH-11 
N
NH
N
NH
CH3
CH3
CH3
-7.7 -8.3 -8.2
pAH-12 
N
NH
N
NH
CH3
CH3
CH3
Cl -6.2 -6.9 -6.9
pAH-13 
N
NH
N
NH
CH3
CH3
-8.5 -8.9 -8.4
pAH-14 
N
NH
N
NH
CH3
CH3
Cl -7.4 -6.8 -7.3
pAH-15 
N
NH
N
N CH3
CH3
CH3
-8.1 -8.0 -8.2
pAH-16 
N
NH
N
N CH3
CH3
CH3
Cl -7.2 -6.8 -7.2
pAH-17 
N
NH
N
NH
CH3
CH3 -7.7 -7.6 -7.9
pAH-18 
N
NH
N
NH
CH3
CH3
Cl -5.9 -5.7 -5.3
pAH-19 
N
NH
N
NH
CH3
-6.5 -6.6 -6.3
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 pAH-20 
N
NH
N
NH
CH3
Cl -7.6 -7.6 -7.9
pAH-21 
N
NH
N
NH
CH3
CH3
CH3 -9.8 -11.2 -8.5
pAH-22 
N
NH
N
NH
CH3
CH3
CH3
Cl -6.6 -6.9 -7.3
pAH-23 
N
NH
N
N
CH3
CH3
CH3
CH3 -6.5 -5.7 -5.4
pAH-24 
N
NH
N
N
CH3
CH3
CH3
CH3
Cl -7.6 -8.0 -8.2
pAH-25 
N
NH
N
NH
CH3
CH3
CH3 -5.6 -5.4 -5.1
pAH-26 
N
NH
N
NH
CH3
CH3
Cl
CH3 -6.8 -7.5 -7.7
pAH-27 
N
NH
N
NH
CH3
CH3
-7.1 -7.8 -8.0
pAH-28 
N
NH
N
NH
CH3
CH3
Cl -8.1 -8.6 -8.3
pAH-29 
N
NH
N
N
CH3
CH3
CH3
-4.4 -4.6 -4.5
pAH-30 
N
NH
N
N
CH3
CH3
Cl
CH3
-6.7 -8.6 -8.0
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 pAH-31 
N
NH
N
NH
CH3
CH3 -4.7 -5.6 -5.0
pAH-32 
N
NH
N
NH
Cl
CH3
CH3 -5.7 -7.0 -6.4
pAH-33 
N
NH
N
NH
CH3
-3.9 -3.5 -4.3
pAH-34 
N
NH
N
NH
CH3
Cl -7.2 -6.6 -6.7
pAH-35 
N
NH
N
N
CH3
CH3
CH3
-7.2 -7.9 -8.0
pAH-36 
N
NH
N
N
Cl
CH3
CH3
CH3
-5.5 -5.1 -4.9
pAH-37 
N
NH
N
N
CH3
CH3
-6.4 -6.7 -6.6
pAH-38 
N
NH
N
N
CH3
CH3
Cl -6.0 -6.2 -6.1
pAH-39 
N
NH
N
NH
CH3
-6.7 -7.4 -7.6
pAH-40 
N
NH
N
NH
Cl
CH3
-5.3 -5.6 -5.2
pAH-41 
N
NH
N
N
CH3 -6.0 -6.8 -6.4
pAH-42 
N
NH
N
N
CH3
Cl -5.6 -6.4 -6.1
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 pAH-43 
N
NH
N
N
CH3 -6.6 -7.6 -7.7
pAH-44 
N
NH
N
N
Cl
CH3 -5.5 -5.4 -5.1
pAH-45 
N
NH
N
N
CH3 -5.9 -6.3 -6.2
pAH-46 
N
NH
N
N
Cl CH3 -5.8 -5.7 -5.3
pAH-47 
N
NH
N
N
CH3 -6.5 -6.7 -6.8
pAH-48 
N
NH
N
N
Cl
CH3 -7.2 -7.6 -7.8
pAH-49 
N
NH
N
N
CH3 -6.4 -7.0 -7.1
pAH-50 
N
NH
N
N
Cl CH3 -4.5 -4.5 -4.6
pAH-51 
N
NH
N
N
CH3 -5.5 -6.6 -6.0
pAH-52 
N
NH
N
N
Cl
CH3 -7.8 -6.4 -6.5
 
Figure 7-15.  Results from in-silico screening using PLS, MLR and ANN-631 models.  Predictions of 
affinity Ki values for each theoretical compound  
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 Descriptors were generated using the Sybyl and Dragon software described earlier and 
model calculations were run to generate a predicted Ki value for each of the compounds 
examined.  Results from the testing are seen in figure 7-15. 
Before any structural analysis is presented it is important to note that the three 
different models are in good agreement in predicting the affinity values of the test 
compound set.  The results from the correlation analysis (R2) between the models are: 
PLS-MLR= 0.897, PLS-ANN= 0.897, and MLR-ANN=0.924.  The result from this 
analysis (data not shown) reveals a high degree of similarity in the predictive ability of 
these three models.  This is not unexpected however, since all three were built around the 
same small set of compounds and all three models have similar R2 and error values. 
Results from the prediction analysis reveal several interesting SAR trends among 
the various prediction set of compounds.  According to the predictions, the act of 
expanding the guanidine-containing ring from a five membered imidazolidine to a seven 
membered ring to improve affinity appears to be disputed by the models.  The addition of 
this structure is not tolerated at all and results in predicted Ki values greater than 100nM.  
The inclusion of a six membered tetrahydropyrimidine (THP) ring to improve affinity 
appears to be rejected completely by the models.  These THP-containing compounds all 
are predicted to have affinity values >10µM.  There appears to be a mixed predictive 
response to the presence of an imidazolidine ring.  Several of the compounds were 
predicted to have promising affinity values while others were predicted to have dismal 
binding affinity values.  These range from >10µM for pAH-40 to a promising ~100nM 
for the pAH-43 compound.  Surprisingly there appears to be little discrimination between 
compounds that do and do not feature a 6-chloro addition.  In a break from the SAR 
trends that have been revealed in this work so far, the models appear to predict several 
non-chloro containing molecules with equal or improved affinity over the most promising 
chloro-containing compounds.  For example, compounds pAH-13, pAH-15 and pAH-21 
all were predicted to have low and even sub-nanomolar affinity values.  These are at least 
as good, or better than the best predicted chloro-containing compounds in the set.  
Among the most promising compounds pAH-2, pAH-4, pAH-6, pAH-13, pAH-15, pAH-
21, and pAH-28 all feature Ki predictions at or below 10nM.  By examining the 
compounds predicted to result in high affinity binding it is clear that the model prefers 
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 multiple short-chain alkyl substituents on the terminal nitrogen atoms of the guanidine 
group.  While no single molecular feature distinguished itself as the key to conferring 
high affinity, the general trend does confirm earlier observed SAR which claimed that 
small and bulky aliphatic N-substitutions and N,N-di-substitutions are important for 
conferring high affinity.  In addition it is not clear that either N-mono or N,N-di 
substitutions are preferred, with 3 mono and 4 di-substitutions making up the seven 
compounds with ≤ 10nM affinity.   
 This small test library is a perfect example of how a good 
molecular/pharamacophore model can be useful in guiding synthesis to generate better 
lead molecules.  Using these models future synthetic efforts can proceed without wasting 
valuable time and effort generating lots of compounds that will result in no activity.  
Instead, fewer compounds can be made in a more targeted way which yield more 
interesting biological results in less time, all while maximizing the potential of the 
particular SAR for the compounds that are being developed and tested.  Of course this 
model, as with all models, can stand to do with more refinement.  It is doubtful that the 
next generation of pAH compounds that are predicted here will result in a blockbuster 
compound with high activity and/or selectivity, but each generation of compound 
synthesis and testing should result in an improvement in compound hit rate or overall 
activity, all while continuously feeding back to, and providing valuable input to the next 
generation model where the process can be allowed to continue.  This basic process is the 
essence of computer-assisted molecular design, and the pharmacophore models presented 
here appear to be successful in establishing a first-step effort in contributing to the 
improvement in future guanidine-containing compound synthesis.             
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 7.5  Discussion 
 
 Review 
 Using a combination of PLS, MLR and ANN-based molecular methods, three 
valid pharmacophore models of high-affinity binding were successfully developed.  By 
applying structure-activity relationship trends associated with sub-molecular structural 
features of the molecules in the 44-compound test library, three distinct prediction 
models were designed, optimized, validated and used to generate predicted affinity values 
for a hypothetical set of guanidine-containing compounds.     
  
 
 
Three Model Comparison 
 
 
•44 compounds 
•110 descriptors 
selected (R≥0.20) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PLS Model
 
Figure 7-16.  Presentation of critical measures of the three pharmacophore models developed to predict 
high affinity neuronal nAChR binding of novel guanidine-containing compounds.  
 
 
 
 
 
 
R2=0.769 
S.E.est  =  0.656 
Rcv2     =  0.696 
F=47.88 
MLR Model 
 
R2=0.759 
S.E.est  =  0.689 
Rcv2     =  0.689 
F=20.89 
ANN-631 Model 
 
P[log Ki]  =  0.8337 
pR2         =  0.694 
RMSE     =  0.629 
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  A PLS model with 11 variables and 3 latent was developed and optimized.  A 12-
component MLR model was developed and then optimized to a more significant 6 
component model.  Finally, a 6 component, 1 hidden layer, 3 node artificial neural 
network model was developed.  All three models were cross-validated using the leave-
one-out method and then validated against the training set.  Analysis of the three methods 
together reveals that they are remarkably similar in predictive power and error with all 
three yielding an rcv2 value of ~0.7, an R2 value of ~0.8 with low inherent error.   
It was found that, in general, the three models possess similar cross-validation and 
training statistics, error, and predictive power.  For this reason all three models were used 
to predict affinity values for each of the molecules in the theoretical prediction set.  This 
prediction set constituted a small library of compounds with structures and molecular 
features that the pharmacophore models would easily be able to use to generate an 
accurate prediction.  All three models successfully predicted theoretical Ki values for the 
test compound (pAH compounds) and the three models yielded very similar results.  This 
was confirmed by the high degree of correlation found among the prediction analysis 
results.     
Molecular modeling tools such as the ones developed here represent an important part of 
modern drug design and discovery.  By continuing to apply and further refine these 
models new generations of ever-more active guanidine-containing nicotinic analogs can 
be synthesized and tested with ever-improving time and cost-efficiency. More 
importantly, this pharmacophore modeling exercise successfully fulfilled the fifth and 
final specific aim of this doctoral project.  By conducting this study, the author gained an 
education, and insight and an appreciation for both the complexity and the potential of 
pharmacophore modeling methods, and their role in modern drug discovery.  Overall the 
methods and results detailed in this chapter were successful in satisfying the goal of 
specific aim #5.          
 
 
 
Copyright © Aaron Joseph Haubner 2008  
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 Chapter 8: Review and Discussion 
 
 The goal at the outset of the current work was to explore the potential of the 
guanidine group in terms of nicotinic receptor ligand development.  The project 
employed several aspects of early-stage drug discovery research (in as much as the 
relevant assays, methods, and resources were available) in order to explore the potential 
of guanidine-containing compounds as subtype selective ligands for neuronal nicotinic 
receptors.  Previous research involving guanidine-containing molecules had revealed 
tantalizing glimpses of the potential that lay unexploited for this class of small molecule, 
but little work had been carried out previously that attempted to classify these 
compounds beyond binding at mammalian subtypes.  Several compounds were identified 
as antihypertensive agents that were believed to interact at a nicotinic receptor (nAChR) 
subtype, while a handful of guanidine-containing, synthetic and natural product 
compounds provided very basic results for nAChR activity, but those relationships were 
not very well developed.  Research carried out on the neonicotinoid insecticide 
imidacloprid (IMI) and its family of related analogs revealed compounds with high 
affinity and selectivity.  These results, however, were mainly limited to selective activity 
at the mammalian nicotinic receptor versus insect nicotinic receptor.  Despite this 
limitation these results, in combination with similar results in the literature, provided 
clear support for the development of the hypothesis that novel guanidine containing 
analogs of the nicotine molecule could be synthesized which interact with high affinity 
and selectivity at mammalian neuronal nicotinic receptor subtypes.   
In an effort to identify novel compounds with pharmacological properties 
selective for individual neuronal nicotinic receptor subtypes a medicinal chemistry 
project was first undertaken.  Centered on the exploitation of the structure-activity 
relationships seen in the neonicotinoid series, a synthetic project was initiated which 
aimed to incorporate structural diversity within a small library of molecules featuring an 
easily recognized “nicotinic” structural core.   
In fitting with the specific aim of the project, a method is described here which 
demonstrates a simple, straight-forward, and efficient procedure that allows for the 
synthesis of a seemingly limitless combination of synthon-amine starting materials that 
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 can be used to further explore the SAR of the molecules in this class through novel 
compound synthesis.  Project highlights include the synthesis of ~140 guanylated 
compounds (AH compounds) using low-cost, commercially-available starting reagents.  
Following preparation of the synthons, reactions were carried out using FirstMate 
parallel bench-top synthesis apparatus in groups of 8-12, convenient for small batch 
handling and purification, while providing sufficient product material for analysis and 
pharmacological testing.  The heterocycle compounds generated using this method 
contains an easily recognizable nicotinic structure reminiscent of the guanidino 
compounds reviewed in the SAR section of chapter 2.  Coincidentally, during the same 
period of time a series of amidino containing nicotinic analogs (JC compounds) were 
being prepared in parallel, as part of an unrelated project.  In all, around 160 AH and JC 
compounds were evaluated in nicotinic receptor binding activity testing. 
While the synthetic procedure developed was effective in generating the 
compounds desired, the synthetic method described was developed for its simplicity and 
robustness and not for its ability to facilitate more “elegant” or complex synthetic 
designs.  In terms of future directions, the possibilities are manifold.  An obvious aim of 
continuing research interest is to further develop the optimization of the guanidine motif 
described here.  Through the inclusion of additional aliphatic groupings, mixed N,N-
substituents and the inclusion of small functional groups more exotic structures could be 
created.  Given the research interest and success seen with the bis-nicotinium, bis-
pyridinium and bis-picolinium series (Ayers 2002, Rahman 2008, Dwoskin 2007) of 
compounds synthesized in the Crooks’ lab, it would make a whole lot of sense to explore 
the potential of bis-guanidines for the development of subtype-selective compounds that 
act as functional agonists and antagonists at neuronal nicotinic receptors.  As in the 
guanidine series described here, SAR-driven synthesis should explore the effects of 
altering alkyl chain length, aliphatic components, size/steric bulk of guanidine 
substituents and ring components in hopes of improving the binding affinity of product 
compounds in these new series.   
Following the synthetic component of the project, compounds were evaluated for 
their ability to bind neuronal nicotinic receptors.  The first tests carried out were simple 
binding screens that examined the ability of a compound to interact with, or bind to the 
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 nicotinic receptor.  Since this basic interaction is required prior to any functional activity 
at the nAChR it is well recognized as a useful starting point in screening compounds for 
nicotinic receptor activity.  In fitting with the specific aims of the project, binding 
experiments in whole rat brain with [3H]epibatidine ([3H]Ebt) were carried out in order 
to identify compounds with high affinity for the α4β2* nAChR subtype.  A large number 
of test plates were evaluated rapidly by developing a [3H]Ebt binding assay and adapting 
it for use on a liquid handling apparatus which facilitated the handling of a large number 
of plates, thus increasing throughput.  All screen hits were evaluated in concentration-
response binding assays to determine pharmacological parameters of binding such as 
IC50, Ki, Imax, and Hill slope of binding.  In all several AH and JC compounds were 
identified as having high affinity (Ki <1.0 micromolar) and were considered lead product 
compounds for further experimental analysis.  Binding assay highlights include the 
successful development of a [3H]Ebt binding assay which was used for screening several 
compound libraries from the Crooks’ lab including those prepared by Josh Ring, Sunny 
Neelekantan, Jianhong Chen and the author. 
Drawbacks and limitations of this assay method are few and relatively simple.  
While it is well-known that Ebt possesses concentration-dependent selectivity at various 
nicotinic receptor subtypes, binding affinity at very low concentrations used here (~170 
pM) are known to selectively probe the high affinity α4β2* subtype (Daly 2005).  
Additionally, the brain preparations used in the experiments are known to be ~85% 
α4β2* preparations (Whiting 1987, Goldman 1987, Flores 1992).  The possibility of 
interfering α7* receptor binding was addressed by assaying for binding inhibition with 
well known α7* ligands like MLA, α-bgt, and the PNU compound described in chapter 
4.  Results with each compound gave little or no activity whatsoever.  In satisfying the 
second specific aim several promising lead compounds were identified by high affinity 
nicotinic receptor binding.  The application of this assay method could continue to serve 
as a first screen to select for compounds that are α4β2* ligands. 
For quite a few years a major goal of nicotinic receptor research has focused on 
increasing the quantity and quality of available compounds that possess selectivity for a 
single nAChR subtype.  Even a brief review of the current nicotinic receptor-related 
literature will reveal a number of high-profile, and highly promising, lines of work 
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 focusing on the development of subtype selective nAChR compounds (Gotti 2000).  In 
fact, numerous subtype selective nicotinic compounds are in clinical trials or have 
already been approved to treat a variety of disorders (Bencherif 2006, Gotti 2006).  
Because of this it was determined that the compounds in the development library should 
be evaluated for potential subtype selectivity between the two major neuronal subtypes.   
In fitting with the specific aims of the project additional binding assays were 
available that allowed for the examination of these compounds at both the α4β2* and 
α7* neuronal nAChR subtypes.  Once again compounds were screened and those 
producing hits were evaluated in a concentration-response experimental design as has 
been described previously by the Dwoskin lab.  Several lead AH and JC compounds 
were singled out which possess high affinity and selectivity for the α4β2* nAChR.  The 
most striking result from this work was the degree of selectivity that a number of AH 
compounds had for the α4β2* subtype versus the α7* subtype.  In light of the 
tremendous push for nicotinic compounds with a wide selectivity window for the high 
affinity subtype these results are promising in terms of future development.  
Unfortunately none of the compounds synthesized revealed a primary selectivity for the 
α7* nAChR subtype.  This would have been a welcomed result due to the dearth of α7 
selective structures that are available for compound and therapeutic development.  
Binding affinity does not usually correlate well with functional potency or efficacy, 
however, and while none of the compounds evaluated here revealed a promising binding 
affinity, future work may reveal valuable and exciting α7* selective functional 
characteristics among some of the guanylated and amidino-containing compounds 
evaluated in this project.   
Additional work should be carried out focusing on expanding the scope of 
subtype-selectivity to include the important α6* (dopamine-releasing) subtype by 
carrying out binding studies with labeled α-Ctx MII, a selective α6* receptor compound 
(Harvey 1996, Salminen 2004).  Given the cost associated with purchasing this custom 
radioligand and the troubles inherent in a radiolabeled polypeptide an alternative binding 
strategy employing α-Ctx MII as an α6* binding inhibitor could be carried out whereby 
guanylated compounds are evaluated for their α6*-sensitive and α6*-resistant binding 
capability.  Given the extraordinary interest and huge therapeutic potential in the 
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 development of compounds active and selective for the neuronal α6* receptor subtype 
this experimental work would be of tremendous ongoing value. 
Schild analysis of binding on compounds AH-132 and JC 3-9 indicated a complex 
picture of molecular interaction that on its face, would indicate a non-competitive 
mechanism, but as discussed previously in the results section of chapter 5, this result 
may not be so easily understandable.  Since the compounds evaluated here are primarily 
interacting with the α4β2* receptor subtype, and knowing that this subtype is rapidly 
driven to a new and unique “desensitized” high-affinity conformation upon binding, the 
Schild-type analysis of binding may not be a system in an equilibrium state suitable for 
clear-cut analysis of the current results.  Given the complex, multi-state receptor 
equilibrium of the high affinity subtype, each with its own regulatory modifications, 
conformation, kinetic characteristics and binding preferences, the Schild analysis alone 
is likely insufficient to describe the mechanism of binding interaction.  The experiment 
was worth carrying out, however, because if, the Schild plot gave a result consistent with 
a single-site competitive interaction then the result would carry a good deal of 
evidentiary weight, and the result could likely be interpreted in a more straightforward 
manner.  While the Schild analysis of binding is certainly not conclusive either way, the 
binding inhibition by AH-132 and JC 3-9 do fit a one-site model with a Hill slope of -1.  
Additionally, functional results (discussed in the next section), where these compounds 
both activate the receptor and inhibit the agonist activity of Ebt, are consistent with a 
one-site competitive mechanism of action.  Certainly, the jury is still out as to the 
definitive mechanism of interaction of these compounds at the α4β2* subtype.  Future 
work should be undertaken where mechanistic analysis is carried out on function and not 
simply binding.  Through these studies a more compelling case could be made for 
defining the mechanism of interaction.       
While binding experiments serve a useful function in the development of new 
nicotinic ligands, functional experiments are needed to reveal the biological actions of 
newly synthesized novel compounds.  As noted earlier, very little work has been carried 
out on nicotinic receptor binding for guanylated compounds like those in the AH series.  
It is no surprise, then, that even less work has been carried out exploring the functional 
ability of guanylated analogs of NIC.  Functional properties of AH and lead JC 
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 compounds were investigated in the next section using whole cell, receptor functional 
assays on recombinantly expressed receptor subtypes.  In fitting with the specific aims of 
the project selected compounds were evaluated for functional activity at recombinantly 
expressed nAChR subtypes using a whole-cell FLIPR plate reading system.  Tests were 
carried out on compounds at major nAChR subtypes including the neuronal α4β2 and α7 
subtypes and the “ganglionic” α3β4 subtype.  Traditionally, the α7 subtype is a 
notoriously difficult subtype for functional expression and does not easily express a 
functional receptor.  This work provided no exception to this rule, where no α7 nAChR 
subtype results were obtained in this project for any of the compounds listed.  In this 
work a method was developed where several compounds could simultaneously be 
screened for both agonist and antagonist activity within the same 96-well plate.  The 
several AH and JC compounds identified in the screening assay component were next 
evaluated in concentration response experiments in order to determine not only 
activating or inhibitory properties but functional characteristics such as EC50, IC50, Emax, 
Imax, Hill slope of response.  Several leading compounds were identified as full agonists, 
partial agonists, and antagonists at the recombinant α4β2 and α3β4 subtypes.  This was a 
remarkable result considering that only ~20 AH compounds were initially screened for 
functional activity due to the time constraints associated with international travel and 
invited guest research (carried out at University College London, UK).  Importantly, 
these results demonstrate the extent of the diverse functional responses obtained with 
only minor structural changes to compounds in this family.  Besides supporting the basic 
hypothesis of the functional potential of guanylated compounds at neuronal nicotinic 
receptors, it represents only a small portion of the potential gold mine of functional SAR 
that exists within the series of compounds evaluated.  This structural series should be 
mined further for exciting subtype-selective functional data. 
One caveat of the FLIPR method involves the possibility of other, non-nicotinic 
receptor mediated responses present in the mammalian cell culture systems that could be 
confounding factors in these experiments.  While this was addressed at some length in 
the chapter 6 discussion it is reiterated here for emphasis, and while experiments to rule 
out these other cellular mechanisms (imidazolidine receptors, other ionotropic receptors, 
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 G-protein coupled receptor systems) should have been carried out, the time limit for the 
proposed project made this extended assay characterization impossible.   
Future work on this aspect of the project would obviously first include a more 
extensive assay characterization and development as described previously to control for 
non-nicotinic effects, but aside from this well-explored aim, the more obvious future 
work would aim to establish quality functional results from an α7 nicotinic receptor 
expression system.  While non-trivial given the well documented difficulties of 
expressing functional α7 receptors in cell culture, some expression tricks exist that could 
be employed that would yield useable functional data.  Given the tremendous interest in 
the development of α7* selective nicotinic compounds this work would should be a top 
priority for any work looking to expand on the subtype-selective characterization of the 
guanylated compounds investigated herein. 
The possibility of the continuing development of subtype selective agonists, 
antagonists, and compounds with mixed functional subtype responses, all from a single, 
structurally-related series of compounds, would not only be an interesting result from an 
SAR standpoint, but also from a drug design standpoint as well.  Of course, as stated in 
the earlier discussion section, these results are only from a single study, using 
artificially-expressed nAChR subunits in a mammalian cell culture system and may not 
reflect native human nAChR function in the brain, and these results certainly need to be 
replicated and confirmed in further work.  Additionally, advanced testing experiments 
need to be carried out that confirm these results in not only other artificial systems, but 
also in native receptor functional systems.  This type of continued investigation, 
however, requires lots of money, lab space, time and resources that were never available 
and were never meant to be a part of this work and, thus, it can only be stated that this 
work should be considered as part of future nAChR drug development and 
pharmacology research projects. 
In an attempt to explore the SAR between these compounds and the high affinity 
nicotinic receptor in a more quantitative manner, a molecular modeling project was 
undertaken where a pharmacophore model was developed based on the α4β2*, high 
affinity binding data collected earlier and described in chapter 4 of this work.  In fitting 
with the specific aims of the project, pharmacological data were compiled and analyzed 
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 in light of structural knowledge of the compounds, in order to generate a SAR database 
that was used to develop a computer model of the high affinity nAChR binding site 
pharmacophore.  Compound structures were sufficiently well described and binding data 
were successfully input to develop three computer-based models of the ligand binding 
site.  A method is detailed which describes a unique PLS, MLR and ANN model which 
were developed and used to identify key structural elements critical for high affinity 
binding.  Theoretical guanylated compounds were designed and tested for potential 
binding affinity using the models as predictive tools and several were identified as high 
priority with theoretical affinity values in the low nanomolar and high picomolar range.  
The models were internally and externally validated using a variety of statistical methods 
and all three were found to possess a reasonable predictive power.  Models like that 
described here, and others like it, are increasingly being relied upon by drug design 
groups, in the nAChR field and others, in order to add to and refine the understanding of 
a particular pharmacophore.  This becomes an invaluable tool to SAR-based medicinal 
chemistry design in order to better develop compounds with more promising 
pharmacological characteristics, to generate compound libraries with the highest hit 
rates, and to do all of this with fewer resources and in less time than without feedback 
from the pharmacophore model. 
While there exist numerous molecular models described in the literature for 
advancing nicotinic receptor research (ie. receptor models, in-silico mutagenesis capable 
models, receptor binding pocket models, docking models, and other pharmacophore-
based models) (Klebe 2000, Bisson 2005, Schmitt 2000, Nicolotti 2002, Dror 2004), the 
one developed and described here is uniquely qualified to evaluate and predict the 
molecular SAR characteristics with respect to the AH series of compounds and the high-
affinity nicotinic receptor specifically.  This is because all of the input to the building of 
the molecular model design derived from research data involving the novel compounds 
of the AH series.  While the structural input of the pharmacophore model remains small 
and the predictive scope of the model remains limited (since the model was derived from 
and based on unique data acquired through the evaluation of novel compounds), the 
molecular models constructed in this work remain singularly well-suited for improved 
prediction of SAR for advanced molecular design related to this series of guanylated 
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 nicotinic compounds.  While a first round of future predictive work has been carried out, 
additional rounds of prediction should be carried out following second and third rounds 
of synthesis and pharmacological testing.  Through this process the scope, predictive 
power and ultimate refinement and accuracy of developing model will be greatly 
improved.        
In total the project described here, in detail, was carried out in order to fulfill the 
requirements set forth in the dissertation research plan as part of the qualifying exam 
process.  Five major specific aims were identified and all five were fulfilled in this 
project to a high degree of completion.  More importantly the primary hypothesis of the 
study was addressed through a well-designed and well-executed experimental initiative.  
This project successfully expanded knowledge and understanding of a novel series of 
guanidine containing molecules as a viable and promising structural basis for the 
continuing development of nicotinic receptor ligand molecules with pharmacological 
properties that are desirable as subtype-selective compounds for potential nAChR 
research tools and therapeutic drug compounds.                             
                             
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Aaron Joseph Haubner 2008  
 
 309
 References 
 
 
Abood LG, Grassi S, Costanza M.  Binding of optically pure (--)-[3H]nicotine to rat 
brain membranes.  FEBS Lett. 1983 Jun 27; 157(1): 147-9. 
 
Adams DJ, Nutter TJ.  Calcium permeability and modulation of nicotinic 
acetylcholine receptor-channels in rat parasympathetic neurons.  J Physiol Paris. 
1992; 86(1-3): 67-76. 
 
Adcock C, Smith GR, Sansom MS.  The nicotinic acetylcholine receptor: from 
molecular model to single-channel conductance.  Eur. Biophys J. 2000; 29(1): 29-37. 
 
Adler LE, Hoffer LD, Wiser A, Freedman R.  Normalization of auditory physiology 
by cigarette smoking in schizophrenic patients.  Am J Psychiatry. 1993 Dec; 150(12): 
1856-61. 
 
Ahmadi J, Ashkani H, Ahmadi M, Ahmadi N.  Twenty-four week maintenance 
treatment of cigarette smoking with nicotine gum, clonidine and naltrexone.  J. Subst. 
Abuse Treat. 2003 Apr; 24(3): 251-5. 
 
Albuquerque EX, Pereira EF, Alkondon M, Schrattenholz A, Maelicke A.  Nicotinic 
acetylcholine receptors on hippocampal neurons: distribution on the neuronal surface 
and modulation of receptor activity.  J Recept Signal Transduct Res. 1997 Jan-May; 
17(1-3): 243-66. 
 
Alkondon M, Albuquerque EX.  Diversity of nicotinic acetylcholine receptors in rat 
hippocampal neurons Pharmacological and functional evidence for distinct structural 
subtypes.  J. Pharmacol Exp Ther. 1993 Jun; 265(3): 1455-73. 
 
 310
 Alkondon M, Pereira EF, Wonnacott S, Albuquerque EX.  Blockade of nicotinic 
currents in hippocampal neurons defines methyllycaconitine as a potent and specific 
receptor antagonist.  Mol Pharmacol. 1992 Apr; 41(4): 802-8. 
 
Allam MF, Campbell MJ, Hofman A, Del Castillo AS, Fernandez-Crehuet Navajas R.  
Smoking and Parkinson's disease: systematic review of prospective studies.  Mov. 
Disord. 2004 Jun; 19(6): 614-21. 
 
Alt A, Weiss B, Ogden AM, Knauss JL, Oler J, Ho K, Large TH, Bleakman D.  
Pharmacological characterization of glutamatergic agonists and antagonists at 
recombinant human homomeric and heteromeric kainate receptors in vitro.  
Neuropharmacology. 2004 May;46(6):793-806. 
 
Anderson DJ, Arneric SP.  Nicotinic receptor binding of [3H]cytisine, [3H]nicotine 
and [3H]methylcarbamylcholine in rat brain. Eur J Pharmacol. 1994 Mar 3; 253(3): 
261-7. 
 
Aoyama T, Suzuki Y, Ichikawa H.  Neural networks applied to quantitative structure-
activity relationship analysis.  J Med Chem. 1990 Sep;33(9):2583-90. 
 
Arendash GW, Sengstock GJ, Sanberg PR, Kem WR.  Improved learning and 
memory in aged rats with chronic administration of the nicotinic receptor agonist 
GTS-21.  Brain Res. 1995 Mar 20; 674(2): 252-9. 
 
Arias HR, Bhumireddy P, Bouzat C.  Molecular mechanisms and binding site 
locations for noncompetitive antagonists of nicotinic acetylcholine receptors.  Int. J. 
Biochem. Cell Biol. 2006; 38(8): 1254-76. Epub 2006 Feb 20. 
 
Arias HR, McCardy EA, Bayer EZ, Gallagher MJ, Blanton MP.  Allosterically linked 
noncompetitive antagonist binding sites in the resting nicotinic acetylcholine receptor 
ion channel.  Arch Biochem Biophys. 2002 Jul 1;403(1):121-31. 
 311
  
Armishaw CJ, Alewood PF.  Conotoxins as research tools and drug leads.  Curr 
Protein Pept Sci. 2005 Jun; 6(3): 221-40. 
 
Arneric SP, Sullivan JP, Decker MW, Brioni JD, Bannon AW, Briggs CA, Donnelly-
Roberts D, Radek RJ, Marsh KC, Kyncl J, et al.  Potential treatment of Alzheimer 
disease using cholinergic channel activators (ChCAs) with cognitive enhancement, 
anxiolytic-like, and cytoprotective properties.  Alzheimer Dis Assoc Disord. 1995; 9 
Suppl 2: 50-61. 
 
Arnold SE, Trojanowski JQ.  Recent advances in defining the neuropathology of 
schizophrenia.  Acta Neuropathol (Berl). 1996 Sep; 92(3): 217-31. 
 
Arunlakshana O, Schild HO.  Some quantitative uses of drug antagonists.  Br J 
Pharmacol Chemother. 1959 Mar;14(1):48-58. 
 
Ascher P, Large WA, Rang HP.  Studies on the mechanism of action of acetylcholine 
antagonists on rat parasympathetic ganglion cells.  J. Physiol. 1979 Oct; 295: 139-70. 
 
Ayers JT, Dwoskin LP, Deaciuc AG, Grinevich VP, Zhu J, Crooks PA.  bis-
Azaaromatic quaternary ammonium analogues: ligands for alpha4beta2* and alpha7* 
subtypes of neuronal nicotinic receptors.  Bioorg. Med. Chem. Lett. 2002 Nov 4; 
12(21): 3067-71. 
 
Ayers JT, Dwoskin LP, Deaciuc AG, Grinevich VP, Zhu J, Crooks PA.  bis-
Azaaromatic quaternary ammonium analogues: ligands for alpha4beta2* and alpha7* 
subtypes of neuronal nicotinic receptors.  Bioorg Med Chem Lett. 2002 Nov 4; 
12(21): 3067-71. 
 
 312
 Azam L, Winzer-Serhan UH, Chen Y, Leslie FM.  Expression of neuronal nicotinic 
acetylcholine receptor subunit mRNAs within midbrain dopamine neurons.  J. Comp. 
Neurol. 2002 Mar 12; 444(3): 260-74. 
 
Badio B, Daly JW.  Epibatidine, a potent analgetic and nicotinic agonist.  Mol 
Pharmacol. 1994 Apr; 45(4): 563-9. 
 
Badio B, Daly JW.  Epibatidine, a potent analgetic and nicotinic agonist.  Mol 
Pharmacol. 1994 Apr; 45(4): 563-9. 
 
Baer JE, Lockwood RG.  Acetylation and S-alkylation of ethylene thiourea.  
J.Am.Chem. Soc. 76; 1162-1164 1953. 
 
Bardo MT, Green TA, Crooks PA, Dwoskin LP.  Nornicotine is self-administered 
intravenously by rats.  Psychopharmacology (Berl). 1999 Oct; 146(3): 290-6. 
Baron JA.  Cigarette smoking and Parkinson's disease.  Neurology. 1986 Nov; 36(11): 
1490-6. 
 
Barrantes GE, Rogers AT, Lindstrom J, Wonnacott S.  Alpha-Bungarotoxin binding 
sites in rat hippocampal and cortical cultures: initial characterisation, colocalisation 
with alpha 7 subunits and up-regulation by chronic nicotine treatment.  Brain Res. 
1995 Feb 20; 672(1-2): 228-36. 
 
Bartus RT, Dean RL 3rd, Beer B, Lippa AS.  The cholinergic hypothesis of geriatric 
memory dysfunction.  Science. 1982 Jul 30; 217(4558): 408-14. 
Beers WH, Reich E.  Structure and activity of acetylcholine.  Nature. 1970 Dec 5; 
228(5275): 917-22. 
 
Bencherif M, Hauser TA, Jordan KG, Gatto GJ.  Therapeutic potential of novel 
selective drugs targeting nicotinic acetylcholine receptors.  J Mol Neurosci. 
2006;30(1-2):17-8.  
 313
  
 
Bencherif M, Lovette ME, Fowler KW, Arrington S, Reeves L, Caldwell WS, 
Lippiello PM.  RJR-2403: a nicotinic agonist with CNS selectivity I. In vitro 
characterization.  J Pharmacol Exp Ther. 1996 Dec; 279(3): 1413-21. 
 
Bencherif M, Schmitt JD.  Targeting neuronal nicotinic receptors: a path to new 
therapies.  Curr Drug Targets CNS Neurol Disord. 2002 Aug; 1(4): 349-57. 
Bennett Max R.  The concept of transmitter receptors: 100 years on.  
Neuropharmacology 39 523-546, 2000. 
 
Benowitz NL.  Pharmacology of nicotine: addiction and therapeutics. 
Ann. Rev. Pharmacol. Toxicol. 1996; 36: 597-613. 
 
Benwell ME, Balfour DJ, Anderson JM.  Evidence that tobacco smoking increases 
the density of (-)-[3H]nicotine binding sites in human brain.  J. Neurochem. 1988 Apr; 
50(4): 1243-7. 
 
Benwell ME, Balfour DJ, Anderson JM.  Evidence that tobacco smoking increases 
the density of (-)-[3H]nicotine binding sites in human brain.  J. Neurochem. 1988 Apr; 
50(4): 1243-7. 
 
Bergmeier SC, Lapinsky DJ, Free RB, McKay DB.  Ring E analogs of 
methyllycaconitine (MLA) as novel nicotinic antagonists.  Bioorg Med Chem Lett. 
1999 Aug 2; 9(15): 2263-6. 
 
Beroukhim R, Unwin N.  Three-dimensional location of the main immunogenic 
region of the acetylcholine receptor.  Neuron. 1995 Aug;15(2): 323-31. 
 
Berrettini WH, Lerman CE.  Pharmacotherapy and pharmacogenetics of nicotine 
dependence.  Am. J. Psychiatry. 2005 Aug; 162(8): 1441-51. 
 314
  
Bertrand D, Ballivet M, Rungger D.  Activation and blocking of neuronal nicotinic 
acetylcholine receptor reconstituted in Xenopus oocytes.  Proc. Natl. Acad. Sci. U S 
A. 1990 Mar; 87(5): 1993-7. 
 
Bertrand D.  Neuronal nicotinic acetylcholine receptors: their properties and 
alterations in autosomal dominant nocturnal frontal lobe epilepsy.  Rev. Neurol. 1999 
Jul; 155(6-7): 457-62. 
 
Bhat RV, Turner SL, Selvaag SR, Marks MJ, Collins AC.  Regulation of brain 
nicotinic receptors by chronic agonist infusion.  J. Neurochem. 1991 Jun; 56(6): 
1932-9. 
 
Bibevski S, Zhou Y, McIntosh JM, Zigmond RE, Dunlap ME.  Functional nicotinic 
acetylcholine receptors that mediate ganglionic transmission in cardiac 
parasympathetic neurons.  J. Neurosci. 2000 Jul 1; 20(13): 5076-82. 
 
Bisson WH, Scapozza L, Westera G, Mu L, Schubiger PA.  Ligand selectivity for the 
acetylcholine binding site of the rat alpha4beta2 and alpha3beta4 nicotinic subtypes 
investigated by molecular docking.  J Med Chem. 2005 Aug 11;48(16):5123-30. 
 
Bitner RS, Nikkel AL, Curzon P, Donnelly-Roberts DL, Puttfarcken PS, Namovic M, 
Jacobs IC, Meyer MD, Decker MW.  Reduced nicotinic receptor-mediated 
antinociception following in vivo antisense knock-down in rat.  Brain Res. 2000 Jul 
14; 871(1): 66-74. 
 
Blackman JG, Ray C.  Actions of Mecamylamine, dimecamine, pempidine and their 
two quaternary metho-salts at the neuron-muscular.  Br. J. Pharmacol Chemother. 
1964 Feb; 22: 56-65. 
 
 315
 Bodnar AL, Cortes-Burgos LA, Cook KK, Dinh DM, Groppi VE, Hajos M, Higdon 
NR, Hoffmann WE, Hurst RS, Myers JK, Rogers BN, Wall TM, Wolfe ML, Wong E.  
Discovery and structure-activity relationship of quinuclidine benzamides as agonists 
of alpha7 nicotinic acetylcholine receptors.  J Med Chem. 2005 Feb 24; 48(4): 905-8. 
 
Bohm, G.  New approaches in molecular structure prediction.  Biophys Chem. 1996 
Mar 7;59(1-2):1-32.  
 
Borea PA, Varani K, Gessi S, Merighi S, Dal Piaz A, Gilli P, Gilli G.  Receptor 
binding thermodynamics at the neuronal nicotinic receptor.  Curr Top Med Chem. 
2004; 4(3): 361-8. 
 
Botta B, Carmignani M, Volpe AR, Botta M, Corelli F, Delle Monache G.  Novel 
hypotensive agents from Verbesina caracasana: structure, synthesis and 
pharmacology.  Curr Med Chem. 2003 Sep; 10(18): 1845-62. 
 
Boulter J, Evans K, Goldman D, Martin G, Treco D, Heinemann S, Patrick J.  
Isolation of a cDNA clone coding for a possible neural nicotinic acetylcholine 
receptor alpha-subunit.  Nature. 1986 Jan 30-Feb 5; 319(6052): 368-74. 
 
Boulter J, Evans K, Goldman D, Martin G, Treco D, Heinemann S, Patrick J.  
Isolation of a cDNA clone coding for a possible neural nicotinic acetylcholine 
receptor alpha-subunit.  Nature. 1986 Jan 30-Feb 5; 319(6052): 368-74. 
 
Braak H, Braak E, Yilmazer D, de Vos RA, Jansen EN, Bohl J.  Pattern of brain 
destruction in Parkinson's and Alzheimer's diseases.  J. Neural Transm. 1996; 103(4): 
455-90. 
 
Brejc K, van Dijk WJ, Klaassen RV, Schuurmans M, van Der Oost J, Smit AB, 
Sixma TK.  Crystal structure of an ACh-binding protein reveals the ligand-binding 
domain of nicotinic receptors.  Nature. 2001 May 17; 411(6835): 269-76. 
 316
  
Brenner DE, Kukull WA, van Belle G, Bowen JD, McCormick WC, Teri L, Larson 
EB.  Relationship between cigarette smoking and Alzheimer's disease in a 
population-based case-control study.  Neurology. 1993 Feb; 43(2): 293-300. 
 
Breslau N, Kilbey M, Andreski P.  Nicotine dependence, major depression, and 
anxiety in young adults.  Arch Gen Psychiatry. 1991 Dec; 48(12): 1069-74. 
 
Brodtkorb E, Picard F.  Tobacco habits modulate autosomal dominant nocturnal 
frontal lobe epilepsy.  Epilepsy Behav. 2006 Nov; 9(3): 515-20. Epub 2006 Aug 22. 
 
Buccafusco JJ, Jackson WJ.  Beneficial effects of nicotine administered prior to a 
delayed matching-to-sample task in young and aged monkeys.  Neurobiol Aging. 
1991 May-Jun; 12(3): 233-8. 
 
Buccafusco JJ, Terry AV Jr, Goren T, Blaugrun E.  Potential cognitive actions of (n-
propargly-(3r)-aminoindan-5-yl)-ethyl, methyl carbamate (tv3326), a novel 
neuroprotective agent, as assessed in old rhesus monkeys in their performance of 
versions of a delayed matching task.  Neuroscience. 2003; 119(3): 669-78. 
 
Bunnelle WH, Dart MJ, Schrimpf MR.  Design of ligands for the nicotinic 
acetylcholine receptors: the quest for selectivity.  Curr Top Med Chem. 2004; 4(3): 
299-334. 
 
Caldoni C, Di Chiara G.  Differential changes in accumbens shell and core dopamine 
in behavioral sensitization to nicotine.  Eur. J. Pharm.  2000 Jan 17; 387(3): R23-5. 
 
Carroll FI, Ware R, Brieaddy LE, Navarro HA, Damaj MI, Martin BR  Synthesis, 
nicotinic acetylcholine receptor binding, and antinociceptive properties of 2'-fluoro-
3'-(substituted phenyl)deschloroepibatidine analogues. Novel nicotinic antagonist.  J. 
Med Chem. 2004 Aug 26; 47(18): 4588-94. 
 317
  
Cartaud J, Benedetti EL, Cohen JB, Meunier JC, Changeux JP.  Presence of a lattice 
structure in membrane fragments rich in nicotinic receptor protein from the electric 
organ of Torpedo marmorata.  FEBS Lett. 1973 Jun 15; 33(1): 109-13. 
 
Celesia GG.  Disorders of membrane channels or channelopathies.  Clin. 
Neurophysiol. 2001 Jan; 112(1): 2-18. 
 
Champtiaux N, Han ZY, Bessis A, Rossi FM, Zoli M, Marubio L, McIntosh JM, 
Changeux JP.  Distribution and pharmacology of alpha 6-containing nicotinic 
acetylcholine receptors analyzed with mutant mice.  J. Neurosci. 2002 Feb 15; 22(4): 
1208-17. 
 
Changeux JP, Devillers-Thiery A, Chemouilli P.  Acetylcholine receptor: an allosteric 
protein.  Science. 1984 Sep 21; 225(4668): 1335-45. 
 
Changeux JP, Edelstein SJ.  Allosteric receptors after 30 years.  Neuron. 1998 Nov; 
21(5): 959-80. 
 
Changeux JP.  The TiPS lecture. The nicotinic acetylcholine receptor: an allosteric 
protein prototype of ligand-gated ion channels.  Trends Pharmacol. Sci. 1990 Dec; 
11(12): 485-92. 
 
Chao SL, Dennehy TJ, Casida JE.  Whitefly (Hemiptera: Aleyrodidae) binding site 
for imidacloprid and related insecticides: a putative nicotinic acetylcholine receptor.  
J Econ Entomol. 1997 Aug; 90(4): 879-82. 
 
Chavez-Noriega LE, Crona JH, Washburn MS, Urrutia A, Elliott KJ, Johnson EC.  
Pharmacological characterization of recombinant human neuronal nicotinic 
acetylcholine receptors h alpha 2 beta 2, h alpha 2 beta 4, h alpha 3 beta 2, h alpha 3 
 318
 beta 4, h alpha 4 beta 2, h alpha 4 beta 4 and h alpha 7 expressed in Xenopus oocytes.  
J Pharmacol Exp Ther. 1997 Jan;280(1):346-56. 
 
Chen J, Deaciuc AG, Dwoskin LP, Crooks PA, Bai D.  N, N -disubstituted 
piperazines and homopiperazines: synthesis and affinities at alpha4beta2* and 
alpha7* neuronal nicotinic acetylcholine receptors.  J Enzyme Inhib Med Chem. 2006 
Dec;21(6):667-80. 
 
Chen J, Deaciuc AG, Dwoskin LP, Crooks PA, Bai D.  N, N -disubstituted 
piperazines and homopiperazines: synthesis and affinities at alpha4beta2* and 
alpha7* neuronal nicotinic acetylcholine receptors.  J Enzyme Inhib Med Chem. 2006 
Dec;21(6):667-80. 
 
Clarke PB, Schwartz RD, Paul SM, Pert CB, Pert A.  Nicotinic binding in rat brain: 
autoradiographic comparison of [3H]acetylcholine, [3H]nicotine, and [125I]-alpha-
bungarotoxin.  J. Neurosci. 1985 May; 5(5): 1307-15. 
 
Clarke PB.  Mapping of brain nicotinic receptors by autoradiographic techniques and 
the effect of experimental lesions.  Prog. Brain Res. 1989; 79: 65-71. 
 
Clarke PB.  The fall and rise of neuronal alpha-bungarotoxin binding proteins. 
Trends Pharmacol. Sci. 1992 Nov; 13(11): 407-13. 
 
Clemson University, Pesticide Information Program. 
 
Colquhoun D.   The quantitative analysis of drug-receptor interactions: a short 
history.  Trends Pharmacol Sci. 2006 Mar;27(3):149-57. Epub 2006 Feb 17. 
 
Consonni V, Todeschini R, Pavan M.  Structure/response correlations and 
similarity/diversity analysis by GETAWAY descriptors. 1. Theory of the novel 3D 
molecular descriptors.  J Chem Inf Comput Sci. 2002 May-Jun;42(3):682-92.  
 319
  
Conti-Tronconi BM, McLane KE, Raftery MA, Grando SA, Protti MP.  The nicotinic 
acetylcholine receptor: structure and autoimmune pathology.  Crit. Rev. Biochem. 
Mol. Biol. 1994; 29(2): 69-123. 
 
Cooper E, Couturier S, Ballivet M.  Pentameric structure and subunit stoichiometry of 
a neuronal nicotinic acetylcholine receptor.  Nature. 1991 Mar 21; 350(6315): 235-8. 
 
Cooper ST, Harkness PC, Baker ER, Millar NS.  Up-regulation of cell-surface 
alpha4beta2 neuronal nicotinic receptors by lower temperature and expression of 
chimeric subunits.  J Biol Chem. 1999 Sep 17;274(38):27145-52. 
 
Corcoran AC, Dustan HP, Page IH, Scheckloth RE.  Mecamylamine in treatment of 
hypertensive disease; observations on an unusual neuromuscular complication.  J. Am 
Med Assoc. 1956 Oct 27; 162(9): 868-75. 
 
Corringer PJ, Sallette J, Changeux JP.  Nicotine enhances intracellular nicotinic 
receptor maturation: a novel mechanism of neural plasticity?  J. Physiol Paris. 2006 
Mar-May; 99(2-3): 162-71. Epub 2006 Feb 3. 
 
Court JA, Martin-Ruiz C, Graham A, Perry E.  Nicotinic receptors in human brain: 
topography and pathology.  J Chem Neuroanat. 2000 Dec; 20(3-4): 281-98. 
 
Court JA, Piggott MA, Lloyd S, Cookson N, Ballard CG, McKeith IG, Perry RH, 
Perry EK.  Nicotine binding in human striatum: elevation in schizophrenia and 
reductions in dementia with Lewy bodies, Parkinson's disease and Alzheimer's 
disease and in relation to neuroleptic medication.  Neuroscience. 2000; 98(1): 79-87. 
 
Coward P, Chan SD, Wada HG, Humphries GM, Conklin BR.  Chimeric G proteins 
allow a high-throughput signaling assay of Gi-coupled receptors.  Anal Biochem. 
1999 Jun 1;270(2):242-8. 
 320
  
Coyle JT, McKinney M, Johnston MV, Hedreen JC.  Synaptic neurochemistry of the 
basal forebrain cholinergic projection.  Psychopharmacol Bull. 1983; 19(3): 441-7. 
 
Craig PJ, Bose S, Zwart R, Beattie RE, Folly EA, Johnson LR, Bell E, Evans NM, 
Benedetti G, Pearson KH, McPhie GI, Volsen SG, Millar NS, Sher E, Broad LM.  
Stable expression and characterisation of a human alpha 7 nicotinic subunit chimera: 
a tool for functional high-throughput screening.  Eur J Pharmacol. 2004 Oct 
11;502(1-2):31-40. 
 
Crooks PA, Dwoskin LP.  Contribution of CNS nicotine metabolites to the 
neuropharmacological effects of nicotine and tobacco smoking.  Biochem Pharmacol. 
1997 Oct 1; 54(7): 743-53. 
 
Dajas-Bailador F, Wonnacott S.  Nicotinic acetylcholine receptors and the regulation 
of neuronal signalling.  Trends Pharmacol Sci. 2004 Jun;25(6):317-24. 
 
Dalack GW, Healy DJ, Meador-Woodruff JH.  Nicotine dependence in 
schizophrenia: clinical phenomena and laboratory findings.  Am J Psychiatry. 1998 
Nov; 155(11): 1490-501. 
 
Dalsgareth OJ, Hansen NC, Soes-Petersen U, Evald T, Hoegholm A, Barber J, Vestbo 
J.  A multicenter, randomized, double-blind, placebo-controlled, 6-month trial of 
bupropion hydrochloride sustained-release tablets as an aid to smoking cessation in 
hospital employees.  Nicotine Tob. Res. 2004 Feb; 6(1): 55-61. 
 
Daly JW.  Nicotinic agonists, antagonists, and modulators from natural sources.  Cell 
Mol Neurobiol. 2005 Jun; 25(3-4): 513-52. 
 
Damaj MI, Patrick GS, Creasy KR, Martin BR.  Pharmacology of lobeline, a nicotinic 
receptor ligand.  J Pharmacol Exp Ther. 1997 Jul; 282(1): 410-9. 
 321
  
Davies AR, Hardick DJ, Blagbrough IS, Potter BV, Wolstenholme AJ, Wonnacott S.  
Characterisation of the binding of [3H]methyllycaconitine: a new radioligand for 
labelling alpha 7-type neuronal nicotinic acetylcholine receptors.  
Neuropharmacology. 1999 May; 38(5): 679-90. 
 
Davies AR, Hardick DJ, Blagbrough IS, Potter BV, Wolstenholme AJ, Wonnacott S.   
Characterisation of the binding of [3H]methyllycaconitine: a new radioligand for 
labelling alpha 7-type neuronal nicotinic acetylcholine receptors.  
Neuropharmacology. 1999 May;38(5):679-90. 
 
Davila-Garcia MI, Musachio JL, Kellar KJ.  Chronic nicotine administration does not 
increase nicotinic receptors labeled by [125I]epibatidine in adrenal gland, superior 
cervical ganglia, pineal or retina.  J. Neurochem. 2003 Jun; 85(5): 1237-46. 
 
De Biasi M, Nigro F, Xu W.  Nicotinic acetylcholine receptors in the autonomic 
control of bladder function.  Eur. J. Pharmacol. 2000 Mar 30; 393(1-3): 137-40. 
 
De Fusco M, Becchetti A, Patrignani A, Annesi G, Gambardella A, Quattrone A, 
Ballabio A, Wanke E, Casari G.  The nicotinic receptor beta 2 subunit is mutant in 
nocturnal frontal lobe epilepsy.  Nat. Genet. 2000 Nov; 26(3): 275-6. 
 
Decker MW, Meyer MD.  Therapeutic potential of neuronal nicotinic acetylcholine 
receptor agonists as novel analgesics.  Biochem Pharmacol. 1999 Sep 15; 58(6): 917-
23. 
 
Decker MW, Rueter LE, Bitner RS.  Nicotinic acetylcholine receptor agonists: a 
potential new class of analgesics.  Curr Top Med Chem. 2004; 4(3): 369-84. 
 
Decker MW.  The analgesic potential of compounds acting at acetylcholine receptors.  
Curr Opin Anaesthesiol. 1999 Oct; 12(5): 597-601. 
 322
  
Delbono O, Meissner G.  Sarcoplasmic reticulum Ca2+ release in rat slow- and fast-
twitch muscles.  J. Membr. Biol. 1996 May; 151(2): 123-30. 
 
Delle Monache G, Botta B, Delle Monache F, Espinal R, De Bonnevaux SC, De Luca 
C, Botta M, Corelli F, Carmignani M.  Novel hypotensive agents from Verbesina 
caracasana. 2. Synthesis and pharmacology of caracasanamide.  J. Med Chem. 1993 
Oct 1; 36(20): 2956-63. 
 
Deneris ES, Boulter J, Connolly J, Wada E, Wada K, Goldman D, Swanson LW, 
Patrick J, Heinemann S.  Genes encoding neuronal nicotinic acetylcholine receptors.  
Clin. Chem. 1989 May; 35(5): 731-7. 
 
Deneris ES, Boulter J, Connolly J, Wada E, Wada K, Goldman D, Swanson LW, 
Patrick J, Heinemann S.  Genes encoding neuronal nicotinic acetylcholine receptors.  
Clin. Chem. 1989 May; 35(5): 731-7. 
 
Dolly JO, Barnard EA.  Nicotinic acetylcholine receptors: an overview.  Biochem. 
Pharmacol. 1984 Mar 15; 33(6): 841-58. 
 
Donger C, Krejci E, Serradell AP, Eymard B, Bon S, Nicole S, Chateau D, Gary F, 
Fardeau M, Massoulie J, Guicheney P.  Mutation in the human acetylcholinesterase-
associated collagen gene, COLQ, is responsible for congenital myasthenic syndrome 
with end-plate acetylcholinesterase deficiency (Type Ic).  Am. J. Hum. Genet. 1998 
Oct; 63(4): 967-75. 
 
Dowell C, Olivera BM, Garrett JE, Staheli ST, Watkins M, Kuryatov A, Yoshikami 
D, Lindstrom JM, McIntosh JM.  Alpha-conotoxin PIA is selective for alpha6 
subunit-containing nicotinic acetylcholine receptors.  J Neurosci. 2003 Sep 17; 
23(24): 8445-52. 
 323
 Drago J, McColl CD, Horne MK, Finkelstein DI, Ross SA.  Neuronal nicotinic 
receptors: insights gained from gene knockout and knockin mutant mice.  Cell. Mol. 
Life Sci. 2003 Jul; 60(7): 1267-80. 
 
Dravid SM, Murray TF.  Fluorescent detection of Ca2+-permeable AMPA/kainate 
receptor activation in murine neocortical neurons. Neurosci Lett. 2003 Nov 
20;351(3):145-8. 
 
Dror O, Shulman-Peleg A, Nussinov R, Wolfson HJ. 
 
Dukat M, Glennon RA.  Epibatidine: impact on nicotinic receptor research.  Cell Mol 
Neurobiol. 2003 Jun; 23(3): 365-78. 
 
Dukat M, Ramunno A, Banzi R, Damaj MI, Martin B, Glennon RA.  3-(2-
Aminoethyl)pyridine analogs as alpha4beta2 nicotinic cholinergic receptor ligands.  
Bioorg Med Chem Lett. 2005 Oct 1; 15(19): 4308-12. 
 
Duleba AJ, Olive DL.  Regression analysis and multivariate analysis.  Semin Reprod 
Endocrinol. 1996 May;14(2):139-53.  
 
Dunlop J, Roncarati R, Jow B, Bothmann H, Lock T, Kowal D, Bowlby M, 
Terstappen GC.  In vitro screening strategies for nicotinic receptor ligands.  Biochem 
Pharmacol. 2007 Jul 10; 
 
Dwoskin LP, Joyce BM, Zheng G, Neugebauer NM, Manda VK, Lockman P, Papke 
RL, Bardo MT, Crooks PA.  Discovery of a novel nicotinic receptor antagonist for 
the treatment of nicotine addiction: 1-(3-Picolinium)-12-triethylammonium-dodecane 
dibromide (TMPD).  Biochem Pharmacol. 2007 Oct 15;74(8):1271-82. Epub 2007 Jul 
21.  
 
 
 324
 Dwoskin LP, Sumithran SP, Zhu J, Deaciuc AG, Ayers JT, Crooks PA.  Subtype-
selective nicotinic receptor antagonists: potential as tobacco use cessation agents.  
Bioorg Med Chem Lett. 2004 Apr 19; 14(8): 1863-7. 
 
Dwoskin LP, Teng L, Buxton ST, Ravard A, Deo N, Crooks PA.  Minor alkaloids of 
tobacco release [3H]dopamine from superfused rat striatal slices.  Eur. J. Pharmacol. 
1995 Mar 24; 276(1-2): 195-9. 
 
Eaton MJ, Pagan OR, Hann RM, Eterovic VA.  Differential effects of dimethyl 
sulfoxide on nicotinic acetylcholine receptors from mouse muscle and Torpedo 
electrocytes.  Neurosci Lett. 1997 Jul 25; 230(3): 163-6. 
 
Efthimiopoulos S, Vassilacopoulou D, Ripellino JA, Tezapsidis N, Robakis NK.  
Cholinergic agonists stimulate secretion of soluble full-length amyloid precursor 
protein in neuroendocrine cells.  Proc Natl Acad Sci U S A. 1996 Jul 23; 93(15): 
8046-50.  
 
Ekelund S, Nygren P, Larsson R.  Guanidino-containing drugs in cancer 
chemotherapy: biochemical and clinical pharmacology.  Biochem Pharmacol. 2001 
May 15; 61(10): 1183-93. 
 
Ellison M, McIntosh JM, Olivera BM.  Alpha-conotoxins ImI and ImII. Similar alpha 
7 nicotinic receptor antagonists act at different sites.  J. Biol Chem. 2003 Jan 10; 
278(2): 757-64. Epub 2002 Oct 15. 
 
Exley R, Clements MA, Hartung H, McIntosh JM, Cragg SJ.  alpha6-Containing 
Nicotinic Acetylcholine Receptors Dominate the Nicotine Control of Dopamine 
Neurotransmission in Nucleus Accumbens.  Neuropsychopharmacology. 2007 Nov 
21;  
 
 325
 Experimental Designs at the Crossroads of Drug Discovery, Olsson, Ing-Marie.  
Doctoral Thesis, Faculty of Science and Technology, Chemistry: Sweden 2006. 
 
Exposito A, Fernandez-Suarez M, Iglesias T, Munoz L, Riguera R.  Total synthesis 
and absolute configuration of minalemine A, a guanidine peptide from the marine 
tunicate Didemnum rodriguesi.  J. Org Chem. 2001 Jun 15; 66(12): 4206-13. 
 
Extoxnet:  University of California, Davis.  Department of Environmental 
Toxicology.  Website and Newsletter.  http://extoxnet.orst.edu/ 
 
Fenster CP, Whitworth TL, Sheffield EB, Quick MW, Lester RA.  Upregulation of 
surface alpha4beta2 nicotinic receptors is initiated by receptor desensitization after 
chronic exposure to nicotine.  J. Neurosci. 1999 Jun 15; 19(12): 4804-14. 
 
Ferretti G, Dukat M, Giannella M, Piergentili A, Pigini M, Quaglia W, Damaj MI, 
Martin BR, Glennon RA.  Chain-lengthened and imidazoline analogues of nicotine.  
Bioorg Med Chem Lett. 2000 Dec 4; 10(23): 2665-8. 
 
Fertig JB, Pomerleau OF, Sanders B.  Nicotine-produced antinociception in 
minimally deprived smokers and ex-smokers.  Addict Behav. 1986; 11(3): 239-48. 
Fighting Our Insect Enemies:  Achievements of Professional Entomology (1854-
1954). 
 
Fiore MC.  US public health service clinical practice guideline: treating tobacco use 
and dependence.  Respir. Care. 2000 Oct; 45(10): 1200-62. 
 
Fisher M, Huangfu D, Shen TY, Guyenet PG.  Epibatidine, an alkaloid from the 
poison frog Epipedobates tricolor, is a powerful ganglionic depolarizing agent.  J. 
Pharmacol Exp Ther. 1994 Aug; 270(2): 702-7. 
 
 326
 Fitch RW, Xiao Y, Kellar KJ, Daly JW.  Membrane potential fluorescence: a rapid 
and highly sensitive assay for nicotinic receptor channel function.  Proc Natl Acad Sci 
U S A. 2003 Apr 15;100(8):4909-14. Epub 2003 Mar 25. 
 
Flores CM, DeCamp RM, Kilo S, Rogers SW, Hargreaves KM.  Neuronal nicotinic 
receptor expression in sensory neurons of the rat trigeminal ganglion: demonstration 
of alpha3beta4, a novel subtype in the mammalian nervous system.  J. Neurosci. 1996 
Dec 15; 16(24): 7892-901. 
 
Flores CM, Rogers SW, Pabreza LA, Wolfe BB, Kellar KJ.  A subtype of nicotinic 
cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-
regulated by chronic nicotine treatment.  Mol. Pharmacol. 1992 Jan; 41(1): 31-7. 
 
Flores CM, Rogers SW, Pabreza LA, Wolfe BB, Kellar KJ.  A subtype of nicotinic 
cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-
regulated by chronic nicotine treatment.  Mol Pharmacol. 1992 Jan; 41(1): 31-7. 
 
Fonck C, Cohen BN, Nashmi R, Whiteaker P, Wagenaar DA, Rodrigues-Pinguet N, 
Deshpande P, McKinney S, Kwoh S, Munoz J, Labarca C, Collins AC, Marks MJ, 
Lester HA.  Novel seizure phenotype and sleep disruptions in knock-in mice with 
hypersensitive alpha 4* nicotinic receptors.  J. Neurosci. 2005 Dec 7; 25(49): 11396-
411. 
 
Fratiglioni L, Wang HX  Smoking and Parkinson's and Alzheimer's disease: review of 
the epidemiological studies.  Behav Brain Res. 2000 Aug; 113(1-2): 117-20. 
 
Freedman R, Adler LE, Myles-Worsley M, Nagamoto HT, Miller C, Kisley M, 
McRae K, Cawthra E, Waldo M.  Inhibitory gating of an evoked response to repeated 
auditory stimuli in schizophrenic and normal subjects. Human recordings, computer 
simulation, and an animal model.  Arch Gen Psychiatry. 1996 Dec; 53(12): 1114-21. 
 
 327
 Fryer JD, Lukas RJ.  Antidepressants noncompetitively inhibit nicotinic acetylcholine 
receptor function.  J. Neurochem. 1999 Mar; 72(3): 1117-24. 
     
Fucile S, Renzi M, Lax P, Eusebi F.  Fractional Ca(2+) current through human 
neuronal alpha7 nicotinic acetylcholine receptors.  Cell Calcium. 2003 Aug; 34(2): 
205-9. 
 
Fucile S.  Ca2+ permeability of nicotinic acetylcholine receptors.  Cell Calcium. 2004 
Jan; 35(1): 1-8. 
 
Galzi JL, Revah F, Bessis A, Changeux JP.  Functional architecture of the nicotinic 
acetylcholine receptor: from electric organ to brain.  Ann. Rev. Pharmacol. Toxicol. 
1991; 31: 37-72. 
 
Gatto GJ, Bohme GA, Caldwell WS, Letchworth SR, Traina VM, Obinu MC, Laville 
M, Reibaud M, Pradier L, Dunbar G, Bencherif M.  TC-1734: an orally active 
neuronal nicotinic acetylcholine receptor modulator with antidepressant, 
neuroprotective and long-lasting cognitive effects.  CNS Drug Rev. 2004 Summer; 
10(2): 147-66. 
 
Gee VJ, Kracun S, Cooper ST, Gibb AJ, Millar NS.  Identification of domains 
influencing assembly and ion channel properties in alpha7 nicotinic receptor and 5-
HT(3) receptor subunit chimaeras.  Br J Pharmacol. 2007 Aug 27; 
 
Geladi P, Kowalski BR, Partial Least Squares: A Tutorial.  Anals Chem Acta 1986, 
185, 1-17 
 
George TP, Vessicchio JC, Termine A, Sahady DM, Head CA, Pepper WT, Kosten 
TR, Wexler BE.  Effects of smoking abstinence on visuospatial working memory 
function in schizophrenia.  Neuropsychopharmacology. 2002 Jan; 26(1): 75-85. 
 
 328
 Gerdeman GL, Partridge JG, Lupica CR, Lovinger DM.  It could be habit forming: 
drugs of abuse and striatal synaptic plasticity.  Trends Neurosci. 2003 Apr; 26(4): 
184-92. 
 
German DC, Manaye K, Smith WK, Woodward DJ, Saper CB.  Midbrain 
dopaminergic cell loss in Parkinson's disease: computer visualization.  Ann. Neurol. 
1989 Oct; 26(4): 507-14. 
 
Gerzanich V, Kuryatov A, Anand R, Lindstrom J.  "Orphan" alpha6 nicotinic AChR 
subunit can form a functional heteromeric acetylcholine receptor.  Mol. Pharmacol. 
1997 Feb; 51(2): 320-7. 
 
Gerzanich V, Peng X, Wang F, Wells G, Anand R, Fletcher S, Lindstrom J.  
Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic 
acetylcholine receptors.  Mol. Pharmacol. 1995 Oct; 48(4): 774-82. 
 
Giniatullin R, Nistri A, Yakel JL.  Desensitization of nicotinic ACh receptors: 
shaping cholinergic signaling.  Trends Neurosci. 2005 Jul; 28(7): 371-8. 
 
Giniatullin R, Nistri A, Yakel JL.  Desensitization of nicotinic ACh receptors: 
shaping cholinergic signaling.  Trends Neurosci. 2005 Jul; 28(7): 371-8. 
 
Glassman AH, Helzer JE, Covey LS, Cottler LB, Stetner F, Tipp JE, Johnson J.  
Smoking, smoking cessation, and major depression.  JAMA. 1990 Sep 26; 264(12): 
1546-9. 
 
Glennon RA, Dukat M, Liao L.  Musings on alpha4beta2 nicotinic acetylcholine 
(nACh) receptor pharmacophore models.  Curr Top Med Chem. 2004; 4(6): 631-44. 
 
Glennon RA, Dukat M.  alpha4beta2 nACh receptor pharmacophore models.  Bioorg 
Med Chem Lett. 2004 Apr 19; 14(8): 1841-4. 
 329
  
Glennon RA, Dukat M.  Central nicotinic receptor ligands and pharmacophores.  
Pharm Acta Helv. 2000 Mar; 74(2-3): 103-14. 
 
Goff DC, Henderson DC, Amico E.  Cigarette smoking in schizophrenia: relationship 
to psychopathology and medication side effects.  Am J Psychiatry. 1992 Sep; 149(9): 
1189-94. 
 
Goldin SM, Subbarao K, Sharma R, Knapp AG, Fischer JB, Daly D, Durant GJ, 
Reddy NL, Hu LY, Magar S, et al.  Neuroprotective use-dependent blockers of Na+ 
and Ca2+ channels controlling presynaptic release of glutamate.   Ann. N Y Acad Sci. 
1995 Sep 15; 765: 210-29. 
 
Goldman D, Evans S, Boulter J, Patrick J, Heinemann S.  Neural regulation of 
acetylcholine receptor gene expression.  Ann. N Y Acad. Sci. 1987; 505: 286-300. 
 
Gopalakrishnan M, Molinari EJ, Sullivan JP.  Regulation of human alpha4beta2 
neuronal nicotinic acetylcholine receptors by cholinergic channel ligands and second 
messenger pathways.  Mol. Pharmacol. 1997 Sep; 52(3): 524-34. 
 
Gorell JM, Rybicki BA, Johnson CC, Peterson EL.  Smoking and Parkinson's disease: 
a dose-response relationship.  Neurology. 1999 Jan 1; 52(1): 115-9. 
 
Gotti C, Riganti L, Vailati S, Clementi F.  Brain neuronal nicotinic receptors as new 
targets for drug discovery.  Curr Pharm Des. 2006;12(4):407-28. 
 
Gotti C, Carbonnelle E, Moretti M, Zwart R, Clementi F.  Drugs selective for 
nicotinic receptor subtypes: a real possibility or a dream?  Behav Brain Res. 2000 
Aug;113(1-2):183-92.  
 
 330
 Gotti C, Fornasari D, Clementi F.  Human neuronal nicotinic receptors.  Prog 
Neurobiol. 1997 Oct; 53(2): 199-237. 
 
Gould TJ.  Nicotine produces a within-subject enhancement of contextual fear 
conditioning in C57BL/6 mice independent of sex.  Integr Physiol Behav Sci. 2003 
Apr-Jun; 38(2): 124-32. 
 
Grady SR, Meinerz NM, Cao J, Reynolds AM, Picciotto MR, Changeux JP, McIntosh 
JM, Marks MJ, Collins AC.  Nicotinic agonists stimulate acetylcholine release from 
mouse interpeduncular nucleus: a function mediated by a different nAChR than 
dopamine release from striatum.  J. Neurochem. 2001 Jan; 76(1): 258-68. 
 
Green TA, Crooks PA, Bardo MT, Dwoskin LP.  Contributory role for nornicotine in 
nicotine neuropharmacology: nornicotine-evoked [3H]dopamine overflow from rat 
nucleus accumbens slices.  Biochem Pharmacol. 2001 Dec 15; 62(12): 1597-603. 
 
Green WN, Millar NS.  Ion-channel assembly.  Trends Neurosci. 1995 Jun; 18(6): 
280-7. 
 
Grinevich VP, Crooks PA, Sumithran SP, Haubner AJ, Ayers JT, Dwoskin LP.  N-n-
alkylpyridinium analogs, a novel class of nicotinic receptor antagonists: selective 
inhibition of nicotine-evoked [3H] dopamine overflow from superfused rat striatal 
slices.  J Pharmacol Exp Ther. 2003 Sep;306(3):1011-20. Epub 2003 May 23. 
 
Grinevich VP, Letchworth SR, Lindenberger KA, Menager J, Mary V, Sadieva KA, 
Buhlman LM, Bohme GA, Pradier L, Benavides J, Lukas RJ, Bencherif M.  
Heterologous expression of human {alpha}6{beta}4{beta}3{alpha}5 nicotinic 
acetylcholine receptors: binding properties consistent with their natural expression 
require quaternary subunit assembly including the {alpha}5 subunit.  J. Pharmacol. 
Exp. Ther. 2005 Feb; 312(2): 619-26. Epub 2004 Sep 8. 
 
 331
 Grutter T, Changeux JP.  Nicotinic receptors in wonderland.  Trends Biochem. Sci. 
2001 Aug; 26(8): 459-63. 
 
Grutter T, Le Novere N, Changeux JP.  Rational understanding of nicotinic receptors 
drug binding.  Curr Top Med Chem. 2004;4(6):645-50. 
 
Grynkiewicz G, Poenie M, Tsien RY.  A new generation of Ca2+ indicators with 
greatly improved fluorescence properties.  J Biol Chem. 1985 Mar 25;260(6):3440-
50. 
 
Guan ZZ, Miao H, Tian JY, Unger C, Nordberg A, Zhang X.  Suppressed expression 
of nicotinic acetylcholine receptors by nanomolar beta-amyloid peptides in PC12 
cells.  J. Neural. Transm. 2001; 108(12): 1417-33. 
 
Hajos M, Hurst RS, Hoffmann WE, Krause M, Wall TM, Higdon NR, Groppi VE.  
The selective alpha7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-
1-Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances 
GABAergic synaptic activity in brain slices and restores auditory gating deficits in 
anesthetized rats.  J Pharmacol Exp Ther. 2005 Mar; 312(3): 1213-22. Epub 2004 
Nov 2. 
 
Hanna C, Macmillan WH, McHugo PB.  Neuromuscular blocking action of dihydro-
beta-erythroidine.  Arch Int Pharmacodyn Ther. 1960 Mar 1; 124: 445-54. 
 
Harkness PC, Millar NS.  Changes in conformation and subcellular distribution of 
alpha4beta2 nicotinic acetylcholine receptors revealed by chronic nicotine treatment 
and expression of subunit chimeras.  J Neurosci. 2002 Dec 1;22(23):10172-81. 
 
Harvey SC, Luetje CW.  Determinants of competitive antagonist sensitivity on 
neuronal nicotinic receptor beta subunits.  J Neurosci. 1996 Jun 15;16(12):3798-806. 
 332
 Harvey SC, McIntosh JM, Cartier GE, Maddox FN, Luetje CW.  Determinants of 
specificity for alpha-conotoxin MII on alpha3beta2 neuronal nicotinic receptors.  
Mol. Pharmacol. 1997 Feb; 51(2): 336-42. 
 
Hatsukami DK, Severson HH.  Oral spit tobacco: addiction, prevention and treatment.  
Nicotine Tob Res. 1999 Mar; 1(1): 21-44. 
 
Hattori T, Yasuda K, Kita K, Hirayama K.  Voiding dysfunction in Parkinson's 
disease.  Jpn. J Psychiatry Neurol. 1992 Mar; 46(1): 181-6. 
 
Hattotuwagama CK, Davies MN, Flower DR.  Receptor-ligand binding sites and 
virtual screening.  Curr Med Chem. 2006;13(11):1283-304.  
 
Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO.  The Fagerstrom Test 
for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire.  Br. 
J. Addict. 1991 Sep; 86(9): 1119-27. 
 
Heinemann S, Boulter J, Connolly J, Deneris E, Duvoisin R, Hartley M, Hermans-
Borgmeyer I, Hollmann M, O'Shea-Greenfield A, Papke R, et al.  The nicotinic 
receptor genes.  Clin. Neuropharmacol. 1991; 14 Suppl 1:  S45-61. 
 
Hellstrom-Lindahl E, Court J, Keverne J, Svedberg M, Lee M, Marutle A, Thomas A, 
Perry E, Bednar I, Nordberg A.  Nicotine reduces A beta in the brain and cerebral 
vessels of APPsw mice.  Eur. J. Neurosci. 2004 May; 19(10): 2703-10. 
 
Henningfield JE, Fant RV, Buchhalter AR, Stitzer ML.   Pharmacotherapy for 
nicotine dependence.  CA Cancer J Clin. 2005 Sep-Oct; 55(5): 281-99; quiz 322-3, 
325. 
 
Henningfield JE.   Nicotine medications for smoking cessation.  N. Engl. J. Med. 
1995 Nov 2; 333(18): 1196-203. 
 333
  
Hey P.  On relationships between structure and nicotine-like stimulant activity in 
choline esters and ethers.  Br J Pharmacol Chemother. 1952 Mar; 7(1): 117-29. 
 
Hodder P, Mull R, Cassaday J, Berry K, Strulovici B.  Miniaturization of intracellular 
calcium functional assays to 1536-well plate format using a fluorometric imaging 
plate reader.  J Biomol Screen. 2004 Aug;9(5):417-26. 
 
Hogg RC, Raggenbass M, Bertrand D.  Nicotinic acetylcholine receptors: from 
structure to brain function.  Rev. Physiol. Biochem. Pharmacol. 2003; 147: 1-46. 
 
Hogue CW Jr, Ward JM, Itani MS, Martyn JA.  Tolerance and upregulation of 
acetylcholine receptors follow chronic infusion of d-tubocurarine.  J Appl Physiol. 
1992 Apr; 72(4): 1326-31. 
 
Holm KJ, Spencer CM.  Bupropion: a review of its use in the management of 
smoking cessation.  Drugs. 2000 Apr; 59(4): 1007-24. 
 
Houghtling RA, Davila-Garcia MI, Kellar KJ.  Characterization of (+/-)(-)[3H] 
epibatidine binding to nicotinic cholinergic receptors in rat and human brain.  Mol 
Pharmacol. 1995 Aug; 48(2): 280-7. 
 
http://entweb.clemson.edu/pesticid/history.htm 
 
Hughes BW, Moro De Casillas ML, Kaminski HJ.  Pathophysiology of myasthenia 
gravis.  Semin. Neurol. 2004 Mar; 24(1): 21-30. 
 
Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale LC, Khayrallah MA, 
Schroeder DR, Glover PN, Sullivan CR, Croghan IT, Sullivan PM.  A comparison of 
sustained-release bupropion and placebo for smoking cessation.  N. Engl. J. Med. 
1997 Oct 23; 337(17): 1195-202. 
 334
  
Hussy N, Ballivet M, Bertrand D.  Agonist and antagonist effects of nicotine on chick 
neuronal nicotinic receptors are defined by alpha and beta subunits.  J. Neurophysiol. 
1994 Sep; 72(3): 1317-26. 
 
Ishikawa A, Miyatake T.  Effects of smoking in patients with early-onset Parkinson's 
disease.  J. Neurol Sci. 1993 Jul;117(1-2):28-32. 
 
Itier V, Bertrand D.  Neuronal nicotinic receptors: from protein structure to function. 
FEBS Lett. 2001 Aug 31; 504(3): 118-25. 
Jensen AA, Frolund B, Liljefors T, Krogsgaard-Larsen P.  Neuronal nicotinic 
acetylcholine receptors: structural revelations, target identifications, and therapeutic 
inspirations.  J. Med Chem. 2005 Jul 28; 48(15): 4705-45. 
 
Jensen AA, Mikkelsen I, Frolund B, Frydenvang K, Brehm L, Jaroszewski JW, 
Brauner-Osborne H, Falch E, Krogsgaard-Larsen P.  Carbamoylcholine homologs: 
synthesis and pharmacology at nicotinic acetylcholine receptors.  Eur. J. Pharmacol. 
2004 Aug 23; 497(2): 125-37. 
 
Jensen AA, Mikkelsen I, Frolund B, Frydenvang K, Brehm L, Jaroszewski JW, 
Brauner-Osborne H, Falch E, Krogsgaard-Larsen P.  Carbamoylcholine homologs: 
synthesis and pharmacology at nicotinic acetylcholine receptors.  Eur.  J Pharmacol. 
2004 Aug 23; 497(2): 125-37. 
 
Jursic BS, Neumann D, MacPherson A.  Preparation of N-formamidinylamino acids 
from amino and formamidinesulfinic acids.  Synthesis 12; 1656-1658 2000.   
 
Kadesjo B, Gillberg C.  Tourette's disorder: epidemiology and comorbidity in primary 
school children.  J. Am Acad Child Adolesc Psychiatry. 2000 May; 39(5): 548-55. 
 
 335
 Kane JM, Honigfeld G, Singer J, Meltzer H.  Clozapine in treatment-resistant 
schizophrenics.  Psychopharmacol Bull. 1988; 24(1) 62-7. 
 
Karczmark AG.  The Otto Loewi Lecture. Loewi's discovery and the XXI century.  
Prog. Brain Res. 109: 1-27, 1996.   
 
Karlin A, Akahabas MH.  Toward a structural basis for the function of nicotinic 
acetylcholine receptors and their cousins.  Neuron. 1995 Dec; 15(6): 1231-44. 
 
Karlin A.  A touching picture of nicotinic binding.  Neuron. 2004 Mar 25; 41(6): 841-
2. 
Karlin A.  Emerging structure of the nicotinic acetylcholine receptors. 
Nat. Rev. Neurosci. 2002 Feb; 3(2): 102-14. 
 
Karlin A.  Structure of nicotinic acetylcholine receptors.  Curr. Opin. Neurobiol. 
1993 Jun; 3(3): 299-309. 
 
Kelton MC, Kahn HJ, Conrath CL, Newhouse PA.  The effects of nicotine on 
Parkinson's disease.  Brain Cogn. 2000 Jun-Aug; 43(1-3): 274-82. 
 
Kem WR, Mahnir VM, Papke RL, Lingle CJ.  Anabaseine is a potent agonist on 
muscle and neuronal alpha-bungarotoxin-sensitive nicotinic receptors.  J. Pharmacol 
Exp Ther. 1997 Dec; 283(3): 979-92. 
 
Kenakin T.  Synoptic receptor function.  Trends Pharmacol Sci. 1993 Dec; 
14(12):431-2. 
 
Kenakin TP.  A Pharmacological Primer: Theory, Application and Methods.  Dec 
2003, Academic Press, 214p. ISBN-10:  0124041612    
 
 336
 Kenakin TP.  Pharmacologic Analysis of Drug-Receptor Interaction.  Raven Press, 
2nd Ed. Aug 1993.  496pg.  ISBN-10:  0781700655. 
 
Khiroug SS, Harkness PC, Lamb PW, Sudweeks SN, Khiroug L, Millar NS, Yakel 
JL.  Rat nicotinic ACh receptor alpha7 and beta2 subunits co-assemble to form 
functional heteromeric nicotinic receptor channels.  J Physiol. 2002 Apr 15; 540(Pt 
2): 425-34. 
 
Kier LB.  A molecular orbital calculation of the preferred conformation of nicotine.  
Mol Pharmacol. 1968 Jan; 4(1): 70-6. 
Kihara T, Shimohama S, Urushitani M, Sawada H, Kimura J, Kume T, Maeda T, 
Akaike A.  Stimulation of alpha4beta2 nicotinic acetylcholine receptors inhibits beta-
amyloid toxicity.  Brain Res. 1998 May 11; 792(2): 331-4. 
 
Kilbourn MR, Zalutsky MR.   Research and clinical potential of receptor based 
radiopharmaceuticals.  J Nucl Med. 1985 Jun;26(6):655-62. 
 
Killen JD, Fortmann SP, Schatzberg A, Hayward C, Varady A.  Onset of major 
depression during treatment for nicotine dependence.  Addict Behav. 2003 Apr; 28(3): 
461-70. 
 
King’s American Dispensatory by Harvey Wickes Felter, M.D., and John Uri Lloyd, 
Phr. M., Ph. D., 1898.  http://www.henriettesherbal.com/eclectic/kings/index.html 
Klebe G.  Recent developments in structure-based drug design. J Mol Med. 
2000;78(5):269-81.  
 
Kövesdi I, Dominguez-Rodriguez MF, Orfi L, Náray-Szabó G, Varró A, Papp JG, 
Mátyus P.  Application of neural networks in structure-activity relationships.  Med 
Res Rev. 1999 May;19(3):249-69.  
 
 337
 Kunath W, Giersig M, Hucho F.  The electron microscopy of the nicotinic 
acetylcholine receptor.  Electron Microsc. Rev. 1989; 2(2): 349-66. 
 
Kuryatov A, Olale F, Cooper J, Choi C, Lindstrom J.  Human alpha6 AChR subtypes: 
subunit composition, assembly, and pharmacological responses.  
Neuropharmacology. 2000 Oct; 39(13): 2570-90. 
 
Lam S, Patel PN.  Varenicline: a selective alpha4beta2 nicotinic acetylcholine 
receptor partial agonist approved for smoking cessation.  Cardiol Rev. 2007 May-
Jun;15(3):154-61 
 
Lancaster T, Stead LF.  Mecamylamine (a nicotine antagonist) for smoking cessation.  
Cochrane Database Syst Rev. 2000; (2): CD001009. 
 
Langley J.N.  On the contraction of muscle, chiefly in relation to the presence of 
"receptive" substances: Part I.  J.Physiology 36: 347-384, 1907. 
 
Lansdell SJ, Gee VJ, Harkness PC, Doward AI, Baker ER, Gibb AJ, Millar NS.  RIC-
3 enhances functional expression of multiple nicotinic acetylcholine receptor 
subtypes in mammalian cells.  Mol. Pharmacol.2005; 68(5):1431-8.  
 
Law RJ, Forrest LR, Ranatunga KM, La Rocca P, Tieleman DP, Sansom MS.  
Structure and dynamics of the pore-lining helix of the nicotinic receptor: MD 
simulations in water, lipid bilayers, and transbilayer bundles.  Proteins. 2000 Apr 1; 
39(1): 47-55. 
 
Lawrence NS, Ross TJ, Stein EA.  Cognitive mechanisms of nicotine on visual 
attention.  Neuron. 2002 Oct 24; 36(3): 539-48. 
 
 338
 Le Novere N, Changeux JP.  Molecular evolution of the nicotinic acetylcholine 
receptor: an example of multigene family in excitable cells.  J. Mol. Evol. 1995 Feb; 
40(2): 155-72. 
 
Le Novere N, Corringer PJ, Changeux JP.  The diversity of subunit composition in 
nAChRs: evolutionary origins, physiologic and pharmacologic consequences.  J. 
Neurobiol. 2002 Dec; 53(4): 447-56. 
 
Le Novère N, Grutter T, Changeux JP.  Models of the extracellular domain of the 
nicotinic receptors and of agonist- and Ca2+-binding sites.  Proc Natl Acad Sci U S 
A. 2002 Mar 5;99(5):3210-5. Epub 2002 Feb 26.  
 
Lee CY, Tseng LF, Chiu TH. Influence of denervation on localization of neurotoxins 
from clapid venoms in rat diaphragm. Nature. 1967 Sep 9; 215(5106): 1177–1178 
 
Lehmann J, Briley M, Langer SZ.  Characterization of dopamine autoreceptor and 
[3H]spiperone binding sites in vitro with classical and novel dopamine receptor 
agonists.  Eur. J. Pharmacol. 1983 Mar 18; 88(1): 11-26. 
 
Lena C, Changeux JP, Mulle C.  Evidence for "preterminal" nicotinic receptors on 
GABA-ergic axons in the rat interpeduncular nucleus.    J. Neurosci. 1993 Jun; 13(6): 
2680-8. 
 
Leonard S, Adams C, Breese CR, Adler LE, Bickford P, Byerley W, Coon H, Griffith 
JM, Miller C, Myles-Worsley M, Nagamoto HT, Rollins Y, Stevens KE, Waldo M, 
Freedman R.  Nicotinic receptor function in schizophrenia.  Schizophr Bull. 1996; 
22(3): 431-45. 
 
Leonard S, Bertrand D.  Neuronal nicotinic receptors: from structure to function. 
Nicotine Tob. Res. 2001 Aug;3(3): 203-23. 
 
 339
 Leutje CW.  Getting past the asterisk: the subunit composition of presynaptic 
nicotinic receptors that modulate striatal dopamine release.  Mol. Pharmacol. 2004 
Jun; 65(6): 1333-5. 
 
Levallet C, Lerpiniere J, Ko SY.  The HgCl2-promoted guanylation reaction; the 
scope and limitations.  Tetrahedron 43(14); 5291-5304  1997. 
 
Levin BE, Katzen HL.  Early cognitive changes and nondementing behavioral 
abnormalities in Parkinson's disease.  Adv Neurol. 2005; 96: 84-94. 
 
Levin ED, McClernon FJ, Rezvani AH.  Nicotinic effects on cognitive function: 
behavioral characterization, pharmacological specification, and anatomic localization.  
Psychopharmacology (Berl). 2006 Mar; 184(3-4): 523-39. Epub 2005 Oct 12. 
 
Levin ED.  Nicotinic systems and cognitive function.  Psychopharmacology (Berl). 
1992; 108(4): 417-31. 
 
Li J, Zhang G, Zhang Z, Fan E.  TFA-sensitive arylsulfonylthiourea-assisted 
synthesis of N,N'-substituted guanidines.  J Org Chem. 2003 Feb 21; 68(4): 1611-4. 
 
Lichtensteiger W, Hefti F, Felix D, Huwyler T, Melamed E, Schlumpf M.  
Stimulation of nigrostriatal dopamine neurones by nicotine.  Neuropharmacology. 
1982 Oct; 21(10): 963-8. 
 
Lindstrom J, Anand R, Gerzanich V, Peng X, Wang F, Wells G.  Structure and 
function of neuronal nicotinic acetylcholine receptors.  Prog. Brain Res. 1996; 109: 
125-37. 
 
Lindstrom J, Anholt R, Einarson B, Engel A, Osame M, Montal M.  Purification of 
acetylcholine receptors, reconstitution into lipid vesicles, and study of agonist-
induced cation channel regulation.  J. Biol. Chem. 1980 Sep 10; 255(17): 8340-50.   
 340
  
Lindstrom J, Criado M, Ratnam M, Whiting P, Ralston S, Rivier J, Sarin V, Sargent 
P.  Using monoclonal antibodies to determine the structures of acetylcholine receptors 
from electric organs, muscles, and neurons. Ann. N Y. Acad. Sci. 1987; 505: 208-25. 
Lindstrom JM.  Acetylcholine receptors and myasthenia.  Muscle Nerve. 2000 Apr; 
23(4): 453-77. 
 
Linton BR, Carr AJ, Orner BP, Hamilton AD.  A versatile one-Pot synthesis of 1,3-
substituted guanidines from carbamoyl isothiocyanates.  J. Org Chem. 2000 Mar 10; 
65(5): 1566-8. 
 
Lippiello PM, Sears SB, Fernandes KG.  Kinetics and mechanism of L-[3H]nicotine 
binding to putative high affinity receptor sites in rat brain.  Mol. Pharmacol. 1987 
Apr; 31(4): 392-400. 
 
Liu C, Nordberg A, Zhang X.  Differential co-expression of nicotinic acetylcholine 
receptor alpha 4 and beta 2 subunit genes in various regions of rat brain.  
Neuroreport. 1996 Jul 8; 7(10): 1645-9. 
 
Liu Q, Kawai H, Berg DK.  beta -Amyloid peptide blocks the response of alpha 7-
containing nicotinic receptors on hippocampal neurons.  Proc Natl Acad Sci U S A. 
2001 Apr 10; 98(8): 4734-9. Epub 2001 Mar 27. 
 
Livett BG, Sandall DW, Keays D, Down J, Gayler KR, Satkunanathan N, Khalil Z.  
Therapeutic applications of conotoxins that target the neuronal nicotinic acetylcholine 
receptor.  Toxicon. 2006 Dec 1; 48(7): 810-29. Epub 2006 Jul 15. 
 
Lloyd KG, Davidson L, Hornykiewicz O.  The neurochemistry of Parkinson's 
disease: effect of L-dopa therapy.  J Pharmacol Exp Ther. 1975 Dec; 195(3): 453-64. 
 
 341
 Lohr JB, Flynn K.  Smoking and schizophrenia.  Schizophr Res. 1992 Dec; 8(2): 93-
102. 
 
Loiacono R, Stephenson J, Stevenson J, Mitchelson F.  Multiple binding sites for 
nicotine receptor antagonists in inhibiting [3H](-)-nicotine binding in rat cortex.  
Neuropharmacology. 1993 Sep; 32(9): 847-53. 
 
London ED, Scheffel U, Kimes AS, Kellar KJ.  In vivo labeling of nicotinic 
acetylcholine receptors in brain with [3H]epibatidine.  Eur J Pharmacol. 1995 May 4; 
278(1): R1-2. 
 
Lucas-Meunier E, Fossier P, Baux G, Amar M.  Cholinergic modulation of the 
cortical neuronal network.  Pflugers Arch. 2003 Apr; 446(1): 17-29. 
 
Luetje CW, Patrick J, Seguela P.  Nicotine receptors in the mammalian brain.  FASEB 
J. 1990 Jul; 4(10): 2753-60. 
 
Luetje CW, Patrick J.  Both alpha- and beta-subunits contribute to the agonist 
sensitivity of neuronal nicotinic acetylcholine receptors.  J. Neurosci. 1991 Mar; 
11(3): 837-45. 
 
Lukas RJ, Cullen MJ.  An isotopic rubidium ion efflux assay for the functional 
characterization of nicotinic acetylcholine receptors on clonal cell lines.  Anal 
Biochem. 1988 Nov 15;175(1):212-8. 
 
Luntz-Leybman V, Bickford PC, Freedman R.  Cholinergic gating of response to 
auditory stimuli in rat hippocampus.  Brain Res. 1992 Jul 31; 587(1): 130-6. 
 
Macallan DR, Lunt GG, Wonnacott S, Swanson KL, Rapoport H, Albuquerque EX.  
Methyllycaconitine and (+)-anatoxin-a differentiate between nicotinic receptors in 
vertebrate and invertebrate nervous systems.  FEBS Lett. 1988 Jan 4;226(2):357-63. 
 342
  
Maelicke A, Samochocki M, Jostock R, Fehrenbacher A, Ludwig J, Albuquerque EX, 
Zerlin M.  Allosteric sensitization of nicotinic receptors by galantamine, a new 
treatment strategy for Alzheimer's disease.  Biol. Psychiatry. 2001 Feb 1; 49(3): 279-
88. 
 
Maelicke A.  Allosteric modulation of nicotinic receptors as a treatment strategy for 
Alzheimer's disease.  Dement Geriatr Cogn Disord. 2000 Sep; 11 Suppl 1: 11-8. 
 
Maillard MC, Perlman ME, Amitay O, Baxter D, Berlove D, Connaughton S, Fischer 
JB, Guo JQ, Hu LY, McBurney RN, Nagy PI, Subbarao K, Yost EA, Zhang L, 
Durant GJ.  Design, synthesis, and pharmacological evaluation of conformationally 
constrained analogues of N,N'-diaryl- and N-aryl-N-aralkylguanidines as potent 
inhibitors of neuronal Na+ channels.  J Med Chem. 1998 Jul 30; 41(16): 3048-61. 
 
Mancuso G, Warburton DM, Melen M, Sherwood N, Tirelli E.  Selective effects of 
nicotine on attentional processes.  Psychopharmacology (Berl). 1999 Sep; 146(2): 
199-204. 
 
Mansvelder HD, De Rover M, McGehee DS, Brussaard AB.  Cholinergic modulation 
of dopaminergic reward areas: upstream and downstream targets of nicotine 
addiction.  Eur. J. Pharmacol. 2003 Nov 7; 480(1-3): 117-23. 
 
Mansvelder HD, McGehee DS.  Cellular and synaptic mechanisms of nicotine 
addiction.  J. Neurobiol. 2002 Dec; 53(4): 606-17. 
 
Mansvelder HD, van Aerde KI, Couey JJ, Brussaard AB.  Nicotinic modulation of 
neuronal networks: from receptors to cognition.  Psychopharmacology (Berl). 2006 
Mar; 184(3-4): 292-305. Epub 2005 Jul 2. 
 
 343
 Marks MJ, Burch JB, Collins AC.  Effects of chronic nicotine infusion on tolerance 
development and nicotinic receptors.  J. Pharmacol Exp Ther. 1983 Sep; 226(3): 817-
25. 
 
Marks MJ, Grady SR, Collins AC. Downregulation of nicotinic receptor function 
after chronic nicotine infusion.  J. Pharmacol Exp Ther. 1993 Sep; 266(3): 1268-76. 
 
Marks MJ, Pauly JR, Gross SD, Deneris ES, Hermans-Borgmeyer I, Heinemann SF, 
Collins AC.  Nicotine binding and nicotinic receptor subunit RNA after chronic 
nicotine treatment.  J Neurosci. 1992 Jul; 12(7): 2765-84. 
 
Martin BR, Aceto MD.   Nicotine binding sites and their localization in the central 
nervous system.  Neurosci Biobehav Rev. 1981 Winter;5(4):473-8. 
 
Martin YC. Quantitative Drug Design:  A Critical Introduction.  Marcel Dekker: New 
York 1978. 
 
Marubio LM, Changeux J.  Nicotinic acetylcholine receptor knockout mice as animal 
models for studying receptor function.  Eur. J. Pharmacol. 2000 Mar 30; 393(1-3): 
113-21.   
 
Marubio LM, del Mar Arroyo-Jimenez M, Cordero-Erausquin M, Lena C, Le Novere 
N, de Kerchove d'Exaerde A, Huchet M, Damaj MI, Changeux JP.  Reduced 
antinociception in mice lacking neuronal nicotinic receptor subunits.  Nature. 1999 
Apr 29; 398(6730): 805-10. 
 
Maryanoff CA, Stanzione RC, Plampin JN, Mills JE.  A convenient synthesis of 
guanidines from thioureas.  J. Org. Chem.  51; 1882-1884 1986. 
 
 344
 Maselli RA, Kong DZ, Bowe CM, McDonald CM, Ellis WG, Agius MA, Gomez 
CM, Richman DP, Wollmann RL.  Presynaptic congenital myasthenic syndrome due 
to quantal release deficiency.  Neurology. 2001 Jul 24; 57(2): 279-89. 
 
Matter H, Baringhaus KH, Naumann T, Klabunde T, Pirard B.  Computational 
approaches towards the rational design of drug-like compound libraries.  Comb Chem 
High Throughput Screen. 2001 Sep;4(6):453-75.  
 
McCallum SE, Parameswaran N, Bordia T, McIntosh JM, Grady SR, Quik M.  
Decrease in alpha3*/alpha6* nicotinic receptors but not nicotine-evoked dopamine 
release in monkey brain after nigrostriatal damage.  Mol. Pharmacol. 2005 Sep; 
68(3): 737-46. Epub 2005 Jun 2. 
 
McCallum SE, Parameswaran N, Bordia T, McIntosh JM, Grady SR, Quik M.  
Decrease in alpha3*/alpha6* nicotinic receptors but not nicotine-evoked dopamine 
release in monkey brain after nigrostriatal damage.  Mol. Pharmacol. 2005 Sep; 
68(3): 737-46. Epub 2005 Jun 2. 
 
McGehee DS, Role LW.  Presynaptic ionotropic receptors.  Curr. Opin. Neurobiol. 
1996 Jun; 6(3): 342-9. 
 
McNamee MG, Ochoa EL.  Reconstitution of acetylcholine receptor function in 
model membranes.  Neuroscience. 1982 Oct; 7(10): 2305-19. 
 
Mekenyan O.  Dynamic QSAR techniques: applications in drug design and 
toxicology.  Curr Pharm Des. 2002;8(17):1605-21.  
 
Middleton LS, Crooks PA, Wedlund PJ, Cass WA, Dwoskin LP.  Nornicotine 
inhibition of dopamine transporter function in striatum via nicotinic receptor 
activation.  Synapse. 2007 Mar; 61(3): 157-65. 
 
 345
 Miledi R, Potter LT.  Acetylcholine receptors in muscle fibres.  Nature. 1971 Oct 29; 
233(5322): 599-603. 
 
Millar NS.  Assembly and subunit diversity of nicotinic acetylcholine receptors.  
Biochem Soc Trans. 2003 Aug;31(Pt 4):869-74. 
 
Milone M, Ohno K, Fukudome T, Shen XM, Brengman J, Griggs RC, Engel AG.  
Congenital myasthenic syndrome caused by novel loss-of-function mutations in the 
human AChR epsilon subunit gene.  Ann. N Y Acad. Sci. 1998 May 13; 841: 184-8. 
 
Min SK, Moon IW, Ko RW, Shin HS.  Effects of transdermal nicotine on attention 
and memory in healthy elderly non-smokers.  Psychopharmacology (Berl). 2001 Dec; 
159(1): 83-8. Epub 2001 Sep 15. 
 
Minta A, Kao JP, Tsien RY.  Fluorescent indicators for cytosolic calcium based on 
rhodamine and fluorescein chromophores.  J Biol Chem. 1989 May 15;264(14):8171-
8. 
 
Mitchell TJ, Tute MS, Webb GA.  A molecular modelling study of the interaction of 
noradrenaline with the beta 2-adrenergic receptor.  J Comput Aided Mol Des. 1989 
Sep;3(3):211-23.  
 
Miyazawa A, Fujiyoshi Y, Stowell M, Unwin N.  Nicotinic acetylcholine receptor at 
4.6 A resolution: transverse tunnels in the channel wall.  J. Mol. Biol. 1999 May 14; 
288(4): 765-86. 
 
MMWR; Morbidity and Mortality Weekly Reports.  Annual smoking-attributable 
mortality, years of potential life lost, and economic cost-United States, 1995-
1999.Centers for Disease Control and Prevention, 2002 Apr 12; 51(14): 300-3. 
 
 346
 Mokdad AH, Marks JS, Stroup DF, Gerberding JL.  Correction: actual causes of 
death in the United States, 2000.  JAMA. 2005 Jan 19; 293(3): 293-4. 
 
Molecular Devices, Application Notes.  (www.moleculardevices.com) FLIPR link. 
 
Mongan NP, Baylis HA, Adcock C, Smith GR, Sansom MS, Sattelle DB.  An 
extensive and diverse gene family of nicotinic acetylcholine receptor alpha subunits 
in Caenorhabditis elegans.  Receptors Channels. 1998; 6(3): 213-28. 
 
Morens DM, Grandinetti A, Reed D, White LR, Ross GW.  Cigarette smoking and 
protection from Parkinson's disease: false association or etiologic clue?  Neurology. 
1995 Jun; 45(6): 1041-51. 
 
Morley BJ, Happe HK.  Cholinergic receptors: dual roles in transduction and 
plasticity.  Hear Res. 2000 Sep; 147(1-2): 104-12. 
 
Moroni M, Bermudez I.  Stoichiometry and pharmacology of two human alpha4beta2 
nicotinic receptor types.  J Mol Neurosci. 2006; 30(1-2): 95-6. 
 
Mukherjee S, Mahadik SP, Korenovsky A, Laev H, Schnur DB, Reddy R.  Serum 
antibodies to nicotinic acetylcholine receptors in schizophrenic patients.  Schizophr 
Res. 1994 May; 12(2): 131-6. 
 
Nakayama H, Nakashima T, Kurogochi Y.  Alpha 4 is a major acetylcholine binding 
subunit of cholinergic ligand affinity-purified nicotinic acetylcholine receptor from 
rat brains.  Neurosci Lett. 1991 Jan 2; 121(1-2): 122-4. 
 
Nelson ME, Kuryatov A, Choi CH, Zhou Y, Lindstrom J.  Alternate stoichiometries 
of alpha4beta2 nicotinic acetylcholine receptors.  Mol Pharmacol. 2003 Feb; 63(2): 
332-41. 
 
 347
 Newhouse PA, Potter A, Corwin J, Lenox R.  Acute nicotinic blockade produces 
cognitive impairment in normal humans.  Psychopharmacology (Berl). 1992; 108(4): 
480-4. 
 
Nicolotti O, Altomare C, Pellegrini-Calace M, Carotti A.  Neuronal nicotinic 
acetylcholine receptor agonists: pharmacophores, evolutionary QSAR and 3D-QSAR 
models.  Curr Top Med Chem. 2004;4(3):335-60.  
 
Nicolotti O, Pellegrini-Calace M, Altomar C, Carotti A, Carrieri A, Sanz F.  Ligands 
of neuronal nicotinic acetylcholine receptor (nAChR): inferences from the Hansch 
and 3-D quantitative structure-activity relationship (QSAR) Models.  Curr Med 
Chem. 2002 Jan;9(1):1-29.  
 
Nordberg A, Lundqvist H, Hartvig P, Lilja A, Langstrom B.  Kinetic analysis of 
regional (S)(-)11C-nicotine binding in normal and Alzheimer brains--in vivo 
assessment using positron emission tomography.  Alzheimer Dis Assoc Disord. 1995 
Spring; 9(1): 21-7. 
 
Nordberg A, Winblad B.  Reduced number of [3H]nicotine and [3H]acetylcholine 
binding sites in the frontal cortex of Alzheimer brains.  Neurosci Lett. 1986 Dec 3; 
72(1): 115-9. 
 
Nordberg A.  Neuronal nicotinic receptors and their implications in ageing and 
neurodegenerative disorders in mammals.  J Reprod. Fertil. Suppl. 1993; 46: 145-54. 
 
Numa S, Noda M, Takahashi H, Tanabe T, Toyosato M, Furutani Y, Kikyotani S.  
Molecular structure of the nicotinic acetylcholine receptor.  Cold Spring Harb. Symp. 
Quant. Biol. 1983; 48 Pt 1: 57-69. 
 
 348
 Ochoa EL, Chattopadhyay A, McNamee MG.  Desensitization of the nicotinic 
acetylcholine receptor: molecular mechanisms and effect of modulators.  Cell Mol 
Neurobiol. 1989 Jun; 9(2): 141-78. 
 
Olale F, Gerzanich V, Kuryatov A, Wang F, Lindstrom J.  Chronic nicotine exposure 
differentially affects the function of human alpha3, alpha4, and alpha7 neuronal 
nicotinic receptor subtypes.  J. Pharmacol Exp Ther. 1997 Nov; 283(2): 675-83. 
 
Olanow CW.  A scientific rationale for protective therapy in Parkinson's disease.  J. 
Neural Transm Gen Sect. 1993; 91(2-3): 161-80. 
 
O'Neill MJ, Murray TK, Lakics V, Visanji NP, Duty S.  The role of neuronal 
nicotinic acetylcholine receptors in acute and chronic neurodegeneration.  Curr Drug 
Targets CNS Neurol Disord. 2002 Aug; 1(4): 399-411. 
 
Orner BP, Hamilton AD.  The guanidinium group in molecular recognition:  Design 
and synthesis approaches.  J. Inclusion Phen. and Macrocyalic Chemistry.  41; 141-
147 2001.     
 
Orr-Urtreger A, Goldner FM, Saeki M, Lorenzo I, Goldberg L, De Biasi M, Dani JA, 
Patrick JW, Beaudet AL.  Mice deficient in the alpha7 neuronal nicotinic 
acetylcholine receptor lack alpha-bungarotoxin binding sites and hippocampal fast 
nicotinic currents.  J Neurosci. 1997 Dec 1; 17(23): 9165-71. 
 
Ortells MO, Barrantes GE.  Molecular modelling of the interactions of carbamazepine 
and a nicotinic receptor involved in the autosomal dominant nocturnal frontal lobe 
epilepsy.  Br. J. Pharmacol. 2002 Jul; 136(6): 883-95. 
 
Palma E, Bertrand S, Binzoni T, Bertrand D.  Neuronal nicotinic alpha 7 receptor 
expressed in Xenopus oocytes presents five putative binding sites for 
methyllycaconitine.  J Physiol. 1996 Feb 15;491 ( Pt 1):151-61. 
 349
  
Papke RL, Dwoskin LP, Crooks PA.  The pharmacological activity of nicotine and 
nornicotine on nAChRs subtypes: relevance to nicotine dependence and drug 
discovery.  J. Neurochem. 2007 Apr; 101(1): 160-7. Epub 2007 Jan 4. 
 
Papke RL, Dwoskin LP, Crooks PA.  The pharmacological activity of nicotine and 
nornicotine on nAChRs subtypes: relevance to nicotine dependence and drug 
discovery.  J Neurochem. 2007 Apr;101(1):160-7. Epub 2007 Jan 4. 
 
Papke RL, Porter Papke JK.  Comparative pharmacology of rat and human alpha7 
nAChR conducted with net charge analysis.  Br J Pharmacol. 2002 Sep;137(1):49-61. 
 
Papke RL, Sanberg PR, Shytle RD.  Analysis of mecamylamine stereoisomers on 
human nicotinic receptor subtypes.  J. Pharmacol Exp Ther. 2001 May; 297(2): 646-
56. 
 
Papke RL.  Estimation of both the potency and efficacy of alpha7 nAChR agonists 
from single-concentration responses.  Life Sci. 2006 May 8;78(24):2812-9. Epub 
2005 Dec 15. 
 
Pascual JM, Karlin A.  State-dependent accessibility and electrostatic potential in the 
channel of the acetylcholine receptor. Inferences from rates of reaction of 
thiosulfonates with substituted cysteines in the M2 segment of the alpha subunit.  J. 
Gen. Physiol. 1998 Jun; 111(6): 717-39. 
 
Paterson D, Nordberg A.  Neuronal nicotinic receptors in the human brain.  Prog. 
Neurobiol. 2000 May; 61(1): 75-111. 
 
Pauly JR, Marks MJ, Robinson SF, van de Kamp JL, Collins AC.  Chronic nicotine 
and mecamylamine treatment increase brain nicotinic receptor binding without 
 350
 changing alpha 4 or beta 2 mRNA levels.  J. Pharmacol Exp Ther. 1996 Jul; 278(1): 
361-9. 
 
Paylor R, Nguyen M, Crawley JN, Patrick J, Beaudet A, Orr-Urtreger A.  Alpha7 
nicotinic receptor subunits are not necessary for hippocampal-dependent learning or 
sensorimotor gating: a behavioral characterization of Acra7-deficient mice.  Learn 
Mem. 1998 Sep-Oct; 5(4-5): 302-16. 
 
Peng X, Gerzanich V, Anand R, Whiting PJ, Lindstrom J.  Nicotine-induced increase 
in neuronal nicotinic receptors results from a decrease in the rate of receptor turnover.  
Mol. Pharmacol. 1994 Sep; 46(3): 523-30. 
 
Perry DC, Xiao Y, Nguyen HN, Musachio JL, Davila-Garcia MI, Kellar KJ.  
Measuring nicotinic receptors with characteristics of alpha4beta2, alpha3beta2 and 
alpha3beta4 subtypes in rat tissues by autoradiography.  J. Neurochem. 2002 Aug; 
82(3): 468-81. 
 
Perry EK, Morris CM, Court JA, Cheng A, Fairbairn AF, McKeith IG, Irving D, 
Brown A, Perry RH.   Alteration in nicotine binding sites in Parkinson's disease, 
Lewy body dementia and Alzheimer's disease: possible index of early 
neuropathology.  Neuroscience. 1995 Jan; 64(2): 385-95. 
 
Pettit DL, Shao Z, Yakel JL.  beta-Amyloid(1-42) peptide directly modulates 
nicotinic receptors in the rat hippocampal slice.  J. Neurosci. 2001 Jan 1; 21(1): 
RC120. 
 
Picard F, Bertrand S, Steinlein OK, Bertrand D.  Mutated nicotinic receptors 
responsible for autosomal dominant nocturnal frontal lobe epilepsy are more sensitive 
to carbamazepine.  Epilepsia. 1999 Sep; 40(9): 1198-209. 
 
 351
 Picciotto MR, Zoli M, Zachariou V, Changeux JP.  Contribution of nicotinic 
acetylcholine receptors containing the beta 2-subunit to the behavioural effects of 
nicotine.  Biochem Soc Trans. 1997 Aug; 25(3): 824-9. 
 
Pictet A., Manevitch B.  Arch. Sci. Phys. Nat. 35, 40 1913. 
 
Pictet, Rotschy.  Chem. Ber. 28, 1224.  1904 
 
Pinner, Chem. Ber. 26, 294 1893. 
 
Pomerleau CS, Teuscher F, Goeters S, Pomerleau OF.  Effects of nicotine abstinence 
and menstrual phase on task performance.  Addict Behav. 1994 Jul-Aug; 19(4): 357-
62. 
 
Pomerleau OF, Downey KK, Stelson FW, Pomerleau CS.  Cigarette smoking in adult 
patients diagnosed with attention deficit hyperactivity disorder.  J Subst Abuse. 1995; 
7(3): 373-8. 
 
Popot JL, Changeux JP.  Nicotinic receptor of acetylcholine: structure of an 
oligomeric integral membrane protein.  Physiol Rev. 1984 Oct; 64(4): 1162-239. 
 
Poss MA, Iwanowicz E, Reid JA, Lin RJ, Gu Z.  A mild and efficient method for 
preparation of guanidines.  Tett. Lett. 33(40);5933-5936  1992. 
 
Predicting molecular interactions in silico: I. A guide to pharmacophore identification 
and its applications to drug design.  Curr Med Chem. 2004 Jan;11(1):71-90. 
 
Putta S, Beroza P.  Shapes of things: computer modeling of molecular shape in drug 
discovery.  Curr Top Med Chem. 2007;7(15):1514-24.  
 
 352
 Quick MW, Lester RA.  Desensitization of neuronal nicotinic receptors.  J. 
Neurobiol. 2002 Dec; 53(4): 457-78. 
 
Raftery MA, Hunkapiller MW, Strader CD, Hood LE.  Acetylcholine receptor: 
complex of homologous subunits.  Science. 1980 Jun 27; 208(4451): 1454-6. 
 
Raggenbass M, Bertrand D.  Nicotinic receptors in circuit excitability and epilepsy.  
J. Neurobiol. 2002 Dec; 53(4): 580-9. 
 
Rahman S, Zhang Z, Papke RL, Crooks PA, Dwoskin LP, Bardo MT.  Region-
specific effects of N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide on nicotine-
induced increase in extracellular dopamine in vivo. 
Br J Pharmacol. 2008 Feb;153(4):792-804. Epub 2007 Dec 3.  
 
Rang H, Dale M, Ritter J, Flower R.  Rang and Dale’s Pharmacology, 6th edition.  
Published by Churchill Livingstone, Edinburgh, 2006. 797 pages.  ISBN 0443071454 
 
Reavill C, Jenner P, Kumar R, Stolerman IP.  High affinity binding of [3H] (-)-
nicotine to rat brain membranes and its inhibition by analogues of nicotine. 
Neuropharmacology. 1988 Mar;27(3):235-41. 
 
Reid RL.  Designing for late-stage dementia care.  Provider. 2000 May; 6(5): 40-3, 
45-6. 
 
RochaE Silvam, Schild HO.  The release of histamine by d-tubocurarine from the 
isolated diaphragm of the rat.  J Physiol. 1949 Sep;109(3-4):448-58. 
 
Romano C, Goldstein A.  Stereospecific nicotine receptors on rat brain membranes.  
Science. 1980 Nov 7; 210(4470): 647-50. 
 
 353
 Rowell PP, Hillebrand JA.  Characterization of nicotine-induced desensitization of 
evoked dopamine release from rat striatal synaptosomes. J. Neurochem. 1994 Aug; 
63(2): 561-9. 
 
Rowell PP, Wonnacott S.  Evidence for functional activity of up-regulated nicotine 
binding sites in rat striatal synaptosomes.  J. Neurochem. 1990 Dec; 55(6): 2105-10. 
 
Rueter LE, Anderson DJ, Briggs CA, Donnelly-Roberts DL, Gintant GA, 
Gopalakrishnan M, Lin NH, Osinski MA, Reinhart GA, Buckley MJ, Martin RL, 
McDermott JS, Preusser LC, Seifert TR, Su Z, Cox BF, Decker MW, Sullivan JP.  
ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor 
agonist for the potential treatment of cognitive disorders.  CNS Drug Rev. 2004 
Summer; 10(2): 167-82. 
 
Russell MA (b), Jarvis M, Iyer R, Fayerabend C.  Relation of nicotine yield of 
cigarettes to blood nicotine concentrations in smokers.  Br. Med. Journal, 280(6219): 
972-976, 1980. 
 
Russell MA.(a)  Nicotine intake and its regulation.  J. Psychosom Res. 24(5): 253-64, 
1980. 
 
Rusted JM, Newhouse PA, Levin ED.  Nicotinic treatment for degenerative 
neuropsychiatric disorders such as Alzheimer's disease and Parkinson's disease.  
Behav Brain Res. 2000 Aug; 113(1-2): 121-9. 
 
Sabban EL, Gueorguiev VD.  Effects of short- and long-term nicotine treatment on 
intracellular calcium and tyrosine hydroxylase gene expression.  Ann N Y Acad Sci. 
2002 Oct; 971: 39-44. 
 
Sacco KA, Termine A, Seyal A, Dudas MM, Vessicchio JC, Krishnan-Sarin S, Jatlow 
PI, Wexler BE, George TP.  Effects of cigarette smoking on spatial working memory 
 354
 and attentional deficits in schizophrenia: involvement of nicotinic receptor 
mechanisms.  Arch Gen Psychiatry. 2005 Jun; 62(6): 649-59. 
 
Sahley TL, Berntson GG.  Antinociceptive effects of central and systemic 
administrations of nicotine in the rat.  Psychopharmacology (Berl). 1979 Nov; 65(3): 
279-83. 
 
Salas R, Orr-Urtreger A, Broide RS, Beaudet A, Paylor R, De Biasi M.  The nicotinic 
acetylcholine receptor subunit alpha 5 mediates short-term effects of nicotine in vivo.  
Mol. Pharmacol. 2003 May; 63(5): 1059-66. 
 
Salin-Pascual RJ, Drucker-Colin R.  A novel effect of nicotine on mood and sleep in 
major depression.  Neuroreport. 1998 Jan 5; 9(1): 57-60. 
 
Salminen O, Murphy KL, McIntosh JM, Drago J, Marks MJ, Collins AC, Grady SR.  
Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic 
acetylcholine receptors mediating dopamine release in mice.  Mol. Pharmacol. 2004 
Jun; 65(6): 1526-35. 
 
Samaritoni JG, Demeter DA, Gifford JM, Watson GB, Kempe MS, Bruce TJ.  
Dihydropiperazine neonicotinoid compounds. Synthesis and insecticidal activity.  J 
Agric Food Chem. 2003 May 7; 51(10): 3035-42. 
 
Samochocki M, Zerlin M, Jostock R, Groot Kormelink PJ, Laymen WH, 
Albuquerque EX, Maelicke A.  Galantamine is an allosterically potentiating ligand of 
the human alpha4/beta2 nAChR.  Acta Neurol Scand Suppl. 2000; 176: 68-73. 
 
Sanberg PR, Silver AA, Shytle RD, Philipp MK, Cahill DW, Fogelson HM, 
McConville BJ.  Nicotine for the treatment of Tourette's syndrome.  Pharmacol Ther. 
1997; 74(1): 21-5. 
 
 355
 Sansom MS.  Ion-channel gating. Twist to open.  Curr. Biol. 1995 Apr 1; 5(4): 373-5. 
Sargent PB.  The diversity of neuronal nicotinic acetylcholine receptors.  Ann. Rev. 
Neuroscience, 1993; 16: 403-43. 
 
Schmitt JD.  Exploring the nature of molecular recognition in nicotinic acetylcholine 
receptors.  Curr Med Chem. 2000 Aug; 7(8): 749-800. 
 
Schneider JS, Tinker JP, Van Velson M, Menzaghi F, Lloyd GK.  Nicotinic 
acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic 
low-dose MPTP-treated monkeys.  J. Pharmacol Exp Ther. 1999 Aug; 290(2): 731-9. 
 
Schneider M.  A rational approach to maximize success rate in target discovery.  Arch 
Pharm (Weinheim). 2004 Dec;337(12):625-33.  
 
Schoepfer R, Conroy WG, Whiting P, Gore M, Lindstrom J.   Brain alpha-
bungarotoxin binding protein cDNAs and MAbs reveal subtypes of this branch of the 
ligand-gated ion channel gene superfamily.  Neuron. 1990 Jul;5(1):35-48. 
 
Schulz DW, Zigmond RE.  Neuronal bungarotoxin blocks the nicotinic stimulation of 
endogenous dopamine release from rat striatum.  Neurosci Lett. 1989 Apr 10; 98(3): 
310-6. 
 
Schwartz RD, Kellar KJ.  In vivo regulation of [3H]acetylcholine recognition sites in 
brain by nicotinic cholinergic drugs.  J. Neurochem. 1985 Aug; 45(2): 427-33. 
 
Seguela P, Wadiche J, Dineley-Miller K, Dani JA, Patrick JW.  Molecular cloning, 
functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel 
highly permeable to calcium.  J. Neurosci. 1993 Feb; 13(2): 596-604. 
 
Sexena K., Scheman A.  Suicide plan by nicotine poisoning: a review of nicotine 
toxicity.  Vet. Hum. Toxicol.  27(6): 495-497, 1985. 
 356
  
Sharples CG, Kaiser S, Soliakov L, Marks MJ, Collins AC, Washburn M, Wright E, 
Spencer JA, Gallagher T, Whiteaker P, Wonnacott S.  UB-165: a novel nicotinic 
agonist with subtype selectivity implicates the alpha4beta2* subtype in the 
modulation of dopamine release from rat striatal synaptosomes.  J. Neurosci. 2000 
Apr 15; 20(8): 2783-91. 
 
Sharples GV, Wonnacott S.  Neuronal nicotinic receptors.  Tocris Reviews 19, Tocris-
Cookson 2001. 
 
Sher E.  Ion channels in drug discovery and development.  Expert Opin Investig 
Drugs. 2004 Dec; 13(12): 1651-4. 
 
Sheridan RP, Nilakantan R, Dixon JS, Venkataraghavan R.  The ensemble approach 
to distance geometry: application to the nicotinic pharmacophore.  J Med Chem. 1986 
Jun; 29(6): 899-906. 
 
Sihver W, Gillberg PG, Svensson AL, Nordberg A.  Autoradiographic comparison of 
[3H](-)nicotine, [3H]cytisine and [3H]epibatidine binding in relation to vesicular 
acetylcholine transport sites in the temporal cortex in Alzheimer's disease.  
Neuroscience. 1999; 94(3): 685-96. 
 
Silagy C, Mant D, Fowler G, Lancaster T.  Nicotine replacement therapy for smoking 
cessation.  Cochrane Database Syst Rev. 2000; (3): CD000146. 
 
Silver AA, Shytle RD, Sheehan KH, Sheehan DV, Ramos A, Sanberg PR.  
Multicenter, double-blind, placebo-controlled study of mecamylamine monotherapy 
for Tourette's disorder.  J. Am Acad Child Adolesc Psychiatry. 2001 Sep; 40(9): 1103-
10. 
 
 357
 Singh A, Das DK, Kelley ME.  Mecamylamine (Targacept).  IDrugs. 2006 Mar; 9(3): 
205-17. 
 
Sixma TK, Smit AB.  Acetylcholine binding protein (AChBP): a secreted glial 
protein that provides a high-resolution model for the extracellular domain of 
pentameric ligand-gated ion channels.  Annu. Rev. Biophys. Biomol. Struct. 2003; 32: 
311-34. Epub 2003 Feb 21. 
 
Slikker W Jr, Xu ZA, Levin ED, Slotkin TA.  Mode of action: disruption of brain cell 
replication, second messenger, and neurotransmitter systems during development 
leading to cognitive dysfunction--developmental neurotoxicity of nicotine.  Crit Rev 
Toxicol. 2005 Oct-Nov; 35(8-9): 703-11. 
Smart D, Jerman JC, Gunthorpe MJ, Brough SJ, Ranson J, Cairns W, Hayes PD, 
Randall AD, Davis JB.  Characterisation using FLIPR of human vanilloid VR1 
receptor pharmacology.  Eur J Pharmacol. 2001 Apr 6;417(1-2):51-8. 
 
Smit AB, Celie PH, Kasheverov IE, Mordvintsev DY, van Nierop P, Bertrand D, 
Tsetlin V, Sixma TK.  Acetylcholine-binding proteins: functional and structural 
homologs of nicotinic acetylcholine receptors.  J Mol Neurosci. 2006; 30(1-2): 9-10. 
 
Soliakov L, Wonnacott S.  Voltage-sensitive Ca2+ channels involved in nicotinic 
receptor-mediated [3H]dopamine release from rat striatal synaptosomes.  J. 
Neurochem. 1996 Jul; 67(1): 163-70. 
 
Spanagel R, Weiss F.  The dopamine hypothesis of reward: past and current status.  
Trends Neurosci. 1999 Nov; 22(11): 521-7. 
 
Spande TF, Garraffo HM, Yeh HJ, Pu QL, Pannell LK, Daly JW.  A new class of 
alkaloids from a dendrobatid poison frog: a structure for alkaloid 251F.  J Nat Prod. 
1992 Jun; 55(6): 707-22. 
 
 358
 Stack NM.  Smoking cessation: an overview of treatment options with a focus on 
varenicline.  Pharmacotherapy. 2007 Nov;27(11):1550-7. 
 
Steinlein OK, Magnusson A, Stoodt J, Bertrand S, Weiland S, Berkovic SF, Nakken 
KO, Propping P, Bertrand D.  An insertion mutation of the CHRNA4 gene in a family 
with autosomal dominant nocturnal frontal lobe epilepsy.  Hum Mol Genet. 1997 Jun; 
6(6): 943-7. 
 
Steinlein OK, Mulley JC, Propping P, Wallace RH, Phillips HA, Sutherland GR, 
Scheffer IE, Berkovic SF.  A missense mutation in the neuronal nicotinic 
acetylcholine receptor alpha 4 subunit is associated with autosomal dominant 
nocturnal frontal lobe epilepsy.  Nat. Genet. 1995 Oct; 11(2): 201-3. 
 
Stergiou C, Siganos D.  Neural Networks: introduction to neural networks.  
www.doc.ic.ac.uk/~nd/surprise_96/journal/vol4/cs11/report.html 
 
Stokes C, Papke JK, Horenstein NA, Kem WR, McCormack TJ, Papke RL.  The 
structural basis for GTS-21 selectivity between human and rat nicotinic alpha7 
receptors.  Mol Pharmacol. 2004 Jul;66(1):14-24. 
 
Sugaya K, Giacobini E, Chiappinelli VA.  Nicotinic acetylcholine receptor subtypes 
in human frontal cortex: changes in Alzheimer's disease.  J. Neurosci Res. 1990 Nov; 
27(3): 349-59. 
 
Sugiyama H.  The mode of action of the nicotinic cholinergic receptor protein in the 
postsynaptic membrane.  Adv. Biophys. 1978; 10: 1-25. 
 
Sullivan E, Tucker EM, Dale IL.  Measurement of [Ca2+] using the Fluorometric 
Imaging Plate Reader (FLIPR).  Methods Mol Biol. 1999;114:125-33. 
 
 359
 Sullivan JP, Decker MW, Brioni JD, Donnelly-Roberts D, Anderson DJ, Bannon 
AW, Kang CH, Adams P, Piattoni-Kaplan M, Buckley MJ, et al.   (+/-)-Epibatidine 
elicits a diversity of in vitro and in vivo effects mediated by nicotinic acetylcholine 
receptors.  J. Pharmacol Exp Ther. 1994 Nov; 271(2): 624-31. 
 
Sumithran SP, Crooks PA, Xu R, Zhu J, Deaciuc AG, Wilkins LH, Dwoskin LP.  
Introduction of unsaturation into the N-n-alkyl chain of the nicotinic receptor 
antagonists, NONI and NDNI: effect on affinity and selectivity.  AAPS J. 2005 Aug 
29;7(1):E201-17. 
 
Sun X, Liu Y, Hu G, Wang H.  Activities of cAMP-dependent protein kinase and 
protein kinase C are modulated by desensitized nicotinic receptors in the rat brain.  
Neurosci Lett. 2004 Aug 26; 367(1): 19-22. 
 
Sutherland G, Stapleton JA, Russell MA, Feyerabend C.  Naltrexone, smoking 
behaviour and cigarette withdrawal.  Psychopharmacology (Berl). 1995 Aug; 120(4): 
418-25. 
 
Tallarida RJ.  Interactions between drugs and occupied receptors.  Pharmacol Ther. 
2007 Jan;113(1):197-209. Epub 2006 Sep 7. 
 
Terry AV Jr, Williamson R, Gattu M, Beach JW, McCurdy CR, Sparks JA, Pauly JR.   
Lobeline and structurally simplified analogs exhibit differential agonist activity and 
sensitivity to antagonist blockade when compared to nicotine. 
Neuropharmacology. 1998; 37(1): 93-102. 
 
Tomizawa M, Casida JE.  Imidacloprid, thiacloprid, and their imine derivatives up-
regulate the alpha 4 beta 2 nicotinic acetylcholine receptor in M10 cells.  Toxicol 
Appl Pharmacol. 2000 Nov 15; 169(1): 114-20. 
 
 360
 Tomizawa M, Casida JE.  Neonicotinoid insecticide toxicology: mechanisms of 
selective action.  Annu Rev Pharmacol Toxicol. 2005; 45: 247-68. 
 
Tomizawa M, Casida JE.  Selective toxicity of neonicotinoids attributable to 
specificity of insect and mammalian nicotinic receptors.  Annu Rev Entomol. 2003; 
48: 339-64. Epub 2002 Jun 4. 
 
Tomizawa M, Cowan A, Casida JE.  Analgesic and toxic effects of neonicotinoid 
insecticides in mice.  Toxicol Appl Pharmacol. 2001 Nov 15; 177(1): 77-83. 
 
Tomizawa M, Zhang N, Durkin KA, Olmstead MM, Casida JE.  The neonicotinoid 
electronegative pharmacophore plays the crucial role in the high affinity and 
selectivity for the Drosophila nicotinic receptor: an anomaly for the nicotinoid cation-
-pi interaction model.  Biochemistry. 2003 Jul 1; 42(25): 7819-27. 
 
Tonder JE, Olesen PH.  Agonists at the alpha4beta2 nicotinic acetylcholine receptors: 
structure-activity relationships and molecular modelling.  Curr Med Chem. 2001 
May; 8(6): 651-74. 
 
Tonnesen P, Tonstad S, Hjalmarson A, Lebargy F, Van Spiegel PI, Hider A, Sweet R, 
Townsend J.  A multicentre, randomized, double-blind, placebo-controlled, 1-year 
study of bupropion SR for smoking cessation.  J. Intern. Med. 2003 Aug; 254(2): 
184-92. 
 
Topliss JG, (Ed.)  Quantitative Structure-Activity Relationship of Drugs.  Academic 
Press New York, 1983. 
 
Tripathi HL, Martin BR, Aceto MD.  Nicotine-induced antinociception in rats and 
mice: correlation with nicotine brain levels.  J. Pharmacol Exp Ther. 1982 Apr; 
221(1): 91-6. 
 
 361
 Tute MS.  History and Objectives of Quantitative Drug Design.  Comprehensive 
Medicinal Chemistry, Vol 4.  Quantitative Drug Design.  Hansch C, Sammes PG, 
Taylor JB (Eds.)  Pergamon Press:  Oxford, 1990 (1-31). 
 
UDHSS Report.  Fiore MC.  US public health service clinical practice guideline: 
treating tobacco use and dependence.  Respir Care. 2000 Oct; 45(10): 1200-62. 
 
vcclab 2006.  (www.vcclab.org/lab/pls) 
 
Verdini AS, Lucietto P, Fossati G, Giordani C.  A facile preparation of Fmoc-
Argω,ω′(Boc)2 -OH and Z-Argω,ω′ (Boc)2 -OH, new arginine derivatives for peptide 
synthesis.  Tetrahedron Lett. 33(43); 6541-6542, 1992.   
 
Vernino S, Amador M, Luetje CW, Patrick J, Dani JA.  Calcium modulation and high 
calcium permeability of neuronal nicotinic acetylcholine receptors.  Neuron. 1992 
Jan; 8(1): 127-34. 
 
Vernino S, Low PA, Fealey RD, Stewart JD, Farrugia G, Lennon VA.  
Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic 
neuropathies.  N. Engl. J. Med. 2000 Sep 21; 343(12): 847-55. 
 
Vickery RG, Amagasu SM, Chang R, Mai N, Kaufman E, Martin J, Hembrador J, 
O'Keefe MD, Gee C, Marquess D, Smith JA.  Comparison of the pharmacological 
properties of rat Na(V)1.8 with rat Na(V)1.2a and human Na(V)1.5 voltage-gated 
sodium channel subtypes using a membrane potential sensitive dye and FLIPR.  
Receptors Channels. 2004;10(1):11-23. 
 
Vijayaraghavan S, Schmid HA, Halvorsen SW, Berg DK.  Cyclic AMP-dependent 
phosphorylation of a neuronal acetylcholine receptor alpha-type subunit.  J. Neurosci. 
1990 Oct; 10(10): 3255-62. 
 
 362
 Villarroya M, Gandia L, Lopez MG, Garcia AG, Cueto S, Garcia-Navio JL, Alvarez-
Builla J.  Synthesis and pharmacology of alkanediguanidinium compounds that block 
the neuronal nicotinic acetylcholine receptor.  Bioorg Med Chem. 1996 Aug; 4(8): 
1177-83. 
 
Vincler MA, Eisenach JC.  Knock down of the alpha 5 nicotinic acetylcholine 
receptor in spinal nerve-ligated rats alleviates mechanical allodynia.  Pharmacol 
Biochem Behav. 2005 Jan; 80(1): 135-43. Epub 2004 Nov 18. 
 
Wada K, Ballivet M, Boulter J, Connolly J, Wada E, Deneris ES, Swanson LW, 
Heinemann S, Patrick J.  Functional expression of a new pharmacological subtype of 
brain nicotinic acetylcholine receptor.  Science. 1988 Apr 15; 240(4850): 330-4. 
 
Wada K, Ballivet M, Boulter J, Connolly J, Wada E, Deneris ES, Swanson LW, 
Heinemann S, Patrick J.  Functional expression of a new pharmacological subtype of 
brain nicotinic acetylcholine receptor.  Science. 1988 Apr 15; 240(4850): 330-4. 
 
Wang F, Gerzanich V, Wells GB, Anand R, Peng X, Keyser K, Lindstrom J.  
Assembly of human neuronal nicotinic receptor alpha5 subunits with alpha3, beta2, 
and beta4 subunits.  J. Biol. Chem. 1996 Jul 26; 271(30): 17656-65. 
 
Wang F, Nelson ME, Kuryatov A, Olale F, Cooper J, Keyser K, Lindstrom J.  
Chronic nicotine treatment up-regulates human alpha3 beta2 but not alpha3 beta4 
acetylcholine receptors stably transfected in human embryonic kidney cells.  J. Biol. 
Chem. 1998 Oct 30; 273(44): 8721-32. 
 
Wang HY, Lee DH, Davis CB, Shank RP.  Amyloid peptide Abeta(1-42) binds 
selectively and with picomolar affinity to alpha7 nicotinic acetylcholine receptors.  J. 
Neurochem. 2000 Sep; 75(3): 1155-61. 
 
 363
 Wang PN, Wang SJ, Hong CJ, Liu TT, Fuh JL, Chi CW, Liu CY, Liu HC.  Risk 
factors for Alzheimer's disease: a case-control study.  Neuroepidemiology. 1997; 
16(5): 234-40. 
 
Ward JM, Cockcroft VB, Lunt GG, Smillie FS, Wonnacott S.   Methyllycaconitine: a 
selective probe for neuronal alpha-bungarotoxin binding sites.  FEBS Lett. 1990 Sep 
17;270(1-2):45-8. 
 
Warpman U, Nordberg A.  Epibatidine and ABT 418 reveal selective losses of alpha 
4 beta 2 nicotinic receptors in Alzheimer brains.  Neuroreport. 1995 Nov 27; 6(17): 
2419-23. 
 
Waud D R.  A Primer on “Grind and Bind”.  Anesthesiology and Analgesia.  1988 
Nov; 67(11):1025-31. 
 
Weiland S, Witzemann V, Villarroel A, Propping P, Steinlein O.  An amino acid 
exchange in the second transmembrane segment of a neuronal nicotinic receptor 
causes partial epilepsy by altering its desensitization kinetics.  FEBS Lett. 1996 Nov 
25; 398(1): 91-6. 
 
Wessler I.  Acetylcholine release at motor endplates and autonomic neuroeffector 
junctions: a comparison.  Pharmacol. Res. 1996 Feb;  33(2): 1-94. 
 
Wewers ME, Dhatt R, Tejwani GA.  Naltrexone administration affects ad libitum 
smoking behavior.  Psychopharmacology (Berl). 1998 Nov; 140(2): 185-90. 
 
Whiteaker P, Davies AR, Marks MJ, Blagbrough IS, Potter BV, Wolstenholme AJ, 
Collins AC, Wonnacott S.  An autoradiographic study of the distribution of binding 
sites for the novel alpha7-selective nicotinic radioligand [3H]-methyllycaconitine in 
the mouse brain.  Eur. J Neurosci. 1999 Aug; 11(8): 2689-96. 
 
 364
 Whiteaker P, Jimenez M, McIntosh JM, Collins AC, Marks MJ.  Identification of a 
novel nicotinic binding site in mouse brain using [125I]-epibatidine.  Br J Pharmacol. 
2000 Oct; 131(4): 729-39. 
 
Whiteaker P, McIntosh JM, Luo S, Collins AC, Marks MJ.  125I-alpha-conotoxin 
MII identifies a novel nicotinic acetylcholine receptor population in mouse brain.  
Mol Pharmacol. 2000 May; 57(5): 913-25. 
 
Whiteaker P, Peterson CG, Xu W, McIntosh JM, Paylor R, Beaudet AL, Collins AC, 
Marks MJ.  Involvement of the alpha3 subunit in central nicotinic binding 
populations.  J. Neurosci. 2002 Apr 1; 22(7): 2522-9. 
 
Whiteaker P, Sharples CG, Wonnacott S.  Pharmacology of nicotinic acetylcholine 
receptor (nAChR) upregulation in the transfected cell line, M10.  Biochem. Soc. 
Trans. 1997 Aug; 25(3): 550S. 
 
Whitehouse PJ, Martino AM, Antuono PG, Lowenstein PR, Coyle JT, Price DL, 
Kellar KJ.  Nicotinic acetylcholine binding sites in Alzheimer's disease.  Brain Res. 
1986 Apr 16; 371(1): 146-51. 
 
Whiting P, Schoepfer R, Lindstrom J, Priestley T.  Structural and pharmacological 
characterization of the major brain nicotinic acetylcholine receptor subtype stably 
expressed in mouse fibroblasts.  Mol. Pharmacol. 1991 Oct; 40(4): 463-72. 
 
Whiting PJ, Lindstrom JM.  Purification and characterization of a nicotinic 
acetylcholine receptor from chick brain.  Biochemistry. 1986 Apr 22; 25(8): 2082-93. 
 
Whiting PJ, Liu R, Morley BJ, Lindstrom JM.  Structurally different neuronal 
nicotinic acetylcholine receptor subtypes purified and characterized using monoclonal 
antibodies.  J. Neurosci. 1987 Dec; 7(12): 4005-16. 
 
 365
 Wilkins LH Jr, Haubner A, Ayers JT, Crooks PA, Dwoskin LP.  N-n-alkylnicotinium 
analogs, a novel class of nicotinic receptor antagonist: inhibition of S(-)-nicotine-
evoked [3H]dopamine overflow from superfused rat striatal slices.  J. Pharmacol Exp 
Ther. 2002 Jun; 301(3): 1088-96. 
 
Wilkins LH Jr, Miller DK, Ayers JT, Crooks PA, Dwoskin LP.  N-n-alkylnicotinium 
analogs, a novel class of antagonists at alpha 4 beta 2* nicotinic acetylcholine 
receptors: inhibition of S(-)-nicotine-evoked 86Rb+ efflux from rat thalamic 
synaptosomes.  AAPS J. 2006 Jan 13;7(4):E922-30. 
 
Wilkins LH, Grinevich VP, Ayers JT, Crooks PA, Dwoskin LP.  N-n-alkylnicotinium 
analogs, a novel class of nicotinic receptor antagonists: interaction with alpha4beta2* 
and alpha7* neuronal nicotinic receptors.  J Pharmacol Exp Ther. 2003 
Jan;304(1):400-10. 
 
Wilkinson DG, Francis PT, Schwam E, Payne-Parrish J.  Cholinesterase inhibitors 
used in the treatment of Alzheimer's disease: the relationship between 
pharmacological effects and clinical efficacy.  Drugs Aging. 2004; 21(7): 453-78. 
 
Williams M, Robinson JL.  Binding of the nicotinic cholinergic antagonist, dihydro-
beta-erythroidine, to rat brain tissue.  J. Neurosci. 1984 Dec; 4(12): 2906-11. 
 
Willoughby JO, Pope KJ, Eaton V.  Nicotine as an antiepileptic agent in ADNFLE: 
an N-of-one study.  Epilepsia. 2003 Sep; 44(9): 1238-40. Erratum in: Epilepsia. 2003 
Oct; 44(10): 1363. 
 
Winkler DA.  Neural networks as robust tools in drug lead discovery and 
development.  Mol Biotechnol. 2004 Jun;27(2):139-68.  
 
 366
 Wonnacott S, Barik J, Dickinson J, Jones IW.  Nicotinic receptors modulate 
transmitter cross talk in the CNS: nicotinic modulation of transmitters.  J. Mol. 
Neurosci. 2006; 30(1-2): 137-40. 
 
Wonnacott S.  alpha-Bungarotoxin binds to low-affinity nicotine binding sites in rat 
brain.  J. Neurochem. 1986 Dec; 47(6): 1706-12. 
 
Wonnacott S.  Presynaptic nicotinic ACh receptors.  Trends Neurosci. 1997 Feb; 
20(2): 92-8. 
 
Wyllie DJ, Chen PE.   Taking the time to study competitive antagonism.  Br J 
Pharmacol. 2007 Mar;150(5):541-51. Epub 2007 Jan 22. 
 
Xu W, Gelber S, Orr-Urtreger A, Armstrong D, Lewis RA, Ou CN, Patrick J, Role L, 
De Biasi M, Beaudet AL.  Megacystis, mydriasis, and ion channel defect in mice 
lacking the alpha3 neuronal nicotinic acetylcholine receptor.  Proc. Natl. Acad. Sci U 
S A. 1999 May 11; 96(10): 5746-51. 
 
Yamamoto I, Tomizawa M, Saito T, Miyamoto T, Walcott EC, Sumikawa K.   
Structural factors contributing to insecticidal and selective actions of neonicotinoids.  
Arch Insect Biochem Physiol. 1998; 37(1): 24-32. 
 
Yeh JJ, Yasuda RP, Davila-Garcia MI, Xiao Y, Ebert S, Gupta T, Kellar KJ, Wolfe 
BB.  Neuronal nicotinic acetylcholine receptor alpha3 subunit protein in rat brain and 
sympathetic ganglion measured using a subunit-specific antibody: regional and 
ontogenic expression.  J. Neurochem. 2001 Apr; 77(1): 336-46. 
 
Yet L.  Recent developments in guanylation chemistry.  Medicinal Chemistry Dept.  
Albany Molecular Research Technical Reports 3(6).  1999 
 
 367
 Yong YF, Kowalski J, Lipton M.  Facile and efficient guanylation of amines using 
thioureas and Mukaiyama’s reagent.  J.Org. Chem.  62; 1540-1542  1997. 
 
Young JM, Shytle RD, Sanberg PR, George TP.  Mecamylamine: new therapeutic 
uses and toxicity/risk profile.  Clin Ther. 2001 Apr; 23(4): 532-65. 
 
Yu CJ, Wecker L.  Chronic nicotine administration differentially affects 
neurotransmitter release from rat striatal slices.  J. Neurochem. 1994 Jul; 63(1): 186-
94. 
 
Yum L, Wolf KM, Chiappinelli VA.   Nicotinic acetylcholine receptors in separate 
brain regions exhibit different affinities for methyllycaconitine.  Neuroscience. 1996 
May;72(2):545-55. 
 
Zevin S, Gourlay SG, Benowitz NL.  Clinical pharmacology of nicotine.  Clin. 
Dermatol. 1998 Sep-Oct; 16(5): 557-64. 
 
Zhang J, Stein P, Atwal K, Li C.  One pot synthesis of N,N-disubstituted 
acylguanidines.  Tet. Lett. 43; 57-59 2002. 
 
Zhang N, Tomizawa M, Casida JE.  Drosophila nicotinic receptors: evidence for 
imidacloprid insecticide and alpha-bungarotoxin binding to distinct sites.  Neurosci 
Lett. 2004 Nov 16; 371(1): 56-9. 
 
Zhang X, Nordberg A.   The competition of (-)-[3H]nicotine binding by the 
enantiomers of nicotine, nornicotine and anatoxin-a in membranes and solubilized 
preparations of different brain regions of rat.  Naunyn Schmiedebergs Arch 
Pharmacol. 1993 Jul;348(1):28-34. 
 
Zhao L, Kuo YP, George AA, Peng JH, Purandare MS, Schroeder KM, Lukas RJ, 
Wu J.  Functional properties of homomeric, human alpha 7-nicotinic acetylcholine 
 368
 receptors heterologously expressed in the SH-EP1 human epithelial cell line.  J. 
Pharmacol. Exp  Ther. 2003 Jun; 305(3): 1132-41. Epub 2003 Mar 6. 
 
Zheng F, Bayram E, Sumithran SP, Ayers JT, Zhan CG, Schmitt JD, Dwoskin LP, 
Crooks PA.  QSAR modeling of mono- and bis-quaternary ammonium salts that act 
as antagonists at neuronal nicotinic acetylcholine receptors mediating dopamine 
release.  Bioorg Med Chem. 2006 May 1;14(9):3017-37. Epub 2006 Jan 20.  
 
Zheng F, Zheng G, Deaciuc AG, Zhan CG, Dwoskin LP, Crooks PA.  Computational 
neural network analysis of the affinity of lobeline and tetrabenazine analogs for the 
vesicular monoamine transporter-2.  Bioorg Med Chem. 2007 Apr 15;15(8):2975-92. 
Epub 2007 Feb 11.  
 
Zoli M, Moretti M, Zanardi A, McIntosh JM, Clementi F, Gotti C.  Identification of 
the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat 
striatum.  J. Neurosci. 2002 Oct 15; 22(20): 8785-9. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 369
 Vita 
 
 
Aaron Joseph Haubner 
 
Born: Covington, KY 11/22/1976     
 
 
EDUCATION 
 
B.S. University of Kentucky, College of Arts and Sciences.   1998 
Department of Biological Sciences:        
Field of concentration: molecular biology.   
Research Honors Award 
 
 
PROFESSIONAL / RESEARCH EXPERIENCE 
 
Research Scientist:  Targacept.       10/2007- 
Design and validation of nicotinic receptor assays.   
Advanced pharmacology of lead nicotinic compounds. 
 
Post-Doctoral Research:  Southern Research Institute.    1/2007-9/2007 
Influenza virus polymerase inhibition assay development.   
Ricin toxin inhibition assay development. 
Fluorescent fusion protein engineering and purification.   
Dr. James Noah 
 
Visiting Researcher: University College London, London, UK. Summerr 2005 
In-vitro nicotinic receptor screening and characterization.   
Dr. Neil Millar.  
 
Doctoral Research:  University of Kentucky, College of Pharmacy.  2000-2007 
Compound synthesis, nicotinic receptor screening and  
pharmacology, molecular model development   
Dr. Peter Crooks 
 
Post-Bac Research:  University of Kentucky, College of Pharmacy. 1998-2000 
Native neuronal nicotinic receptor assay pharmacology.   
Dr. Linda Dwoskin 
 
Undergraduate Research:  U K, College of Medicine.   1996-1998 
In-vitro CAD protein enzyme purification and assay.   
Dr. Jeffrey Davidson 
 
 
 370
  
TEACHING EXPERIENCE 
 
Teaching Assistant: University of Kentucky, College of Pharmacy. 2000-2002 
 
 
 
EDUCATION 
 
B.S. University of Kentucky, College of Arts and Sciences.  1998 
Department of Biological Sciences:        
Field of concentration: molecular biology.   
 
 
HONORS AND AWARDS 
 
? Dissertation Enhancement Award, University of Kentucky.  2005 
(International research travel award)  
? International Foundation for Ethical Research, Pre-doctoral  2002-2005  
fellowship award (three competitive renewals).       
? University of Kentucky, Center on Drug and    1999 
Alcohol Research: Petite Research Grant. 
? Undergraduate Research Honors award, Dept. of Biology.  1998 
? Howard Hughes Medical Institute, Undergraduate    1997 
Summer Research Award. 
 
 
ASSOCIATION MEMBERSHIPS 
? American Association of Pharmaceutical Sciences (AAPS).  2002-2007 
? Society for Neuroscience, Kentucky chapter.   2003-2006 
? Kentucky Academy of Science.     1998-2000 
 
 
ABSTRACTS AND PRESENTATIONS 
 
Aaron Haubner, John M. Littleton, Neil Millar, Linda P. Dwoskin, and Peter A. 
Crooks.  Subtype Selective, Guanylated Nicotine Analogs; Functionally Active Non-
competitive Agonists and Antagonists at the Neuronal Nicotinic Receptor.   
Twentieth Annual Meeting and Exposition of the American Association of 
Pharmaceutical Scientists, October, 2006, San Antonio, TX, Abstract M1098.  
 
Aaron J. Haubner, Joshua R. Ring, John M. Littleton, Neil S. Millar, Peter A. Crooks.  
Synthesis and Pharmacological Evaluation of Guanylated Nicotinic Receptor 
Ligands:  Affinity and Functional Activity at the Neuronal Nicotinic Receptor 
Subtypes. AAPS, Nov. 2005. 
 
 371
  
Aaron J. Haubner, May Fu, John M. Littleton, Peter A. Crooks. 
Synthesis and Pharmacological Evaluation of Second Generation Guanidino-
containing Nicotine Anaolgs; Improvements in Affinity at the Neuronal Nicotinic 
Receptor. AAPS, Nov. 2004. 
 
Joshua Ring, John M. Littleton, Peter A. Crooks.  Synthesis and Evaluation of Novel 
Aromatic Agmatine Analogs at Polyamine Binding Sites within the N-Methyl-D-
Aspartate (NMDA) Receptor Complex.  Annual Meeting and Exposition of the 
American Association of Pharmaceutical  Scientists, November, 2004, Baltimore, 
MD., Abstract W4084, p95. 
 
Jianghong Chen, Aaron J. Haubner, Peter A. Crooks.  Synthesis and Evaluation of 
Nicotine Analogs as Ligands for α4β2* Neuronal Nicotinic Acetylcholine Receptors.  
Annual Meeting and Exposition of the American Association of Pharmaceutical 
Scientists, November, 2004, Baltimore, MD., Abstract W4065, p95. 
 
Aaron J. Haubner, May Fu, John M. Littleton, and Peter A. Crooks.  Synthesis and 
High-Throughput Pharmacological Evaluation of Novel Nicotinic Receptor Ligands.  
Annual Exposition and Meeting of the American Association of Pharmaceutical 
Scientists, Salt Lake City, UT, AAPSPharmSci, 2003, 5, (4) Abstract M1130.  
 
J.T. Ayers, Aaron J. Haubner, Vladimir P. Grenevich, Linda P. Dwoskin and Peter A. 
Crooks.  Synthesis and Evaluation of N-Alkylated Pyridinium Derivatives as 
Antagonists at the Nicotinic Acetylcholine Receptor.  ACS, Mar. 2000. 
 
Haubner A.J., Xu R., Grinevich V.P., Crooks P.A. and Dwoskin L.P.  Development 
of conformationally restricted, subtype-selective nicotinic receptor antagonists.   Soc. 
Neurosci. Abstr., 26:378, 2000. 
 
Rui Xu, Aaron J. Haubner, Vladimir P. Grenevich, Linda P. Dwoskin and Peter A. 
Crooks.Synthesis and Evaluation of Some Conformationally-Restricted Pyridino N-
Alkylated Nicotine Analogs as Nicotinic Receptor Antagonists.  ACS, Mar. 2000. 
  
 
Green T.A., Bardo M.T., Crooks P.A., Haubner A.J. and Dwoskin L.P.  Nornicotine 
evokes [3H]overflow from rat nucleus accumbens slices preloaded with 
[3H]dopamine.  NIDA Res. Monograph 180:195, 1999. 
 
Ayers J.T., Haubner A., Wilkins L.H., Grinevich V.P., Ghosheh O., Dwoskin L.P. 
and Crooks P. A.  N-Alkylated pyridine analogs: Potent and selective antagonists at 
nicotinic acetylcholine receptors.  2nd International Symposium on Nicotinic 
Acetylcholine Receptors: Advances in Molecular Pharmacology and Drug 
Development, IBC Abstracts, 1999. 
 
 372
  373
A.J. Haubner, J.N. Davidson.  Allosteric Regulation of CAD.  Molecular and Cellular 
Biology: annual meeting of the Kentucky Academy of Sciences, May 1998. 
 
 
 
PUBLICATIONS 
 
Haubner AJ, Chen J, Kennard EJ, Young G, Papke RL, Millar NS, Dwoskin LP, 
Crooks PA.  Bridged amidino nicotine analogs: non-competitive, functionally active 
subtype-selective ligands for neuronal nicotinic receptor subtypes.  Bioorg. Med. 
Chem.  (In Preparation Feb 2008) 
 
Haubner AJ, Fu M, Ring JR, Kennard EJ, Littleton JM, Dwoskin LP, Crooks PA.  
Development of guanylated nicotine analogs: non-competitive ligands for the 
alpha4beta2 and alpha7 neuronal nicotinic receptor subtypes.  Bioorg. Med. Chem. 
Lett. (In Preparation Feb 2008) 
 
Simmons CQ, Simmons AJ, Haubner A, Ream A, Davidson JN.   
Substitutions in hamster CAD carbamoyl-phosphate synthetase alter allosteric 
response to 5-phosphoribosyl-alpha-pyrophosphate (PRPP) and UTP.  Biochem J. 
2004 Mar 15; 378(Pt 3): 991-8. 
 
Grinevich VP, Crooks PA, Sumithran SP, Haubner AJ, Ayers JT, Dwoskin LP.   N-n-
alkylpyridinium analogs, a novel class of nicotinic receptor antagonists: selective 
inhibition of nicotine-evoked [3H] dopamine overflow from superfused rat striatal 
slices.  J. Pharmacol. Exp. Ther. 2003 Sep; 306(3):1011-20.  
 
Crooks P.A., Ayers J.T., Haubner A.J., Grinevich V.P., Sumithran S.P., Deaciuc A.G. 
and Dwoskin L.P.  The bis-picolinium salt, bPiDDB, is a potent and selective 
antagonist at nicotinic acetylcholine receptors mediating nicotine-evoked dopamine 
release in rat striatum.  Drug Alcohol Depend. 64:38, 2002. 
 
Ring JR, Haubner AJ, Crooks PA.   Novel antiepileptic and anticonvulsive 
therapeutic agents.  I Drugs. 2002 Oct; 5(10): 990-9. 
 
Wilkins LH, Haubner AJ, Ayers JT, Crooks PA, Dwoskin LP. 
N-n-alkylnicotinium analogs, a novel class of nicotinic receptor antagonist: inhibition 
of S(-)-nicotine-evoked [3H]dopamine overflow from superfused rat striatal slices.  
Journal of Pharmacol. Exp. Ther. 2002 Jun; 301(3):1088-96. 
